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Cellular Delivery using Peptoid Carriers 
 
By Géraldine Escher 
 
Efficient delivery into cells is essential for many applications. However, cellular 
access of “cell-impermeable” molecules, such as drugs, sensors, proteins and 
oligonucleotides, can often be severely limited due to the plasma membrane which 
protects cells from unregulated influx of hydrophilic materials. In order to solve this 
issue, several physical techniques and bio-chemical products are today available. 
One of them is called peptoids (N-alkylglycines). These compounds are 
peptidomimetics which are resistant to enzymatic degradation, non-immunogenic 
and are readily prepared by an Fmoc chemical approach. Peptoids based on the 
"TAT"-peptide (RKKRRQRRR) offer rapid cellular uptake/delivery and low 
cytotoxicity. 
In this thesis, based on previous works using fluorescein-cationic peptoids, various 
fluorescent N-substitued glycines (lysine-like) were prepared by the monomer 
method followed by solid-phase synthesis. Their cellular uptakes in vitro into several 
cell lines (such as HeLa, B16F10, HEK293T and primary immune cells) were 
examined via flow cytometry and microscopy. The cellular delivery of small 
molecules mediated by the 9mer polymer achieved an efficient and rapid penetration. 
These results open up a vast number of applications for delivery of macromolecules 
using nonalysine-like peptoid. In order to demonstrate this ability, the nonalysine-
like carrier was used to deliver various biopolymer molecules such as peptides, GFP 
protein and DNA (in collaboration with Dr. Stefano Caserta). In addition, thanks to 
the non-cytotoxicity of this cellular transpoter (MTT assays); experiments were 
carried out in vivo in mice using peptoids labelled near-infrared dyes. The first 
results have shown that the peptoid is not toxic for the mouse and does not block cell 
movements. These results allowed the use of 9mer-peptoid as a cellular tracking 
agent. Based on the development on antimicrobial peptides, the polylysine-like 
peptoid was also tested as an antibiotic. Recent experiments carried out in 
collaboration with Dr. Kevin Dhaliwal have revealed a new antimicrobial property of 
the peptoids. In vitro and in vivo studies have been carried out using both gram 
positive and negative bacteria. These results present a promising alternative to 
conventional antibiotics and antimicrobial peptides (AMPs).  
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CHAPTER 1 : INTRODUCTION  
 
1.1. Cellular entry 
For many years, the focus of research in chemistry has been on the synthesis of 
fascinating compounds including small molecules, polymers and biologically 
intriguing macromolecules. Although chemists have great skills in producing a 
myriad of interesting biologically active compounds, the uptake and the delivery of 
these new materials into cells or tissues can be difficult. To enable efficient cellular 
uptake of foreign materials (such as drugs and sensors), the characteristics of 
bilipidic membranes as well as natural pathways through it have to be understood 
and cytoplasmic delivery of compounds of interest should be carried out while 
maintaining cell integrity. 
 
1.1.1. Cell membrane-characteristics  
Cells are the building blocks of life and are the place where DNA, RNA and proteins 
are synthesized. This natural laboratory is protected thanks to a membrane (Figure 
1.1) which creates a remarkable barrier delimitating the intracellular space and 
providing excellent control of the movement between intra and extracellular fluids. 
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‘Traffic control’ is mainly based on transport proteins, ionic charges (through ionic 
interactions) and hydrophobicity as the cell membrane is a lipid bilayer made of 
phospholipids. These lipids have hydrophilic heads and hydrophobic tails that 
organise themselves with their polar heads facing the aqueous extra and intracellular 
domains while their long hydrophobic carbon chains are held together by 
hydrophobic interactions (Figure 1.2).  
 
Figure 1.2: A phospholipid. 





Although cell membranes are mainly composed of phospholipids, they are much 
more complex and contain several other molecules. Inside and crossing the lipid 
bilayer are proteins and other lipids (e.g. cholesterol, sphingolipids and glycolipids) 
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buildings blocks allow numerous cellular functions to occur, including cell 




1.1.2. Natural pathways for cellular uptake 
Transport of compounds through the cell membrane depends on the nature of the 
molecules. Cellular phospholipid membranes are impermeable to most molecules, 











), but allowing the passive diffusion of certain small materials 
(non-polar and non-charged). Nevertheless, polar molecules can access the 
cytoplasm through active transport that requires adenosine-5'-triphosphate (ATP). 
1.1.2.1. Passive diffusion 
For molecules to diffuse freely through the cellular membrane they typically have to 
be small, hydrophobic, non-polar or non-charged.  
 






Small, non-polar molecules, including gases (e.g. O2 and N2), are able to dissolve 
into the lipidic bilayer and therefore rapidly diffuse across. Due to random vibration 
occurring in the membrane, small uncharged polar molecules that do not interact 
with the negatively charged head of the phospholipids, such as CO2, water, alcohol 
and urea, are able to translocate slowly through the hydrophobic fatty region. The 
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diffusion of such molecules across the cellular membrane is not energy-dependent. 
Compounds cross the membrane according to a concentration gradient and thanks to 
their kinetic energy and to random motions due to the other molecules present in the 
lipid bilayer. However, the lipid bilayer is totally impermeable by diffusion to 
charged molecules, no matter how small they are, and to large polar compounds such 
as proteins, amino acids and other foreign materials (Figure 1.3). 
 
1.1.2.2. ATP independent membrane transport  
There are two major classes of energy free (ATP free) membrane transport proteins. 
In both of them, the protein creates a gate that allows the solutes to cross the cellular 
barrier without being in contact with the phospholipids. 
The first class is carrier proteins, also known as facilitated diffusion. This 
mechanism requires the solute bounded to a specific binding site. This interaction 
causes various conformation changes of the protein that transfers the bounded solute 
from one side of the membrane to the other. Facilitated diffusion always goes down 
the concentration gradient and continues until equilibrium is reached. However, it is 
important to note that other carrier proteins act as a pump and use ATP (see 
Paragraph 1.1.2.3). 
 
Figure 1.4: Principles of ATP free membrane transport proteins. 
Left: Representation of carrier protein for carrier-mediated diffusion; Right: Representation of channel 
protein. [Permission, Appendix 1]1 
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The second class is ion channels, pores made across the membrane by 
transmembrane proteins. This transport mode works as a voltage ‘gate’ that allows 




) to travel across the lipid bilayer according to a 
electrochemical gradient and does not require any binding between the solute and the 
protein channel (Figure 1.4). 
 
Although these classes of protein transport offer efficient cellular penetration of ions, 
they are limited for the transport of macromolecules as each transporter protein is 
specific to one, and only one, molecule. Transport of polar molecules (such as amino 
acids and carbohydrates) cannot occur by diffusion or facilitated diffusion and 
requires an energy dependent pathway. 
 
1.1.2.3. Energy dependent mechanisms 
In synergy with passive diffusion, energy dependent mechanisms or active transport 
allows the transport of molecules or ions against their concentration gradient and 
requires the consumption of energy. The main source of energy comes from the 
hydrolysis of the adenosine-5'-triphosphate (ATP) that generates one molecule of 
adenosine-5’-diphosphate (ADP) and one of monophosphate (Pi). ADP can be 
further hydrolysed into adenosine-5’-monophosphate and another molecule of Pi to 
release more energy. Two main types of mechanism using chemical energy can be 
distinguished: endocytosis that creates a vesicle around the macromolecules and 
pumps that drive the compound across the membrane. 
 
Endocytosis 
Endocytosis is a process by which cells uptake materials (such as macromolecules, 
particles). A small portion of cellular membrane invaginates a foreign substance to 
form a vesicle that plays the role of carrier. Once internalised, the vesicle pinches off 
internally to form an endosome or endocytic vesicle that contains the material which 
is then released into the cytoplasm. Largely, the term ‘endocytosis’ describes this 
mode of encapsulation by the lipid bilayer. This general mechanism can be divided 
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in three sub-pathways: phagocytosis, pinocytosis and receptor mediated 
endocytosis (Figure 1.5). 
 Phagocytosis (cell eating) is a cellular process in which specific solid 
particles (typically 1 µm or more), such as apoptotic cells or microbes, are ingested.
3
 
This operation occurs only in specialist cells known as phagocytes, which include 
neutrophils, macrophages and monocytes. The specific particle binds onto the cell 
surface and is encapsulated into a vesicle called a phagosome. Once internalized, 
these phagosomes are transformed into lysosomes and the contents are degraded or 
transformed as nutriments.  
 Pinocytosis (cell drinking) is similar to phagocytosis. This non-specific 
process creates very small vesicles that typically contain extracellular fluids. Once 
the small pinocytic vesicle is created, it penetrates inside the cytosol where its 
contents are released. 
 
 
Figure 1.5: Pictorial representation of the three main endocytosis. 
On the left: Phagocytosis uptake; in the middle: Transport by pinocytosis; on the right: Formation of 
coated vesicle through receptor-mediated endocytosis.  
 
 Receptor mediated endocytosis (RME) refers to specific endocytic 
mechanisms, which take place via an interaction between a particular cellular 
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membrane receptor and the macromolecule ligand.  Once bound to each other, the 
complex transforms itself onto a specialist coated vesicle. These include clathrin-
mediated endocytosis (such as for cholesterol using the Low-Density-Lipoprotein 
receptor)
4
 or caveolae-mediated endocytosis.
5
 Clathrin-mediated endocytosis 
depends on formation of clathrin-coated endocytic vesicles. Clathrins bind to the 
receptor through another protein called adaptin. After removal of their clathrin coats, 
these vesicles fuse together to form early endosomes, where the constructs receptor-
ligand are acidified to separate them. Receptors are then sorted to be recycled back to 
the membrane or degraded in the late endosome. In the meantime, ligands are, often 
but not always, degraded inside the lysosomes. More than 25 receptors are known to 
use this uptake mechanism. For instance transferrin (blood plasma protein) accesses 
cells through this pathway. In comparison to clathrin-mediated endocytosis, caveolae 
mediated endocytosis are small distinct invaginations (50 to 100 nm) present on the 
plasma membrane. These small flask shaped vesicles are rich in caveolin, an integral 
membrane protein. Caveolae can be in most cells but are especially abundant in 
smooth tissues such as smooth muscle cells and pneumocytes (cells lining the alveoli 
in lung). Caveolae dependant cellular mechanism is used by the full length TAT 
(trans-activator of transcription) protein of human immunodeficiency virus type 1 









-ATPase) is an enzyme bound onto the cell 
membrane. This membrane-bound ion pump belongs to the family of P-type 
ATPases.
7
 During each cycle of ATP hydrolysis, three sodium and two potassium 
ions are involved (Figure 1.6).  
At the beginning of each cycle the enzyme is facing the cytoplasm and three sodium 
ions bind to the protein channel. Due to ATP, the channel changes its shape that in 
turn drives the Na
+
 through the channel. Sodium ions are then released on the other 
side of the membrane. The channel now has a high affinity for two potassium ions. 
This potassium-protein interaction generates a new shape change and rotation of the 
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Figure 1.6: Schematic representation of a sodium-potassium pump. 
After ATP hydrolysis, the enzyme begins to exchange sodium and potassium through the cell 
membrane.  
 
In this pump system, sodium and potassium are both moving against their 
concentration gradient (from areas of low concentration to areas of high 
concentration). This transmembrane ATPase plays a vital role of osmoregulation in 
animal cells by regulating their volume (stopping water from entering into cells), 
intracellular pH and potential.  
 
1.2. Available cellular delivery methods 
As described above, cytoplasmic access to molecules is difficult and strongly 
regulated by various natural tools present on the cell membrane. In order to enable 
cellular penetration of exogenous materials (such as DNA, siRNA, organic drugs and 
proteins), a large number of techniques have been developed. These techniques can 
be grouped into three classes: physical, chemical and carrier based methods. 
 
1.2.1. Physical methods 
Physical methods (also defined as mechanical methods) allow cellular delivery of 
foreign materials to the cytoplasm by disturbing the lipidic bilayer. This disturbance 
generates a transitory hole in the cell membrane, which gives access to the cytoplasm 
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for any molecules present in the extracellular fluid. After a few moments, the cell 
membrane starts to repair itself and reorganises its phospholipids to become 







 They have been used to deliver 
molecules from small organic drugs to DNA.
12,13
  
Photoporation, or laser assisted cell poration, is a physical technique which allows 
the permeabilisation of single cells. In order to destabilise the cell membrane or to 
create a transient pore, a highly localised laser beam is applied onto the outer 
membrane of the target cell.
14
 This permeability modification allows foreign DNA, 






Figure 1.7: Pictorial representation of microinjection technique. 
 
However, even if these methods are widely used by biologists, they can be laborious 
with low efficiency
16




1.2.2. Chemical approaches 
Some chemical techniques are based on the same principles as the physical methods. 
They disrupt for a short period of time the cell membrane allowing compounds to 
penetrate into the cytoplasm. This disruption can be carried out to deliver for 
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example DNA by the use of simple chemical agents such as DMSO
18
 or proteins by 
complexation with the detergent SDS (sodium dodecyl sulphate).
19
 However, like 





1.2.3. Carrier based cellular delivery 
In order to overcome this cytotoxicity issue, scientists have developed less 
aggressive techniques. The molecules of interest are delivered through a carrier that 
is able to cross the cell membrane with a minimum effect on its natural organisation. 
Numerous cellular transporters offer various modes of uptake and two different 
linking techniques with their cargos: ionic and covalent.  
Cationic lipids
21
 were introduced in 1987 by Felgner.
22
 These amphiphilic organic 
molecules are composed with a hydrophilic cationic head, which interacts with 
negatively charged oligonucleotides through ionic interactions, and one or two fatty 





 to form stable complexes or micelles that promote cellular 
penetration thanks to their similarity with the cell membrane.  
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Several of these non-viral vectors are commercially available, like Lipofectamine
®25
 
(Figure 1.8) and DOSPER
®26,27
 (Figure 1.9). These lipids or mixture of lipids are 
used to efficiently transfect an important range of cell lines including stem cells.
28
 










Carbon nanotubes were first described in 1952, but only became popular almost 40 
years later.
30
 They exist in two types: single wall (SWNT) and multi wall (MWNT) 







). Although efficient and diverse, 
carbon nanotubes suffer from high cytotoxicity
34
 and biocompatibility issues.
35
 
Microspheres are small spherical particles made of various materials such as glass, 
ceramics or polymers (e.g. polystyrene or polyethylene), and have been used in 
research for decades. During the last few decades, the interest in microspheres as 
cellular delivery devices has kept increasing. These particles can be biodegradable 
when composed with biodegradable polymer such as poly(D, L-lactide) (PLA) 
and/or poly(D,L-lactide-co-glycotide) (PLGA)
36
 or non-biodegradable (e.g. 
polystyrene).
37









) either by encapsulation
44
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Even if the previous methods are very promising and efficient, cytotoxicity remains 
their main problem. In order to solve this problem, scientists get inspiration from 
Nature.  
Dendrimers are polymeric hyperbranched structures (Figure 1.10). Their 







Figure 1.10: Schematic representation of dendrimer and drug incorporation. 
 
Many foreign materials can be internalized using this technique. For instance, DNA 
is delivered into eukaryotic cells using dendrimers based on polyamidoamines 
(PAMAM)
46
 while antisense oligodeoxynucleotides (OGNs) can be transfected using 
covalent bonding to an anionic dendrimer (pentaerythritol-based anionic 
dendrimer)
47
 and drugs complexed with dendrimer to facilitate oral delivery.
48
 
Another type of cellular delivery system involves the use of natural peptides.  
 
1.3. From peptide domains of viral proteins to cell penetrating peptides 
In Nature some proteins, cytokines, transcription factors, antibacterial peptides and 
transmembrane proteins, are able to interact and translocate across the cell 
membrane. These properties are often due to a short sequence of amino acids, known 
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as a protein transduction domain (PTD), which mediates the delivery of protein 
inside the cell in an energy independent mechanism (also termed as a membrane 
translocating sequence (MTS)). They are the basis of many cell penetrating peptides 
(CPPs).
49
 The most famous of these “Trojan peptides” has a viral origin and is the 
HIV-1 transactivator of transcription (TAT).
50
 This 86 amino acid protein was first 
described in 1988
51
 and is known to transactivate genes that are expressed from HIV-
LTR (long terminal repeat). Various studies of TAT resulted in the identification of 
two specific sequences allowing cellular penetration: a highly basic sequence 
(GRKKRRQRRR) between the amino acids 48 and 60
52
 allowing ionic interactions 
with the cell membrane and a nuclear localization signal (NLS) at position 48-52 
(GRKKR).
53
 Although the TAT peptide is the most well-known of the CPPs, it is not 
the only one to be used.  
 
1.3.1. Various cell penetrating peptides 
The number of CPPs keeps on growing. They have been used to deliver various 




 and small molecules into cells.
56
 They 
can be organised into four main categories. Three of them are based on their 
physicochemical properties, while the forth one is based on natural peptides: 
- Basic: based on amino acids like lysine, histidine and arginine.   
- Basic-amphipatic: having both basic amino acids and hydrophobic regions. 
- Hydrophobic: based on amino acids like valine, leucine and tryptophan. 
- Chimera: also known as fusion peptides which are created through the joining 
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Category Name Sequence Origin 
Basic HIV-1 TAT
57


























































Synthetic and NLS 












Galanin (1-12) and 
C-terminal sequence 












associated with NLS 
of SV-40 
 
Table 1.1: Selection of cell penetrating peptides.  
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Thanks to the efficiency and low cytotoxicity of cell penetrating peptides, 
biotechnology and pharmaceutical companies have shown an interest in this type of 
carrier. For instance, Transporter
TM
 peptides are a range of modified cell penetrating 
peptides commercialised by Cambridge Research Biochemicals. These peptides were 
described to deliver several cargos (proteins, DNA and organic dyes) that are 
coupled to the CPP through a disulphide bond.
67
 DeliveryX is a siRNA transfection 
kit commercialised by Panomics and based on MPG
68
 (Table 1.1). The nucleic acids 
interact with the cationic sequence of the peptide to generate a nanoparticle able to 
cross the cell membrane. The siRNA encapsulated within the peptide cluster can 
access the cytoplasm without using endocytic pathway and, thus, avoiding its 
degradation (lysosomal degradation).
69
 SynB vectors are small linear synthetic 
peptides (e.g. SynB1 H-RGGRLSYSRRRFSTSTGR-OH) inspired by natural peptide 
protegrin-1.
70
 They are covalently bound to the drug of interest (such as doxorubicin, 





1.3.2. CPPs  and cellular uptake mechanisms 
Despite the fact that CPPs are widely used to deliver an important range of bioactive 
molecules into various cell lines and animals,
49,87
 their cellular uptake is still subject 
to many discussions and several studies carried out with the same carrier have led to 





 and temperature independent.
74
 Nevertheless, in 2003, these results (CPP 





 Their experiments have shown that several cell-penetrating peptides 
containing a cationic sequence (e.g. TAT, R9,
75
 SynB5 and penetratin
76
) were found 
inside endocytic vesicles. These data suggest that this type of CPPs crossed the 
bilipidic membrane via an endocytosic pathway.  
 
1.3.2.1. Energy free mechanism 
Energy free mechanisms (Figure 1.11) were initially thought to describe the efficient 
cellular uptake of CPPs. The theory being that positively charged amino acids of the 
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peptides interact with the anionic head of the phospholipids. Where this ionic 
interaction takes place, the overall charge of the cell membrane is modified (neutral). 
This change leads to instability of the cell surface that could facilitate cavity, pore 
formation and/or membrane disruption. The cationic charges on the peptides are 
essential to link the CPP to the membrane. The following steps depend on the other 
amino acids present in the peptide sequence.  
 
 
Figure 1.11: Mechanisms of direct translocation across the cellular membrane. 




In early studies on direct translocation, Derossi
72
 described the formation of a 
hydrophilic cavity, known as an ‘inverted micelle’ (Figure 1.11-D). The positive 
charges of penetratin peptides (homeodomain of Antennapedia, a Drosophila 
transcription factor) are attracted by the anionic phospholipids. This ionic bonding is 
a crucial step for the integration of the CPP. Thanks to this ionic interaction and the 
structure of the peptides, the tryptophan residues (known to be inducers of inverted 
micelles) are orientated to penetrate the cell membrane. This lipid disturbance leads 
to the formation a hexagonal phase, known as inverted micelle. This small pocket 
contains the peptide-cargo conjugate until its release inside the cytosol.  
Pore formation was suggested by analogy with mechanisms of penetration across cell 
membrane by antimicrobial peptides (AMPs), such as Magainin-2 (GIGKFLHSAK 
KFGKAFVGEIMNS) and Buforin-2 (TRSSRAGLQFPVGRVHRLLRK).
77
 These 
peptides penetrate into the cytoplasm thanks to an ionic disturbance and a channel 
through the phospholipid bilayer. As far as pore formation is concerned, three types 
of pore formation can be described.
78
 The first of these mechanisms, the ‘barrel-
stave’ model (Figure 1.11-B), was described in the 1970s. Amphipatic peptides, 
after interacting with the cell surface, position themselves perpendicularly to the 
membrane. Thanks to their amphipathic alpha helix structures, antimicrobial peptides 
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or cell penetrating peptides generate an “aqueous hole”, where the hydrophobic 
amino acids face the aliphatic chains of the phospholipids, while the polar regions 
face each other.
79
 The second mechanism, called the ‘toroidal-pore’ model (Figure 
1.11-A), is very similar to the first one.
80
 In both models, the final result is the 
formation of a perpendicular channel into the cell membrane. However in this pore 
formation mechanism, the peptides interact firstly with the polar groups of 
phospholipids to create a complex that forces the lipids to reorganize themselves 
inside the membrane to fashion a toroidal hole (similar to O-ring shape) composed 
by both peptides and phospholipids.
81
 The last mechanism, known as the ‘carpet 
model’ (Figure 1.11-C), begins by the parallel association of the cationic amino 
acids of the peptides, as single units or oligomers, onto the negative charges of the 
cell surface. At this stage, the membrane surface is covered by peptides. Then they 
reoriented themselves: non-polar amino acids towards the long carbon chains of 
phospholipids and the hydrophilic ones facing the phosphate head of the 
phospholipids. Once the peptide concentration is above a threshold concentration, 
they penetrate thanks to the low stability of the cell membrane. During the whole 
integration process, the peptides conserve the same organisation towards the 
phospholipids.
82
 All these models seem to be efficient and applicable to various 
exogenous materials. However, due to the size of the inverted micelle, cellular access 
of macromolecules through this mechanism is not possible.
83
  
Several studies have also demonstrated the uptake of CPPs via energy dependent 
mechanisms. 
 
1.3.2.2. Endocytosis pathways 
As discussed in Paragraph 1.1.2.3, endocytosis is an energy dependent mechanism 





Mechanism studies on CPPs have shown that several of these peptides are able to 




The exact endocytosis pathway is still up for discussion for most of these CPPs. 
Indeed, the same peptide has shown various energy dependent cell penetration 
mechanisms. For instance, it was shown that a TAT-fusion accessed the cytoplasm 
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thanks to interaction with lipid rafts (cholesterol and sphingolipids) and through 
caveolar mediated endocytosis.
85
 Nevertheless, two years later, Chernomordik
86
 
using heparinase III (specific inhibitors of heparan sulfate receptor) reported that 
unconjugated TAT internalisation was based mainly on a clathrin-dependent 
endocytic pathway. 
Collectively, these data have shown that cellular uptake is a function of the peptide 
(charge, size and secondary structure), its cargo and the cell type.
87
 Furthermore, 
studies have demonstrated the importance of the interactions between the CPP and 
the cell surface that could lead to direct translocation and/or an endosome formation. 
 
1.4. Analogues of CPPs 
Analogues of peptides or peptidomimetics are mutants which can mimic natural 
peptides while modifying their biostability, action and/or bioavailability. Analogues 
of peptides have been developed to counteract various problems that limit the clinical 
applications of peptides as delivery systems (CPPs
88
) or as drugs.
89
 One of the main 
concerns about peptides is their rapid degradation by proteases.
90
 Although TAT 
peptide is the most used of all the CPPs, its in vivo applications are highly limited 
because of its cytotoxicity and proteolytic sensibility. For instance, trypsin can cleave 
the TAT sequence up to seven times.
91
 
Many peptide modifications are available to give access to a range of 
peptidomimetics.  
Peptidomimetics can be obtained from natural peptides by an inversion of the α-
chiral centre (D-peptides
92
) or by a chemical modification of the amide structure (e.g. 
thioamides). Peptidomimetics can be organised into three categories: spatial, 
backbone and amide bond modification (Figure 1.12). These changes play important 
roles in their conformation and/or their proteolytic stability. 
D-peptides are made of D-amino acids instead of the natural L-amino acids. Various 
D-enantiomeric peptides have shown similar cellular penetrating properties (cellular 
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 (β-peptides) are made of β-amino acids that generate normal amide 
bonds while increasing the spacing between two consecutive side chains. Their 
secondary structures (α-helix and/or β-sheets) are stabilised thanks to the formation 
of intramolecular hydrogen bonds between their C=O and their NH. In β-amino 
acids, carboxyl group and nitrogen are separated by two carbons. This methylene 
group allows two types of β-peptides to be generated as a function of where the side 




-peptides refer to the side chain positioned onto, 
respectively, the carbon C2 (carbon next to carbonyl), and C3 (carbon next to 
nitrogen). Thanks to this structural change, this type of peptidomimetics is usually as 
biologically active (e.g. delivery) as normal peptides, highly resistant toward 
protease degradation and offers extremely stable helical structure (sequence 
dependent).
94, 95
 β-amino acids can be synthesised using a number of reactions, such 
as Arndt-Eistert homologation of an α-amino acid.
96
  
Thioamide peptides are peptides in which the oxygen of one or more amide bonds 
has been replaced by sulphur. This atom substitution leads to retention of the planar 
amide bond but to a disruption or distortion of the secondary structure (β-sheet and 
α-helix), due to the larger size of the Van der Waals radius of sulphur (180 pm for S, 
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against 152 pm for O). This change has been reported to increase the enzymatic 
stability of these molecules against proteases.
97
 Thioxopeptides can be prepared by a 







Figure 1.13: Chemical structure of the Lawesson’s reagent. 
 
 
1.5. Peptoids: a promising analogue 
The term ‘peptoid’ was used for the first time in 1982 by Ariens
99
 to describe small 
and flexible chemical structures with the ability to mimic peptidic biological activity 
without direct structural resemblance. 10 years later, Simon
100
 published the first 
paper on peptoids as we know them today, an oligomer of N-substituted glycines. 
Like α-peptides, peptoids are composed by a succession of building blocks linked 
together by an amide bond. As opposed to α-amino acids, the side chains of peptoid 
building blocks (as suggested by the name N-substituted glycines) are attached to the 
nitrogen group on the backbone (Figure 1.14). This shift retains the distance 
between two consecutive side chains as in natural peptides and carbonyl.  
Nevertheless, this small structural modification plays a crucial role in the properties 
of this compound. Indeed, in comparison with peptides and other peptidomimetics 
(Figure 1.12), peptoids are much more flexible polymers than peptides as they do 
not possess any chirality and any hydrogen bond donors on their backbone. 
Moreover, in comparison with structures containing secondary amide bond, the 
presence of the tertiary amide decreases the polarity of the oligomer, the formation of 
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Nowadays, peptoids are used in medical and biological chemistry
103
 as an efficient 
cellular delivery system of small molecules
104,105
 and macromolecules like DNA 
(dendrimer peptoids).
106
 For instance, peptoids have been used to mimic 
antimicrobial peptides and have demonstrated promising antibacterial activities 
(CHAPTER 5).
107
 Researches have shown that arginine rich N-substituted glycines 
were able, like proteins, to bind RNA with high affinity.
108
 Peptoids have as well 
been used to coordinate metals. Zinc was bound with high affinity to a two-helix 
peptoid containing thiol and imidazole moieties. This work was carried out with the 
aim of mimicking protein nanostructures. When the ion was coordinated to the thiol 
and imidazole, the peptoid was folded up into two-helix bunbles (U shape).
109
 In the 
same spirit, copper II and cobalt II were coordinated to small peptoids (pentamer or 
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hexamer) made with one or two units of hydroxyquinoline N-substituted glycine. 
The metal-peptoid coordination generates a well-defined secondary structure of the 





1.6. Aim of this work and carrier design 
The aim of the work in this thesis was the synthesis and study of peptoid-based 
cellular penetrating systems. Due to the data discussed in this chapter, the cellular 
penetrating system chosen was based on polycationic peptides like HIV-1 TAT (49-
57). Although arginine is the most common amino acid in the TAT sequence, this 
thesis work focused on lysine-based transporters. This choice was determined by 
several studies, notably research that demonstrated polylysine oligomers are less 
cytotoxic than their corresponding polyarginine analogues.
111
 In addition, even 
though polyarginines oligomers possess a more efficient cellular uptake, polylysine 
compounds (peptides or peptoids) have demonstrated great properties to deliver 




 In addition to the choice of lysine N-side chain, the length of the carbon chain was 
increased from butyl to hexyl as this side chain extension was demonstrated by 
Wender to improve the cell penetration as it increases flexibility and the hydrophobic 
character of the side chain.
113
 
Previously, several polylysine-like peptoids were synthesised (3, 5, 7 and 9mer) and 
tested with various cell lines.
104, 114
 The studies showed that the number of monomer 
units played a major role on the cellular efficiency of the carrier. Indeed the 3mer 
was the least penetrating, while the 9mer was the most rapidly taken up by cells.  In 
addition, the comparison of peptoids (N-alkylglycines) and their peptide homologues 
(polylysines or polyarginines) clearly demonstrated the greater efficiency (faster to 
penetrate cells) of the peptoids compared to the peptides. Even though, this type of 
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Following peptoid synthesis, the following questions about its properties and 
characteristics were targeted: 
- Can small molecules be delivered into cells without cytotoxicity? 
- Is the cellular uptake of the peptoid cargo dependent? 
- Is peptoid delivery applicable for in vivo research? 
- Could macromolecules be internalized into cells? 
- Do they have any other interesting applications? 
CHAPTER 2 
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CHAPTER 2 : RHODAMINE-PEPTOID: SYNTHESIS 
AND IN VITRO CELLULAR DELIVERY STUDIES 
 
Previously a fluorescein-9mer peptoid was synthesised and analysed with K562, 
L929 and HeLa cells.
104
 In this chapter, the aim was to synthesise a rhodamine 
labelled 9mer peptoid and carry out a detailed analysis in several cell lines to 
demonstrate that labelling was dye independent.  
 
2.1. Synthesis of N-Fmoc-N-(6-N’-Boc-aminohexyl)-glycine  
2.1.1. Background 
In order to synthesise a peptoid, two main routes are used. The first technique, the 
so-called “monomer” synthesis, was first described by Zuckermann
100
 in 1992. This 
approach was optimised by Liskamp
115
 in 1995, Peretto in 2003 and by Fara
116
 in 
2006. The second technique, the so-called “submonomer” synthesis route, was 




2.1.1.1. Monomer synthesis 
“Monomer” peptoid synthesis involves the synthesis of protected building blocks 
(monomers), which can then be coupled together using the techniques developed for 
solid-phase peptide synthesis (SPPS). As for peptides, peptoids are synthesised from 
the C-terminus to the N-terminus, by reaction between an activated carboxylic acid 
(AA+1) with an amino group of AA. In order to avoid side reactions, the side chains 
of amino acids and the amine group have to be orthogonally protected. In the first 
paper describing the “monomer” synthesis of peptoids,
100
 side chain protecting 
groups were acid labile (Boc, Bu
t
, Trt and Pmc) and the amino groups were protected 
using an Fmoc moiety (base labile).  
The original methods used for peptoid “monomer” synthesis were carried out by 
reductive amination of an amine with a glyoxylic acid (2.1) (Scheme 2.1-A) or 
reaction of a glycine methyl ester (2.2) with an aldehyde (Scheme 2.1-B). 
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Scheme 2.1: Original synthetic routes towards N-substituted glycines (2.3).
100
 
R = representing side chains, protected as necessary. 
These original methods were very convenient bringing together two approximately 
equal fragments, but were not suitable for all side chains and protecting groups. 
Alternative routes were developed to overcome this issue including: 
- Alkylation of an amine with chloroacetic acid (2.4) (Scheme 2.2-A). 
- 1,4-addition of glycine (2.5) to acrylamide (2.6) (Scheme 2.2-B). 
 
 
Scheme 2.2: Alternative synthetic routes toward N-substituted glycines.
100
 
R = representing side chains, protected as necessary. NGln = N-substituted glutamine. 
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The amine group of the N-substituted glycines (NSGs) could then be protected using 
N-(9-fluorenylmethoxycarbonyl)succinimide (Fmoc-OSu). 
In 1995, Liskamp described his three step monomer synthesis based on 
Zuckermann’s work (Scheme 2.3). Ethyl bromoacetate (2.8), as a starting material, 
was alkylated with the desired primary amine. This N-alkylation was followed by a 
classical saponification of the ethyl ester using sodium hydroxide to obtain the salt 
that was then Fmoc protected. This method allowed an impressive variety of NSGs 
to be made as any amines (alkylamine, amino acid or diamine) could be used to 
alkylate the bromo ester.  
 
 




Three years later, the same group proposed a modification of their synthetic route to 
access Fmoc-NArg(Boc)2-OH (2.16) in high yield.
118
 In this N-substituted glycine 
synthesis, N-Boc-1, 3-propanediamine (2.9) was alkylated using benzyl bromoacetate 
(2.10) instead of ethyl bromoacetate (Scheme 2.4). Once the protected N-substituted 
glycine of the non-standard amino acid ornithine (2.11) had been prepared, the amino 
group was protected by treatment with benzyl chloroformate to obtain Cbz-
NArg(Boc)2-OH (2.12). The side-chain amine was then deprotected selectively under 
acidic conditions and the free amine was guanylated with N,N’-bis(Boc)-1-
guanylpyrazole (2.13) to give Cbz-NArg(Boc)2-OBn (2.14). The benzyl ester and 
Cbz group were removed simultaneously by hydrogenolysis, followed by Fmoc 
protection of the free secondary amine to give Fmoc-NArg(Boc)2-OH (2.16). 
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Scheme 2.4: Synthetic route proposed by Lyskamp to access Fmoc-NArg(Boc)2-OH (2.16).
118 
 





developed their own method to obtain specific peptoid monomers. Once the 
monomers were synthesised, they can be coupled using solid-phase synthesis. Solid-
phase synthesis of the peptoid will be described later in this chapter. 
 
2.1.1.2. Submonomer synthesis 
The “submonomer” process was introduced by Zuckermann
117
 in order to avoid the 
necessity of producing multiple peptoid building blocks as starting materials. In this 
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new approach (Scheme 2.5), each monomer is created directly on the solid-phase 
using two rapidly available “submonomers”, a haloacetic acid and a primary amine. 
In this synthesis, each extension cycle is composed of two steps: an acylation 




Scheme 2.5: “Submonomer” synthesis of peptoids 
In this synthesis, Step 1 is an acylation and Step 2 is a nucleophilic displacement. 
(R and R’ = protected side chains) 
 
The acylation (Scheme 2.5, Step 1) of the secondary amine on the solid support by 
the pre-activated α-haloacetyl submonomer (bromo, chloro or iodoacetic acid) was 
carried out using a carbodiimide as an activating agent. The combination of the high 
concentration of the haloacetic acid (0.6 M in DMF) and DIC (0.66 M in DMF) 
generates a highly potent acylating agent that facilitates secondary amine acylation.  
The nucleophilic displacement (Scheme 2.5, Step 2) of the halogen was carried out 
in order to introduce the side chain (protected if needed). This reaction was carried 
out in presence of an excess of primary amine (40 equivalents, 2.5 M in DMSO). In 
his paper, Zuckerman studied the efficiency of nucleophilic displacement function of 
the halogen. His work revealed that the yield of this second step appeared to be 
greatly superior when carried out on an iodo and bromo solid support compared to 
chloro derivate. Zuckerman published the synthesis of nine peptoids (mainly 
pentamers) using a robotic synthesizer.
120
 Each cycle taking approximately 3 hours 
with the peptoids obtained after TFA cleavage of the Rink amide linker. 
Nowadays, numerous groups have modified the original submonomer synthesis in 







) or to be able to apply 
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2.1.1.3. Solid-phase synthesis of peptoids 
As previously described in Paragraph 2.1.1.1, monomers synthesised in solution 
phase have to be coupled to each other in order to prepare the desired peptoid. The 
easiest way to do so is to use a solid support. 
Fmoc peptoid solid-phase synthesis is based on the same techniques as Fmoc-SPPS 
and can be divided in two parts: 
- 1: Elongation of the peptide or peptoid chain (coupling and Fmoc 
deprotection). 
- 2: Cleavage and deprotection. 
 
Scheme 2.6: Fmoc solid-phase synthesis of peptoids. 
R=side chains, protected as necessary.  
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The nature of the amino group will affect the ease of the coupling reaction. Indeed, 
N-alkylamino acids (such as proline), due to their steric hindrance, are known to 
couple poorly under standard conditions
125
, a problem that can affect the yield and 
purity of peptoid oligomers. In order to solve this issue, standard carbodiimide 
coupling reagents have often been substituted with PyBOP and PyBrOP, developed 
for the coupling of hindered or disubstituted amino acids.
126
 In 2006, Fara
116
 was 
able to reduce the coupling reaction time using a mixture of DIC/HOBt for 20 
minutes at 60°C using microwave irradiation. 
 
2.1.1.4. Monomer or submonomer synthesis - that is the question? 
Nowadays, both techniques are used; Zuckermann and Barron work using the 
submonomer synthesis while Bradley and Bräse prefer the “monomer” approach.
103 
Before starting any work on a peptoid, it is important to know which synthetic route 
will be the most efficient (time and material) for the project. In order to do so, the 
advantages and the disadvantages of both methods must be evaluated. Some of these 
criteria are summarised in the following table. 
 









- Usual Fmoc SPPS techniques 
- Monitoring of each coupling 
reaction and Fmoc deprotection 
using a colorimetric test 
- Automation possible 
- Microwave assisted 
DIC/HOBt protocol: 40 minutes 
per residue (including Fmoc 
deproctection) 
- High purity  
- High yield 
- Precise control of peptoids 
library using “split and mix” 
- Synthesis of each protected 
monomer in large quantities 
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- Full solid-phase process  
- Large range of commercially 
available primary amines 
- Efficient acylation mediated 
by the DIC/haloacetic acid mix 
- Automation 
- Ease of solid-phase synthesis 
- Microwave heating can be 
applied 
-Excess of amine can be 
recovered and reused 
 
- High quantities of reagents 
- Need to purify final product 
- Low yield for hindered 
amines 
- 2.5 to 3 hours per residue at 
room temperature 
- Protection of side chains 
 




The submonomer synthesis allows the creation of large libraries of peptoids thanks 
to the number of commercially available primary amines.
128
 However this incredible 
flexibility has some important limitations. The main drawback is the use of large 
excesses of starting materials, up to forty equivalents at high concentrations (primary 
amine or haloacetic acid solutions up to 2.5 M). The second concern about this 
method resides in the efficiency of the SN2 step. Indeed, incorporation of hindered, 
poor nucleophilic and low solubility amines cannot be carried out with high yield. 
Therefore, this step will decrease the synthesis efficiency of the peptoid (purity and 
yield).  
The “monomer” approach, thanks to its analogy with peptide synthesis, uses well 
known and optimized conditions and requires a relatively small amount of material 
(3 equivalents) per residue. The oligomerisation progress can be easily monitored 
using the colorimetric methods (primary amine using ninhydrin test
129
 and secondary 
amine using chloranil test
130
). Another advantage, based on the fact that peptoid 
solid-phase synthesis uses the same reagent as SPPS, is automation using 
commercially available peptide synthesisers. However, the main limitation of this 
method is the preparation of the protected monomer in large quantity.  
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To conclude, if the project requires the screening of numerous small peptoids the 
submonomer route is the method of choice. However, if the aim of the study is to 
analyse the capacity of a specific peptoid with a known sequence, the monomer 
approach is the best choice, as the purity using this second method is much higher.  
 
This thesis project deals with a peptoid (2.17, Figure 2.1) as a cell penetrating 
peptidomimetic that is based on polylysine. As the peptoid structure is a repetition of 
the same building blocks the “monomer” synthesis was demonstrated to be the most 
efficient approach. Indeed, once the monomer unit synthesised, the peptoid polymer 
can be carried out on solid-phase allowing clean synthesis and awoiding purification. 
 
 
Figure 2.1: Structure of polylysine-like peptoids (2.17). 
 
2.1.2. Synthesis of the Boc protected building block : N-Fmoc-N-(6-N’-Boc-
aminohexyl)-glycine  
The method used in this project for the synthesis of N-Fmoc-N-(6-N’-Boc-
aminohexyl)-glycine (2.22) was previously published by Bradley
104, 114




2.1.2.1. Previous synthetic routes 
The first synthetic route of N-Fmoc-N-(6-N’-Boc-aminohexyl)-glycine (2.22) was 
described by Peretto
114 
and began with the 1,6-diaminohexane (2.18) (Scheme 2.7). 
This synthesis was inspired by the synthetic work of Liskamp.
115
 The choice of the 
monomer was guided by the several advantages of polylysine (described in 
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After Boc mono-protection of 1,6-diaminohexane (2.18),
132
 the monoprotected 
reagent (2.19) was alkylated using one equivalent of ethyl bromoacetate (2.20) to 
give the lysine-like N-substituted glycine ethyl ester (2.21) (55% yield). The tert-
butyloxycarbonyl group (Boc) chosen is extremely resistant under basic conditions 
and catalytic hydrogenolysis. These characteristics make it an ideal orthogonal 
partner to the Fmoc group. The ethyl ester was saponified under basic conditions, 
followed by N-Fmoc protection to give the desired monomer in a yield of 40%. 
 
 
Scheme 2.7: Peretto monomer synthesis of N-Fmoc-N-(6-N’-Boc-aminohexyl)-glycine (2.22) 
 
Despite the fact that the reaction worked, the global yield was fairly low (22%) 
compared to Liskamp’s synthesis (72% for Fmoc-NLys(Boc)-OH, 2.23, Scheme 
2.3). This difference of yield was due to the lower efficiency of the mono-alkylation 
reaction (55% in Peretto’s protocol and 75% in Liskamp’s synthesis). Also the 
saponification/Fmoc protection step was lower in Peretto’s synthesis (40% for the 




2.1.2.2. Fara’s synthetic route 
In order to increase the yield of this monomer (2.22) synthesis, ethyl bromoacetate 
was replaced with benzyl bromoacetate, as described for the synthesis of Fmoc-
NArg(Boc)2-OH (2.16).
118
 Using the benzyl bromoacetate, saponification would not 
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The first step of Fara’s synthesis
104
 was the creation of the N-substituted glycine 
(2.24) from 1,6-diaminohexane (2.18).
 
The Boc monoprotection was carried out 
using di-tert-butyl dicarbonate in DCM at room temperature for three hours. Without 
further purification, the free primary amine was monoalkylated with benzyl-2-
bromoacetate (2.10) to obtain the desired N-substituted glycine protected by a benzyl 
ester and a Boc group (2.24). Compound 2.24 was isolated by column 
chromatography in a final yield of 68% over the first two steps. The non-protected 
secondary amine group was then protected by a Fmoc group using Fmoc-OSu. After 
purification by chromatography, 2.25 was obtained in a 94% yield. Benzyl group 
deprotection was carried out using Pd/C catalyst under H2. After purification, the 
monomer 2.22 was obtained in 80% yield. In this thesis, the desired compound (2.22) 
was synthesised using Fara’s method and a classical palladium-based hydrogenation 
with a global yield of 51% from the unprotected diamine.  
 
2.2. Solid-phase synthesis of nonalysine-like peptoid 
2.2.1. Previous work : solid-phase synthesis of nonalysine-like peptoid 
Bradley described the preparation of 3 (2.30), 5 (2.31) and 7 (2.32) lysine-like 
peptoids using
 
 N-Fmoc-N-(6-N’-Boc-aminohexyl)-glycine (2.22) and Fmoc solid-
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phase peptide chemistry using polystyrene aminomethyl resin (2.27) functionalised 




Scheme 2.9: Synthesis of the functionalised polystyrene aminomethyl resin with Rink amide 
linker (2.28). 
 
This TFA-labile trialkoxybenzhydryl-type linker (2.28) was inspired by the 1987 
design by Rink
133
 for the preparation of peptide amides using an Fmoc-SPPS 
strategy.
134
 In this original paper, peptide amides were prepared by direct “amide” 
attachment with the 4-(2',4'-dimethoxyphenyl-hydroxymethyl)-phenoxymethyl-
polystyrene (the alcohol version of the Fmoc Rink linker). 
 
 
Scheme 2.10: TFA cleavage of the peptoid from the functionalised Rink amide polystyrene resin. 
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For the solid-phase synthesis of the polylysine-like peptoid (3mer (2.30), 5mer (2.31) 
and 7mer (2.32)), oligomerisation was carried out over 4 hours using 2 equivalents of 
2.22, 2 equivalents of bromo-tris(pyrrolidino)phosphonium hexafluorophosphate 
(PyBrOP)
126
 and 4 equivalents of N,N-diisopropylethylamine (DIPEA) in DCM 
(concentration of monomer 2.22 = 0.08 M) (Scheme 2.11). Each building block 
coupling was alternated with a Fmoc group deprotection (20% piperidine in DMF). 
This succession of coupling and deprotection was repeated as desired to produce the 
required peptoid, after which the peptoid was released from the resin by TFA 
treatment (TFA/TIS, 95: 5)
114
 (Scheme 2.10). 
These coupling steps were difficult and long (4 hours) due to the nature of the 
building blocks. Indeed, since the reaction is carried out between a free acid and a 
secondary amine group it often had to be repeated in order to obtain an efficient 
coupling. Although PyBroP partially solves this problem,
126
 this compound has some 
important drawbacks. First of all, this coupling reagent is very expensive. Secondly, 





Scheme 2.11: Peretto’s solid-phase synthesis of polylysine-like peptoid. 
Coupling using PyBOP and DIPEA; n = 3, 3mer (2.30); n = 5, 5mer (2.31); n = 7, 7mer (2.32) 
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In order to obtain an efficient coupling (time and yield), the use of microwave 
heating was studied and described by Fara.
116
 Microwave synthesis was first reported 
in 1986,
135
 while microwave peptide coupling was described by Wang
136
 to allow 
difficult peptide couplings. Microwave energy (2.45 GHz or 12.2 cm
-1
) can be 
transferred to the substances present in a microwave vessel (polar solvent or 
conducting ions). Microwave heating is based on the ability of chemicals to absorb 
energy and convert it into heat. Microwaves are made of an electric and a magnetic 
field component. In chemistry, it is the electric part that plays the most important 
role. Two main mechanisms are causing the heat production: dipolar polarization and 
ionic conduction. Molecules with a dipole moment try to align themselves in the 
applied electric field. However, this field oscillates, so the molecule attempts to 
realign itself with the field. During this process, energy is lost as heat due to 
“molecular friction” and dielectric loss. For the ionic conduction, heat is produced 
due to the oscillation (back and forth) of the charged particles in solution. Under the 
influence of the microwave field, they move and enter in collision with their 
neighbours (molecules or atoms) producing heat.  
 
In association with the microwave system, Fara used a standard and robust N,N’-
diisopropylcarbodiimide and N-hydroxy-benzotriazole coupling protocol.
116
 Peptoid 
couplings were carried out in a single-mode microwave reactor (Biotage Initiator 
instrument) in sealed vials using 3 equivalents of the Boc monomer (2.22), 3 
equivalents of HOBt and 3 equivalents of DIC in DMF (C = 0.1 to 0.2 M). The 
reaction time dropped from 4 hours at room temperature to 20 minutes at 60°C under 
microwave radiation. 
 
2.2.2. Synthesis of Rho-9mer peptoid 
In a recent paper, Unciti-Broceta has shown that the cellular penetration of the 
lysine-like peptoid composed of nine units (Fluo-9mer) is more efficient than the 
peptoid with only 7 units.
104
 In order to increase the knowledge about the capacity of 
this peptoid as cellular transporter, a Rhodamine-9mer lysine-like peptoid (Rho-
9mer, 2.37) was prepared using HOBt/DIC assisted microwave solid-phase synthesis 
(Scheme 2.12).  
CHAPTER 2 




Scheme 2.12: HOBt/DIC microwave assisted solid-phase synthesis of Rho-9mer peptoid (2.37). 
 
The 9mer lysine-like peptoid (2.33) was covalently linked to 5(6)-carboxyrhodamine 
(2.36) via an aminohexanoic spacer unit (2.34) (Scheme 2.12). The hexanoic spacer 
unit decreases the steric congestion between the peptoid and the dye. Furthermore, 
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spacer units have been described to enhance the biocompatibility and the interaction 
between cellular transporters and the cell surface.
137
  Bräse have also shown that 





After TFA cleavage and precipitation in cold Et2O, 2.37 was obtained in 94% yield 
(based on the loading of 2.28) and analysed by MS (MALDI-TOF), HPLC (purity > 
98% for both isomers), fluorescence spectroscopy (Figure 2.2-A) and NMR. The 
HPLC spectrum of Rho-9mer peptoid (2.37) (Figure 2.2-B) showed two peaks, 
though only one compound appeared on the MS analysis. The carboxyrhodamine 
(2.36) used for this peptoid synthesis has two isomers (5 and 6), therefore, these two 
peaks were expected to be both Rho-9mer (2.37). In order to confirm this, the peaks 































Figure 2.2: Analysis of Rho-9mer peptoid (2.37). 
A) Emission spectrum of Rho-9mer peptoid 2.37 in MeOH (abs max = 525 nm; em max = 584 nm); 
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From the proton NMR analysis of 5(6)-carboxyrhodamine 2.36, one third of the 
carboxyrhodamine corresponds to the isomer 6 which was also confirmed by the 
HPLC peak areas (Appendix 2-1). Isomer 6 of the Rho-9mer peptoid came first at 
3.625 minutes, while the isomer 5 had a retention time of 3.757 minutes. 
The successfully labelled peptoid could be now used to study its properties as a 
cellular delivery device. 
 
2.3. In vitro studies of Rho-9mer 
In order to study more deeply the efficiency of the 9mer lysine-like peptoid, the 
cellular uptake of the Rho-9mer peptoid (2.37) was tested in several cell lines and 
primary immune cells. The various cells were analysed using techniques such as flow 
cytometry and/or microscopy. The cytotoxicity of the labelled 9mer was also 
evaluated while mechanistical studies of the uptake were also carried out. 
 
2.3.1. Cellular uptake 
2.3.1.1. Flow cytometry analysis 
Flow cytometry (Figure 2.3) is an analytical technique based on light scattering, 
excitation and emission of fluorophores. This method can generate various data for 
cells or particles in the size range of 0.5 to 40 μm diameter. In cellular analysis, it can 
be applied to an important range of studies such as cell counting and fluorophore 
analysis. The flow analyser performs these studies by passing thousands of cells per 
second through a laser beam and capturing the emerging light. 
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Figure 2.3: Pictorial representation of the flow cytometer. 
SS: Side Scatter; FS: Forward Scatter 
 
 
When a molecule passes through the laser, light is reflected in many directions. 
Forward scatter (FS) corresponds to the amount of light “going forward”. This type 
of emerging light is proportional to the size of the cell passing through at a precise 
moment (Figure 2.4-A, X axis: small size toward the left). Side scatter (SS) refers to 
the light going to all angles, except forward. Usually the detector of SS is located at 
90 degrees from the original laser path. This light derivation can be caused by 
granularity on the surface or by the complexity inside the cell (Figure 2.4-A, Y axis: 
low complexity toward the bottom). FS and SS data can be plotted as a histogram in 
order to give us information about cell size and complexity.
138
 
Fluorescence is another parameter that can be analysed by flow cytometry. When the 
fluorophore on the particle of interest is struck by the laser (at the proper 
wavelength), a fluorescent signal is emitted. This signal travels on the same path as 
SS (usually analysed at 90
o
 to the particle) toward its specific detector.  
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Figure 2.4: Flow cytometry histograms of HeLa cells. 
A) Histogram of the FS against the SS of the untreated cells with P1 corresponding to the healthy 
population of HeLa cells, P2 corresponding to dying cells and the yellow color to other particles 
including cell debris and cell agglomerates; B) Analysis of number of cells against fluorescence; Grey 
peak: cell population before peptoid incubation; Red peak: cell population after peptoid incubation (10 
μM of Rho-9Mer (2.37) for 24 hours). SSC axis: Complexicity level; FSC axis: Analyte size; PE axis: 
Rhodamine fluorescence intensity. 
 
Fluorescent data can be plotted, like FS and SS data, as a histogram (Figure 2.4-A). 
Typically, the fluorescence is plotted on the X axis while the Y axis refers to the 
number of events (cells) passing through the laser (Figure 2.4-B). 
 
The cellular uptake of Rho-9mer (2.37) was evaluated in three different cell lines: 
-HeLa: Helacyton Gartleri, human cervical tumour cells, 
- B16F10: Murine melanoma cells, 
- HEK293T: Human embryonic kidney 293T cells. 
The cells were labelled at 37
o
C using 10 μM of peptoid for incubation times of 5 
minutes, 30 minutes, 2 hours, 4 hours and 24 hours. Afterwards, the cells were 
washed and detached. Prior to analysis by flow cytometry, extracellular fluorescence 
needs to be quenched. Indeed, it is essential to distinguish intracellular peptoids from 
those contained on the membrane. To do so, the cells were mixed with a solution of 
trypan blue (2.38, Figure 2.5) (0.2% trypan blue in foetal bovine serum 
(FBS)/phosphate buffered saline (PBS)). Trypan blue is an intercalating dye 
(excitation ~ 520 nm and emission ~ 650 nm) that is unable to penetrate in healthy 
cells. Instead, it coats the exterior surface of cell membrane. Any fluorophore 
emitting at less than 610 nm and localised on the cellular membrane will be 
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Figure 2.5: Structure of trypan blue (2.38). 
 
Cellular uptake by various cell lines was measured by flow cytometry and was 
represented in the following graphs. Labelling time of the whole population of cells 
was first measured for Rho-9mer peptoid (2.37) (Graph 2.1-A). Then, the cellular 
uptake of Rho-9mer (2.37) was compared with the one of naked rhodamine dye 
(2.36) (as a negative control) (Graph 2.1-B) thanks to the fluorescence intensity of 
cells. 
 
Uptake was found to be high across all the cell lines analysed with at least 95% of 
cells labelled after 24 hours of incubation with the Rho-9mer (2.37) (Graph 2.1-A). 
Cellular penetration was dependent on the incubation time and the cell lines. 
HEK293T cells showed an impressive and quick cellular uptake (> 90% in 2 hours), 
while for B16F10 cancer cells, which can be more difficult to deliver external cargo 
to, this high level of penetration was obtained after 4 hours. 90% of the HeLa cells, 
another type of cancer cells, were penetrated by the nonalysine-like peptoid after 
only 30 minutes of incubation with the compound.  These data clearly illustrated that 
Rho-9mer (2.37) was able to label the whole population of cells in less than 24 hours.  
The relative fluorescence intensity of cells treated with Rho-9mer (2.37) was 
compared to carboxyrhodamine (2.36). Unsurprisingly, Rho-9mer (2.37) showed a 
much greater cellular uptake than naked Rhodamine (2.36). After 24 hours of 
incubation, cells treated with the Rho-9mer showed fluorescence intensity at least six 
times superior to the ones treated by the naked dye (Graph 2.1-B). Furthermore, the 
amount of uncoupled rhodamine inside the cells started to decrease after 4 hours of 
incubation suggesting diffused out, while the rhodamine labelled peptoid showed 
increasing cellular penetration. 
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         A) Uptake of Rho-9mer                          B) Comparison of cellular uptake 
between Rho-9mer (Red) and 
   Rhodamine (Orange) 
 
Graph 2.1: Uptake of Rho-9mer (2.37) and free 5(6)-carboxyrhodamine (2.36) (10 μM). 
A) % uptake measured for Rho-9mer (2.37) as the % of cells with a fluorescent emission exceeding 
untreated control as 0% uptake; B) Relative fluorescence intensity inside the cell for free 5(6)-
carboxyrhodamine (2.36) and Rho-9mer (2.37). The errors bar represents the standard error of the 
average (n = 3).  
 
By comparing the percentage of cellular uptake and the relative fluorescence 
intensity, it was shown that even though the whole population of cells were labelled 
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by the peptoid, the Rho-9mer was still able to penetrate the cells. For instance, all the 
HeLa cells were labelled by the peptoid after 4 hours (2006 units of fluorescence) but 
after 24 hours the units of fluorescence were doubled. 
The cellular uptake of Rho-9mer peptoid (2.37) was also tested in immune cells 
during a collaboration with Dr. Stefano Caserta (from Professor Rose Zamoyska 
group). Three different cells were incubated for 1 hour with 1 and 10 μM of 2.37: 
- S2 - Drosophila cells: Drosophila melanogaster embryos Schneider 2 
(S2) cells.   
- Primary LN-derived cells: Primary Lymph Node-Derived cells. 
- F5 hybridoma cells: mouse T cell hybridoma, F5. 
 
 
                    
   
Figure 2.6: Uptake of Rho-9mer (2.37) in immune cells. 
A) S2 - Drosophila cells; B) F5 hybridoma cells; C) Primary LN-derived cells. Cells were labelled for 
1 hour at 37
o
C using 1 (blue line) and 10 μM (green line) of Rho-9mer (2.37). The percentage of 
cellular uptake measured as the percentage of cells with a fluorescent emission exceeding untreated 
cells. Control cell population was taken as 0% of uptake. PE axis: Rhodamine fluorescence intensity. 
Data courtesy of Dr. Stefano Caserta from the Institute of Immunology & Infection Research (Prof. 
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The histograms (Figure 2.6) clearly showed that the rhodamine peptoid (2.37) was 
able to penetrate within the three primary immune cell types after 1 hour of 
incubation using 10 μM peptoid with the following cellular uptake: 
- 58% for S2 Drosophila, 
- 89% for mouse F5 hybridoma, 
- 76% for primary LN-derived cells. 
 
2.3.1.2. Microscopy analysis 
Flow cytometry results were confirmed using microscopic techniques. Live cells 
images were taken using a Leica fluorescence microscope after a simple PBS wash to 
remove of the excess fluorescent probe.  
 
 
Figure 2.7: Live HeLa cells imaging with a Leica fluorescent microscope.  
These images were taken after incubation of the HeLa cells for 4 hours at 37
o
C with 10 μM of Rho-
9mer (2.37). A) Brightfield image; B) Rhodamine fluorescent image (excitation 515-560 nm) (peptoid 
as red spots); C) Fluorescence image merge with brightfield. 
 
Using this technique, the presence of Rho-9mer (2.37) inside HeLa cells could be 
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and C). However, this method is not precise enough to say if the cell penetrating 
peptoid is inside the cells or in the membrane. A more defined technique, called 
confocal microscopy, allows more precise pictures of the peptoid location inside 
cells. In order to do so, cells can be alive or fixed onto glass cover slips. 
Confocal microscopy is an optical technique based on the use of pinhole and point-
by-point illumination. Using this method, cells are imaged as a succession of slices 
(‘Z-slices’) taken along the vertical axis. At any one time, only one “slice” of cell is 
in focus. After acquisition, the slices can be stacked together and reconstructed to 
generate a 3-D model. In comparison with the standard fluorescence microscopy, this 
technique offers much sharper images by excluding most of the light from the 
specimen that is not within the microscope’s focal plane. 
 
 
Figure 2.8: Pictorial representation of confocal microscopy 
 
For confocal microscopy study, the cells were cultured on sterilised cover slips. After 
incubation (24 hours) with the Rho-9mer (2.37, concentration of 10 μM), the cells 
were washed with PBS and fixed using 4% paraformaldehyde. Nuclei were stained 
with HOECHST-33342 and membranes were labelled with 1,1’-dioctadecyl-
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3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DilC18). The confocal images 
(Figure 2.9) clearly showed the intracellular presence of Rho-9mer (red dots).  
 
 
       
       
Figure 2.9: Confocal images of HEK 293T labelled with Rho-9Mer (2.37) (10 μM) for 24 hours 
A) Nuclei staining using HOECHST-33342 (excitation at 405 nm and emission filter 413-482 nm); B) 
Cellular labelling with Rho-9mer (excitation laser 561 nm and emission filter 567-630 nm); C) 
Membrane staining with DilC 18 (excitation at 595 nm and emission filter 670-690 nm); D) 
Composite image. The arrows show the localisation of the Rho-9mer inside the cells. 
 
2.3.1.3. Mechanistical studies 
 
In order to confirm the possible uptake mechanism, a simple study of the effects of 
the temperature onto the cellular uptake of the rhodamine penetrating peptoid (2.37) 
was carried out. Low temperatures can have a substantial effect on cellular uptake. 
Energy dependant mechanisms, such as endocytosis, are generally ‘blocked’ as the 
transformation of ATP onto ADT dramatically slows down.
142
 As far as the energy 
free mechanisms are concerned, the decrease of temperature will result in a 
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HEK293T and HeLa cells were incubated for 3 hours with Rho-9mer (2.37) at 
several temperatures (4, 20 and 37
o




Figure 2.10: Effect of temperature on the cellular uptake of the Rho-9mer peptoid (2.37) (10 
µM, 3 hours). 
Top graphs: Flow cytometry analysis: A) HeLa uptake; B) HEK293T uptake; 
Lower images: A-1) Brightfield image of HeLa cells incubated at 20
o
C; A-2) Fluorescence image 
merge with brightfield of HeLa cells incubated at 20
o
C; B-1) Brightfield image of HEK293T cells 
incubated at 4
o
C; B-2) Fluorescence image merge with brightfield of HEK293T cells incubated at 
4
o
C. The errors bar represents the standard error of the average (n = 6).  
 
Flow cytometry results (Figure 2.10-A and B) showed that peptoid uptake was 




C, uptake by both 
cell lines slightly decreased. As expected, at 4
o
C cellular access of Rho-9mer (2.37) 
to both cell lines was dramatically lowered with a maximum uptake of 24% for HeLa 
cells. These results were confirmed by fluorescence microscopy (Figure 2.10), but 
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diverged slightly with the results described by Peretto’s paper.
114
 Indeed, in this work 
from 2003, no internalisation was observed at 4ºC with none of the three fluorescein 
labelled peptoids (3mer, 5mer and 7mer), while only a few cells were showing green 
fluorescence at 20ºC. This difference of results could be explained by the length 
variation of the peptoid. In a previous paper,
104
 a comparison between the Fluo-7mer 
and the Fluo-9mer peptoids showed that using 9mer doubled the amount of  peptoid 
inside the cells. Furthermore, the uptake kinetic increased when cells were treated 
with the longer peptoid.  
In order to confirm the result that some 9mer peptoid was able to penetrate cells 
without involving an energy dependant mechanism the cells were treated with 
sodium azide (NaN3). Sodium azide is known to be a general inhibitor of adenosine 
triphosphate (ATP) production as it interferes with cytochrome oxidase in the 
mitochondria.
144
 In previous work,
114
 treatment of cells by NaN3 has shown a total 
inhibition of polylysine-like peptoid (n = 3, 5 and 7) uptake. Therefore in this 
experiment HeLa and HEK293T cells were analysed using the same conditions. Both 
cell lines were treated with 0.5% of sodium azide for 30 minutes before being 
exposed to Rho-9mer peptoid (2.37) (10 µM).
114 
After 3 hours of incubation with the 
Rho-9mer, the cells were analysed by flow cytometry and the results are summarised 
in Graph 2.2. 
 
Graph 2.2: Effect of sodium azide on cellular uptake of Rho-9mer (2.37). 
Red represents the uptake of Rho-9mer (10 µM) without ATP inhibition. The hatched red represents 
the uptake of Rho-9mer (10 µM) under ATP inhibition by 0.5% of sodium azide. The errors bar 
represents the standard error of the average (n = 6).  
 
In opposition to the previous study,
114
 0.5% sodium azide did not completely inhibit 
the Rho-9mer internalisation. The peptoid uptake decreased to 36% in HeLa cells 
and to 23% in HEK293T cells. These results showed that there are multiple uptake 
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routes. The main mechanism for cellular uptake of the 9mer polylysine-like peptoid 
involves an energy dependent mechanism involving the formation of vesicles. Indeed 
during both microscopic studies, peptoids appeared like red dots inside cells (Figure 
2.9 and Figure 2.10). This confirms the previous observations obtained using Fluo-
9mer.
104
 Even though the main cellular uptake mechanism seems to be endocytosis, 
results (low temperature and sodium azide) have demonstrated the ability of the 
peptoids to penetrate the cells using other pathways that do not require ATP. This 
energy free penetration could be carried out thanks to the high number of positive 
charges on the 9mer peptoid. This finding is not surprising: various cationic cell 
penetrating peptides are known to use both type of mechanisms.
145,75.
   
 
2.3.2. Cytotoxicity analysis 
Cellular uptake of the Rho-9mer peptoid has been shown to be high in various cell 
lines. However, it is essential for the future of this compound as a cellular transporter 
that it does not exhibit cytotoxicity in cells.  
In order to evaluate the toxic potential of the 9mer peptoid (2.37), MTT assays were 
carried out on HEK293T, HeLa and B16F10 cells. This test measured the cellular 
enzymatic activity. Cells were incubated using several concentrations of Rho-9mer 
(0, 1, 5, 10 and 20 μM). At the end of the incubation time, a solution of MTT (2.39) 
was added to the washed cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) is a tetrazole dye which is able to freely diffuse in 
healthy cells. Once inside, the soluble dye is reduced by mitochondria enzymes to 
form purple insoluble formazan crystals.
146
 After 3 hours, the insoluble dye was 
dissolved and the absorbance measured at 570 nm. 
 
Figure 2.11: Structure of MTT (2.39). 
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Graph 2.3 summarises the effect of various concentrations of Rho-9mer peptoid 
2.37 (1, 5, 10 and 20 μM) on the health of HEK293T, HeLa and B16F10 cells. After 




Graph 2.3: MTT assays to evaluate the cytotoxicity of Rho-9mer, 2.37.  
A) HEK293T; B) HeLa and C) B16F10 cells treated with 1, 5, 10 and 20 μM of Rho-9mer for 24 
hours prior to MTT analysis. The errors bar represents the standard error of the average (n = 10). 
 
Cytooxicity of the Rho-9mer (2.37) was also tested on immune cells (S2 Drosophila, 
mouse F5 hybridoma and primary LN-derived cells). After the exposure to the 
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Figure 2.12: Structure of TO-PRO-3 (2.40).
147 
 
This cyanic dye (absorbance at 642 nm and emission at 661 nm) is a high affinity 
DNA binder but is unable to cross the membrane of healthy cells. In opposition to 
MTT assays, TO-PRO-3 analysis measures the amount of dead cells. Once a cell 
begins to die, its membranes are compromised (cytoplasmic and nuclear) allowing 
TO-PRO-3 to enter to bind to the nuclear DNA.
148
 
The cells were first treated with the Rho-9mer (2.37) (1 and 10 μM) for 1 hour. Prior 
to flow cytometry analysis, TO-PRO-3 was added to each flow tube (final 
concentration 0.25 μM). Both rhodamine and TO-PRO-3 fluorescences were 
measured (Figure 2.13).  
 
In Figure 2.13-A, the histogram showed two populations of labelled primary LN-
derived cells. In order to know if one of the populations corresponded to dead cells, a 
second type of histogram was plotted. In this new graph, the X axis corresponded to 
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Figure 2.13: TO-PRO-3 analysis of primary LN-derived cell viability. 
Cells were treated with 0, 1 and 10 μM of Rho-9mer (2.37) for 1 hour prior TO-PRO-3 analysis. A) 
Histogram plotting the rhodamine fluorescence (X axis) against the number of event (Y axis) before 
gating; B) Histogram plotting the rhodamine fluorescence (X axis) against the number of event after  
gating; C) Gating of the histogram plotting the TO-PRO-3 fluorescence (X axis) against rhodamine 
fluorescence (Y axis) for untreated cell; D) Gating of the histogram plotting the TO-PRO-3 
fluorescence (X axis) against rhodamine fluorescence (Y axis) for cells treated with 1 μM of Rho-
9mer (2.37) ; E) Gating of the histogram plotting the TO-PRO-3 fluorescence (X axis) against 
rhodamine fluorescence (Y axis) for cells treated with 10 μM of Rho-9mer (2.37). The red arrows 
show the healthy cells, while the black ones point the dead cells. PE axis: Rhodamine fluorescence 
intensity; APC axis: TO-PRO-3 fluorescence intensity. Data courtesy of Dr. Stefano Caserta from the 
Institute of Immunology & Infection Research (Prof. Rose Zamoyska) at the University of Edinburgh. 
 
The healthy cells (low TO-PRO-3 fluorescence) were gated in the histograms 
(Figure 2.13-C, D and E). By doing this selection, the high rhodamine fluorescence 
population (pointed by the black arrows in Figure 2.13-B) was supressed, as only 
healthy cells appeared. Gating allowed a comparison of the percentage of dead cells 
between untreated and treated samples. Rho-9mer (2.37) did not affect the cell 
viability (94.7% of healthy for the negative control and 95.3% for the 10 μM positive 
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hybridoma cells (Appendix 2-2). The results of these studies were summarised in the 
following table (Table 2.2). 
 
Untreated Cells Treated with 1 μM 
of Rho-9mer 
(2.37) 
Treated with 10 




97.4 97.6 98.7 
Mouse F5 
hybridoma cells 
81.7 87.3 84.2 
Table 2.2: Percentage of healthy cells calculated by TO-PRO-3 cytotoxicity assay. 
As shown in the above table, a one hour treatment of S2 Drosophila and mouse F5 
hybridoma cells by 10 μM of Rho-9mer (2.37) did not induce any cytotoxicity.  
 
2.4. Conclusions 
Rhodamine-9mer peptoid was prepared via the monomer synthesis route and SPPS 
and characterised. As expected, the Rho-9mer peptoid (2.37) showed very good 
cellular uptake in various adherent cell lines, both human and murine. In HeLa and 
HEK293T cells, the whole populations of cells were labelled in less than 2 hours at 
37
o
C. This is two times faster than the 7mer polylysine-like peptoid that labelled 
99% of HEK293T cells after 4 hours. Using MTT assays, the non-cytotoxic nature of 
this cellular carrier was confirmed over 24 hours and at a concentration up to 20 μM. 
Rho-9mer was also delivered, without any cytotoxicity (TO-PRO-3 analysis), to 
primary immune cells (S2 Drosophila, mouse F5 hybridoma and primary LN-derived 
cells). Over an hour, the peptoid (10 μM) enabled cellular labelling of at least 50%. 
During the mechanistic studies, the peptoid 2.37 showed some uptake at low 
temperature and when using an inhibitor of ATP synthesis. Even if these results do 
not allow any definitive conclusion about the cellular uptake mechanism of this 
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cellular penetrating peptoid, they do suggest the possibility that this peptoid enters 
cells via several mechanisms. 
 
In the future, cellular delivery of the Rho-9mer peptoid could be compared to known 
CPPs such as TAT, polylysine and polyarginine. In addition, the penetrating pathway 
could be more deeply studied using, for instance, endosomal tracker (e.g. 
LysoTracker Red) to prove the presence of the peptoid within this type of vesicle.
149
 
The endocytosis pathway could also be evaluated more deeply using specific 
inhibitors allowing specific endocytosis inhibition. For instance, the cholesterol 
synthesis could be inhibited using mβ-cyclodextrin
150
 as well as the caveolae-
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CHAPTER 3 : IN VIVO APPLICATIONS OF PEPTOIDS 
LABELLED WITH NEAR-INFRARED DYES 
3.1. Imaging and near-infrared dyes 
3.1.1. Imaging techniques    
Over the past decades, numerous imaging techniques have been developed including 
in the molecular imaging area. Molecular imaging (MI) is a new biomedical 
discipline used in drug development and in diagnosis. This field combines several 
imaging techniques allowing the characterisation, quantification and determination of 
molecular events and pathways, ideally carried out in real-time (without interfering 
with the natural processes).
152
  
Imaging techniques can be divided in two categories:  
1. Morphological and anatomical imaging technologies: computerised tomography 
(CT), magnetic resonance imaging (MRI)
 153
 and ultrasound (US). 
2. Molecular imaging technologies (including cellular changes): optical molecular 
imaging (OMI), positron emission tomography (PET)
154
 and single photon emission 
computerised tomography (SPECT).  
These techniques can be used on their own or by combining two or more of these 
imaging processes (e.g. PET-CT
154
 or PET-MRI) to allow high structural resolution 
images to be obtained. Optical molecular imaging is widely used in cell biology as it 
offers an important number of advantages compared to other imaging methods such 




Even though all the OMI techniques do not require the use of fluorescence probes, 
fluorescent labelling of biomolecules facilitates the visualisation of their location, 
interaction and migration and therefore the understanding of their activities.
156
 Prior 
to performing in vivo fluorescent imaging studies, the choice of an appropriate 
labelling agent is essential. This molecule must not interfere with the innate 
biological functions of the studied cells, tissues or organs and offer suitable 
sensitivity for in vivo detection. Fluorescent optical imaging compounds are usually 
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composed of two units: a dye that allows visualisation and a targeting device that 
enables the covalent or non-covalent interaction with the biological entity of interest. 
 
3.1.2. Cyanine dyes 
Fluorescent molecules are an indispensable part of any fluorescent imaging agent, 
enabling real time analysis as tracking agents or as measures of enzyme activity (e.g. 





Step 1: The emission energy from dye 1 is  
transferred to dye 2 as excitation energy, 











Step 3: Dye 1 is excited and emits.   
Now the dyes are too far apart so 
the emission energy of dye 1 is not  





Figure 3.1: Principle of fluorescence resonance energy transfer (FRET). 
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Many dyes are available either commercially (Figure 3.2) or through laboratory 
synthesis. The main concern is the choice of the suitable one for any specific 
project.
157
 Before selecting a fluorophore is essential to check the auto-fluorescence 
of the organ or cells related to the project. This fluorescence is due to endogenous 
components capable of emitting light at different wavelengths (Table 3.1).
158
  
Organs and components Emission wavelength 
Lung 630-520 nm ratio 
Cervix 450 nm 
Esophagus 480 and 640 nm 
Tryptophan 348 nm 
Collagen 405 nm 
NADH (Nicotinamide adenine 
dinucleotide) 3.1 
440-462 nm 
Carotene (skin) 482 nm 
 
Blood 
Plasma 330-340 nm 
Oxy-hemoglobin 541 and 577 nm 
Porphyrin 590 and 630 nm 
 




In the case of an in vivo study, studies have shown that the autofluorescence of 
organs and tissues is at its maximum emission using blue filter (excitation blue filter 
460-500, emission green filter 505-560 nm), with minimum emission detected using 
NIR filter set (725-775 nm/790-830 nm). Therefore dyes having a maximum 
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Figure 3.2: List of commercially available fluorophores with their λmax and brightness.
157
 
Brightness = ɛ × ɸ, where ɛ is the coefficient of extinction of a molecule at a given wavelength and ɸ 
is the quantum yield of the fluorophore. [Permission, Appendix 1] 
 
 
The repertoire of fluorophores operating in the NIR window (between 650 nm and 
1000nm) is increasing with new dyes such as naphthofluorescein 3.6 (λabs = 595 nm, 
λem = 660 nm, under basic conditions)
157
 and seminaphthofluorones (λem maxima 
from 713 to 757 nm in aqueous solution)
161
 having been synthesised. Polymethine 
cyanine (Cy) dyes, like Cy5 (3.7) and Cy7 (3.8), remain the most common NIR 
fluorophores due to their tunable wavelengths (λem from 506 for Cy2 up to 788 nm 
for Cy7 (3.8)), high coefficient of extinction and good quantum yields (e.g. 0.18 for 
Cy5, 3.7). The generic structure of these dyes corresponds to two nitrogens (one 
positively charged) linked together by a conjugated chain of an odd number of 
carbon. In biology and chemistry, the Cy abbreviation (e.g. 2, 5.5 and 7) refers to the 
core of the dye only. The number following the Cy refers to the number of 
insaturated carbon between the two heteroaromatic cycles (indol). The notation “.5” 
can be added after the carbon referencing number. In that case, the indol group is 
replaced by benzoindol heteroaromatic cycle. The functionnalised group allowing its 
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coupling to a delivery system (carboxylic group) or increasing its solubility 
(sulfonated group) is usually omitted.  
One of the most attractive subgroups is the indocyanine type (Figure 3.3) that, in 
contrast with other cyanine dyes, avoids self-aggregation when sulfonated.
160
 In 
addition, since the discovery of cyanine dyes in 1856, the synthesis of this subclass 
NIR dyes has been widely studied and improved.
162
 Today, indocyanine dyes can be 





Figure 3.3: General structure of indocarbocyanine dye.
162
 
n = 1, 3, 5, 7; R1, R2, R9, R10 = H, -(CH=CH)2-, SO3
-
; R3, R4, R7, R8 = H, CH3, -(CH2)n-COOH; R5 and 




3.1.3. Cell mediated delivery of cyanine dyes 
Once the fluorophore is chosen, labelling of the cells or organs of interest can be 
carried out. Physical cellular penetration can be carried out using the methods 
described in CHAPTER 1. These techniques (e.g. electroporation) generate 
disturbance in the cell membrane allowing the penetration of the dye present in the 
surrounding environment. Chemical modification of the dye (often by sulfonation) 
aims to make the fluorophore more hydrophilic and less susceptible to aggregation in 
water.
164
 Cellular uptake and cellular retention is mainly due to the relative 
hydrophobicity/hydrophilicity properties of these sulfonated species.
165
 Sulfonated 
cyanines have been used to label tumour cells, tissues and to image cancer.
166
  
The most famous of these dyes is the indocyanine green (3.9, Figure 3.4, λabs = 805 
nm and λem = 835 nm in water). Since 1959, the FDA (U.S. food and drug 
administration) approved its intravenous application for diagnostic purposes. This 
dye is mainly used in determination of cardiac output, liver function diagnostics 
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Figure 3.4: Structure of the indocyanine green (3.9) 
 
 







 can be coupled to cyanine dyes and used as imaging agents. As far as 
peptoids are concerned, no studies have described peptoids coupled to an NIR dye 
and then applied in molecular imaging. The imaging applications reported with 
peptoids (as labelling agents) were the MRI and PET analysis of the tumours.  
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In 2010, a peptoid dimer known (3.10, Figure 3.5) to have a high affinity for the 
vascular endothelial growth factor receptor 2 (VEGFR2) was conjugated to eight 
molecules of gadolinium (Gd
3+
). The peptoid 3.11 was used to target and analysed 
via MRI tumours in mice.
171
 The same peptoid dimer (3.10, Figure 3.5) was also 
applied to analyse the vascular activity of a tumour in a prostate cancer mouse model 
using PET imaging. For this study, the peptoid 3.10 was conjugated with 
64
Cu (3.12, 




In this project, carried out in collaboration with Dr. Kevin Dhaliwal, the first aim was 
to synthesise a peptoid coupled to a NIR cyanine dye. 9mer lysine-like peptoids were 
covalently linked to carboxy-Cy5.5 and carboxy-Cy7 dyes. The second aim was to 
test the cellular uptake of these peptoids into various cell lines and evaluate their 
cytotoxicity. The final aim was to apply this cellular labelling to in vivo models of 
inflammation leading to a greater understanding of the migration and trafficking of 
primary cells. Macrophages, neutrophils and monocytes were labelled ex vivo before 
being injected into mouse models of inflammation. Cell migration was tracked using 
OMI, tomographic imaging or MI coupled to X-ray.
173, 174 
 
3.2. Synthesis of peptoids labelled with NIR dyes  
3.2.1. Catch-and-release synthesis of carboxy-Cy7 and carboxy-Cy5.5 
The modified Cy7 (3.20) and Cy5.5 dyes (3.26) were synthesised using a microwave 
assisted catch-and-release strategy (Scheme 3.3) developed in 2008 by Lopalco.
163 
This strategy allowed the synthesis of any cyanine dye with low time consuming 
purifications and high final yield. The first step to access carboxy-Cy7 (3.20) and 
carboxy-Cy5.5 (3.26) was the preparation of 4-aminophenol resin (3.16) (Scheme 
3.1).  N-
t
butyloxycarbonyl-4-hydroxyaniline PS resin (3.15) was synthesised by 
nucleophilic substitution of chloromethyl resin (3.13) (Merrifield resin, 1% DVB 
cross-linking) by N-
t
butyloxycarbonyl-4-hydroxyaniline (3.14), monitored using the 
chloromethyl group colorimetric test.
175
 The formation of the desired resin was 
confirmed by IR analysis (peak at 1687 cm
-1
, C=O stretch of the Boc group). The 
Boc protecting group was removed by treatment of the resin 3.15 with a solution of 
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20% TFA in DCM. The formation of 3.16 was monitored by ninhydrin colorimetric 
test
129




Scheme 3.1: Preparation of the 4-aminophenyl resin (3.16). 
 
The synthesis of carboxy-Cy7 (3.20, Scheme 3.3) was carried out in two steps from 
the unprotected 4-aminophenol resin (3.16). The first step was the formation of the 
polymer-bound polyene-precursor 3.18 by loading of the hemicyanine intermediate 
3.17 onto the solid support 3.16. Compound 3.17 was synthesised in solution by 
nucleophilic attack of the quaternary indoleninium salt (3.28) onto the 
glutaconaldehyde dianilido hydrochloride (3.27) and acetylated using acetic 
anhydride (Scheme 3.2).
164
 The formation of the desired hemicyanine intermediate 
3.17 was monitored by UV/vis spectrometry to reduce the formation of the undesired 
symmetrical dye. Hemicyanine (3.17) had a maximum absorption around 489 nm 
while the starting material (3.28) absorbed at 290 nm and the symmetrical cyanine 
fluorophore at 750 nm. The compound 3.17 was isolated by precipitation in cold 
ether as a red solid (75%). 
 
 
Scheme 3.2: Synthesis of the hemicyanine intermediate (3.17). 
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Scheme 3.3: Catch and release synthesis of the modified heptamethine dye, carboxy-Cy7 (3.20) 
and the modified pentamethine dye, carboxy-Cy5.5 (3.26). 
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Without further purification, the hemicyanine 3.17 was added to the polymer-bound 
aniline 3.16 giving the polymer-bound polyene-precursor 3.18 via the nucleophilic 
attack of the hemicyanine by the amine on the resin (3.16), generating the 
displacement of a molecule of acetanalide. The PS derivate 3.18 was isolated by 
filtration as a dark blue resin. The unsymmetrical heptamethine dye 3.20 (carboxy-
Cy7) was cleaved from the resin 3.18 by nucleophilic attack of the modified 
quaternary indoleninium salt 3.19 onto the polymer-bound hemicyanine in the 
presence of pyridine and acetic anhydride. Carboxy-Cy7 (3.20) was obtained as a 
green-blue solid in high yield (92% based on the amount of heterocycle (3.19) used) 
and high purity (97%) as determined by HPLC (Figure 3.6) and 
1
H NMR analysis. 
 
 
Figure 3.6: HLPC trace (ESLD) of the crude heptamethine dye carboxy-Cy7 (3.20), purity 97%.  
 
As for the synthesis of the carboxy-Cy7 dye (3.20), preparation of the pentamethine 
dye carboxy-Cy5.5 (3.26) was carried out over three steps using the “catch and 
release” method.  The fluorophore synthesis started with the polymer-bound 
precursor 3.24 (Scheme 3.3). The polyene-chain precursor 3.22 was prepared from 
the 4-aminophenol PS (3.16) using 1,1,3,3-tetramethoxypropane (3.21) in the 
presence of BF3.Et2O (confirmed by a ninhydrin test and changes of colour). 3.16 
had an orange colour while the resin 3.22 was dark blue. Furthermore, the formation 
of the imidate can be confirmed by IR detection of a sharp peak at 1624 cm
-1
 
corresponding to the –C=N– stretch. Once the precursor 3.22 was synthesised, the 
next step was the preparation of the immobilised hemicyanine 3.24 by condensation 
of the quaternised indolenine derivative 3.23 onto the solid support. The 
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condensation reaction was carried out in DMF under microwave irradiation (120
o
C 
for 15 minutes). After filtration and washes, the formation of the desired immobilised 
hemicyanines was confirmed by IR analysis (loss of the sharp peak at 1624 cm
-1
). 
The desired unsymmetrical pentamethine carboxy-Cy5.5 (3.26) was obtained by 
treatment of the modified quaternary indoleninium salt 3.25 onto the polymer-bound 
hemicyanine in the presence of pyridine and acetic anhydride.  
 
 
Figure 3.7: HLPC trace (ELSD) of the crude pentamethine dye carboxy-Cy5.5 (3.26), purity 
100%.  
 
After precipitation in ether and filtration, the carboxy-Cy5.5 3.26 was obtained as a 
green-blue solid with high yield (90% based on 3.25) and high purity (100%) 
determined by HPLC (Figure 3.7) and 
1
H NMR analysis. 
 
3.2.2. Preparation of peptoids labelled with NIR dyes  
In order to deliver cyanine dyes into cells, carboxy-Cy7 (3.20) and carboxy-Cy5.5 
(3.26) were coupled to the lysine-like peptoids functionalised with an aminohexanoic 
spacer (2.35 for 9mer (CHAPTER 2) and 3.33 for 1mer). After Fmoc deprotection, 
the solid supports were coupled to the dyes (3.20 and 3.26, Scheme 3.4) with two 
activation techniques evaluated: a succimido (OSu) active ester or a 1-
hydroxybenzotriazole (OBt) active ester.  
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Scheme 3.4: Synthesis the cyanine dye labelled peptoids. 
Cy7-9mer (3.28), Cy5.5-9mer (3.29), Cy7-1mer (3.30) and Cy5.5-1mer (3.31).  
 
The first method (OSu active ester) was previously applied by Maria Lopalco to 
couple cyanine dyes for the synthesis of enzymatically cleavable fluorescent 
nucleotides.
176
 This method was applied to these dyes as it allowed recovery of 
unreacted cyanine dyes. The carboxylic group of the carboxy-Cy7 (3.20) was 
activated using N,N’-disuccinimidyl carbonate (DSC) (reaction was monitored by 
HPLC and MS until completion). After precipitation, the activated cyanine dye was 
added to the previously Fmoc deprotected resin 2.35 and coupling completion 
monitored by a ninhydrin test. Unfortunately, this coupling method was not very 
efficient and had to be repeated in order to label all the free amino groups. The NHS-
Cy7 was very sensitive to hydrolysis and free cyanine dye (3.20) was recovered after 
coupling. Resin-bound labelled Cy7-peptoid was deprotected and cleaved from the 
solid support by treatment with a mixture of TFA/TIS/H2O (95: 2.5: 2.5) for 2 hours. 
The resulting product was impure mainly due to incomplete coupling. Once purified, 
the Cy7-9mer (3.28) (Figure 3.8) was isolated as a green-blue solid in a final yield of 
60% (calculated from the theoretical loading of 2.35) and a purity of 98% (ELSD). 
Although the desired compound was successfully synthesised, HOBt activation was 
tested to increase the yield and avoid purification. 
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Figure 3.8: Structure of Cy7-9mer (3.28) and Cy7-1mer (3.30). 
 
HOBt activation of cyanine dyes was previously described by Lois Alexander to 
couple carboxy-Cy5 and carboxy-Cy7 onto microspheres. The drawback of this 
synthesis was the number of equivalents used (10 equivalents of the dye, HOBt, 
PyBOP and DIPEA).
177
 The HOBt/DIC coupling method was previously used to 
prepare nonalysine-like peptoids and was efficient for the coupling of rhodamine 
onto the 9mer peptoid (CHAPTER 2) with only three equivalents of each reagent. 
Therefore, HOBt/DIC was applied to couple the carboxy-Cy7 (3.20) to the Fmoc 
deprotected resin (2.35). After activation of the dye (mixture of 3.20, HOBt and DIC 
in DMF), it was added to the resin and mixed for four hours. The coupling was 
monitored by ninhydrin test. Before running the colorimetric test, the resin 
supporting the Cy7-9mer was washed extensively to avoid Cy7 trace. The reaction 
was complete after only one coupling. Cleavage and deprotection of Cy7-9mer (3.28) 
(TFA/TIS/H2O, 95:2.5:2.5) gave a green-blue solid (isolated after precipitation in 
Et2O). MS (MALDI-TOF) and NMR analysis confirmed the synthesis of the 
compound while HPLC (Figure 3.9-B) showed the purity of 3.28 as 98% (ELSD) 
with a yield of 94% (calculated from the theoretical loading of 2.35).  
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Figure 3.9: Analysis of the crude Cy7-9mer (3.28) obtained with HOBt/DIC activation. 
A) Emission spectrum of Cy7-9Mer peptoid 3.28 in MeOH (λabs = 744 nm, λem = 777 nm); B) 
HPLC trace (λ = 750 nm) of Cy7-9mer peptoid 3.28, purity > 98% 
 
Cy5.5-9mer (3.29, Figure 3.10) was synthesised using the same protocol (HOBt/DIC 
activation) as Cy7-9mer (3.28, Scheme 3.4). The Cy5.5-9mer peptoid (3.29) was 
cleaved and deprotected (TFA/TIS/H2O, 95: 2.5: 2.5) to give after precipitation (cold 
Et2O) a blue solid in a yield of 87% (based on the theoretical loading of 2.35) and a 
purity of 97% (HPLC (Figure 3.11-B) and confirmed by 
1
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Figure 3.11: Analysis of the Cy5.5-9mer (3.29). 
A) Emission spectrum of Cy5.5-9Mer peptoid 3.29 in MeOH (λabs = 678 nm, λem = 710 nm); 
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As a negative control was required for cell analysis and as both carboxy-cyanine 
dyes (3.20 and 3.26) were not soluble in water (unless addition of DMSO), Cy7-
1mer (3.30, Figure 3.8) and Cy5.5-1mer (3.31, Figure 3.10) were synthesised using 
the same protocol as their 9mer analogues (Scheme 3.4). 
 
3.3. In vitro assays 
3.3.1. Cell labelling 
 
The cellular uptake of Cy7-9mer 3.28 and Cy5.5-9mer 3.29 by HeLa, B16F10 and 
HEK293T cells was carried out with a 10 μM peptoid concentration. The cells were 
incubated with the peptoids at 37
o
C for 5 minutes, 30 minutes, 2 hours, 4 hours and 
24 hours. Afterwards, the cells were washed, trypsinated and analysed by flow 
cytometry. Results of representative cellular uptakes are shown in the Graph 3.1. 
Uptake was found to be high across all the cell lines analysed with at least 95% of 
cells labelled after 24 hours of incubation with the Cy-9mer (3.28 and 3.29). Cellular 
penetration was dependent on the incubation time and the cell lines but the type of 
cyanine dye did not affect the uptake. HEK293T cells showed an impressive and 
quick cellular uptake (> 90% in only 30 minutes). Surprisingly, B16F10 cancer cells, 
which are known to be more difficult to deliver external cargo to, showed a high 
level of penetration (> 90%) after 2 hours. More than 80% of the HeLa cells (82% 
with Cy7-9mer and 99% with Cy5.5-9mer), another type of cancer cells, were 
penetrated by the nonalysine like peptoid after only 30 minutes of incubation.  
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Graph 3.1: Cellular uptake of Cy7-9mer (3.28, blue) and Cy5.5-9mer (3.29, green).  
 A) HeLa cells; B) B16F10 cells; C) HEK293T cells. % uptake was measured as the % of cells with a 
fluorescent emission exceeding untreated control cells, which were defined as 0% uptake. Compound 
concentration 10 μM. The errors bar represents the standard error of the average (n = 6).  
 
3.3.2. Cytotoxicity assays 
Cellular uptake of both peptoids, Cy7-9mer (3.28) and Cy5.5-9mer (3.29), was 
shown to be high in various cell lines. Cell viability of HEK293T, HeLa and B16F10 
cells was tested against Cy7-9mer and Cy5.5-9mer at various concentrations (1, 5, 10 
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             MTT with Cy7 peptoids                         MTT with Cy5.5 peptoids 
 
 
Graph 3.2: MTT results to evaluate cellular viability of cyanine peptoids.  
HEK293T,  HeLa and B16F10 cells in presence of  1, 5, 10 and 20 μM of peptoids ( Cy7-9mer (3.28), 
Cy5.5-9mer (3.29), Cy7-1mer (3.30) and Cy5.5-1mer (3.31)) for 24 hours before being treated with 
MTT. The errors bar represents the standard error of the average (n = 5).  
 
Surprisingly, both cyanine peptoids demonstrated some cytotoxicity in all the tested 
cell lines (Graph 3.2).  Indeed, with 10 µM of Cy7-9mer (3.28) and Cy5.5-9mer 
(3.29), less than 60% of the cells were viable. These results were very surprising 
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after the non-cytotoxicity of the Rho-9mer peptoid shown in CHAPTER 2 (Graph 
2.3) and in previous papers.
104, 114 
However, several studies have reported the 
cytotoxicity of cyanine dyes when delivered into cells even at low concentration (1 
µM for 4 hours).
178,179
 For instance, Cy5.5 labelled nanoparticles showed cellular 
toxicity in HeLa cells when incubated at a concentration of 20 µg/mL.
180
 As far as 
the Cy7 was concerned, nothing about its cytotoxicity has been published so far in 
the literature.
181
 Therefore, the cytotoxicity of the Cy-9mer could be due to the dye. 
Although the cytotoxicity of the cyanine-1mer peptoids was less than for the 
cyanine-9mer peptoids, MTT assays showed similar results (Graph 3.2). As the 
Cy7-1mer (3.30) and Cy5.5-1mer (3.31) had a lower uptake than their 9mer 
analogues (Appendix 3), they were less toxic to cells. Cyanine-1mer peptoids 
demonstrated a maximum cytotoxicity with 50% of viable cells (HeLa) after 24 
hours of incubation at 20 μM, while cyanine-9mers showed, under the same 
conditions, a maximum of 42% healthy cells. 
MTT assays were carried out on unlabelled peptoid (3.32) (Figure 3.12-A) to prove 
the non cytotoxicity of the cellular transporter. In order to compare the cytotoxicity 
of each peptoid, MTT assays were done using the same conditions for all of them 
(concentrations of peptoids = 1, 5, 10 and 20 μM, 24 hour incubation time, 37
o
C) on 
the HEK293T, HeLa and B16F10 cells. 
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Figure 3.12: Structure of H-Ahx-9mer (3.32) and its cellular viability. 
A) Structure of the H-Ahx-9mer (3.32); B) MTT assay in HEK293 T cells; C) MTT assay in HeLa 
cells; D) MTT assay in B16F10 cells. The errors bar represents the standard error of the average  
(n = 5).  
 
As far as the H-Ahx-9mer (3.32) was concerned, MTT assays did not show any 
cytotoxicity. This result was obtained for all cell lines tested and for all the peptoid 
concentrations (Figure 3.12).   
 
In view of these data, in vivo applications did not seem possible. Therefore, it was 
important to find an incubation time and a concentration that would allow good 
cellular penetration without cytotoxicity. Cells (HeLa and HEK293T cells) were 
treated with 5 μM of Cy7-9mer (3.28) and Cy5.5-9mer (3.29) for 15 and 30 minutes 
prior to cytotoxicity analysis (MTT assays, Graph 3.3).  
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Graph 3.3: MTT results to evaluate cellular viability of cyanine peptoids.  
HeLa (A) and HEK293T (B) cells in presence of 5 μM of peptoids (Cy7-9mer (3.28), Cy5.5-9mer 
(3.29), Cy7-1mer (3.30) and Cy5.5-1mer (3.31)) for 15 and 30 minutes before being treated with 
MTT. The errors bar represents the standard error of the average (n = 5).  
 
As demonstrated in Graph 3.3, none of the 4 cyanine peptoids (Cy7-9mer (3.28), 
Cy5.5-9mer (3.29), Cy7-1mer (3.30) and Cy5.5-1mer (3.31)) showed cytotoxicity at 
5 μM with an incubation time for 15 and 30 minutes. Therefore, the cellular labelling 
of Cy7-9mer and Cy5.5-9mer was assessed using the same conditions (5 μM for 15 
and 30 minutes). 
 
 
Graph 3.4: Cellular uptake of Cy7-9mer (3.28) and Cy5.5-9mer (3.29). 
HEK293T (A) and HeLa (B) cells incubated with 5 μM of peptoids (Cy7-9mer (3.28) and Cy5.5-9mer 
(3.29)) for 15 and 30 minutes at 37
o
C. The errors bar represents the standard error of the average (n = 
6). 
 
5 μM of  the cyanine peptoids (Cy7-9mer and Cy5.5-9mer) allowed efficient cellular 
labelling of HeLa and HEK293T cells with at least 80% of the cells labelled after 15 
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minutes of incubation and more than 90% labelled (HeLa) after 30 minutes (Graph 
3.4). These results were confirmed by confocal microscopy. HeLa cells were more 
difficult to label in comparison to HEK293T, therefore they were incubated with 5 
μM of Cy5.5-9mer (3.29) for 30 minutes at 37
o
C. At the end of the incubation time, 
cells were washed with PBS and their membrane and nucleus were stained (Figure 
3.13). 
 
       
       
 
Figure 3.13: Confocal images of HeLa cells labelled with Cy5.5-9mer (3.29) (5 μM) for 30 
minutes. 
A) Nuclei staining using HOECHST-33342 (excitation laser 405 nm and emission filter 413-482 nm); 
B) Cellular labelling with Cy5.5-9mer (excitation laser 633 nm and emission filter 646-762 nm); C) 
Membrane staining with DilC 18 (excitation at 595 nm and emission filter 670-690 nm); D) 
Composite image. The arrows show the localisation of the Cy5.5-9mer inside the cells. 
 
These confocal images clearly show that the Cy5.5-9mer (3.29) was inside the cells 
(appearing as blue dots), confirming cellular uptake of the peptoid within 30 minutes 
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3.4. In vivo studies (collaboration with Dr. Kevin Dhaliwal) 
The first step in the design of new anti-inflammatory treatments is a greater 
understanding of the migration and trafficking of immune cells (such as macrophages 
and neutrophils). Macrophages are a type of white blood cells that are crucial in 
microbial defence. They orchestrate the subsequent innate response. In the case of 
lung infection due to bacteria, macrophages create ‘early’ interactions with the 
pathogens that will command the clearance of bacteria within the lung.
182
 
Neutrophils are another type of white blood cells. They are known as circulating 
granulocytes, filled with neutrally-staining granules (sacs of enzymes) that are 
involved in the killing and digestion of microorganisms. Neutrophils are recruited to 
sites of acute inflammation and constitute the first line of cellular defence against 
bacterial infection. Although they are efficient phagocytes, they are also known to 
cause tissue damage as a result of an imbalance between neutrophil elastase and its 
inhibitor.
183
 Given the potential of neutrophils to injure tissues, the inflammatory 
response has evolved to facilitate their efficient clearance once their phagocytic 
function has been completed. However in some instances, especially in response to 
certain infections, neutrophils may continue to be recruited and in the face of poor 





In order to obtain a better understanding of immune cells, primary cells were labelled 
with Cy7-9mer (3.28) or Cy5.5-9mer (3.29) before being followed inside murine 
bodies. Experiments were carried out on mice aged between 6 and 12 weeks old with 
all animal experiments were undertaken by Dr Kevin Dhaliwal with an approved 
licence from the Animal Scientific Procedure Division of the Home Office, London, 
U.K. 
 
3.4.1. Cellular labelling of primary cells 
Using the data obtained during the in vitro studies, the labelling capacity of both 
Cy7-9mer and Cy5.5-9mer was tested on immune cells. Cellular labelling of murine 
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marrow machrophages by Cy5.5-9mer (3.29) (10 minutes, 4.8 μM) was 
demonstrated by confocal microscopy.  
 
       
       
 
Figure 3.14: Confocal images of freshly-flushed murine marrow macrophages after cells 
labelled with Cy5.5-9mer (3.29) (4.8 μM) for 30 minutes. 
A) Composite image; B) Cy5.5-9mer image (excitation laser 633 nm and emission filter 680-770 nm); 
C) Actin staining with Alexa
555
 (excitation laser 543 nm and emission filter 550-590 nm); D) Nuclei 
staining using DAPI (excitation laser 405 nm and emission filter 415-490 nm). Data courtesy of Dr. 
Kevin Dhaliwal from MRC (Medical Research Council) Centre for Inflammation Research, Queen’s 
Medical Research Centre, University of Edinburgh. 
 
The images (Figure 3.14) showed clearly the intracellular accumulation of the 
peptoids. Similar experiments were carried out by Niel MacDonald on monocytes 




3.4.2. Toxicity assays 
In order to study the optical accessibility of Cy7 labelled peptoids in vivo and to 
evaluate the functional viability of peptoids-treated cells, primary murine 
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simultaneously transfected with a replication-deficient adenovirus encoding 
luciferase. The cells were then instilled (via spontaneously breathing leading in high 
concentration of light around the head) into the murine lung and imaged 24 hours 
later using IVIS SPECTRUM. The Cy7 (Figure 3.15-A) allowed tracking of the 




Figure 3.15: In vivo imaging of primary murine macrophages labelled with Cy7-9mer (3.28) 
(also transfected with adenovirus encoding luciferase) and instilled in murine lungs. 
A)  Image shows fluorescence imaging with Cy7 filters; B) Luminescence imaging of the same animal 
after intraperitoneal luciferin administration. Images captured on the Xenogen Spectrum. Data 
courtesy of Dr. Kevin Dhaliwal from MRC (Medical Research Council) Centre for Inflammation 
Research, Queen’s Medical Research Centre, University of Edinburgh. 
 
 
As expected, Cy7-9mer labelled cells could be easily visualised, thanks to 
fluorescence imaging and were localised in the lungs (Figure 3.15-A). To 
demonstrate the non-toxicity of the Cy7-9mer peptoid (3.28), luciferin was 
intraperitonealy injected. As the cells were transfected with adenovirus encoding 
firefly luciferase, the presence of luciferin would allow the generation of 
luminescence in the same region as the Cy7-9mer (Figure 3.15-B). These images 
showed the bioluminescence and labelling of the macrophages. Therefore, these 
results demonstrated that in vivo the Cy7-9mer (3.28) labelling was retained and did 
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3.4.3. Tracking of cells to inflammation sites 
In vivo studies were extended to assess the dynamic migration and functional 
viability of labelled cells during inflammation over several days. 
Lipopolysaccharides (LPS) were instilled into the lungs of a healthy mouse. The 
presence of LPS generated an inflammation of the murine lungs. Bone marrow-
derived macrophages (BMDMs) were isolated and treated with Cy7-9mer peptoids 
(3.28) (10 minutes). After incubation, BMDMs were washed and injected into the 




Figure 3.16: Tracking of Cy7-9mer (3.28) labelled BMDMs (Bone Marrow-Derived 
Macrophages) on 2 days of LPS injury. 
X-ray superimposed on reflectance fluorescent images on Kodak Multispectral FX Pro (excitation 
745nm, emission 820nm); A) Image after injection day 0; B) Image at day 1; C) Image at day 2. Data 
courtesy of Dr. Kevin Dhaliwal from MRC (Medical Research Council) Centre for Inflammation 
Research, Queen’s Medical Research Centre, University of Edinburgh. 
 
Figure 3.16-A was taken on the day of the cell injection. Labelled primary cells were 
easily localised in the lungs (where the inflammation took place) and in the liver. 
Once the inflammation ended the BMDMs cell migrated the from the inflammation 
site (lungs) to the liver and to the hips (the bone marrow) (Figure 3.16-B). This 
result was confirmed on the image taken two days after LPS injury (Figure 3.16-C). 
This last image showed clearly the localisation of Cy7-9mer (3.28) labelled cells into 
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the liver and the bone marrow. Furthermore, the intensity of fluorescence inside the 
liver decreased between day 1 (Image B) and day 2 (Image C). This diminution could 
be associated with the degradation of the BMDMs and thus of the Cy7 dye.  
So far, in vivo studies showed that using the cyanine-9mer peptoids, primary cells 
could be tracked in lung tissues where the inflammation takes places. Furthermore, 
the cell movements were followed over several days and up to the liver and the bone 
marrow, where macrophages can be regenerated and/or degraded.  
 
3.5. Conclusions 
Cyanine-9mer peptoids, Cy7-9mer (3.28) and Cy5.5-9mer (3.29), have shown rapid 
and efficient cellular labelling of various cell lines (HeLa, B16F10 and HEK293T 
cells) and primary immune cells (macrophages and neutrophils) without cytotoxicity. 
Ex vivo labelling of primary cells by peptoids did not affect their prime functions, 
their movement and their efficiency. Furthermore, thanks to the proteolytic resistance 
of peptoids, cell imaging was possible over a few days. These experiments and the 
cell-labelling characteristics (including remarkably low cytotoxicity) described the 
NIR-labelled 9mer peptoids as a highly attractive tool for optical imaging. 
The next step of this project could be the study of the stability of the peptoid and the 
NIR-infrared dye in vitro and in vivo. This experiment could be carried out using 
longer cell tracking analysis and/or cell lysis. Once lysed, the intracellular content 
could be separated, the peptoid recovered and analysed by HPLC and MS to 
determinate any possible degradation. 
Another perspective could lead to introducing a specific sequence to the peptoid to 
enable cell selectivity. Indeed, one of the main limitations of this cellular penetrating 
system is its poor selectivity to different cells. If this project works, the peptoid could 
be injected intravenously and label only the desired cells. 
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CHAPTER 4 : MACROMOLECULE DELIVERY 
When coupled to dyes, 9mer peptoids have been shown to rapidly, efficiently and 
without cytotoxicity penetrate multiple cell lines including primary cells. 
Furthermore, the peptoids have demonstrated to be applicable for both in vitro and in 
vivo studies. In this chapter, the capacity of the 9mer peptoid was evaluated for its 
ability to deliver macromolecules (peptides, proteins and DNA) into cells.  
4.1. Peptide delivery 
4.1.1. Previous cellular delivery of peptides using CPPs and peptoids 
Cellular delivery of exogenous macromolecules is essential in several scientific 
fields of research as well in the treatment of diseases. Delivery of biologically active 
peptides has been carried out, in vitro and in vivo, using Antennapedia and TAT 
peptides (Table 1.1: peptide strucutre). These two CPPs are known to rapidly and 
efficiently enter cells including non-dividing primary cells.
185
 The peptides of 
interest can be coupled to the CPPs through either ionic or more normally covalent 
bonding.
 
For covalent coupling the conjugates are typically synthesised using solid-
phase peptide synthesis. An important range of peptides have been delivered into 
various cell lines such as cancer cells (HeLa, E49 and BMRPA1), blood cells 
(monocytes and neutrophils), muscle cells and neurons. These biologically active 
peptide-CPPs have been studied for several applications (Table 4.1) including 
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Peptide of interest CPPs used Aim and Cellular response 
Bcl-2 homology (BH3) domain of Bcl-2 





Binding to Bcl-2 leading 




Putative signalling mediator (PSM) 




Positive stimulation of 
PDGF/ IGF/ insulin 
signalling (SH3 domain) 
leading to DNA synthesis 
and proliferation of cells
191
 
β3-integrin cytoplasmic tail 
Tyrosine 747: H-ANNPLYKEATS-OH 
Tyrosine 759: H-FTNITYRGT-OH 
TAT 
 
Inhibition of PI3K leading 




N-terminal influenza hemagglutinin 
peptide derivative: H-LFEAIEGFI-OH 
Polylysine 
 
Creation of cancer 
vaccines
187 
Binding to MHC class I 
haplotype H2-K leading to 
immune system 
recognition and tumour 
cell aptosis 




Inhibition of NF- κB and 







TAT Induce apoptosis by 





Table 4.1: CPP-mediated peptide delivery. 
MHC: major histocompatibility complex; PDGF: platelet-derived growth factor; PI3K: 
phosphoinositide 3-OH kinase; PKI: protein kinase inhibito peptide; PMNs: polymorphonuclear 
leukocytes. 
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In 2008, polylysine-like peptoids (five and nine units) were covalently coupled to a 
nuclear localizing sequence (NLS, PKKKRKV).
194
 After incubating the fluorescein 
labelled peptide-peptoid hybrid (9mer-NLS: 4.1 and 5mer-NLS: 4.2, Figure 4.1) 
with cells (HeLa and 16HBE14o-), flow cytometry analysis demonstrated efficient 
cellular delivery, while confocal microscopy showed co-localization of the 




Figure 4.1: NLS peptide delivery constructs. 
 
The hormone α-MSH (α-melanocyte stimulating hormone, Ac-
SYSMEHFRWGKPV-NH2) is a 13 amino acid peptide that binds to the 
melanocortin 1 receptor expressed on the surface of melanocytes and melanoma 
cells.
195
 In vitro studies have shown α-MSH stimulated pigmentation of melanocytes 
and melanoma cells. Once the hormone binds to melanocortin 1 receptor (MC1R), it 
generates a succession of steps leading to an increased production of eumelanin (one 
of the two type of melanin produced by mammalian melanocytes).
196
 Using the 
peptoid delivery system, two α-MSH peptide-peptoids (4.3 and 4.4, Figure 4.2) were 
synthesised. The 7mer peptoid successfully delivered the hormone into skin and cells 
(confirmed by confocal microscopy and flow cytometry analysis). Ex-vivo mouse, 
pig and human skin model studies demonstrated the skin penetration of the 
compounds 4.3 and 4.4 within these three different skin types. Furthermore, 
pigmentation analysis showed that the conjugation of α-MSH-peptide with the 




- 87 - 
 
 
Figure 4.2: α-MSH (α-melanocyte stimulating hormone) delivery system 
α-MSH = SYSMEHFRWGKPV 
 
4.1.2.  Cellular delivery of peptide inhibitor of MDM2-E3 activity : synthesis 
4.1.2.1. Background 
In cancer research, one short-lived transcription factor has been extensively studied: 
p53. This tumour suppressor protein recognises DNA damage (stand breaks and 
single stranded gaps). Once activated p53 can lead to various biological outcomes 
namely; cell repair or oncogene-induced senescence (growth arrest) or apoptosis. p53 
is mainly controlled by a multidomain nuclear phosphoprotein, MDM2 (murine 
double minute 2 gene). Human MDM2 (Figure 4.3) is a RING-type E3 ubiquitin 
ligase of 491 amino acids that is divided in four regions. Two of these regions allow 
the control p53 through two distinct mechanisms. On one hand, MDM2 (its N-
terminal region) can directly bind to the N-terminus of p53 leading to an inhibition of 
its transcriptional activational function. On the other hand, MDM2 RING finger (C 
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Figure 4.3: Human MDM2 with its four regions.
199, 201
 
p53 binding site on the N-terminus; Acidic and Zn finger in the middle section are binding sites of 
several regulatory factors (including p14
ARF
  an alternate reading frame that hinibits MDM2); Ring 
finger on the C-terminus that includes ATP and MDMx binding sites. E3 ubiquitin ligase activity of 




 which works on the regulation of the E3 ubiquitin ligase activity 
of MDM2,
201
 has isolated a twelve amino acids peptide (KEIQLVIKVFIA) that 
binds to the Ring domain of MDM2. Therefore, the interaction between p53 and 
MDM2 could not occur leading to the inhibition of E3 ubiquitin ligase activity and of 
the proteasomal degradation of p53. However, this peptide is unable to cross the cell 
membrane on its own thus the polylysine-like peptoid was coupled to it with a 
flurorescein dye attached (in order to analyse cellular uptake). 
For this project four peptide-peptoid hybrids were synthesised based on two 12 
amino acids sequences defined by the Ball group: 
- sequence 1 (KEIQLVIKVFIA): peptide of interest (4.16 and 4.18, 
Scheme 4.3) that could bind to MDM2  
- sequence 2 (KEIQLVIKVAAA): negative control (4.17 and 4.19, Scheme 
4.3) that should not bind to the multidomain nuclear phosphoprotein. 
Both of these peptides were prepared using solid-phase synthesis with either an acid 
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4.1.2.2. Synthesis of the fluorescein peptide-peptoid hybrids 
The synthesis of the fluorescein peptide-peptoid hybrids (4.16, 4.17, 4.18 and 4.19) 
began with the synthesis of the supported peptides. 
 
The 2-chlorotrityl linker is known to be very sensitive to moisture leading to a 
substitution of the chloride by a hydroxy group (4.6).
202
 The 2-chlorotrityl chloride 
polystyrene resin (4.5) was first activated in dry DCM in the presence of an excess of 





Scheme 4.1: Activation of hydrolysed 2-chlorotrityl chloride polystyrene resin (4.5). 
 
The 2-chlorotrityl chloride polystyrene resin (4.5) was loaded with Fmoc-Ala-OH 
(4.7) in presence of DIPEA. For all the peptide sequences of this project, the first 
amino acid was alanine. The Fmoc-Ala-2-chlorotrityl polystyrene resin 4.8 was 
Fmoc deprotected (20% piperidine in DMF) to give the H-Ala-2-chlorotrityl 
polystyrene resin (4.9, Scheme 4.2).  
 
Scheme 4.2: Preparation of the H-Ala-2-chlorotrityl polystyrene resin (4.9). 
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The peptides 4.10 and 4.11 on solid support were synthesised manually from the 
resin 4.9 using a DIC/HOBt microwave assisted technique. Peptide couplings were 
performed using three equivalents of protected amino acids, DIC and HOBt in DMF 
(0.2 M) and under microwave irradiation at 60°C for 20 minutes.  Fmoc 
deprotections were carried out at room temperature (2 cycles of 10 minutes). The 
resins 4.12 and 4.13 were also prepared using the same microwave assisted SPPS on 
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Scheme 4.3: Synthesis of the Fluorescein peptide-peptoid hybrids (4.16, 4.17, 4.18 and 4.19). 
Acid peptide-peptoid synthesis in blue using Trityl PS resin and amide peptide-peptoid synthesis in 
red using Rink amide PS resin. Reagents and conditions: Coupling of amino acids, Fmoc-Ahx-OH 
(2.34), Fmoc-Lys(Dde)-OH (4.14) and peptoid monomer (2.22): Acid (3 eq), HOBt (3 eq), DIC (3 eq) 
in DMF (0.2 M), µw 20 minutes, 60
o
C; Fmoc deprotection: 20% piperidine in DMF, 2 cycles of 10 
minutes, rt; Selective Dde deprotection: NH2OH.HCl/imidazole in NMP/CH2Cl2, 3 hours, rt; Coupling 
of 5(6)-carboxyfluorescein (4.15): FAM (5 eq), HOBt (5 eq), DIC (5 eq) in DMF (0.2 M), 4 hours, rt 
followed by washings with 20% piperidine in DMF; Cleavage and deprotection: For 4.16 and 4.17, 
TFA/DCM/TIS (90: 5: 5), 2 hours, rt; For 4.18 and 4.19, TFA/TIS/H2O (95: 2.5: 2.5), 4 hours, rt.  
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The peptide sequence and the cell penetrable peptoid were separated from each 
another using two units of the aminohexanoic acid spacer (Fmoc-Ahx-OH, 2.34) and 
one Fmoc-Lys(Dde)-OH (4.14, prepared from Fmoc-Lys-OH and DdeOH 4.20) 
which was used as the attachment point for the 5(6)-carboxyfluorescein (4.15, 
Scheme 4.3). The nine units of lysine-like N-substituted glycine were coupled using 
the monomer 2.22.  
The 5(6)-carboxyfluorescein 4.15 was attached to the side chain of the Lys spacer. 
The Dde group was deprotected using a mixture of hydroxylamine 
(NH2OH.HCl)/imidazole in N-methyl-2-pyrrolidone (NMP)/DCM.
204
 The 5(6)-
carboxyfluorescein coupling was carried out over 4 hours using 5 equivalents of 
4.15, DIC and HOBt in DMF (0.2 M). The excess of dye and Fmoc group were 
removed by an hour treatment of the resin with 20% piperidine in DMF.
205
 
The fluorescein peptide-peptoid hybrids were cleaved and deprotected using 
TFA/TIS/DCM (90: 5: 5) for 2 hours (4.16 and 4.17) or TFA/TIS/H2O (90: 2.5: 2.5) 
for 4 hours (4.18 and 4.19). After precipitation in cold diethylether, they were 
purified by preparative HPLC (Table 4.2).  
 
Peptide-peptoid hybrids Yield (%) Purity (%) 
4.16 58 99 
4.17 69 98 
4.18 79 100 
4.19 75 100 
 
Table 4.2: Yields and purities of the peptide-peptoid hybrids. 
 Yields were calculated from the loading of respectively the resin 4.10, 4.11, 4.12 and 4,13; Purities 
were measured by HPLC (ELSD). 
 
4.1.3.  In vitro delivery and cytotoxicity assays of the peptide-peptoid hybrids 
The cellular uptake of the fluorescein peptide-peptoid hybrids was tested in HeLa 
cells. For comparison, the peptide 4.21 (synthesis from the resin 4.10, Figure 4.4, 
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yield = 66%, purity ELSD = 99%) was used as negative control, while the peptoid 
4.22 (Fluo-9mer, Figure 4.4)
104
 as positive control.  
            
Figure 4.4: Structure of the peptide 4.21 and the peptoid 4.22 (Fluo-9mer). 
The peptoids 4.16, 4.17, 4.18, 4.19 and 4.22 were dissolved in PBS while the 
negative control 4.21 was dissolved using 10% of DMSO in PBS. Each probe was 
incubated with HeLa cells at a concentration of 10 µM. Incubations were run over 2 
and 24 hours (Graph 4.1).   
 
 
Graph 4.1: Uptake of the Fluorescein peptide-peptoid hybrids.  
 % uptake measured for peptide-peptoid hybrids (4.16, 4.17, 4.18 and 4.19), the peptide (4.21) and the 
Fluo-9mer (4.22). The % of cells with a fluorescent emission exceeding untreated cells as 0% uptake. 
The cells were treated with 10 µM of the desired compound for 2 and 24 hours prior to analysis. The 
errors bar represents the standard error of the average (n = 3).  
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Uptake was found to be high for the peptide-peptoid hybrids and the positive control 
4.22 with at least 69% of labelled cells during the two first hours of incubation with 
the hybrids 4.19. As expected, the cellular uptake was dependent on incubation time 
with longer incubation times resulting in higher uptake (85% after 24 hours with the 
hybrid 4.18). Results were confirmed by microscopy (Figure 4.5). Unsurprisingly, 
the negative control 4.21 penetrated very poorly into the cells.  
 
 
Figure 4.5: Live HeLa cells imaging. 
These images were taken after incubation of the HeLa cells for 4 hours at 37
o
C with 10 μM of 
peptoid-peptide hybrids 4.16 and 4.17. A) Brightfield image; B) Fluorescent image (Fluorescein 
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Graph 4.2 summarises, the effect of various concentrations (5, 10 and 20 μM) of 
peptoid-peptide hybrids 4.16, 4.17, 4.18, 4.19 and Fluo-9mer (4.22) on the health of 
HeLa cells. After 24 hours of incubation, only compound 4.18 showed any 
noticeable cytotoxicity but only at 20 µM with 75% of cells still viable. 4.16 showed 
some reduction in cell viability, but this was within experimental error. These results 
were unsurprising as the binding of the peptide should lead to cell apoptosis. Indeed, 
if as expected the peptide binds with the C-terminus of MDM2 (Ring finger), the E3 
ubiquitin ligase activity is inhibited and the p53 is not degraded anymore, therefore, 
the amount of p53 increases. 
 
Graph 4.2: MTT assays to evaluate the cytotoxicity of peptoid-peptide hybrids and Fluo-9mer 
peptoid. 
HeLa cells in presence of 5, 10 and 20 μM of 4.16, 4.17, 4.18, 4.19 and 4.22 for 24 hours. The errors 
bar represents the standard error of the average (n = 6). 
 
4.1.4.  Conclusions 
The four fluorescein peptide-peptoid hybrids (4.16, 4.17, 4.18 and 4.19) were 
successfully synthesised via solid-phase microwave assisted synthesis with a yield 
between 59% and 79%. The cellular uptake of these probes was shown by flow 
cytometry and microscopy. These results demonstrated and confirmed the ability of 
the 9mer peptoid as a cellular transporter for peptides. As the delivery of this specific 
peptide-sequence was never published, the comparison with another delivery system 
cannot be done. Nevertheless, the peptide-peptoid showed a cellular uptake 
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equivalent to the one of the Fluo-9mer peptoid, which contained a smaller cargo. The 
probes were transferred to the Ball group where they are being analysed to test their 
binding effects with the Ring domain of MDM2. Assays (cellular uptake and 
apoptosis study) are being carried out on a selection of cell lines derived from the 
human tumour cell line (NCI 60 panel). 
 
4.2. Green Fluorescent Protein delivery 
4.2.1. Green Fluorescent Protein: discovery and applications 
Green fluorescent protein (GFP) is a chemiluminescent protein, which was first 
described in 1962 by Shimomura. GFP, a 238 amino acids protein, was isolated from 
the Aequorea jellyfish. When exposed to light (~ 400 nm), GFP emits bright green 
fluorescence with an emission at 508 nm. 
 
Figure 4.6 : GFP, 3D structure. 
3D structure of GFP in which the yellow component corresponds to the chromophore.  
[Modified with permission, Appendix 1] 
 
The fluorescence was identified to come from a chromophore located in the 11-
strand β-barrel. The 4-(p-hydroxybenzylidene)-imidazolid-5-one chromophore (4.23) 
is formed, in the presence of oxygen, by the intramolecular autocatalytic cyclisation 
of 65Ser-Tyr-Gly67 (formation of the imidazolidone moiety by backbone 
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Figure 4.7: GFP, chromophore structure. 
Chemical structure of GFP chromophore 4.23 (one-letter code and number for side chains amino acid 








- Protein tag to visualise and locate proteins of interest within living 
organism, 
- Flurorophore for FRET systems to study cellular mechanism (e.g. lipid 
metabolism), 
- Gene reporter to analyse the activity of a specific gene, 
- Biomarker of tumour cells to track their migrations. 
The importance of this protein was acknowledged by the Nobel Prize in Chemistry 




4.2.2. Previous GFP delivery 
For several applications of GFP, it is essential to take the protein inside cells. One 
way to achieve this could be by using cell penetrating peptides. These carriers could 
directly deliver the protein or the DNA (plasmid) encoding GFP. eGFP is a popular 
synthetic version of the original protein in which the Ser65 was substituted with a 
Thr, Ala or Gly resulting in an increase of the excitation from ~400 nm to ~ 488 
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 In 2007, eGFP was delivered into HeLa cells using a mixture a polyarginine 
and lipids. The principle of this technique was based on the delivery of nucleic acids 
such as plasmid DNA using multifunctional envelope-type nano device (MEND).
210
 
The eGFP was delivered into cells after formation of 3 layers particles around the 
protein. The eGFP was first condensed thanks to stearyl-R8. This first layer 
interacted with the protein via electrostatic interactions between the positive charges 
of the poly-arginine and the negative charges of the protein (aspartic and glutamic 
acid) while the stearyl acid, with hydrophobic character formed a lipid layer. The 
second layer, a mixture of DOPE/CHEMS (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (Figure 1.8)/cholesteryl hemisuccinate 4.24 (Figure 4.8), 9:2) 
was used to form the MEND. However, this structure cannot cross the cell membrane 
without a positively charge surface made by a final treatment on stearyl-R8 (third 
layer). The nanoparticles were delivered into HeLa cells with cellular uptake 





Figure 4.8: Structure of CHEMS (4.24) used for the GFP-R8-MEND (DOPE). 
 
GFP was also delivered via protein transduction.
212
 This technology, first described 
in 1988,
213
 allows the internalisation of protein thanks to the synthesis of fusion 
proteins between a known protein or peptide being able to penetrate into cells (CPP 
or PTD) and the protein of interest. TAT-mediated GFP transduction was carried out 
in several cell types including primary brain cells,
214
 mitochondria of breast cancer 
cells
215
 and protozoan parasites.
216
 The GFP-TAT proteins were prepared via 
expression of a modified vector. The TAT sequence was usually on the C-terminus 
while the purification sequence (hexahistidine-tag) was located on the N-terminus.  
In addition to the purification tag, the GFP-TAT protein could also be fused with 
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another protein or peptides. For instance, in a project aiming at labelling of 
mitochondria of breast cancer cells, the original GFP was modified with a 
mitochondrial targeting signal (MTS) on its N-terminus and the TAT sequence on its 
C-terminus.
215215
 Even though, GFP transduction was mainly mediated by TAT, 




 and others CPPs.
219
  
As far as peptoid cellular transporters are concerned, only one GFP delivery device 
has been reported in the literature. The conjugation of the hexahistidine (His6) tag 
present on the protein to a heptalysine-like peptoid functionalised with two Ni
2+
 
ligands (4.25, Figure 4.9). However only 8.6% (flow cytometry data) of B16F10 
cells were labelled after 24 hours incubation using 10 μM of the heptapeptoid-Ni
2+
-
GFP complexes. The confocal microscopy images confirmed this result as most of 








So far, the cellular delivery of protein (GFP as a model) has not been tested using a 
covalent attached cell penetrating peptoid. Therefore, one of the aims was to deliver 
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GFP using a peptoid via the formation of two types of covalent bond a thiol-
maleimide or an active ester.  
 
4.2.3. GFP delivery via thiol-maleimide chemistry 
4.2.3.1. Thiol-maleimide chemistry an efficient bioconjugation technique 
For decades, maleimides 4.26 (maleic acid imides, Scheme 4.4) have been used as 
crosslinking agent (substance that allows the colavent bonding of two structures 
together) for protein modifications. Maleimides are the product of the reaction of 
maleic anhydride 4.27 and ammonia or any primary amine (Scheme 4.5). Since the 
middle of the 70s, this chemical structure has been used as an alkylation trap for 
sulfonyl groups. Even though, the maleimide can react with the amino group of 
peptides or imidazole of histidine, the nucleophilic attack on the double bond of the 
maleic acid imides by the thiolate anion of cysteine is 1000 times faster than by any 
amine. The optimal pH to create a thioether linkage using this agent is between 6.5 
and 7.5. Above this pH, alkylation of the maleimide with an amine group tends to 
dominate. 
 
Scheme 4.4 : Reactivity of the maleimide compounds. 
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The reaction of the maleic anhydride with an aminoalkaloic acid, such as glycine or 
4-aminobutanoic acid, produced an maleimidoalkanoic acids 4.28. This type of 
crosslinking agent offers two orthogonal bonding spots. First, the activated 
carboxylic acid (via, for example, a N-hydroxysuccinimide ester) can react with 
primary or secondary amine group to create an amide bond and then the thiol can 
attack the double bond of the maleimide. Nevertheless, maleic acid imides have one 
major backdrawn, hydrolysis. Water can react with the compound leading to the 
opening of the heterocycle and to the loss of reactivity.
220, 221
  
For this project, a Cys-GFP was used to couple to a nonalysine-like peptoid 
functionalised with a maleimidoalkanoic acid. 
 
4.2.3.2. Cys-GFP expression   
For this project, a modified GFP (Cys-GFP, 4.29) was used and produced using 
recombinant DNA technology (rDNA). The plasmid for the His6-Cys-GFP (4.30) 
was prepared by Dr David Nagel (Appendix 4-1) and contained a His6 tag to purify 
the protein, a Asp-Asp-Asp-Asp-Lys enterokinase specific cleavage sequence (to 
remove the His6 tag)
222
 and a final Cys on its N-terminal separated from the GFP by 
a (Ser-Gly)6 spacer (Appendix 4-2) 
The plasmid encoding His6-Cys-GFP (4.30) was transformed into BL21(RPS)DE3 
(E.Coli strains) competent cells using a heat shock technique (succession of hot and 
cold shock to open the cell membrane). The modified GFP (4.30) was then expressed 
within the bacterial cells by the addition of isopropylthio-β-galactoside (ITPG, 4.31, 
1mM). IPTG binds to the lac repressor (lacI, from the E. coli genome of modified 
strains only) leading to the production of T7 RNA polymerase. This polymerase then 
binds with the T7 promoter on the pET system resulting in the transcription of the 
target DNA. The SDS-PAGE (sodium dodecyl sulfate - polyacrylamide gel 
electrophoresis) gel clearly showed the presence of the GFP (Figure 4.11-A, white 
circle line 2). The His6-Cys-GFP (4.30) was purified using Ni-NTA agarose beads. 
After purification, the protein 4.30 was released from the beads using a buffer rich in 
imidazole (250 mM) (Figure 4.10).   
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Figure 4.10: Images of the fractions of His6-Cys-GFP (4.30) eluted from the Ni-NTA beads. 
Picture taken under light of transilluminator (λ = 365 nm). Fractions 3 and 4 contained the protein 
4.30. 
 
The His6 tag was cleaved from the protein using a protease which cleaves selectively 
after the Lys of this sequence Asp-Asp-Asp-Asp-Lys. Finally the Cys-GFP 4.29 
protein was desalted using a PD 10 column and concentrated using an Amicon ultra-











Figure 4.11: Analysis of the Cys-GFP protein (4.29). 
A) SDS-PAGE analysis (lanes left to right): Marker See Blue® Plus 2 prestained; 1. Products of cell 
lysis without IPTG induction, no GFP 4.30 band in the white circle; 2. Product of cell lysis with IPTG 
induction, GFP 4.30 band in the white circle; 3. His6-Cys-GFP 4.30 after purification; 4. Cys-GFP 




The Cys-GFP 4.29 was analysed via SDS-PAGE and by MS (MALDI-TOF, Figure 
4.11). 
 
4.2.3.3. Synthesis of maleimide-9mer 
Several synthesis of 4.34 (6-maleimidocaproic acid) have been described in the 
literature including the original by Rich
223
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(Scheme 4.5). Only Christmann has published a large scale synthesis of 
maleimidoalkanoic acids 4.28. In addition to the large scale production of the desired 
maleimide, this synthesis has the advantages of being carried out in one step and 
without chromatography purification. The 6-maleimidohexanoic acid 4.34 was 
synthesised using aminocaprioic acid (4.32) and the maleic anhydride (4.27) in acetic 
acid. The mixture was heated to reflux for 90 minutes. The desired maleimide 4.34 





Scheme 4.5: Synthesis of 6-maleimidohexanoic acid, 4.34. 
In red: Rich synthesis; In black: Christmann synthesis; In blue: Marnett synthesis. 
The maleimide-9mer peptoid (Mal-9mer, 4.35) was synthesised by coupling of 6-
maleimidohexanoic acid 4.34 on the resin 2.35 previously Fmoc deprotected. The 
maleimide-9mer peptoid 4.35 (Mal-9mer) was released from the solid support by 
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treatment of the resin with TFA/TIS/H2O, 95: 2.5: 2.5, (Scheme 4.6) with a yield of 
92% and a purity of 98% (ELSD, Figure 4.12). 
 
Scheme 4.6: Solid-phase synthesis of the maleimide-9mer, 4.35. 
 
 
Figure 4.12: HPLC trace (ELSD) of the crude 4.35, purity 98%. 
 
 
4.2.3.4. Preliminary coupling assays. 
The capacity of the maleimide-9mer (4.35) to react with thiol compounds was tested 
using a modified rhodamine dye. 5-(6)-carboxyrhodamine 2.36 was functionalised 
with a thiol group using cysteamine (4.36) (Scheme 4.7). Cysteamine (5 equivalents) 
was coupled to 2-chlorotrityl chloride polystyrene resin (4.5) in the presence of 
DIPEA (5 equivalents) in DCM. The 5-(6)-carboxyrhodamine 2.36 was then attached 
to the primary amine of the resin 4.37 using a HOBt/DIC coupling and the thio-
rhodamine 4.38 was cleaved from the solid support using TFA/DCM/TIS, 50: 45: 5 
(yield = 82%, purity ELSD = 98%). The thio-rhodamine 4.38 was coupled to the 
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maleimide-9mer 4.35 in PBS (pH 7.0). For the coupling to work, it was essential to 
make sure that the pH of the peptoid solution was at 7.0. Indeed once the peptoid 
4.35 was dissolved in PBS, the pH was measured as 3.6 therefore it was adjusted to 
pH 7.0 by addition of NaOH (1M). The thio-rhodamine was linked to the peptoid to 
give 4.39 (Rho-S-maleimide-9mer) with a yield of 96% (determined by HLPC 
analysis (ELSD), Appendix 4-3). 
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Figure 4.13: HPLC trace (ELSD) of the synthesis of the Rho-S-maleimide-9mer 4.39. 
In red, the starting material (Mal-9mer, 4.39); in black the reaction mixture after 16 hours at room 
temperature. 
 
4.2.3.5. Cys-GFP delivery via single thiol-maleimide coupling 
As the bio conjugation between the thio-rhodamine 4.38 and the maleimide-9mer 
4.35 was a success, the previous protocol was repeated to link the GFP-SH 4.29 to 
the maleimide-peptoid (Scheme 4.8). However, the coupling did not work as 
analysed by SDS-PAGE gel and MS analysis (MALDI-TOF spectrum and SDS-
PAGE gel, Appendix 4-4). 
 
Scheme 4.8: Bioconjugation of the GFP-SH (4.29) with the maleimide-9mer (4.35). 
 
The non-coupling of the Cys-GFP with the maleimide could be due to the formation 
of disulphide bonds between two molecules of Cys-GFP. Disulfide bonds can be 
completely reduced by dithiothreitol (DTT, 4.41).
226, 227
  For this project, the 
reducing conditions of the DTT must not denaturate the GFP.
207
 Therefore, 10 
equivalents of DTT were used at room temperature using a pH of 7.0. After 
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overnight reaction, the peptoid 4.35 was added to the reduced protein. An excess of 
80 equivalents of maleimide-9mer was used to ensure maximum coupling (PBS, pH 
7.0), as part of the maleimide would also be attacked by the unreacted DTT. 
However, the excess of peptoid leaded to precipitation of the protein. The precipitate 
was re-solubilised by the addition of PBS and the coupling was carried on for 
another ten hours. To remove uncoupled peptoid 4.35, the coupling mixture was 
purified using two different techniques.  
1. The reaction solution was placed in a dialysis tube with a molecular weight limit 
of 10 000 daltons. The comparison between the lane 2 (without purification) and 3 of 
the SDS-PAGE gel (Figure 4.14-A) clearly showed that this technique decreased the 
amount of free peptoid. Purification was incomplete.   
2. The protein was purified using a SpinTrap G-25 (centrifugation, Figure 4.14-B). 
The SDS gel (Figure 4.14-A, lane 2 (without purification) and 4) proved that the 
majority of the unreacted peptoid was removed from the reaction. This technique 
offered several advantages; firstly the purification time was very short as the sample 
was centrifuged 4 × 5 minutes with addition of fresh PBS for each centrifugation 
cycle. Secondly, the loss of protein can easily be analysed. If the protein passed 
through the 5000 Da filter, the fluorescence was observed at the bottom of the tube. 
Finally, this technique allowed concentration of the protein to the desired volume. 
Using DTT and 80 equivalents of peptoids, the coupling product (4.40) was obtained. 
Indeed, the SDS-PAGE (Figure 4.14-A) showed the presence of a second band on 
top on the Cys-GFP. This result was confirmed by MS analysis (MALDI-TOF, 
Figure 4.14-C).  
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Figure 4.14: SDS-PAGE gel of the coupling with DTT and 80 equivalents of peptoid 4.35. 
A) SDS-PAGE analysis (lanes left to right): Marker See Blue® Plus 2 prestained; Lane 1: untreated 
GFP 4.29; 2: Coupling reaction without purification of the peptoid excess; 3: Coupling reaction with 
purification of the peptoid excess by dialysis; 4: Coupling reaction with purification of the peptoid 
excess by centrifugation. B) Image of the purification of the protein using SpinTrap-25. The picture 
was taken after 4 cycles of centrifugation. 
 
Even though, the coupling efficiency was very poor, the use of DTT (4.41) and a 
major excess of Mal-9mer (4.35) clearly played a role in the formation of the 
conjugate 4.40. One parameter that could have decreased the formation of the 
thioether between the maleimide and the Cys-GFP might be the precipitation of the 
protein due to the large excess of peptoid. For the first attempt of coupling, 10 
equivalents of peptoid 4.35 (C = 0.28 mM) did not crash out the protein while, in the 
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precipitation of the GFP. Using these previous data, the best coupling was obtained 
using first 10 equivalents of DTT. After overnight reduction, the excess of DTT was 
removed by centrifugation and 25 equivalent of peptoid 4.35 were used to couple the 
Cys-GFP 4.29 in PBS (pH 7.0). The bioconjugation was carried out at room 
temperature for 16 hours. The reaction was followed by size exclusion purification. 
The presence of the 9mer-S-GFP 4.40 was confirmed by SDS-PAGE gel with the 
presence of a second band on top of the GFP trace. This result was also observed 




Figure 4.15: Analysis of the GFP bioconjugation with DTT and 25 equivalents of peptoid 4.35. 
SDS-PAGE analysis (lane left to right): LMW SDS marker; Lane 1: Coupling reaction with 
purification of the peptoid excess by centrifugation; 2: untreated GFP 4.29 
 
Although, the coupling efficiency was not optimal, the cellular uptake of the last 
attempt was tested. The coupling reaction (containing the bioconjugate 4.40) purified 
from the excess peptoid was incubated for 24 hours with HeLa cells. As the 9mer-S-
GFP (4.40) was not separated from the Cys-GFP (4.29), the uncoupled protein was 
also incubated with the cells as a negative control. The maleimide-9mer 4.35 was 
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Figure 4.16: Flow analysis of cellular uptake of the bioconjugate 4.40 in HeLa cells. 
A) Flow cytometry histogram of each sample after 24 hours; B) % uptake measured for the Cys-GFP 
(4.29, 6 µg/mL), 9mer-S-GFP bioconjugate (4.40-a: 2.7 µg/mL and 4.40-b: 5.4 µg/mL) and 
maleimide-9mer (4.35, as negative control, 10 µM) as the % of cells with a fluorescent emission 
exceeding untreated control as 0% uptake (incubation time = 24 hours). The errors bar represents the 
standard error of the average (n = 6). 
  
 
The flow cytometry analysis demonstrated cellular uptake of the bioconjugate with a 
maximum of 49% of labelled HeLa cells. For this experiment, the use of trypan blue 
to quench the external emission was essential as some of the bioconjugate and the 
uncoupled protein bound to the cell membrane. The cellular uptake of the 
bioconjugate (4.40) was confirmed using living cell microscopy after 24 hours 
(Figure 4.17). This result demonstrated the potential of the nonalysine-like peptoid 






 Control cells   
4.35, Mal-9mer    
4.29, Cys-GFP   
4.40-a   
4.40-b   
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Figure 4.17: Fluorescence microscopy of HeLa cells. 
These images were taken with a Leica fluorescent microscope after incubation of the HeLa cells for 
24 hours at 37
o
C with the bioconjugate 4.40-b (5.4 µg/mL). A) Brightfield image; B) GFP fluorescent 




4.2.3.6. Cys-GFP delivery via multiple thiol-maleimide couplings 
Although, cellular delivery of the Cys-GFP (4.29) was achieved using a single 
nonalysine-like peptoid, the cellular uptake remained under 50% mainly because of 
the poor bioconjugation of the protein with the cellular transporter. One solution 
could be to increase of the number of thiol groups within the protein.
228
 Free 
sulfhydryl groups can be introduced to the first entity (protein) by reduction of 
disulphide bridges and/or thanks to a thiol generator.
229
  A thiol generator is an 
organic compound that reacts with a free amine groups (e.g. a lysine side chain) 
resulting in the introduction of a new thiol. 2-iminothiolane (4.42, 2-IT, known as 
Traut’s reagent) has been widely used to modify proteins and peptides
230
 and was 
chosen as a thiolation agent. Thus Cys-GFP (4.29) was modified using 2-IT to 
increase the number of free sulfhydryl groups available. GFP contains 19 lysines 
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create the modified GFP (4.43).  Each sulfhydryl group could then form a thioether 
bond with one molecule of meleimide-9mer resulting in a new bioconjugate (4.44, 
(9mer-S)n-GFP) (Scheme 4.9). 
The first attempt began with the overnight modification of the Cys-GFP protein 
(4.29) with the 2-IT (4.42) at pH 7.4. The excess of thiolation agent was then 
removed and the buffer was exchanged for one at pH 7.0. The maleimide-9mer 
peptoid (4.35) was added and the overnight coupling reaction was analysed by SDS-
PAGE gel and MS (Appendix 4-6). The analysis showed that none of the reactions 
worked (introduction of sulfhydryl groups via 2-IT reaction and coupling with the 
maleimide-9mer).  The protein was not modified or at a very low level that could not 
be detected by any of these techniques (Scheme 4.9). 
Studies have shown that the 2-IT modified 95% of ethanolamine in 100 minutes at 
pH 8 while 90% were thiolated in 6 hours at pH 6.5. Furthermore, Lambert et al. 
reported that the thiol adducts generated with 2-IT could be unstable.
230 
The most 
efficient attempt was obtained when the thiolation reaction was carried out over 4 
hours at room temperature. After removal of the excess of 2-IT, the protein was 
treated with DTT (4.41) for an hour. The protein was purified from the reducing 
agent and the maleimide-9mer (4.35) was added. After reaction, the reaction was 
analysed by SDS-PAGE and MS (Figure 4.18). 
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Scheme 4.9: Bioconjugation of the Cys-GFP (4.29) with peptoid (4.35) using 2-IT.HCl (4.42). 
 
The SDS-PAGE gel (Figure 4.18-A) showed three bands for the reaction mixture. 
The lowest band corresponded to uncoupled Cys-GFP 4.29, the middle one to the 
protein coupled with one unit of peptoid (4.35) and the highest one to the GFP bond 
to two entities of maleimide-9mer (4.35). The gel result was confirmed by the 
presence of the both peaks on the MALDI-TOF spectra (Figure 4.18-B).  
 - m/z = 27701, 4.29; 
 - m/z = 29534, 4.44 with n = 1 (29534-27701 = 1833; expected + 1847); 
 - m/z = 31355, 4.44 with n = 2 (31355-27701 = 3654; expected + 3694). 
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Figure 4.18: Analysis of the GFP bioconjugation with 2-IT and 25 equivalents of peptoid 4.35. 
A) SDS-PAGE analysis (lanes left to right): LMW SDS marker; Lane 1: untreated GFP 4.29; 2: 
Coupling reaction before purification of the peptoid excess by centrifugation; 3: Coupling reaction 
after purification of the peptoid excess by centrifugation. B) MALDI-TOF spectra of the coupling 
reaction. 
 
The cellular uptake of this bioconjugation (4.44) was tested in HeLa cells under the 
same conditions as previously described. The flow cytometry analysis showed a 
small amount a cellular uptake with a maximum of 15% of cells labelled after 24 
hours of incubation (Appendix 4-7). 
The cytotoxicity of the bioconjugates (4.40 and 4.44) was also assessed using MTT 
assay. The cell viability was not affected under any of the concentrations used for the 
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4.2.3.7. Conclusions 
A nonalysine-like peptoid was synthesised and functionalised with a maleimide 
using microwave assisted HOBt/DIC solid phase synthesis. Using a thio-rhodamine 
(4.38), the reactivity of the maleimide-9mer (4.35) was proven efficient and 
biocompatible. However, the coupling between the Cys-GFP (4.29) and the 
maleimide-9mer was not carried out with the same success. This could be due to the 
positively charged primary amine groups, which could interact with the protein and 
therefore not allow correct positioning of the maleimide leading to a poor coupling 
rate. In order to demonstrate this hypothesis the peptoid could be fully protected and 
the maleimide-thiol reaction re-tested. Nevertheless, flow cytometry, microscopy and 
cytotoxicity assays demonstrated positive and non-cytotoxic cellular delivery of the 
GFP in HeLa cells using a nonalysine-like peptoid. Therefore, the principle of 
coupling and the cellular delivery were demonstrated but there is still major room for 
improvement, mainly by increasing the coupling yield between the maleimide 
transporter and the protein. The analysis of the tertiary structure of the GFP could 
show that the lysine side chains are probably not available due to steric hindrance 
leading in the low reaction between the amine groups and the thiolation agent (2-IT).  
In the future, after fixing the maleimide-thiol issues, the cellular uptake of GFP-
peptoid should be compared to another cellular delivery system such as TAT or 
polyarginine. So far, the fusion TAT-GFP delivery is still much more efficient than 
this GFP-peptoid system. Nevertheless, it is important to remember that these 
carriers are known to be efficient but remain cytotoxic and very sensitive to proteases 
while the peptoid carrier did not show any cytotoxicity and is resistant to proteolytic 
degradations. 
 
4.2.4. GFP delivery via active ester coupling chemistry 
4.2.4.1. Aim and choice of protecting group  
Another approach was to attach the peptoid to GFP via formation of an amide 
bond.
220
 However, the nonalysine-like peptoid contains nine primary amines that can 
be very reactive depending on the pH (pKb around 10.5). These primary amines are 
mainly under the form of protonated amine at low pH (under 8) generating some 
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aggregations. At pH>10, the amines are not protonated and very reactive. Therefore, 
in this new approach the side chains of the peptoids were kept protected and the 
protein was coupled to the protected peptoid via an active ester. Once the protein was 
coupled, the side chain would need to be deprotected under physiological conditions.  
The choice of the side chains protecting group was dictated by several requirements: 
1. Being resistant to the final acidic cleavage from the solid support, 
2. Being orthogonal to Fmoc group, that protects the α-secondary amine of the 
peptoid chain, 
3. Allowing being deprotection under physiological conditions. 
The Dde protecting group seemed an interesting choice. The only doubt being if 
deprotection could occur under physiological conditions. In 2006, S-acetylated 
thiopropionul residues were deprotected in situ using hydroxylamine (500 mM) 
without degradation of the antibody
231
 while Dde can be deprotected by 
hydroxylamine (300 mM) with imidazole.
204
 Based on these two publications, the 
following deprotecting solution was prepared with hydroxylamine.HCl (500 mM), 
EDTA dipotassium (25 mM) and sodium phosphate dibasic (50 mM) at pH 7.5. 
The deprotection solution was tested on the compound Fmoc-Lys(Dde)-OH 4.14.  
 
 
Figure 4.19: HPLC trace (λ = 240 nm) of the Dde deprotection under physiological conditions. 
In red, the starting material (Fmoc-Lys(Dde)-OH); in blue, the reaction mixture after 4 hours at room 
temperature; in black the reaction mixture after 6 hours at room temperature. 
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HPLC analysis (Figure 4.19) showed transformation of the starting material (Fmoc-
Lys(Dde)-OH, 4.14, retention time 3.6 minutes) to the non-protected Fmoc-Lys-OH 
(retention time 3.5 minutes). Thus, due to the good deprotection of the Dde group 
under physiological conditions, its orthogonality to the Fmoc group and its stability 
under acidic cleavage, a peptoid monomer was prepared with the side chain protected 
with a Dde (instead of a Boc) group and the α-amine group with an Fmoc group.  
 
4.2.4.2. Dde monomer synthesis 
The Dde monomer 4.48 was synthesised based on the synthesis of the Boc monomer 
(2.22, described in CHAPTER 2) (Scheme 4.10).
 
The Dde monoprotection was first 
carried out using the same protocol than for the Boc monoprotection, using 8 
equivalents of 1,6-diaminohexane (2.18) and 1 equivalent of DdeOH (4.20). 
However, analysis of the crude reaction revealed the presence of unprotected, mono-
protected and di-protected amine. Furthermore, the washing step to remove the 
excess of diamine (2.18) resulted on the degradation of the desired Dde mono-
protected compound (4.45). Previously, in the Bradley group, other diamine 
compounds were monoprotected using DdeOH with the synthesis carried out using a 
1:1 molar ratio of the diamine and the DdeOH. This protocol was repeated here. 
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Scheme 4.10: Synthesis of the Dde protected lysine-like peptoid monomer 4.48 and its Dde 
deptrotected analogue 4.49. 
The synthesis corresponded to the synthesis of the Dde protected lysine-like peptoid monomer 4.48 
and the selective Dde deprotection of the monomer 4.48 under physiological conditions (blue). 
 
The free primary amine was monoalkylated with benzyl-2-bromoacetate (2.23) to 
obtain the desired N-substituted glycine protected by a benzyl ester and a Dde group 
(4.46). Compound 4.46 was isolated by column chromatography in 32% yield over 
the first two steps (calculated from 4.20). This low yield was mainly due to the poor 
stability of 4.45. The non-protected secondary amine group was then protected by an 
Fmoc group using Fmoc-OSu. After purification by chromatography, 4.47 was 
obtained in a 98% yield (calculated from 4.46). Benzyl group deprotection was 
carried out using Pd/C as a catalyst under H2 and the Dde monomer 4.48 was 
obtained in a 80% yield.  
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Before synthesising a fully Dde protected peptoid, the Dde deprotection at 
physiologic pH was also tested on the monomer 4.48 (Scheme 4.10). The Dde 
removal assay was carried out in a biphasic mixture composed with DCM (to 
dissolve the monomer) and the Dde deprotection solution (500 mM of NH2OH.HCl, 
25 mM of EDTA dipotassium, 50 mM of anhydrous sodium phosphate dibasic, pH 
7.5). As expected the Dde protected monomer 4.48 was deprotected to form 4.49 
(Figure 4.20). The synthesis of the protected peptoid was then started. 
 
Figure 4.20: HPLC trace (ELSD) of the Dde deprotection of the Dde monomer 4.48 under 
physiological conditions. 
In red, the starting material (Dde monomer 4.48); in black the reaction mixture with the formation of 
the compound 4.49 after 6 hours at room temperature. 
 
 
4.2.4.3. Synthesis of the fully protected peptoid 
The fully Dde protected peptoid was synthesised using the previously described 
(CHAPTER 2) solid-phase synthesis protocol used for the synthesis of the non-
protected peptoid using a Rink amide polystyrene resin (2.28), the Dde monomer 
4.48 and an HOBt/DIC microwave assisted coupling protocol. The Fmoc-
9mer(Dde)9-NH2 peptoid 4.51 was released from the solid support by treatment of 
the resin (4.50) with TFA (TFA/TIS/H2O, 95: 2.5: 2.5) (Scheme 4.6) in a purity of 
67% (ELSD) before purification. The synthesis of this peptoid was more complicated 
(a few couplings had to be repeated) than the synthesis of the Boc-protected analogue 
and less pure. The product 4.51 was isolated after reverse phase chromotography in 
an overall yield of 51%.  
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Scheme 4.11: HOBt/DIC microwave assisted solid-phase synthesis of  
Fmoc-9mer(Dde)9-NH2 peptoid (4.51) and formation of the Fmoc-9mer peptoid (4.52) by 
physiologic Dde deprotection. 
 
Before carrying on any further in the project, it was essential to confirm that the Dde 
deprotection buffer was also efficient for the deprotection of the purified Fmoc-
9mer(Dde)9-NH2. The Fmoc-9mer(Dde)9-NH2 was treated with the Dde deprotection 
solution. Once the water was removed, the crude was precipitated in cold diethyl 
ether.  
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Figure 4.21: HPLC trace (ELSD) of the Dde deprotection of the protected peptoid 4.54 under 
physiological conditions. 
In red, the pure starting material (Fmoc-9mer(Dde)9-NH2, 4.51); in black the reaction mixture with the 
formation of the compound 4.52 (Fmoc-9mer-NH2) after overnight reaction at room temperature.  
 
After precipitation the reaction was analysed and the HPLC trace showed 100% of 
conversion from the fully protected peptoid (4.51) to the nonprotected 9mer (4.52). 
The result was confirmed by comparison with Fmoc-9mer peptoid (4.52) synthesised 
using the same protocol as the peptoid 4.51 but using the Boc monomer (2.22) 
instead of the Dde monomer (4.48). 
 
4.2.4.4. Choice of the active ester 
After synthesising the Dde protected peptoid, work focused on the choice of the 
active ester. The best synthetic route would be to couple the active ester on the 
peptoid while it was still on the solid support and to purify everything as one. In 
order to do so, the active ester has to be stable under the acidic conditions used to 
cleave the protected peptoid from the Rink amide polystyrene resin. The N-
hydroxysuccinimide active ester (NHS) is the most commonly used for 
bioconjugation however it is easily hydrolysed below pH 2. The NHS ester has a 
half-life of a few hours at pH 7-8. The fluorophenyl esters, including 
pentafluorophenyl (OPfp or PFP), tetrafluorophenyl and sulfo-tetrafluorophenyl 
ester, are another famous family that react with amine containing biomolecules (e.g. 
proteins) to give an amide bond. This family of active esters has the same reactivity 
than NHS esters with a better stability toward hydrolysis making these esters a 
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Commercially available Fmoc-Leu-OPf (4.53) was treated for different time periods 
with different TFA concentrations (1, 5, 10, 25 and 50% TFA in DCM). The stability 
of the active ester was monitored using HPLC (ELSD) and MS after neutralisation 
(with triethyamine). 
 
Graph 4.3: Stability assay of the OPfp ester with 50% TFA in DCM. 
 
None of the concentrations of TFA tested caused the hydrolysis of the OPfp ester 
independent of the reaction time (Graph 4.3 and Appendix 4-9). These results 
validated the choice of the pentafluorophenyl ester for this project. 
 
4.2.4.5. Results and discussion 
Fmoc-9mer(Dde)9-resin (4.50, Scheme 4.11) was Fmoc deprotected and coupled to 
the cyclised 3, 6, 9 trioxaudecanedioic acid 4.54 in DCM. The cyclisation reaction 
was carried out in DCM in presence of DCC before being added to the resin without 
purification.
232
 As the chloranil test was negative (no sign of free secondary amine), 
the formation of the active ester was activated using pentafluorophenol (4.56) and 
DCC in DCM.
233
 After overnight reaction, the resin was treated with 50% TFA in 
DCM to cleave the expected peptoid 4.60. Unfortunately, the analysis of the crude 
revealed that the synthesis had not worked. The HPLC showed a very unpure 
cleavage product that, once purified, was mainly the Fmoc deprotected version of the 
peptoid 4.51. The synthesis was repeated with PEG coupling step repeated twice. 
However, the same result was observed. The coupling with the 4.54 may have failed 
due to a steric hindrance. One alternative could be to couple first an Fmoc-Ahx-OH 
CHAPTER 4 
- 124 - 
 
spacer (2.34) and then the cyclised PEG (4.54). Unfortunatly, this hypothesis could 
not be tested due to lack of time.  
 
Scheme 4.12: Tested synthesis of the OPfp activated protected peptoid 4.57. 
In black, the part of the synthesis that worked; in red, the part that did not work. The compound 4.54 
was cyclised before being added to the resin. 
 
4.3. eGFP DNA plasmid delivery  
4.3.1.  Introduction 
Efficient cellular delivery of DNA, commonly known as transfection, is a key 
technique for numerous biomedical sciences leading, potentially, to the treatment of 
countless diseases. In the past decade, new technologies have been developed to 
overcome the major barriers of this technique (permeability of the cell membrane to 
DNA and specific targeting). New cellular carriers are very diverse in shapes, 










 and cell penetrating peptides.
238
 Thanks to the negative 
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charges of the phosphate deoxyribose DNA backbone, the DNA can be encapsulated 
via electrostatic interactions by positive charged molecules such as poly-lysine or 
poly-arginine (Figure 4.22).
239 
In 2007, Davis published a paper in which DNA containing nanoparticles were 
prepared by encapsulation of the DNA with polyethylene glycol (PEG) substituted 
cysteine-polylysine peptides (PEG-CK30).
240
 In order to track the nanoparticles inside 
the cells, the compacted DNA/polylysines were labelled with rhodamine dye. 
Previously in this thesis was described the synthesis and the efficient cellular uptake 
without cytotoxicity of the Rho-9mer peptoid (2.37) in several cell lines. Although, 
the peptoid 2.37 was shorter than the PEG-CK30 compound,
240
 its nine positive 
charges should interact strongly with the anionic phosphates of DNA. The 
complexation of the eGFP plasmid (pEGFP) was first evaluated with the Rho-9mer 
peptoid (2.37) and then with a PEG-peptoid (4.61). 
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4.3.2. Cellular delivery of pEGFP by complexation with the Rho-9mer 
4.3.2.1. Formation of the pEGFP/Rho-9mer complex 
The Rho-9mer synthesis was described earlier in this thesis (CHAPTER 2). The first 
step of this project was the evaluation of the complexation power of the peptoid Rho-
9mer (2.37). The amount of peptoid used was calculated from the number of negative 
charges on the plasmid. The eGFP plasmid (pEGFP-C1) contained 4731 bases. Each 
base was composed of one molecule phosphate deoxyribose therefore the plasmid 
used had 4731 negatives charges. The Rho-9mer 2.37 has a maximum of nine 
positive charges thanks to its primary amines, therefore to obtain a charge ratio of 1:2 
between the DNA and the peptoid, 1052 molecules of nonalysine-like peptoid were 
required. 
 
Figure 4.23: Electrophoresis gel of the binding of pEGFP-C1 with the Rho-9mer peptoid (2.37). 
Lanes left to right: Marker 1 kilobase (KB), Lane 1: charge ratio pEGFP/Rho-9mer = 1: 2, 2: charge 
ratio pEGFP/Rho-9mer = 1: 5, 3: charge ratio pEGFP/Rho-9mer = 1: 10, 4: charge ratio pEGFP/Rho-
9mer = 1: 20. 
 
The eGFP plasmid was mixed at room temperature with different amounts of Rho-
9mer (2.37) but with the same DNA concentration (0.01 µg/µL). Several charge 
ratios pEGFP-peptoid were tested and the results were summarised below (Figure 
4.23). 
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- Lane 1, 1: 2: bands were very intense but decreased compare to the untreated 
DNA, 
- Lane 2, 1: 5: almost as intense as the first ratio, 
- Lane 3, 1: 10: intensity of the bands decreased but there was still some 
uncomplexed plasmid, 
- Lane 4, 1: 20: all DNA trapped within peptoid complexes. 
From the previous data, cellular delivery in HEK293T cells was tested using a charge 
ratio of 1: 20, pEGFP/Rho-9mer.  
 
4.3.2.2. Cellular delivery of the pEGFP/Rho-9mer complex 
The cellular delivery of the pEGFP-C1 was assessed by production of green 
fluorescent protein. Lipofectamine
TM
 2000 (L2000, Figure 1.8) was used as a 
positive control and uncomplexed pEGFP-C1 and untreated cells as a negative 
control. After 24 and 48 hours, cells were analysed by flow cytometry (Figure 4.24) 
and microscopy (live cells microscopy: Figure 4.25; confocal microscopy: Figure 
4.26). 
Using the rhodamine, the cellular penetration of the complex was confirmed. Flow 
cytometry analysis showed that the pEGFP/Rho-9mer complex 4.58 penetrated as 
easily as the free Rho-9mer 2.37 (Figure 4.24-A) with almost 100% of cell labelled 
after 24 hours of incubation with the complex 4.61 and the uncomplexed peptoid 
2.37. After 48 hours, the whole population was highly labelled. As expected the 
Lipofectamine/pEGFP complex was not detected after 24 and 48 hours using the 
rhodamine filter. The presence of the peptoid was also confirmed by microscopy 
(Figure 4.25-B). Direct GFP expression was analysed using the FITC filter via flow 
cytometry (Figure 4.24-B). After 24 hours of incubation, no GFP expression was 
detected in the cells transfected with the pEGFP/peptoid complexes (4.58). As far as 
the positive control was concerned (Lipofectamine
TM
2000/DNA), 10% of the treated 
cells showed GFP expression. After 48 hours, the cells treated with the complexes 
4.58 clearly expressed GFP (Figure 4.25-C) and this result was confirmed with flow 
analysis (Figure 4.24). The pEGFP/Rho-9mer peptoid 4.58 was not as efficient as 
the Lipofectamine complex with only 20% of cell labelling (expression of GFP) for 
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the peptoid complex while the commercially available reagent achieved a cellular 
labelling of 52%.  
 
 
Figure 4.24: Flow analysis of cellular uptake of the pEGFP/Rho-9mer complexes (4.58) in 
HEK293T cells. 
A) Histogram showing the cellular uptake based on the rhodamine. PE axis: Rhodamine fluorescence 
intensity; B) % uptake measured for the direct expression of GFP using pEGFP/Rho-9mer complexes 
4.58 (0.5 µg of DNA/well), Rho-9mer (2.37, 13 µM) and Lipofectamine
TM
 2000 (0.5 µg of 
DNA/well) as the % of cells with a fluorescent emission exceeding untreated control as 0% uptake 
(incubation time = 24 (hatched columns) and 48 hours (plain columns)). The errors bar represents the 








 Control cells 48 h   
Lipofectamine/pEGFP 48 h   
2.37, Rho-9mer 24 h   
2.37, Rho-9mer 48 h   
4.58,  
pEGFP/Rho-9mer 24 h   
4.58,  
pEGFP/Rho-9mer 48 h   
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After 24 hours, even though live cell microscopy (Figure 4.25) shown that the DNA 
complex 4.58 or the free peptoids (2.37) penetrated the cells (red colour within the 
HEK293T cells), no GFP fluorescence was detectable. These results were similar to 
the data obtained via flow cytometry. However after 48 hours, direct GFP expression 
was clearly observed.  
 
Figure 4.25: Microscopy analysis of the cellular delivery of DNA/Rho-9mer complexes (4.58). 
These images were taken after incubation of the HEK293T cells for 48 hours at 37
o
C with 0.5 µg of 
eGFP plasmid complexed with Rho-9mer (2.37). A) Brightfield image; B) Rhodamine fluorescent 
image, Rho-9mer detection (excitation 515-560 nm); C) GFP fluorescent image (excitation 450-490 
nm); D) Fluorescence image merge with brightfield. 
 
Confocal microscopy (Figure 4.26) showed the presence of rhodamine peptoid 
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Figure 4.26: Confocal microscopy of the DNA/Rho-9mer complexes (4.58) delivery. 
These images were taken after incubation of the HEK293T cells for 24 hours at 37
o
C with 4.58 (2.5 
µg of DNA/well). A) GFP fluorescent image (excitation laser 490 nm and emission filter 528-550 
nm); B) Rhodamine fluorescent image, Rho-9mer 2.37 (excitation laser 561 nm and emission filter 
567-630 nm) and nuclei staining using HOECHST-33342 (excitation at 405 nm and emission filter 
413-482 nm); C) GFP fluorescent image (excitation laser 490 nm and emission filter 528-550 nm) and 
nuclei staining using HOECHST-33342 (excitation at 405 nm and emission filter 413-482 nm); D) 
Composite image. The circles showed the co-localisation of the peptoid (in red) in the nucleus while 
the green colour of the GFP protein was localised in the cytoplasm. 
 
4.3.2.3. Delivery of the pEGFP/Rho-9mer complex into active T-cells 
(collaboration with Dr. Stefano Caserta) 
In the CHAPTER 2, the Rho-9mer (2.37) peptoid was shown to penetrate without 
cytotoxicity primary cell lines. Therefore, the cellular delivery of DNA via peptoid 
complexation was also tested in T-cells. 
All experiments carried out in T-cells were performed by Dr. Stefano Caserta from 
Prof. Zamoyska’s group at the Institute of Immunology and Infection Research, 
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The first flow cytometry analysis (Appendix 4-10) was carried out on the direct 
detection of the eGFP expression and on the detection of the rhodamine. The data 
showed the presence of rhodamine inside the cells, therefore the peptoids penetrated. 
However, no trace of eGFP was observed. These results could have several 
explanations: 
1. complex 4.58 was degraded before its cellular penetration in the cells resulting to 
the penetration of the peptoid only, 
2. complex 4.58 was taken up by the cells but it was too stable and the DNA was not 
released, 
3. complex 4.58 was able to penetrate in the cytoplasm, but could not access the 
nucleus (trap in endosomes), therefore the DNA could not be expressed in proteins. 
In order to confirm the presence of the DNA in the cells, the second detection of 
eGFP expression was carried out with an anti-GFP-antibody. Anti-GFP-antibody 
binds specifically to eGFP protein and is commonly used for the low detection of 
protein.
241
 The flow cytometry analysis showed a clear increase of the antibody 
fluorescence intensity (Figure 4.27 and Figure 4.28). A higher concentration of 
peptoid did not affect the percentage of cells expressing eGFP. However, the high 
concentration of peptoid gave broader cell populations (Figure 4.28).  This result 
might be due to some interactions between the peptoid and the antibody as the 
control population (no DNA just Rho-9mer and antibody) was already quite disperse. 
This could correspond to an aggregation of peptoid within the cell membrane.  
 
4.3.3.  Cellular delivery of pEGFP by complexation with PEG-9mer 
The DNA delivery was also tested with a dye-free peptoid to confirm the previous 
results and to try to improve the cellular uptake. Polyethylene glycol (PEG) is a 
polymer known to be non-toxic, non-immunogenic and non-antigenic. PEGylation, 
the process to functionalise proteins, peptides or drugs with one or several units of 
PEG, have demonstrated several advantages including an increase of hydrophilicity, 
of proteolytic resistance and an decrease or elimination of immunogenicity.
242
 
PEGylation was also reported to improve the cellular uptake of nanoparticle formed 
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For this project, the PEGylation of the nonalysine-like peptoid could compensate the 
loss of positive charges and stabilise the DNA/peptoid complexes leading to a higher 
transfection. 
 
4.3.3.1. Synthesis of HO-PEG-PEG-9mer-NH2 
As previously described in CHAPTER 2, the PEG nonalysine-like peptoid  4.61 was 
prepared on a Rink amide polystyrene resin using the Boc monomer 2.22 and an 
HOBt/DIC microwave assisted coupling protocol. The cellular penetrating peptoid 
was first functionalised with the Fmoc-PEG-OH (4.59) spacer. After Fmoc 
deprotection (20% piperidine in DMF), the resin 4.60 was coupled at room 
temperature with the cyclised 3, 6, 9 trioxaudecanedioic acid 4.54 in DCM.
232
 The 
HO-PEG-PEG-9mer-NH2 (4.61) was deprotected and cleaved from the solid support 
by treatment of the resin with TFA (TFA/TIS/H2O, 95: 2.5: 2.5) (Scheme 4.13) with 
a purity of 96% (ELSD). 
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Scheme 4.13: Solid-phase synthesis of the HO-PEG-PEG-9mer peptoid (4.61). 
Peptoid monomer couplings were carried using 3 equivalents of the Fmoc, Boc protected monomer 
2.22, HOBt and DIC in DMF for 20 minutes at 60
o
C µw; Fmoc deprotection were carried over 2 
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4.3.3.2. Formation of the pEGFP/PEG-9mer complex 
The DNA was encapsulated within the PEG-peptoid 4.61 was carried out using the 
same protocol as previously used with the Rho-9mer (2.37). The complexation was 
confirmed by electrophoresis. As expected, a DNA/peptoid charge ratio of 1:20 was 
sufficient to have 100% of complexation. Therefore, the complex DNA/PEG-9mer 
4.62 was prepared using the ratio 1: 10 for the in vitro cellular delivery assays. 
 
Figure 4.29: Electrophoresis gel of the binding of pEGFP-C1 with the PEG-9mer peptoid (4.61). 
Lanes left to right: Marker 1 kilobase (KB), Lane 1: charge ratio DNA/peptoid = 1: 10, 2: charge ratio 
DNA/peptoid = 1: 20, 3: charge ratio DNA/peptoid = 1: 30, 4: charge ratio DNA/peptoid = 1: 40, 5: 
charge ratio DNA/peptoid = 1: 50. 
 
4.3.3.3. Cellular delivery of the pEGFP/PEG-9mer complex 
The delivery was then tested on HEK293T cells using the Lipofectamine
TM
 2000 
(L2000, Figure 1.8) as positive control and uncomplexed pEGFP-C1 and untreated 
cells as negative control. Direct GFP expression was only analysed after 48 hours 
and, as expected, similar results to DNA/Rho-9mer complex were obtained. The 
complex 4.62 achieved 27% of cellular labelling. This result was still lower than the 
one obtained with the Lipofectamine
TM
2000 (48%).  
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Graph 4.4: Flow analysis of cellular uptake of the DNA complexation with HO-PEG-PEG-9mer 
peptoid (4.61) in HEK293T cells. 
% uptake measured for the direct expression of GFP using eGFP plasmid (0.5 µg of DNA/well),  
Lipofectamine
TM
 2000 (0.5 µg of DNA/well), HO-PEG-PEG-9mer (4.61, 13 µM) and DNA/ HO-
PEG-PEG-9mer complex 4.62 (0.5 µg of DNA/well) as the % of cells with a fluorescent emission 
exceeding untreated control as 0% uptake (incubation time = 48 hours). The errors bar represents the 
standard error of the average (n = 3). 
 
The direct expression of the GFP was confirmed by live cells microscopy (Figure 
4.30), where the direct GFP expression can be easily monitored. Unfortunately, the 
images were not as good as expected. Indeed after washing most of the cells were 
detached due to a too high confluence of the cells. Indeed, the cells were plated for 3 
days before being analysed and the confluence of the cells was 85% at day 1. To 
ensure that it was just a problem of confluence, the cytotoxicity of the DNA/peptoid 
complexes was assessed using MTT assays. 
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Figure 4.30: Microscopy of the cellular delivery of DNA/HO-PEG-PEG-9mer complex, 4.62. 
These images were taken after incubation of the HeLa cells for 48 hours at 37
o
C with the complex 
4.62. A) Brightfield image; B) eGFP fluorescent image (excitation 450-490 nm); C) Fluorescence 
image merge with brightfield.  
 
4.3.4. Cytotoxicity assays of the DNA/pepoid complexation 
The MTT assay was carried out using 85% of confluency on the day on the injection 
of the several compounds to test. At the concentrations and time of incubation used 
none of the peptoids (2.37 and 4.61) and their DNA/peptoids complexes shown 
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Graph 4.5: MTT analysis of the several pEGFP/peptoid complexes in HEK293T cells. 
HEK293T cells incubated with pEGFP (0.1 µg of DNA/well), pEGFP/Rho-9mer (4.58, 0.1 µg of 
DNA/well), Rho-9mer (2.37, 13 µM), HO-PEG-PEG-9mer (4.61, 13 µM) and pEGFP/PEG-9mer 
(4.62, 0.1 µg of DNA/well), for 24 and/or 48 hours before being treated with MTT. Healthy cells 
corresponded to 100% cell viability. The errors bar represents the standard error of the average  
(n = 8).  
 
4.3.5. Conclusions 
The nonalysine-like peptoid was able to complex the eGFP plasmid and to deliver it 
into the nucleus of HEK293T. Once inside the nucleus, the DNA was released and 
was transformed into RNA before being translated in the cytoplasm into eGFP. Both 
peptoids 2.37 and 4.61 enabled transfection without cytotoxicity. Although, the DNA 
delivery obtained with the peptoids was lower than the ones with the 
Lipofectamine
TM
 2000, the peptoids showed no cytotoxicity in various cell lines and 
allowed a delivery of the DNA into T cells. To increase the cellular labelling, studies 
could be carried out on the stability of the complex and on the capacity of the 
complex to access the nucleus. As the complex DNA/peptoid is not cytotoxic, longer 
incubation time (72 hours) could also be tested. Also, studies on the cellular uptake 
mechanism could be carried out allowing a better understanding of the poor eGFP 
expression. Indeed, use of lysosome/endosome trackers could show if the complex is 
isolated and, therefore, unable to be released to the cytoplasm for expression of the 
DNA. The presence of the DNA inside the cells could also be confirmed by labelling 
the DNA prior to complexion with the peptoid. 
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CHAPTER 5 : UNLABELLED NONALYSINE-LIKE 
PEPTOID AS AN ANTIBIOTIC (COLLABORATION 
WITH DR. KEVIN DHALIWAL)  
5.1.  Small peptides and peptoids as antimicrobial agents 
5.1.1. Bacteria-Introduction 
Bacteria are prokaryotic cells with a size range from 0.1 up to 10 micrometers (linear 
dimension). These microorganisms possess a simple structure. The cytoplasm is 
protected by a tough protective coat, the so-called cell wall. In comparison to 
eukaryotes, prokaryotic organisms are devoid of a specific defined cell nucleus. 
Indeed, the genetic material of the organism, circular DNA contained within the so-
called nucleoid, which is located into the cytoplasmic compartment, as well as the 





Figure 5.1: Schematic representation of both types of cells, prokaryotic on the left and 
eukaryotic on the right. 
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Bacteria are characterised using two major criteria. The first is the morphology of the 
bacteria (size, shape and organisation), namely rod-like, spherical and spiral 
(helical). The second criterion is based on the cell wall structure. The bacteria cell 
wall is composed of liposaccharides, proteins and peptidoglycans. Using the Gram’s 
method or Gram staining, bacteria can be sorted as a function of their percentage of 
peptidoglycans present in the cell wall.
245
 This colorimetric technique, based on 
crystal violet, was published in 1884 by Hans Christian Gram.
246
 Using this protocol, 
bacteria are readily separated into two large groups: Gram positive (stains purple) 
and Gram negative (stains pink) bacteria. Gram positive bacteria (e.g. 
Staphylococcus aureus) have a thick cell wall consisting of three layers, which are 
(going from the exterior to the inside) peptidoglycans (at least 50% of the whole cell 
wall), periplasmic space and the plasma membrane (lipid bilayer). Gram negative 
(e.g. Escherichia coli) have a thinner cell wall composed by five layers starting 
outside with outer membrane (lipopolysaccharides and proteins), periplasmic space, 
peptidoglycans (10% of the whole cell wall), periplasmic space and finishing inside 
by the plasma membrane. 
Bacteria are present everywhere
247
 including in Human body with 10
13
 bacteria in the 
human gut,
248
 therefore all the bacteria are not harmful. Nevertheless, several species 





 and Lyme disease (Borrelia burgdorferi)
251
 are 
human illnesses mediated by bacteria. In developed countries, a major concern is 
community-acquired pneumonia. This infection contracted during hospitalisation is 
mainly caused by three bacteria: Streptococcus pneumoniae, Haemophilus influenzae 
and Moraxella catarrhalis.
252
 Meanwhile worldwide the most fatal bacterial malady 
is tuberculosis (Mycobacterium tuberculosis), with 9.3 million new cases in 2007 





Antibiotics are, by definition, substances that work against bacteria by killing them 
or inhibiting their growth. The first modern antibiotic, penicillin 5.1 was discovered 
in 1929 by Alexander Fleming, with the clinically useful antibiotic benzylpenicillin 




 but nowadays many antibiotics are known and 
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used daily. They are often classified according to their target. For instance, 
quinolones (e.g. nalidixic acid 5.2) inhibit DNA gyrase and therefore DNA 
replication,
256
 while aminoglycosides (e.g. streptomycin 5.3) block the synthesis of 
proteins by binding to a ribosomal subunit preventing the translocation of mRNA to 
proteins.
257
 As far as the penicillin family (penicillin and cephalosporin) is 
concerned, it prevents the cross-linking of peptidoglycans.
258
 Peptidic chains of 





Figure 5.2: Structures of some common antibiotics. 
5.1: penicillin G (benzylpenicillin), 5.2: nalixidic acid, 5.3: streptomycin and 5.4: general structure of 
fluoroquinolones. 
 
Even though antibiotics have proven their worth (estimated in 2002 to up to 200 000 
tonnes of antibiotics per year), their excessive use is partially responsible for a 
problem known as antibacterial resistance.
260
 This medical issue is not new as it was 
first observed in a military hospital in 1938.
261
 Bacteria thus protect themselves from 
antibiotic treatments thanks to one or several genetic modifications. These changes 
are manifold and may allow decreasing the cell wall permeability, blocking the drug 
binding site or deactivation of the drug.
262
 Unfortunately, antibacterial resistance has 
kept increasing generating major concerns within the medical community leading to 
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complications and numerous fatal outcomes, and warnings of a return to the pre-
antibiotic era.  
Antibacterial resistance is not the only issue to this treatment. Side effects, low 
efficiency and low bioavailability
263
 at sites of chronic infection are known problems 
linked to antimicrobial cure. For instance, fluoroquinolones (5.4, Figure 5.2) are 
often associated with adverse gastrointestional reactions, central nervous system 
disorders or photo-toxicity.
264
 Another limitation to antibiotic treatment is access to 
the intracellular niche.
265
 These intracellular niches are small pockets located in the 
eukaryotic cells. These niches can contain bacteria inactive or duplicating without 
affecting the cells. Later on, these “dormant” bacteria can get released into healthy 
cells and generate infection. Helicobacter pylori, as an example, are bacteria 
involved in peptic ulcer disease, have shown the ability to penetrate epithelial cells 
and to survive inside macrophages and neutrophils.
266
 Even if the bacteria within 
these sites are often non-multiplying, they act like a reserve, from where multiplying 
bacteria can easily emerge and generate chronic infections.
267
 One solution to this 
issue could be based on the study of the antibacterial potential of natural compounds 
known to cross both eukaryotic and prokaryotic cell membranes like peptides.  
 
5.1.2.1. Antimicrobial peptides (AMPs) 
In 1925, Gratia reported that some peptides were toxic to certain strains of 
Escherichia coli.
268
 These peptides were the bacteriocins, synthesised ribosomally 
but with extensive post-translational modifications. The most famous of these 
peptides, nisin 5.5 (Figure 5.3) was discovered in 1933 by Whitehead
269
 and isolated 
in 1947 by Mattick and Hirsch.
270
 This 34 amino acid polycyclic peptide was 
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Figure 5.3: Structure of the commercial nisin (5.5). 
 
Nevertheless bacteriocin peptides were not the only class of molecules to gain the 
attention of scientists. For more than 50 years, peptides have been described in the 
literature for being able to penetrate the bacterial cell wall.
272
 At first, most of these 
peptides did not seem to possess any other activity than being bacteria’s nutriments. 
Nevertheless, in the early 1980’s, cationic peptides possessing antibacterial activities 
were discovered in the cecropia moth.
273
 Since this discovery, any peptide with toxic 
effects on bacteria has been termed as antimicrobial peptide (AMP). This 
breakthrough continued with the publication of a family of cationic peptides, termed 
the Magainins (e.g. magainin-1, 23 AAs), which was isolated from the skin of a Sub-
Saharian frog, Xenopus laevis.
274
 This group of AMPs is composed of 23-27 amino 
acids that organize themself into amphipathic α-helices able to penetrate the cell-
wall.
275
 Defensins (e.g. Human Beta-Defensin 1, HBD1, 68 AAs) are another famous 
family of AMPs. These cationic peptides often contain 6 to 8 cysteines that generate 
disulfide bridges and form β-sheets. The killing process of defensins is based on the 
permeabilisation of the bacterial cell wall allowing the uncontrolled penetration and 
efflux of small molecules into the cytoplasm. Once within the bacteria, these small 
compounds can inhibit RNA, DNA and protein synthesis leading
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Nowadays, more than 850 eukaryotic and prokaryotic AMPs have been listed in 
databases
277
 and some of them are commercially available, such as Nisin
278
 (5.5, 
Figure 5.3) and Gramicidin
279
 (5.6, Figure 5.4).  
 
 




In Nature, a large diversity of antimicrobial peptides (sequences and structures) 
exists preventing or delaying antimicrobial resistance. At this time, even if some 
papers described some examples of antibiotic resistance towards some AMPs,
280, 281
 
they remain the type of antimicrobial treatment having so far demonstrated the 
smallest resistance while showing potent effects.
282, 283 
Nevertheless, as for the CPPs 
(CHAPTER 1) and peptides in general (except for instance cyclic peptides,
284
 
proline and D-amino acids based peptides
285
), antibacterial peptides can be very 




The use of analogues of theses peptides can be considered allowing them to retain 
biological activity while increasing the resistance against proteases and controlling 
the cytotoxicity to the host cell. 
 
5.1.2.2. Use of peptoids as antibacterial agents 
N-substituted glycines have been reported to be an efficient peptidomimetics of 
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Thanks to their structure (N-substituted rather than α-carbon-substituted glycine), 
peptoids have demonstrated a higher resistance to proteolysis compared to the 
analogous peptides, while remaining similar biological activity.
289
  
Peptoids as antibacterial agents were first reported by Goodson in 1999.
290, 291
 Using 
combinatorial chemistry, a library of trimer peptoids was synthesised and screened 
for antibacterial activity. Trimers were tested using a growth inhibition assay against 
Staphylococcus aureus (gram positive) and Escherichia coli (gram negative).
291
 
Using these data, a series of peptoids containing DHAA (dehydroabiethylamine, 5.7, 
Figure 5.5) was identified. DHAA possesses antibacterial activity and is structurally 
similar to totarol (5.8, Figure 5.5), a natural compound with anti-staphylococcal 
activity.  
 
         
Figure 5.5: Structure of DHAA (5.7), totarol (5.8) and DHAA-trimer peptoids (5.9 and 5.10). 
 
DHAA-trimer peptoids (5.9) were shown to have efficient in vitro bactericidal 
activities against various bacteria (gram positive and gram negative). In vivo studies 
demonstrated 100% survival of mice infected with S. aureus after treatment with 30 
mg/kg of trimer 5.10 (Figure 5.5).
292
 Although these results were very promising and 
demonstrated the potential of peptoid as antibiotic, the next paper based on a peptoid 
as an antibacterial agent was published four years later by Messeguer.
292
 Using a 
submonomer approach, the synthesis of 10648 peptoids was carried out. These N-
substituted glycine trimers were screened against six bacterial strains (including 
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Staphyloccocus aureus (gram positive) and Pseudomonas aeruginosa (gram 
negative)). From this study, one potential trimer peptoid (Figure 5.6, 5.11) was 
isolated. Surprisingly, this hit (5.11) had a similar structure to Goodson’s agent (5.7) 
but with a lower efficiency (similar MIC data but at least 2.5 less potent for MBC 
assays). The same year, 2003, two new classes of antibacterial peptoids were 
synthesised. The first class was made with at least three N-substituted glycine units 
and mimicked natural or non-natural AMPs.  The family of compounds, published by 
Barron, were named as AmPetoids, or anti-microbial peptoid oligomers.
293
 After 
publishing a paper with Zuckermann on the synthesis of stable α-helical peptoids,
294, 
295
 Barron reported the design and the antibacterial character of a peptoid series that 
mimicked the antibiotic Magainin-2-amide.
293
 All these oligomer structures were 
composed with N-lysine and N-α-chiral side chains, such as N-phenylethyl. These 
two kinds of N-substitution were used to generate an amphipathic α-helical 
secondary structure. The highest antibacterial efficiency was achieved by a 12mer 
(5.12) made of N-(4-aminobutyl)glycine (NLys) and (S)-N-(1-phenylethyl)glycine 
(Nspe) residues only (Figure 5.6, 5.12). This analogue showed the lowest MIC 
against both gram positive (0.82 ± 0.14 µg/mL) and gram negative (5.4 ± 0.9 µg/mL) 
bacteria. Furthermore, using these MIC concentrations, peptoid 5.12 did not 
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 5.12: 12mer peptoid mimicking magainin-2-amide based on NLys 
and Nspe units,
293





Another class are the hybrid or mixed peptide-peptoids. Robisson was pioneer in this 
area with the synthesis of hybrid protegrin-I mimics.
296
 They substituted into their 
lead peptide mimic
297
 one or more lysines and arginines by at least one NLys peptoid 
residue. One of these hybrids (Figure 5.6, 5.13) showed a higher efficiency 
compared to the lead peptide (up to 2 times more efficient for MIC assays) against 
both gram bacteria but was less potent compared to protegrin (16 fold less potent in 
MIC assays). The hybrid (5.13) showed almost no hemolysis (0.5%) while the 
natural antibiotic hemolysed 37% of the human red blood cells at 100 mg/mL. Some 
antibacterial studies have been carried out using β-peptoids, but so far β-peptoids 
have not shown a good efficiency-toxicity ratio (toward red blood cell).
298
 Hybrids 
have been also studied by Shin.
299
 His work consisted of the substitution of a few key 
amino acids inside a known peptide by a N-substituted glycine, for instance of a 
proline unit was replaced by an N-alanine (NAla).
300
 Hansen isolated a peptoid lead 
(Figure 5.7, 5.14) that was composed by three different N-substituted glycines.
301
 
Using these results, 20 new peptoid-peptide hybrids were prepared by introducing 
one or several lysine units (up to six Lys, outside 5.15 or mixed 5.16) to the peptoid 
lead core (5.14). These both hybrid matched the MIC values of the peptoid 5.14 
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(MIC values for S. aureus: 5.14 and 5.15 = 2 and 5.16 = 5 µM) while decreasing 
dramatically hemolysis (from 100% for 5.14 down to 4% for 5.15 and 6% for 5.16 at 
50 μM). Nevertheless none of these hybrids have been tested in vivo. Many papers on 
peptoid oligomers as antibiotics have been published by the Barron group, such as 
helical peptoids (based on 5.12)
302
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In this chapter, the naked 9mer, termed nonalysine-like peptoid, (NLLP, Figure 5.8, 
5.17) was studied as an antibacterial agent. The term NLLP was used to emphasise 
the difference between the labelled peptoid and the non-labelled one.  
 
 
Figure 5.8: Structure of NLLP (nonalysine-like peptoid) 5.17. 
 
This peptoid core has already been reported (CHAPTER 2 and CHAPTER 3) as an 
efficient and non-toxic cellular penetrating compound in both in vitro and in vivo. 
Here its antimicrobial properties were explored. 
 
5.2. Synthesis, purification and quantification of the nonalysine-like 
peptoid (NLLP) 
5.2.1. Solid-phase synthesis and analysis of the NLLP before purification 
As described in the CHAPTER 2 (Scheme 2.12), the peptoid 5.17 was prepared 
using a monomer strategy followed by a microwave assisted solid-phase synthesis. 
However, at the time of this project (between July 2008 and December 2010) the use 
of the coupling reagent HOBt was restricted.
304,305
 Thus, the solid-phase synthesis 
couplings were carried out in the same conditions than HOBt/DIC but HOBt was 
replaced by oxyma (Figure 5.9, 5.18)
306
 using 3 equivalent of reagents at 60
o
C for 20 
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minutes (microwave) and a concentration of 0.2 M. Coupling completion was 
confirmed using ninhydrin
129




Figure 5.9: Structure of the coupling reagent oxyma (ethyl 2-cyano-2-(hydroxyimino)acetate, 
5.18). 
 
Once the nine units of N-Fmoc-N-(6-N’-Boc-aminohexyl)-glycine (2.22) were 
coupled on to the Rink amide polystyrene resin, the Fmoc group was removed and 
NLLP 5.17 was Boc-deprotected and cleaved from the resin. NLLP peptoid (5.17) 
was analysed by 
1
H-NMR, MS (Appendix 5-2) and HPLC (Figure 5.10).  
 
 
Figure 5.10: HPLC trace (ESLD) of the unpured NLLP (5.17). 
 
The synthesis of the peptoid 5.17 was a success, however, the exact yield of this 
reaction was difficult to calculate due to the high hygroscopic character of the NLLP 
(based on the theoretical loading capacity (Equation 6.2)
307
, the mass was superior 
to what was expected).  
In addition due to its nature it eluted very rapidly by HPLC (Figure 5.10). An exact 
quantification of the NLLP peptoid and its purification were essential before starting 
any biological assays. Therefore, a solution was required to be able to separate and 
isolated the NLLP from the other materials (e.g. 8mer, 7mer, etc…). 
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5.2.2.  Purification of the NLLP 
5.2.2.1. Design of the purification protocol 
In order to separate the several peptoids (9mer, 8mer,…), one solution was to the 
decrease the hydrophilicity of the peptoids thanks to protecting groups. During the 
SPPS of the NLLP, amino groups on the side chains were protected with Boc groups. 
The initial idea was to keep the Boc groups during the cleavage of the NLLP from 
the Rink amide polystyrene resin. Until now, the only publication dealing with 
selective deprotection between Boc protective group and the Rink amide linker 
describes the deprotection of the tert-butyloxycarbonyl while the peptides were still 
attached on the resin.
308
 Therefore, a new method allowing the cleavage of the 
peptoid from the Rink amide polystyrene resin without deprotection of the Boc side 
chains was required. Before investigating the peptoid cleavage from the resin, the 
stability of the Boc group against TFA was determined using Fmoc-Lys(Boc)-OH 
and different concentrations of TFA. The reactions were monitored after 
neutralisation (using Et3N) by HPLC and MS. 
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Graph 5.1: Boc group stability against TFA in DCM. 
Blue line: % of Fmoc-Lys(Boc)-OH; Red line: % of Fmoc-Lys-OH calculated from the HPLC trace 
(ELSD). 
 
Graph 5.1 showed that the Boc group was stable in solutions containing up to 3% 
TFA. A 10% TFA solution fully removed the Boc group in less than 30 minutes.  
 
 
Graph 5.2: Boc group stability against TFA in DCM/water (99:1). 
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Secondly, the effect of TFA in presence of water (1% in DCM) on Boc stability was 
also tested (Graph 5.2). For 10% TFA in DCM/water (99: 1), the addition of water 
clearly slowed down Boc removal and in 5% TFA in DCM/water, the Boc group was 
stable, even after 2 hours. Using these data, the cleavage of Rink amide linker will 
need to be carried out using a maximum of 5% TFA in DCM/H2O (99: 1). 
 
In order to cleave the Rink amide linker while keeping the amines protected, two 
strategies were tested: a traditional cleavage protocol and a flow band approach. Both 
techniques were applied on the trimer model (5.19, Figure 5.11-A).  
 
                                 
Figure 5.11: Structure of the 3mer lysine-like peptoids. 
 A) Fmoc and Boc protected 3mer peptoid on Rink amide polystyrene resin (5.19); B) Fmoc-3mer 
peptoid (5.20); C) Fmoc and Boc protected 3mer (5.21). 
 
Strategy 1: traditional cleavage protocol. 
The first test was inspired by Brown’s paper.
309
 In this publication, small alkylated 
molecules were prepared on the Rink amide polystyrene resin. The cleavage of these 
amide materials from the solid support was achieved over two 20 minutes treatments 
using a mixture DCM/TFA/H2O (95: 5: 1). For the first assay of this method, the 
same cleavage solution (DCM/TFA/H2O, 95: 5: 1) was applied onto the resin 5.19. 
Previously, data showed that the Boc group started to be deprotected after 15 minutes 
using 5% of TFA in DCM. The resin 5.19 was treated with TFA solution 
(DCM/TFA/H2O, 95: 5: 1) for 4 × 10 minutes cycle with the filtrate collected in 3% 
triethylamine (DCM) and analysed by HPLC and MS. The change of the resin colour 
was also monitored. For this first cleavage, the colour of the polystyrene beads has 
changed from yellowish to reddish and to very dark red (corresponding to the 
formation of a carbocation (Scheme 2.10, CHAPTER 2)). HPLC and MS analysis 
(Figure 5.12 and Appendix 5-3) of the filtrate revealed the presence of three 
C) A) B) 
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Graph 5.3 : Percentage of each product present at the end of each cleavage cycle. 
Treatment of the resin 5.19 with DCM/TFA/H2O (95: 5: 1), 4 cycles of 10 minutes. The percentage of 
products was calculated from the area of each peak by HPLC (ELSD). 
 
Graph 5.3 summarised the percentage of each product present in each cycle filtrate. 
From the third cycle of cleavage, only the fully deprotected compound was recovered 
in the filtrate. 
 
 
Figure 5.12: HPLC trace (ELSD) of the first cycle filtrate.  
tR = 2.8 min corresponded to Fmoc-3mer-NH2 (5.20); tR = 3.6 min corresponded to Fmoc-3mer-NH2 + 
1 Boc; tR = 3.6 min corresponded to Fmoc-3mer-NH2 + 2 Boc.  
 
Having three different Boc protected peptoids clearly did not help the purification 
process. To solve this problem, various conditions were tested, in which the 
percentage of TFA and the reaction time were changed (CHAPTER 6, 6.6.4.1). The 
peak corresponding (m/z = 1008.42 [M+H]
+
) to the protected 3mer peptoid 5.21 was 
only detected by MS analysis (Appendix 5-4) using DCM/TFA/H2O (96: 3: 1) for 2 
hours. Unfortunately, the quantity of protected peptoid 5.21 recovered was tiny and 
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unpure (mixture of protected and non-protected 3mer). Treatment of the orange 
remaining resin with 95% TFA in DCM showed that more than 90% of product 
(5.20) was still attached to the solid support.  
 
Strategy 2: Flow chemistry. 
A flow cleavage was carried out.
310
 A continuous flow of TFA solution was passed 
through the resin 5.19 before being collected into a solution of TEA (3% in DCM). 
The filtrate was analysed by HPLC and MS while the resin colour and the formation 
of precipitate (in diethylether) were also observed.  
From the previous experiments, the addition of water clearly slows down the 
deprotection of the Boc group. Initially, solutions containing between 2 and 5% TFA 
in DCM/water (99: 1) were tested. As no cleavage product was detected or observed 
(resin color and precipitation), the percent of TFA was increased up to 10%. Only 
from 8% TFA were cleavage products observed, but once again it was a mixture of 
peptoid fully or partially deprotected. 
As neither of these two methods allowed selective cleavage of the Rink amide 
polystyrene resin, another approach was applied. The principle was to fully deprotect 
the peptoid (including the terminal Fmoc group) and then reprotect each amino group 
with a Boc group.  
 
5.2.2.2. Synthesis and purification of Boc-9mer(Boc)9-NH2 
The 9mer peptoid resin 2.33 was Fmoc deprotected (20% piperidine in DMF) and 
then Boc deprotected and cleaved from the solid using TFA/TIS/H2O (95: 2.5: 2.5). 
The peptoid isolated 5.17 was precipitated in cold ether before being Boc protected. 
 
 
Scheme 5.1: Synthesis of Boc-9mer(Boc)9-NH2 peptoid (5.22). 
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The peptoid 5.17 unpure was dissolved in water with triethylamine (pH>10) before 





 Once Boc-protected, the peptoid started to precipitate out of the solvent 
leading to a mixture of partially protected and fully protected peptoids. In order to 
solve this issue, the peptoid 5.17 was first dissolved in water with triethylamine as 
above (pH>10). A solution of Boc2O (11 equivalents) in dichloromethane was then 
added to the aqueous solution of peptoid. The biphasic system was mixed for an 
hour. This version of Boc protection offered an easy isolation of the compounds with 
fully protected peptoid (5.22) automatically transferred into the organic phase. The 
Boc protection was carried out with 100% conversion calculated by HPLC analysis 
(Figure 5.13) (MS data: Appendix 5-5).  
 
 
Figure 5.13: HPLC trace (ELSD) of crude Boc-9mer(Boc)9-NH2 peptoid (5.22). 
 
The several peptoids were separated using preparative HPLC and the Boc-
9mer(Boc)9-NH2 was isolated in a final yield of 80% (calculated from the theoretical 
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Figure 5.14: HPLC trace (ELSD) pure Boc-9mer(Boc)9-NH2 peptoid (5.22). 
 
5.2.3. Quantification by NMR 
Usually, the concentration of the peptoid solution was calculated using UV or 
weight. However, due to the highly hydroscopic character of the NLLP, the 
concentration was calculated using quantitative NMR (qNMR). NMR is typically 
used for qualitative purpose but can also be used as a quantitative analytical tool 
(quantitative NMR (qNMR)) and can be applied to all atoms possessing a nuclear 
spin. In the literature, qNMR refers to proton quantitative NMR. The interest in this 
quantitative technique has increased continuously over the past 40 years, especially 
thanks to the work of Turczan.
312
 Several studies have demonstrated the power of 
this technique and its small error (0.5 to 2% range). In order to achieve a 
reproducible quantitative analysis, quantitative experimental conditions, post-
acquisition processing and the choice of internal standard are three crucial factors.
313
  
Efficient quantitative proton NMR required several parameters to be modified by the 
user: 
- D1: relaxation delay in seconds, 
- NS: number of scans, 
- AQ: acquisition time in seconds. 
For the following experiments, the temperature was fixed at 298 K and the samples 
were not spun. Spinning samples are usually used to improve the line shapes. This 
eliminates the need to adjust manually shims (shims are adjusted to have the 
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narrowest and most uniform line shape possible). Once all the shim axes are set up, 
all the other parameters can be modified.  
Before starting a quantitative NMR experiment, the choice of an appropriate internal 
standard is essential. Efficient internal standard must possess all the following 
criterions: 
- high purity, 
- stable and chemically inert, 
- non volatile, but with a boiling point allowing removal by evaporation, 
- non hygroscopic, 
- soluble in the NMR solvent, 
- non interfering signal with the analyte ones.
313, 314
 
Several organic compounds have already proven their efficiency as internal standard, 









       
 
Figure 5.15: Structure of internal standards for quantitative NMR. 
A) hexadimethyldisiloxane, 5.23; B) 1,4-dioxane, 5.24; C) 2,5-dimethylfuran, 5.25. 
 
For the quantitative NMR of 5.22, HMDS (5.23, Figure 5.15-B) was first thought. 
This internal standard has a singlet at 0.09 ppm (18H) corresponding to its six 
methylene groups and was previously used for quantitative NMR of β-peptoids.
315 
HMDS possess all the criterion for a good internal standard (boiling point 101
o
C) 
and its signal does not interfere with the protons of Boc-9mer(Boc)9-NH2. However, 
the 
1
H-NMR of 5.22 was run in deuterated chloroform (CDCl3) and this solvent 
contained some trimethylsilane (TMS). All the protons of TMS and HMDS have 
same chemical shifts at 0.09 ppm and overlap. Therefore, the integration of HMDS 
would not be accurate resulting in an incorrect and non-precise quantitative NMR. 
A) B) C) 
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In literature, the control of another criterion, the ratio between signal and noise, was 
described as crucial for a quantitative NMR analysis. The use of an internal standard 
with two signals allows a good calibration of the instrument (internal relaxation 
standard) and thus a good control of the ratio noise/signal. 2,5-dimethylfuran (2,5-
DMFu, 5.25, Figure 5.15-C) possesses two types of protons and all the conditions to 
be an efficient internal standard for qNMR (boiling point 92-97
o
C). The methyl 
protons (s, 6H, 2 × CH3) appear as a singlet at 2.27 ppm while the two heterocyclic 
hydrogens (s, 2H, 2 × CH) have a chemical shift of 5.85 ppm (Appendix 5-7). The 
quantitative NMR assay was carried out using 2,5-dimethylfuran as internal standard. 
The best relaxation delay (D1) was evaluated. From a previous paper, it was 
demonstrated that the best D1 for the 2,5-DMFu was 30 seconds.
314
 This result was 
confirmed with 
1
H NMR of 5.22 containing 2,5-DMFu (5.25) (Table 5.1 and 
Appendix 5-7). In this experiment, the integration of the two heterocyclic protons 
(CH=CH) was fixed at 2 and the integration of the methylene hydrogens were 
measured. The best D1 for 2,5-DMFu (30 seconds) was obtained when the ratio 
between the two signals (CH3 and CH) was equal to 1.00 to 3.00. The error with a 
D1 of one second was equal to 5.7% with little error observed with a D1 of 10 (error 






(δH = 5.85 ppm) 
Integration 2 × 
CH3  
(δH = 2.27 ppm) 
Ratio between the 
two signals 
1 2 6.34 1 : 3.17 
10 2 6.04 1 : 3.02 
30 2 6.00 1 : 3.00 
Table 5.1: Relaxation delay assays on 2,5-dimethylfuran. 
1
H NMR parameters used for this experiment: NS = 16, AQ = 2 sec, no spin, 400 MHz. 
 
 
Relaxation time (T1) and relaxation delay (D1, D1 = 5 × T1) are inversely 
proportional to molecular weight.
314
 The 2,5-DMFu (5.25) has a molecular weight 
(96.1 g/mol) much lower than the protected peptoid 5.22 (2422.7 g/mol), therefore a 
D1 of ten seconds should be enough for obtaining a relaxation of the peptoid protons. 
This theory was proved by measurement of integration of two types of peptoid 
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hydrogens (NCH2O, δH = 4.12 ppm and CH2CH2N, δH = 3.32 ppm). The ratio 






(δH = 3.32 ppm) 
Integration 
NCH2O  
(δH = 4.12 ppm) 
Ratio between the 
two signals 
1 10.14 10.20 1 : 1.005 
10 9.04 9.09 1 : 1.005 
30 9.03 9.09 1 : 1.006 
Table 5.2: Relaxation delay assays for the peptoid 5.22. 
1
H NMR parameters: NS = 16, AQ = 2 sec, no spin, 400 MHz. 
 
As expected, the Boc-9mer(Boc)9-NH2 peptoid (5.22) with a higher molecular 
weight was less sensitive to the relaxation time delay than 2,5-DMFu. In order to 
have a good ratio for the internal standard and a fair experiment time, the following 
spectra were acquired using a D1 of 10 seconds.  
Once the relaxation delay was set up, the next parameters to be adjusted were the 
number of scans (NS) and the acquisition time (AQ). Both factors were modified 
(NS tested = 16, 32, 64 and 128; AQ = 2, 16 and 32 seconds) without affecting the 
ratio N/S neither between two integrations (6.6.6.2). Therefore, the NMR parameters 
for the quantitative assays were the following: NS = 16, AQ = 2 seconds, D1 = 10 
seconds, T = 298 K, CDCl3 as solvent and 400 MHz (irradiation frequency). 
Now that the experimental parameters were defined, the effect of concentrations was 
studied. In case of one of the both concentrations is much higher than the other, the 
ratio N/S for the lower concentrated compound will not be correct. In order to simply 
the process, commercially available Fmoc-Lys(Boc)-OH was used. One solution 
with a precise concentration was prepared in CDCl3 for each compound (analyte: 
Fmoc-Lys(Boc)-OH and internal standard: 2,5-DMFu). The both solution were 
mixed together in order to increase the concentration of the internal standard in 
comparison to the one of the analyte. Once mixed, each sample was analysed and the 
integration of one type of proton for each molecules were recorded. To ensure a good 
quantification, the peaks chosen must have a good baseline and not overlap with 
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another signal. From these two criterions the following protons were used for the 
quantification: 
- Analyte: d, δH = 7.75 ppm, 2H, ArCH-Fmoc; 
- Internal standard: s, δH = 5.87 ppm, 2H, CH. 
From the integrations and the concentration of the internal standard, the 
concentration of the analyte was calculated for each sample. In the Table 5.3, the 
ratio between the both concentrations was calculated from the expected 
















0.8 2.56 68.7 53.5 : 1 
1.4 4.26 67.1 27 : 1 
1.6 4.52 64.6 20 : 1 
3.73 3.95 5.5 4.5 : 1 
4.2 4.17 0.7 3 : 1 
4.8 4.77 0.6 1.5 : 1 
 
Table 5.3: Effect of the concentration variation between the internal standard and the analyte 
by qNMR. 
Internal standard: 2,5-dimethylfuran (5.25); analyte: Fmoc-Lys(Boc)-OH. Concentration expected was 
calculated from the mass of Fmoc-Lys(Boc)-OH used for each sample. Concentration calculated was 
determined by qNMR. 
The data obtained during these concentration experiments (Table 5.3) clearly shown 
that the highest the concentration of the standard increased was compared to the 
analyte concentration, the bigger was the error. The best results were obtained when 








H NMR of the protected peptoid Boc-9mer(Boc)9-NH2 
Peptoid 5.22 (concentration estimated at 6 mM by weight) and 12 mM of 2,5-DMFu 
(5.25) in CDCl3 were analysed by NMR using the following parameters: 400 MHz 
(irradiation frequency), NS = 16, AQ = 2 seconds, D1 = 10 seconds, T = 298 K. 
The calculated concentration was 5.86 mM with an error of 2.9%. The quantified 
protected peptoid 5.22 was then deprotected before being evaluated as an 
antimicrobial agent. 
5.2.4. NLLP via N-tert-butyloxycarbonyl deprotection 
The peptoid 5.22 (Boc protected) was deprotected under acidic to give the NLLP 
5.17. 
5.2.4.1.  Boc deprotection using 1,4-dioxane/HCl (4N) 
4 N HCl in 1,4-dioxane allowed efficient and rapid Boc deprotection at room 
temperature in 1 hour.
317
 Although this method was efficient for the Boc removal, it 
was difficult to eliminate all the traces of the dioxane. Purification was achieved by 
multiple lyophilisations (10 times) of the NLLP (5.17). 72 mg of the final compound 
5.17 were isolated. This mass was greater to what was expected (by quantitative 
NMR) due to the remaining traces of 1,4-dioxane (estimated by 
1
H NMR to 2.7 mg, 
Appendix 5-8) that could not be totally removed. In addition, the hygroscopic 
property of the NLLP-HCl salt lead to an increase in weight. This Boc deprotection 
was time consuming and did not allow the isolation of clean pure peptoid. 
5.2.4.2. Boc deprotection using trifluoroacetic acid 
Full deprotection of the peptoid was carried out at room temperature using 20% TFA 
in dichloromethane. After an hour, all the Boc groups on the peptoid 5.22 were 
removed. The DCM and TFA were rapidly removed under vacuum and the pure 
NLLP (5.17) did not require any further treatment. The mass of the final compound 
(59 mg, expected 50 mg) was still greater than expected due to the hygroscopic 
property of the peptoid (5.17).  
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5.2.4.3. Boc deprotection using diethylether/HCl 
Unprotected peptides or peptoids precipitate in cold diethylether, allowing direct 
isolation of the compound. Boc removal of 5.22 was carried out using 1 M HCl in 
diethylether. The NLLP-HCl salt 5.17 was isolated after one hour of reaction. Once 
again the mass (65 mg) was higher than expected mass. Initial NMR analysis showed 
some remaining traces of diethylether but those were removed after several days 
under vacuum. 
5.2.5. Conclusions 
The NLLP 5.17 was successfully synthesised, purified, analysed (HPLC, MS 
(Appendix 5-9) and NMR (Appendix 5-10 and 5-11)) with a final yield of 75%. For 
this project the use of quantification by NMR was essential to know the exact 
concentration of NLLP as the pure peptoid was to be tested for its antimicrobial 
activity. However after purification the peptoid is highly hygroscopic, so after 
purification of the fully protected peptoid 5.22, its quantification was carried out 
using the internal standard 2,5-dimethylfuran (5.25). This internal standard allowed 
the optimisation of the relaxation delay which is a crucial parameter for efficient 
qNMR. In order to removal the acid labile protective group, the most efficient, clean 
and rapid technique was the use of 20% TFA in DCM. The pure peptoid was then 
tested for its antimicrobial activity. 
5.3. Antibacterial activity of the NLLP 
The antibacterial efficiency was evaluated in association with Jagath Kasturiarachchi 
(Ph.D. student in the Dr Kevin Dhaliwal group). All animal experiments were 
undertaken by Kevin Dhaliwal with an approved licence from the Animal Scientific 
Procedure Division of the Home Office, London, U.K.. 
5.3.1. Cellular labelling and NLLP cytotoxicity  
Efficient cellular penetration and non-cytotoxicity of labelled peptoids have been 
demonstrated in the previous chapters (CHAPTER 2 for Rho-9mer 2.37 and 
CHAPTER 3 for Cy7-9mer 3.28 and Cy5.5-9mer 3.29). This cellular carrier allowed 
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accessing to the cytoplasm of various cells lines such as HeLa, B16F10 and 
HEK293T and primary cells like monocytes and neutrophils.  
As the NLLP is a non-labelled compound, the efficiency of its cellular uptake is 
difficult to assess. As the core of the peptoid remained the same, the protonation of 
the labelled and non-labelled peptoid should be very similar. In addition previous 
data on cellular delivery carried out using labelled peptoid showed clear cell 
penetration. Thus, it was hypothetised that non-fluorescent NLLP (5.17), should have 
the same cellular penetration as its labelled homologues.  
 
Before applying the NLLP for bacteria killing, it is essential to prove its non-
cytotoxicity towards eukaryotic cells. Graph 5.4 showed that the NLLP was not 
toxic for all the tested cell lines and at all the tested concentrations. 
 
 
Graph 5.4: MTT assays of NLLP 5.17 in HeLa, HEK293T and B16F10 cells. 
HeLa, HEK293T and B16F10 cells incubated with peptoid 5.17 (1, 5, 10, 20 and 50 µM) for 24 hours 
before being treated with MTT. Healthy cells corresponded to 100 % cell viability. The errors bar 
represents the standard error of the average (n = 14).  
 
 
5.3.2.  In vitro antibacterial activity of NLLP 
Bacteria contained within the eukaryotic intracellular niche multiply very slowly.
267, 
318
 In this study, the pathogens used were all shown to persist in the intracellular 
niche
265, 319
 and are also major causes of morbidity and mortality. Pathogens within 
the Bcc complex (Burkholderia cepacia complex) are inherently resistant to all 
known antibiotics.
320
 The following bacteria were tested with the NLLP: 
-  S.aureus (Staphylococcus aureus): gram positive bacteria. 
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o MRSA: Methycillin-resistant Staphylococcus Aureus 
o MSSA: Methicillin-sensitive Staphylococcus aureus 
- B.cepacia (Burkholderia cepacia complex): gram negative bacteria. 
- P.aeuriginosa (Pseudomonas aeruginosa): gram negative bacteria. 
The non-dividing cultures of bacteria were left untreated in PBS or treated with 
NLLP (6.5, 12.5, 25, 50 or 100 µM) and the O.D.600 was measured using a 
spectrophotometer every hour over a 6 hour time period.  
 
 
Graph 5.5: Curves showing the killing activity of the NLLP against 4 non-multiplying bacteria. 
Data courtesy of Dr. Kevin Dhaliwal from MRC (Medical Research Council) Centre for Inflammation 
Research, Queen’s Medical Research Centre, University of Edinburgh. 
 
Under these conditions, NLLP displayed dose dependent antibacterial activity with a 
complete kill of MRSA, MSSA and P.aeuriginosa and a 1 to 3 log kill of Bcc. 
 
Transmission electron microscopy was used to analyse cell morphology. The 
experiment was carried out on P.aeuriginosa (PAO1) and S.aureus (RN6390) under 
non-multiplying conditions. Images (Figure 5.16) clearly showed major disturbances 
in their membranes after treatment by the peptoid. These images did not allow 
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defining an exact mechanism of action but the images of the colonies demonstrated 
the loss of filaments between the cells and a total disorganisation. The images of 
S.aureus cell showed that the septum was well defined in the case of healthy 
bacteria, whilst it was distorted under NLLP treatment. The distortion of the septum 
will play a major role in the malformation of the two progeny bacteria. As eukaryotic 
and prokaryotic cell membranes do not possess the same properties, the cationic 
charges on the peptoid could more affect the prokaryotic cell wall while mainting the  
eukaryotic cell integrity. 
 
 
Figure 5.16: Transmission electron microscopy of NLLP treated bacteria (P.aeuriginosa and 
S.aureus). 
Non-multiplying batecria treated with 100 µM of NLLP (5.17). Data courtesy of Dr. Kevin Dhaliwal 
from MRC (Medical Research Council) Centre for Inflammation Research, Queen’s Medical 
Research Centre, University of Edinburgh. 
 
 
In order to evaluate the real antimicrobial potential of the NLLP peptoid, it was 
important to determine the minimum inhibitory concentration (MIC). MIC 
determination was carried out using the same bacteria than in the non-multiplying 
test, growing in Mueller Hinton Broth (MHB).
321
  The absorbance was measured 
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every 15 minutes and at the end of an overnight experiment, bacteria cultures were 
plated for CFU determination to confirm kill effects. (n = 3 independent 
experiments). NLLP displayed a MIC100 against MSSA (400 µM) and MRSA (300 
µM) under these conditions. In comparison to the slow growth experiments, the 
MIC100 for these multiplying bacteria was obtained using higher concentrations of 
NLLP. The growth of Bcc also decreased, but MIC100 was not reached.  Similar 
results were obtained for P.aeuriginosa. NLLP clearly inhibited the growth of these 
both gram negative cells without achieving a MIC100 at the concentrations used in 
this study.  
 
 
Graph 5.6: Curves showing the killing activity of the NLLP on 4 multiplying bacteria. 
Data courtesy of Dr. Kevin Dhaliwal from MRC (Medical Research Council) Centre for Inflammation 
Research, Queen’s Medical Research Centre, University of Edinburgh. 
 
Even though the concentrations of NLLP required to completely kill multiplying 
bacteria were 3 fold greater than in non-multiplying conditions, the absence of any 
significant haemolysis at 60 fold higher concentrations (20 mM) than used in the 
MIC assays (300 µM) generates a favourable selectivity ratio (S.R.) for the clinical 
application of the NLLP. 
Although promising results were obtained for in vitro studies, in vivo experiments 
after show very often different data than the ones obtained in vitro. Therefore, it was 
essential to evaluate the in vivo activity of the NLLP.  
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5.3.3.  In vivo antibacterial activity of NLLP 
In order to determine whether the NLLP retained therapeutic antibacterial activity in 
vivo, a model of PAO1 pneumonic infection was developed. Mice received 10
7
PAO1 
lux (with intrinsic bioluminescence) via intratracheal instillation.
322
 30 minutes later, 
NLLP (2 mg/kg) was instilled into the murine lung. Whole body bioluminescence of 
the mice (9 hours after PAO1 lux administration) revealed the presence of the 
bacteria in the lungs and in all the airways (Figure 5.17, Control). Imaging clearly 
showed a decrease in luminescence intensity in the mice that were treated with 
NLLP. Almost no trace of bacteria was observed in the nose of mice which received 
the peptoid. These observations indicated the killing process of the bacteria. 
 
 
Figure 5.17: Luminescence capture of light using a in vivo PAO1 lux pneumonia model following 
treatment with NLLP (5.17). 
Data courtesy of Dr. Kevin Dhaliwal from MRC (Medical Research Council) Centre for Inflammation 
Research, Queen’s Medical Research Centre, University of Edinburgh. 
 
The efficiency of the NLLP as antibiotic was thus demonstrated for in vivo.  
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5.4. Conclusions 
In summary, the NLLP peptoid offers a new antibiotic approach. Although, this 
peptidomimetic does not possess a specific secondary structure or clear amphipathic 
properties, it demonstrated promising antibacterial activity. NLLP was able to kill 
both, non-growing and growing, bacteria. In addition, to its low cytotoxicity, this 
peptoid remains active during in vivo studies. All these findings suggest that the 
NLLP could offer a new direction in antimicrobial reagents. 
Even if these results are promising, the amount for peptoid used is still too high to be 
applied for clinical applications.
323
 In comparison with the antibiotic 5.12 
(ampetoid), the NLLP is less efficient (MIC of 5.4 µM against Gram negative and 
0.84 µM against Gram positive for the compound 5.12).
293
 The efficiency of the 
peptoid as antibiotic could be increased, for instance, by forcing α-helix secondary 
structure or by creating a proper amphipathic property via longer side chain, for 
example. This conformation change could be carried by introducing chiral centres or 
benzene ring. The helical structure could be obtained by π-interactions of several 
benzene rings. Finally, mechanical studies of the killing mechanism of the peptoid 
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CHAPTER 6 : EXPERIMENTAL SECTION 
6.1. General information 
All solvents and reagents were obtained from commercial suppliers and used without 
purification, unless otherwise stated. 
Thin-layer chromatography (TLC) was carried out using silica gel 60 F250 plates 
with a thickness of 0.25 mm. TLC plates were visualised by ultra-violet light (254 
nm) and/or with ninhydrin staining (0.3% ninhydrin and 3% acetic acid in n-
butanol). Column chromatography was carried out on Silica gel 60 (mesh 0.040-
0.063 mm) (Merck). 
1
H NMR spectra were recorded in the solvents indicated at 298 K on Bruker 
ARX250, DPX360, AVA400 or DMX500 spectrometers operating at 250, 360, 400 
and 500 MHz, respectively. 
13
C NMR spectra were recorded in the solvents 
indicated at 298 K on Bruker ARX-250, DPX360, or DMX500 spectrometers 
operating at 63, 90 and 126 MHz, respectively. Chemical shifts for proton and 
carbon spectra are reported on the δ scale in ppm and were referenced to residual 
non-deuterated solvent. All coupling constants (J values) were measured in Hz. 
Low resolution electrospray mass spectra (ES/MS) were recorded on an Agilent 
Technologies LC/MSD 1100 Quadrupole Mass Spectrometer (QMS) with an 
electrospray ion source.  
Matrix assisted laser desorption ionisation-time of flight (MALDI-TOF) mass 
spectra were performed using an Applied Biosystems Voyager-DE™ STR 
instrument and analysed with the Voyager Instrument Control Panel software. For 
peptoid and protein analysis, sinapic acid was used as a matrix and positive ion mass 
spectra were reported.  
High resolution mass spectrometry (HRMS) was recorded by the MS Section of 
the University of Edinburgh on a Finnigan MAT 900 XLP high resolution, 
double-focussing mass spectrometer.  
Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) was 
recorded by the SIRCAMS (School of Chemistry, Edinburgh) on a Bruker Daltonics 
12T SolariX Fourier Transform Ion Cyclotron Resonance mass spectrometer. 
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Microwave reactions were carried out using a Biotage Initiator instrument in sealed 
(vial caps, Biotage AB) heavy-walled Pyrex tubes (Biotage AB, size 2 mL or 5 mL). 
UV/Vis spectrophotometry was performed on an Agilent 8453 spectrophotometer 
using a 1 cm path length disposable cuvette (Fisherbrand). 
Fluorescence measurements were performed on a Jobin Yvon Spex Fluoromax 
spectrofluorometer or a FS900 spectrofluorometer. 
Infrared (IR) spectra were obtained on a Fourier transform IR Bruker Tensor 27 
Spectrometer (FTS) fitted with a Specac single reflection diamond attenuated total 
reflection (ATR) Golden Gate. All samples were run neat and frequencies are 
reported in cm
-1
 and only frequencies corresponding to significant functional groups 
are reported.  
Melting points (Mp) were determined using a Gallenkamp melting point apparatus. 
High pressure liquid chromatography (HPLC) analyses were performed using the 
following eluents:  
A: H2O + 0.1% FA;  
B: MeOH + 0.1% FA;  
C: H2O + 0.1% TFA;  
D: MeCN + 0.04% TFA; 
E: MeCN + 0.1% TFA. 
Analytical HPLC were performed on an Agilent 1100 analytical system with a 
Supelco Discovery
®
 C18, 5 μm, 5 cm column coupled to a Polymer laboratories 100 
ES evaporative light scattering detector (ELSD). HPLC grade eluents were 
employed, at a flow rate of 1 mL/min with samples filtered prior to injection. The 
following methods were used:  
 - Method 1 (eluents A and B): 5 to 95% B over 3 min, then 95% B for 1 min.  
- Method 2 (eluents A and B): 5 to 95% B over 6 min, then 5% B for 3 min.  
 - Method 3 (eluents C and D): 5 to 95% D over 6 min, then 5% D for 3 min.  
- Method 4 (eluents A and B): 85 to 95% B over 6 min, then 95% B for 3 
min.  
Preparative reverse phase-HPLC purifications were performed on an Agilent 
Technologies HP1100 Chemstation eluting on a Waters X-Terra RP18 preparative 
column (150 mm x 19 mm, 5 μm), at a flow rate of 2.5 mL/min. Detection was 
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carried out at 214, 254 nm and at the wavelength of the specific dye. The following 
gradients were used: 
- Gradient 1: 5 to 95 % E over 20 min, 95% E for 5 min.  
- Gradient 2: 85 to 95% E over 18 min, 95% E for 9 min.  
- Gradient 3: 15 to 55% E over 20 min, 55 to 95% E over 10 min, 95% B for 
5 min.  
- Gradient 4: 75 to 95% B over 18 min, 95% B for 9 min.  
Cell cultures were performed in a HERAcell 150 incubator from Heraeus. 
Cell experiments were carried out in a HERAsafe KS 18 class II negative-flow 
cabinet from Heraeus. 
Cell viability was assessed using a Bio-Rad microplate reader (Version 1.15) 
measuring absorbance at 570 nm. 
Flow cytometry was performed on a BD FACS Aria
® 
System using the BD FACS 
Diva
®
 software. The data were analysed using the software Flowjo
®
 7.5. 
Live cells were imaged on a Leica fluorescence microscope (DM IRB) under 
brightlight and the desired excitation wavelength (Filter I3 (450-490 nm) for GFP 
and FITC, Filter N2.1. (515-560 nm) for Rhodamine). 
Confocal microscopy was performed on a Leica SP5 Confocal. Zeiss 510 Meta 
software was used for digital acquisition. Deconvolution was carried out using the 
software AutoQuant X. 
 
For in vivo analysis: 
All animal procedures were performed by Dr. Kevin Dhaliwal with ethical review 
and licences. CD1 inbred mice aged between 6-12 weeks old were used. 
In vivo optical imaging was performed on the Xenogen Spectrum (Caliper LS) and a 
Visen FMT 2500. 
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6.2. General methods 
6.2.1.  Chemistry 
6.2.1.1. Qualitative ninhydrin test129 
The test was carried out on a few resin beads by the addition of 3 drops of reagent A 
and 1 drop of reagent B. The mixture was heated at 100°C for 5 minutes. A blue 
solution indicated the presence of free amine on the resin while a yellow solution 
corresponded to no free amine.  
Preparation of ninhydrin solutions A and B: 
Reagent A: 
 Solution 1: Reagent grade phenol (40 g, 0.43 mol) was added to absolute 
ethanol (10 mL) and the mixture was heated until complete dissolution of the phenol. 
Amberlite mixed-bed resin MB-3 (4 g) was added to the solution and stirred for 45 
minutes and filtered. 
Solution 2: KCN (65 mg, 1 mmol) was dissolved in water (100 mL). The 
KCN solution (2 mL) was diluted to 100 mL with pyridine (freshly distilled from 
ninhydrin). Amberlite mixed-bed resin MB-3 (4 g) was added, stirred for 45 minutes 
and filtered. Solution 1 and 2 were mixed. 
Reagent B: Ninhydrin (2.5 g, 14 mmol) was dissolved in absolute ethanol (50 mL). 
 
6.2.1.2. Quantitative ninhydrin test324 
A known mass of resin (5 mg) was placed in a small test tube and 6 drops of reagent 
A (6.2.1.1) and 2 drops of reagent B (6.2.1.1) were added. The mixture was heated at 
100°C for 5 minutes. The test tube was placed in a cold water bath, 60% aqueous 
ethanol (2 mL) was added and mixed thoroughly. The resin was removed by 
filtration through cotton wool and the deep blue filtrate collected in a 25 mL 
volumetric flask. The resin was washed with a solution of Et4NCl (0.5 M in DCM, 2 
x 0.5 mL) and the sample made up to 25 mL with 60% aqueous ethanol. The 
absorbance at 570 nm was measured three times against a blank solution and the 
average value was used. The level of amine present was calculated using the 
following equation (Equation 6.1): 
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Amount of primary amine (mmol/g) = [(A570 x V) / (ε570 x m)] x 10
3
 
Equation 6.1: Amount of primary amine residues (mmol/g), where A570 is the recorded 
absorbance at 570 nm, V is the final volume (mL), ε570 is an extinction coefficient suitable for 






) and m is the mass of resin (mg). 
 
6.2.1.3. Qualitative chloranil test130 
The test was carried out on a few resin beads by the addition of 1 drop of solution A 
and 1 drop of solution B. The mixture is shacked at room temperature for 3 minutes. 
Blue resin beads indicated free secondary amine group, whilst colourless resin beads 
correspond to no free secondary amine group. 
Chloranil solutions A and B: 
 Solution A: 2% of acetaldehyde in DMF 
 Solution B: 2% of chloranil in DMF 
 
6.2.1.4. Preparation of samples for MALDI-TOF MS. 
1 µL of compound solution (0.01 M in HPLC solvent) was loaded onto the MALDI 
plate. 1 µL of the specific matrix solution was added on top of the compound and 
mixed up and down. The plate was allowed to dry at room temperature for 10 
minutes prior to analysis. Sinapic acid matrix solution was used and prepared by 
dissolution of 15 mg of sinapic acid in 1 mL of 70% of H2O and 30% of ACN with 
0.1% of TFA. 
 
6.2.1.5. Calculation of the theoretical loading 
Theoretical loading of a resin after a reaction was calculated using the Equation 6.2. 
 
         SR loading  
      New theoretical loading  =  
          (mmol/g of resin)            [1 + (SR loading * Difference of Mw)/1000] 
 
Equation 6.2: Theoretical loading, where: “SR loading” is the loading of the starting resin 
(mmol/g) and Difference of Mw refers to the difference of formular weight between the product 
and the starting resin (g/mol). 
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6.2.1.6.  Solid-phase synthesis: generalities 
All peptoids were prepared on polystyrene resin (1% DVB, loading = 1.6 mmol/g) 
functionalised with a Rink amide linker. The functionalization of the solid support is 
described in section 6.3.5. The ratio of solvent-resin used for coupling washes was 
15 mL of solvent for 1 g of dry resin. The resin (100 mg) must be swollen for 20 
minutes at room temperature in DCM (1.5 mL). Fmoc deprotection and final Boc 
deprotection/resin cleavage steps were carried out in solid-phase extractor (SPE), 
polypropylene syringe equipped with a frit and a valve.  
All the following protocols are described for 100 mg of dry resin.  
 
6.2.1.7. Soli-phase synthesis coupling of monomer units, amino acids and dyes 
at room temperature 
The Fmoc-protected monomer unit, amino acid or dye (3 equiv., 0.2 M) and HOBt (3 
equiv., 0.2 M) were dissolved in DMF (0.2 M). DIC (3 equiv., 0.2 M) was then 
added to the solution and the mixture was stirred for 10 minutes at room temperature. 
The solution was added to the Fmoc deprotected pre-swollen resin and the mixture 
was mixed for 4 hours. The resin was then washed with three times with DMF (1.5 
mL) and DCM (1.5 mL). Coupling completion was monitored using the appropriate 
qualitative colorimetric tests (qualitative ninhydrin test for detection of primary 
amines (6.2.1.1) and qualitative chloranil test for detection of secondary amines 
(6.2.1.3)) and repeated if unsatisfactory. 
 
6.2.1.8. Solid-phase coupling of monomer units and amino acids under 
microwave irradiation 
The Fmoc-protected monomer unit or amino acid was activated as described earlier 
(6.2.1.7). The solution of monomer, DIC and HOBt in DMF (0.2 M) was added to 
the Fmoc deprotected pre-swollen resin and the mixture transferred into a 2.5 mL 
microwave vial containing a small stir bar. The Pyrex tube was capped with an 
aluminium crimp cap fitted with a silicon septum and introduced into the single-
mode microwave. The mixture was subjected to microwave irradiation at a 
temperature of 60°C for 20 minutes under magnetic stirring. The resin was then 
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transferred to a solid-phase extractor (SPE) and washed with DMF (3 x 1.5 mL) and 
DCM (3 x 1.5 mL). Couplings were monitored using the appropriate qualitative 
colorimetric test (qualitative ninhydrin test for detection of primary amines (6.2.1.1) 
and qualitative chloranil test for detection of secondary amines (6.2.1.3)) and 
repeated if unsatisfactory. 
 
6.2.1.9. Fmoc deprotection 
Fmoc deprotection was carried out by suspending the resin in 20% piperidine in 
DMF (1.5 mL) and shaking for 10 minutes. The resin was then filtered, washed with 
DMF (3 x 1.5 mL), DCM (3 x 1.5 mL). The treatment of the resin by 20% piperidine 
in DMF (1.5 mL) was repeated for another 10 minutes after which time the resin was 
washed with DMF (3 x 1.5 mL) and DCM (3 x 1.5 mL).  
 
6.2.1.10. TFA cleavage/deprotection and cold ether precipitation 
The resin containing the acid-labile protected peptoids, peptides or peptoid-peptide 
hybrids was washed with DMF (3 x 1.5 mL), DCM (3 x 1.5 mL), MeOH (3 x 1.5 
mL), Et2O (3 x 1.5 mL) and dried in vacuo on the manifold for 30 minutes. Once 
washed and dry, the resin was suspended in 2.5 mL of a mixture of TFA/TIS/H2O 
(95: 2.5: 2.5, or other specific mixture) and stirred for 4 hours (unless stated 
otherwise). After cleavage, the resin was separated from the solution by filtration and 
washed with 2.5 mL of TFA solution (25 mL per gram of resin). The TFA filtrates 
were collected and concentrated in vacuo (1 mL ca.). The concentrated mixture was 
then added dropwised in a centrifuge tube containing cold Et2O (12 mL). The 
precipitated peptoid was then sonicated and recovered by centrifugation. The solid 
was then washed with cold ether (12 mL) and centrifuged three times. After the last 





6.2.1.11. General Dde deprotection 
Dde deprotection was carried out by suspending the resin in 2% N2H4 in DMF (1.5 
mL) and shaking for 30 minutes. The resin was then filtered, washed with DMF (3 x 
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1.5 mL), DCM (3 x 1.5 mL) and re-suspended in 2% NH2OH-H2O in DMF (1.5 mL) 
and shaken for a further 30 minutes after which time the resin was washed with DMF 
(3 x 1.5 mL) and DCM (3 x 1.5 mL). 
 
6.2.1.12. Selective Dde deprotection in presence of Fmoc group204 
1.25 g (1.80 mmol) of NH2OH.HCl and 0.92 g (1.35 mmol) of imidazole were 
suspended in NMP (5 mL) and the mixture was sonicated until complete dissolution. 
Just before reaction, 1 mL of this solution was diluted with 0.2 mL of DCM. 
Selective Dde deprotection was carried out by suspending the resin in 1.2 mL of the 
freshly prepared mixture and shaking it for 3 hours at room temperature. The resin 
was filtered and washed with DMF (3 x 1.5 mL) and DCM (3 x 1.5 mL). 
 
6.2.2.  Biology 
6.2.2.1. Cell culture 
All cells were cultured at 37°C/5% CO2 in the appropriate culture medium (Roswell 
Park’s Memorial Institute (RPMI-1640, Sigma-Aldrich) medium for HEK293T, 
B16F10 and Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) for 
HeLa) supplemented with 10% of foetal bovine serum (FBS, Gibco), 100 U/mL 
penicillin and streptomycin and 4mM L-glutamine (Gibco). Cells were grown in T-
25 flask coated with 0.1% gelatine/PBS until 80-90% confluency. Old media was 
removed and cells were washed with PBS and were harvested via trypsination (0.5 
mL) (trypsin/EDTA, Gibco) at 37°C/5% CO2 for 5 minutes. The detached cells were 




Cell densities were determined by haemocytometry. An aliquot (10 µL) of cells 
detached from a T-25 flask and collected in growth media (total volume: 5 mL) was 
mixed with 0.2% trypan blue (40 µL, Sigma-Aldrich) and pipetted into a Bright 
Line™ haemocytometer (an etched glass device with an H-shaped moat forming two 
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cell-counting areas (with 4 quadrants in each area), with surface features enhanced 
by Neubauer rulings, Sigma-Aldrich). Cell concentration and the densities required 
for experiments were determined by Equation 6.3 and Equation 6.4 respectively. 
 
Concentration (cell/mL) = (N / Q) × 5×10
4
 
Equation 6.3: Concentration of cell/mL by haemocytometry, where ‘N’ is the total number of 
cells counted and ‘Q’ is the number of quadrants counted. 
 
VExp (mL) = (VTot × CWell) × (1000 / VWell) / CTot 
Equation 6.4: Volume of cells detached from T-75 flask (VExp) required in an experiment a total 
medium volume of VTot and a concentration per well of CWell. VWell is the volume required per 
well and CTot is the concentration of cells/mL as calculated in Equation 6.3. 
 
6.2.2.3. Cell labelling and flow cytometry analysis 
Detached cells in fresh media were seeded at appropriated density onto polystyrene 
well-plates (Nunc, Table 6.1). Cells were incubated (37°C/5% CO2) for 24 hours 
prior to peptoid treatment at the desired concentration (μM). After the desired 
incubation time, the old media was removed and cells washed with PBS. Cells were 
detached by trypsination at 37°C (trypsin/EDTA, 80 μL per well) and collected in 
2% FBS/PBS with or without 0.2% of trypan blue (final volume per well of 300 μL). 
Samples were analysed by flow cytometry using the appropriate filters according to 
the dyes under investigation (Table 6.2) using the BD Biosciences FACSDiva 
software. Results were analysed and histograms produced using the software FlowJo 
(see raw data on the attached CD-ROM). 
 
Well plate Density of cells per well Volume of media per well 
6 1 × 10
5 
2 mL 
12 6 × 10
4
 800 µL 
24 3 × 10
4
 350 µL 
96 1 × 10
4
 100 µL 
Table 6.1: Well plate characteristic for cell experiment 
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Laser Wavelengths (nm) Band Pass Filters Dyes 
633 780/60 (APC-Cy7-A) Cy7 







Fluorescein and eGFP 
Rhodamine B  
PI 
375 450/20 DAPI/HOECHST Blue 
Table 6.2: BD Biosciences FACSAria® system specifications (lasers and band pass filters) and 
corresponding fluorophores. 
 
6.2.2.4. MTT assays 
Cells were seeded into 96-well plates at a density of 1 × 10
4
 cells/well (100 μL per 
well). The last row of the well plate was used as a blank (no cells). Cells were 
incubated (37°C/5% CO2) for 24 hours prior to peptoid treatment at the desired 
concentrations. After the desired incubation time, the old media was removed and 
replaced with fresh phenol-red free medium (90 µL). 10 μL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) at 
concentration of 5 mg/mL in PBS buffer were added to the fresh media.  Cells were 
incubated for 3 hours (37°C/5% CO2) prior dissolving the formed formazan using 
100 μL of the solubilising solution (10% TRITON X-100, 0.1 N HCl in isopropanol) 
and gentle shaking for 1 hour. The 96-well plate was read on a microplate reader at 
570 nm and cellular viability was calculated according to the Equation 6.5. 
 
% of cellular viability = (Abs 570 exp / Abs 570 control) × 100 
Equation 6.5: Viability of cells as determined by a MTT assay, where “Abs 570 exp” refers to the 
absorbance at 570 nm of cells treated with peptoids and “Abs 570 control” refers to the absorbance 
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6.2.2.5. Confocal miscroscopy 
Cells were seeded onto 24 mm glass coverslips at a density of 1 × 10
5
 cells/coverslip 
(volume of culture media per well: 2 mL). Cells were incubated (37°C/5% CO2) for 
24 hours prior to peptoid treatment at the desired concentrations. After the desired 
incubation time with the peptoids, cells were washed with PBS (3 times).  Cells were 
fixed with 4% formaldehyde in PBS for 30 minutes. Nuclei were stained by 
treatment with a 10 µg/mL solution of HOECHST-33342 in media in 5 minutes at 
37
o
C. After PBS washes (3 × 2 mL), the membrane was stained using 1 nM of 1, 1’-
dioctadecyl-3, 3, 3’, 3’-tetramethylindocarbocyanine perchlorate (DilC 18) in Hank’s 
buffered salt solution (HBSS) (30 minutes), followed by six PBS washes (2 mL). The 
glass coverslip was mounted on a Leica SP5 microscope and cells were imaged 
confocally. DilC 18 was excited using a 595 nm excitation laser and collecting 
emission using a 670-690 nm band-pass filter. HOECHST-33342 was excited using 
an excitation laser at 405 nm and collecting emission using a 413-482 nm band-pass 
filter. Zeiss 510 Meta software was used for digital acquisition. Deconvolution was 
carried out using the software AutoQuant X.  
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6.3. Experimental for Chapter 2 




Di-tert-butyl carbonate (10.0 g, 46 mmol) in DCM (100 mL) was added drop-wise to 
1,6-diaminohexane (2.18) (42.5 g, 367 mmol) in DCM (150 mL) and the reaction 
was stirred for 3 hours. The solvent was evaporated under vacuum and the white 
solid was dissolved in H2O (200 mL). The aqueous phase was extracted using DCM 
(3 × 150 mL). The combined organic phase was then washed with brine (2 × 100 
mL), dried over MgSO4, and concentrated in vacuo to give pale yellow oil. The crude 
compound (2.19) was analysed and used for the next step without any further 





): C11H24N2O2 calculated   216.2; found 217.1 [M+H]
+




HPLC (Method 1): tR = 2.9 min, purity = 95% (ELSD). 
1
H NMR (CDCl3, 250 MHz): δ = 1.27-1.35 (m, 4H, BocNHCH2CH2CH2CH2CH2 
CH2NH2) 1.37-1.52 (m, 13H, BocNHCH2CH2CH2CH2CH2CH2NH2 and C(CH3)3), 
1.89 (br sg, 2H, CH2NH2), 2.68 (m, 2H, CH2CH2NH2), 3.14 (m, 2H, BocNHCH2), 
4.57 (br sg, 1H, BocNHCH2). 
13
C NMR (CDCl3, 63 MHz): δ = 26.5, 26.6 (BocNH(CH2)2CH2CH2CH2), 28.4 
(C(CH3)3), 30.4 (CH2CH2NH2), 33.1 (BocNHCH2CH2), 40.5 (CH2NH2), 41.9 
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A solution of benzyl-2-bromacetate (2.23) (5.3 mL, 33 mmol) in THF (25 mL) was 
added drop-wise to a stirred solution of N-Boc-1,6-hexanediamine  (2.19) (7.2 g, 33 
mmol) and triethylamine (14 mL, 99 mmol) in THF (50 mL) over 2 hours. The 
reaction was stirred for a further 2 hours. The THF was removed in vacuo. The white 
solid was suspended in Et2O (100 mL) and filtered. The solution was concentrated in 
vacuo and the crude product was purified by column chromatography (silica gel) 
using ethyl acetate as an eluent to yield compound 2.24 as a pale yellow oil (11.4 g, 





): C20H32N2O4 calculated 364.2; found 365.1 [M+H]
+




Rf: 0.36 (EtOAc). 
HPLC (Method 1): tR = 3.4 min, purity = 100% (ELSD). 
1
H NMR (CDCl3, 250 MHz): δ = 1.11-1.43 (m, 17H, BocNHCH2(CH2)4CH2 and 
C(CH3)3), 1.56 (br s, 1H, CH2NHCH2), 2.53 (t, J = 7.30 Hz, 2H, CH2CH2NHCH2), 
3.00-3.08 (m, 2H, BocNHCH2), 3.36 (s, 2H, NCH2CO), 4.46 (br sg, 1H, 
BocNHCH2), 5.08 (s, 2H, COOCH2), 7.26-7.43 (m, 5H, ArCH). 
13
C NMR (CDCl3, 63 MHz): δ = 26.8, 26.6 (BocNH(CH2)2CH2CH2CH2, 27.5 
(C(CH3)3), 31.5, 32.8 (BocNHCH2CH2(CH2)2CH2), 41.5 (BocNHCH2), 52.3 
(CH2CH2NHCH2), 61.5 (NCH2CO), 66.8 (NCH2COOCH2), 72.7 (C(CH3)3), 128.6, 
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Fmoc-OSu (10.5 g, 31 mmol) was added to a solution of 2.24 (11.3 g, 31 mmol) in 
DCM (100 mL). The reaction was stirred and monitored by TLC until completion (2 
hours). The solvent was removed in vacuo and the crude product was purified by 
column chromatography (silica) eluting with EtOAc/Hexane (1: 1) to yield 2.25 as a 





): C35H42N2O6   calculated 586.7 ; found 609.2 [M+Na]
+
 (100%), 487.2 [M-
Boc+H]
+
 (17.3%), 587.3 [M+H]
+
 (4.6%). 
Rf: 0.39 (EtOAc/Hexane, 1: 1). 
HPLC (Method 2): tR = 6.9 min, purity = 99% (ELSD). 
1
H NMR (CDCl3, 500 MHz): two rotamers δ = 1.15-1.53 (m, 17H, 
BocNHCH2(CH2)4CH2 and C(CH3)3), 3.21 and 3.50 (m, 4H, BocNHCH2 and 
FmocNCH2CH2), 3.99 and 4.03 (s, 2H, NCH2CO), 4.16 and 4.30 (t, J  = 6.10 Hz, 
1H, CH-Fmoc), 4.41 and 4.50 (d, J  = 6.15 Hz, 2H, CH2-Fmoc)), 4.55 (br sg, 1H, 
BocNHCH2), 5.19 and 5.21 (s, 2H, COOCH2), 7.29-7.45 (m, 9H, ArCH-Fmoc and 
Ph), 7.58-7.65 (m, 2H, ArCH-Fmoc), 7.69-7.72 (m, 2H, ArCH-Fmoc). 
13
C NMR (CDCl3, 126 MHz): two rotamers δ = 26.2, 26.4 
(BocNH(CH2)2CH2CH2CH2),  26.5,  27.8 (CH2CH2NCH2), 28.3 (C(CH3)3), 28.5, 
30.0 (BocNHCH2CH2), 40.5 (BocNHCH2), 47.3 (CH-Fmoc), 48.8 , 48.9 
(CH2CH2NCH2), 49.2 (NCH2CO), 66.9 (NCH2COOCH2), 67.0 (CH2-Fmoc), 79.1 
(C(CH3)3), 120.0, 124.8, 125.0, 127.1, 127.7, 128.3, 128.6 (ArCH-Fmoc and ArCH-
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Ph), 135.3, 135.4 (ArC-Ph), 141.3, 141.4 (ArC-Fmoc), 144.0 (ArC-Fmoc), 155.9, 
156.0, 156.4 (C=O-Boc and C=O-Fmoc), 169.5 and 169.6 (COOBn). 
 
6.3.4. Synthesis of [(6-tert-butoxycarbonylamino-hexyl)-(9H-fluoren-9-






Pd/C 10% (0.24 g) was added to a solution of 2.25 (8 g, 13.6 mmol) in ethanol (150 
mL). The air was purged with N2. N2 was removed by suction (vacuum) and H2 was 
slowly added thanks to a tap. The reaction was stirred under an atmosphere of H2 for 
4 hours. The reaction mixture was filtered through celite to remove the catalyst and 
the filtrate concentrated in vacuo. The product was purified by column 
chromatography (silica, eluting with DCM/MeOH, 1: 1) to yield 2.22 as a white solid 







): C28H36N2O6  calculated 496.3; found 397.0 [M-Boc+H]
+
 (100%),   519.1 
[M+Na]
+
 (74.3%), 497.1 [M+H]
+
 (4.6%). 
Rf: 0.42 (DCM/MeOH, 10: 1). 
HPLC (Method 2): tR = 5.9 min, purity = 100% (ELSD). 
1
H-NMR (CDCl3, 500 MHz): two rotamers δ = 1.03-1.36 (m, 17H, BocNHCH2 
(CH2)4CH2 and C(CH3)3), 2.97 and 2.99 (two br m, 4H, BocNCH2 and 
FmocNCH2CH2), 3.20 and 3.25 (br sg, 2H, NCH2CO), 4.02 (m, 1H, CH-Fmoc), 4.40 
and 4.46 (two m, 2H, CH2-Fmoc), 4.58 (br sg, 1H, BocNHCH2), 7.23 (m, 2H, ArCH-
Fmoc), 7.31 (m ,2H, ArCH-Fmoc), 7.49 (d, J =  7.00 Hz, 2H,  ArCH-Fmoc), 7.68 (d, 
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13
C-NMR (CDCl3, 126 MHz): two rotamers δ = 26.0, 26.3 
(BocNH(CH2)2CH2CH2CH2),   27.8 (CH2CH2NCH2),  28.1 (C(CH3)3),   28.4,  29.4 
(BocNHCH2CH2), 40.4 (BocNHCH2), 47.3 (CH-Fmoc), 48.5 (CH2CH2NCH2), 51.4 
(NCH2CO),  67.4 (NCH2COOCH2), 68.9 (CH2-Fmoc), 78.9 (C(CH3)3), 120.0, 124.8, 
127.0, 127.6 (ArCH-Fmoc), 141.3, 143.9 (ArC-Fmoc), 156.0, 157.5 (C=O-Boc and 
C=O-Fmoc), 167.6 and 168.2 (COOH).  
 




Fmoc-Rink linker (2.26, 4.3 g, 8 mmol) was coupled to aminomethyl polystrene 
resin (2.27, 1 g, 1.6 mmol) using the protocol 6.2.1.7. After coupling, the solid 
support was Fmoc deprotected using 20% piperidine in DMF (6.2.1.9). A new 
loading of the resin 2.28 was calculated using a quantitative ninhydrin test 6.2.1.2 
(0.86 mmol/g). 
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2.35 was synthesised on 2.28 and using the monomer 2.22. The resin (50 mg, 0.043 
mmol) was first swollen in DCM (0.75 mL) for 20 minutes. Each peptoid monomer 
unit (65 mg, 0.130 mmol) was coupled using the protocol 6.2.1.8 followed by Fmoc 
deprotection 6.2.1.9. These reactions corresponded to one coupling cycle. This 
coupling cycle was repeated 8 times in order to obtain the desired oligomer of the 
required length. The first monomer coupling was monitored by a qualitative 
ninhydrin test (6.2.1.1), while the following Fmoc deprotections and couplings were 
controlled using the chloranil test (6.2.1.3). The solid supported 9mer peptoid (2.33, 
0.27 mmol/g) was Fmoc deprotected and then coupled to Fmoc-aminohexanoic acid 
spacer 2.34 (46 mg, 0.130 mmol) using the coupling procedure 6.2.1.8 (monitored by 
chloranil test 6.2.1.3). The resin was washed with DMF, DCM, MeOH and Et2O (3 × 
1 mL) before being dried overnight at 40
o
C in a vacuum oven (299 mg). The new 
theoritical loading (6.2.1.5) calculated from the measured Rink amide resin (6.3.5) 
was 0.28 mmol/g. 
 




20 mg of the resin 2.35 was cleaved using a TFA/TIS/DCM (95: 2.5: 2.5) solution 




) C93H168N20O12 calculated 1757.3, found 440.34 [M+4H]
4+
 (20.2%), 352.5  
[M+5H]
5+
 (100%), 293.9 [M+6H]
6+
 (80.1%), 252.2 [M+7H]
7+
 (13.9%). 




m/z (FT-MS) C93H168N20O12 calculated [M+2H]
2+
 879.66535, found 879.67800. 
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HPLC (Method 4): tR = 2.8 min; purity = 100% (ELSD, 254 nm) 
1
H NMR (500 MHz, D2O, eSpresat water suppression) δ = 1.58-1.72 (m, 78H, 72H 
for NH2CH2(CH2)4CH2-9mer (H2,3,4,5), 6H for CH2(CH2)3CH2-Ahx (H3’, 4’, 5’)), 2.1-
2.21 (m, 2H, COCH2-Ahx, H2’), 2.88 (m, 18H, NH2CH2-9mer, H6), 3.23 (m,  20H, 
18H for CH2CH2NCH2-9mer (H1), 2H for CH2NH-Ahx (H6’)), 3.76-4.42 (m, 21H, 
18H for NCH2CO, 1H for CH-Fmoc, 2H for CH2-Fmoc),  7.34 (t, J = 7.15 Hz, 2H, 
ArCHc-Fmoc), 7.42 (m, 4H, 2H for ArCHb-Fmoc, 2H for CONH2), 7.62 (d, J = 6.20 
Hz, 2H, ArCHd-Fmoc), 7.75 (m, 2H, ArCHa-Fmoc). 
13
C NMR (D2O, 126 MHz) δ = 25.2, 25.3, 25.4, 25.5, 25.6, 25.7, 26.2, 26.3, 26.4, 
26.5, 26.7, 26.8, 27.1, 27.2, 27.3, 27.5 (NH2CH2(CH2)4CH2-9mer and 
CH2(CH2)3CH2-Ahx), 32.4 (CH2CO-Ahx), 39.3, 39.4, 39.5 (NH2CH2-9mer), 46.7, 
47.0, 47.2, 47.5, 47.8, 48.0, 48.2, 48.3, 48.4, 48.5, 48.6, 49.1, 49.2 (CH2CH2NCH2-
9mer, CH-Fmoc, NCH2CO), 64.2 (CH2-Fmoc), 120.2 ( ArCH-Fmoc, Cd), 120.5 
(ArCH-Fmoc, Ca),  127.5, 127.6 (ArCH-Fmoc, Cc), 128.0, 128.1 (ArCH-Fmoc, Cb),  
143.7, 143.8, 144.5, 145 (ArC-Fmoc), 159.1 (C=O-Fmoc), 162.4,  162.7, 162.8, 
163.0, 163.1, 163.3 (C=O-9mer), 170.0 (C=O-Ahx). 
 





10 mL of rhodamine WT (from Keystone) were acidified by addition of 0.15 mL of 
HCl 2 M. The red solution was frozen in a mixture of acetone and dry ice and 
lyophilised overnight in the dark to protect the dye. 
Tetraethylrhodamine 2.36 was isolated as a purple powder (3.2 g). 
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  calculated 487.2; found 487.1 [M]
+






HPLC (Method 3): tR = 4.0 (isomer 6’) and 4.2 (isomer 5’) min, purity = 97% 
(ELSD). 
1
H-NMR (D2O, 500 MHz, eSpresat water suppression): δ = 0.98-1.18 (m, 12H, 
CH2CH3), 3.26-3.52 (m, 8H, NCH2CH3),  6.55 (d, J = 7.95 Hz, 2H, ArCH, H5 and 
H4), 6.72 (dd, J = 7.05 Hz, J = 7.95 Hz, 2H, ArCH, H7 and H2), 7.03 (dd, J = 7.00 
Hz, J = 7.90 Hz, ArCH, 2H, H8 and H1), 7.51 (d , J = 6.90 Hz, 0.66H, ArCH, H7’ for 
isomer 5’), 7.80 (d, J = 7.25 Hz, 0.33H, ArCH, H5’ for isomer 6’), 8.08 (d, J = 7.30 
Hz, 0.33H, ArCH, H4’ for isomer 6’), 8.14 (d, J = 6.90 Hz, 0.66H, ArCH,  H6’ for 
isomer 5), 8.18 (s, 0.33H, ArCH, H7’ for isomer 6’), 8.21 (s, 0.66H, ArCH, H4’ for 
isomer 5’). 
13
C-NMR (D2O, 126 MHz): δ = 12.0 (CH2CH3),   45.6 (CH2CH3),  96.0 (ArCH, C5 
and C4), 112.5, 113.7 (ArCH, C2 and C7), 128.7 (ArCH, C5’ for isomer 6’), 128.9, 
129.1 (ArCH, C7’ for isomer 6’ and C6’ for isomer 5’), 130.1 (ArCH, C7’ for isomer 
5’), 130.3 (ArCH, C4’ for isomer 6’), 130.5 (ArCH, C4’ for isomer 5’), 131.1, 133.2 
(ArCH, C1 and C8), 133.2, 137.6, 138.0, 140.4, 142.1, 155.2, 156.9, 157.5 (ArC), 
173.5, 174.2 (COOH). 
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The Rho-9mer peptoid 2.37 was synthesised on the resin 2.34. The resin (150 mg, 
0.043 mmol) was first swollen in DCM (1.5 mL) for 20 minutes. The Fmoc group 
was deprotected with 20% piperidine in DMF (6.2.1.9) and 2.36 (63 mg, 0.130 
mmol) was conjugated to the solid supported peptoid using method 6.2.1.7. The 
coupling was monitored by a qualitative ninhydrin test (6.2.1.1). Finally, the resin 
bound Rho-9mer was deprotected and cleaved from the solid support using the 
cleavage protocol (6.2.1.10). Rho-9mer 2.37 was obtained as a red powder (80 












 (100%), 335.0 [M+6H]
6+

















 669.15306, found 669.16793  
HPLC (Method 3): tR = 3.6 (Rho
6
-9mer) and 3.8 (Rho
5
-9mer) min, purity > 98% 
(220 and 540 nm). 
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1
H-NMR (D2O, 500 MHz, eSpresat water suppression): δ = 1.15-1.69 (m, 90H, 12H 
for CH2CH3-Rho, 6H for CH2-Ahx (H 3’, 4’ and 5’) and 72H for CH2-9mer  (H 2, 3, 4 and 
5)), 2.04-2.26 (m, 2H, CH2CO-Ahx, H2’), 2.89 (m, 18H, CH2NH2-9mer, H6), 3.24 (m, 
18H, CH2N-9mer, H1), 3.37-3.46 (m, 2H, CH2NH-Ahx, H6’), 3.57 (m, 8H, 
NCH2CH3-Rho),  3.87-4.43 (m, 18H, NCH2CO),  6.91 (m, 4H, ArCH, H2, H4, H5 and 
H7), 7.03 (dd, J = 11.65 Hz, J = 8.85 Hz, ArCH, 2H, H8 and H1), 7.45 (br s, 2H, 
CONH2), 7.63 (m, 0.66H, ArCH, H7’ for isomer 5’), 7.76 (m, 0.33H, ArCH, H5’ for 
isomer 6’), 7.85 (m, 0.33H, ArCH, H4’ for isomer 6’), 8.05 (d, J = 6.90 Hz, 0.66H, 
ArCH,  H6’ for isomer 5’), 8.16 (s, 0.33H, ArCH, H7’ for isomer 6’), 8.42 (s, 0.66H, 
ArCH, H4’ for isomer 5’). 
13
C-NMR (D2O, 126 MHz): δ = 11.8 (CH2CH3-Rho),  25.3, 25.4, 25.5, 25.6, 25.7, 
26.0, 26.3, 26.6, 26.7, 27.2, 27.3, 27.4 and 27.5 (CH2,C3’, 4’, 5’,C2, 3, 4, 5), 31.9 (CH2, 
C2’), 39.2, 39.3, 39.4, 39.5 (CH2, C6), 45.7 (CH2CH3-Rho),  47.3, 47.4, 47.5, 47.7, 
47.8, 48.2, 48.3, 48.4, 48.5, 48.6 (CH2, CH2NH-Ahx, NCH2CO and C1), 96.3 (ArCH, 
C5 and C4), 112.4, 113.8 (ArCH, C2 and C7), 128.7 (ArCH, C5’ for isomer 6’), 129.2, 
129.8 (ArCH, C7’ for isomer 6’ and C6’ for isomer 5’), 130.2 (ArCH, C7’ for isomer 
5’), 130.4 (ArCH, C4’ for isomer 6’), 130.6 (ArCH, C4’ for isomer 5’), 131.1, 133.3 
(ArCH, C1 and C8), 134.9, 137.5, 138.1, 140.5, 142.1, 154.9, 156.6, 157.4 (ArC), 
162.7, 162.8, 163.0, 163.3 (CO-9mer), 173.8 (CO-Ahx).  
UV (MeOH) λabs = 525 nm, λem = 584 nm. 
 
6.3.9. Cellular uptake of Rho-9mer peptoid (2.37) 
Cells (HeLa, B16F10 and HEK293T) were labelled 35 µL of Rho-9mer peptoid 
(2.37) (100 µM) or 35 µL of free Rhodamine dye (2.36) (100 µM) in PBS were 
placed into three random wells (final concentration 10 µM). Cellular uptake was 
analysed after 5, 30 minutes, 2, 4 and 24 hours of incubation by flow cytometry in 


















5 min 68.5 6.5 
30 min 96.1 2.3 
2 h 99.0 0.1 
4 h 99.4 0.1 
24 h 99.9 0.1 












5 min 410.7 13.5 
30 min 424.3 4.5 
2 h 535.3 5.1 
4 h 518.7 13.5 




5 min 305.0 124.5 
30 min 942.0 75.5 
2 h 1539.3 67.0 
4 h 2006.7 104.8 
24 h 4005.1 163.7 
Table 6.4: Fluorescence intensity of HeLa cells (arbitrary units) labelled with Rho (2.36, 10 µM) 













5 min 10.2 5.0 
30 min 31.6 1.6 
2 h 80.7 1.1 
4 h 90.4 0.7 
24 h 93.6 1.1 


















5 min 221.7 45.6 
30 min 202.7 22.5 
2 h 270.0 51.0 
4 h 290.3 44.9 




5 min 192.0 22.6 
30 min 319.3 9.0 
2 h 630.3 20.6 
4 h 936.7 61.8 
24 h 2530.3 36.1 
Table 6.6: Fluorescence intensity of B16F10 cells (arbitrary units) labelled with Rho (2.36, 10 













5 min 33.8 3.0 
30 min 57.8 3.6 
2 h 93.3 0.4 
4 h 97.7 0.8 
24 h 99.6 0.2 












5 min 417.7 41.1 
30 min 446.7 22.2 
2 h 569.3 36.3 
4 h 541.0 23.3 




5 min 382.3 103.5 
30 min 913.0 59.4 
2 h 1780.3 125.8 
4 h 3795.3 66.7 
24 h 10220.7 496.2 
Table 6.8: Fluorescence intensity of HEK293T cells (arbitrary units) labelled with Rho (2.36, 10 
µM) and Rho-9mer (2.37, 10 µM) (n = 3).  
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6.3.10. Microscopy of Rho-9mer peptoid (2.37) into cells 
Cells were seeded onto a 12-well plate at a density of 6 × 10
4
 cells/well (volume of 
culture media per well: 800 µL). After 24 hours, 80 µL of Rho-9mer peptoid (2.37) 
(100 µM) in PBS were added to three random wells. After 4 hours of incubation with 
the peptoids, cells were washed with PBS and microscopy was performed in 2% FBS 
in PBS without further staining. 
 
6.3.11. Confocal microscopy of Rho-9mer peptoid (2.37) into HeLa cells 
HEK293T cells were seeded, stained and analysed as described in 6.2.2.5. The cells 
were labelled for 24 hours with 200 µL of Rho-9mer peptoid (2.37) (100 µM) prior 
to imaging. The rhodamine dye on the Rho-9mer peptoids 2.37 was excited using a 
561 nm excitation laser and collecting emission using a 567-630 nm band-pass filter.  
 
6.3.12. Temperature effect on cellular uptake 
HeLa and HEK293T cells were seeded onto a 24-well plate. After 24 hours, 35 µL of 
Rho-9mer peptoid (100 µM, 2.37) in PBS were placed in three wells. Cells were 
incubated for 3 hours at 37, 20 or 4ºC prior to washing, trypsination and flow 














4 0.6 0.1 
20 0.6 0.3 
37 0.4 0.2 
 
2.37 
4 23.6 3.6 
20 94.7 3.2 
37 98.6 0.9 
Table 6.9: Effect of temperature on the cellular uptake of Rho-9mer (2.37, 10 µM) in HeLa cells 


















4 0.7 0.3 
20 0.5 0.2 
37 0.3 0.1 
 
2.37 
4 18.6 1.5 
20 71.7 6.3 
37 96.4 1.3 
Table 6.10: Effect of temperature on the cellular uptake of Rho-9mer (2.37, 10 µM) in 
HEK293T cells (n = 6). 
 
6.3.13. Temperature effect on cellular uptake: Microscopy 
HeLa and HEK293T cells were seeded onto a 12-well plate at a density of 6 × 10
4
 
cells/well (volume of culture media per well: 800 µL). After 24 hours, 80 µL of Rho-
9mer peptoid (100 µM, 2.37) in PBS were added in three wells. Cells were incubated 
for 3 hours at 37, 20 or 4ºC prior to PBS washing. Microscopy of the cells was 
performed in 2% FBS/PBS without further staining. 
 
6.3.14. Effect on sodium azide on cellular uptake114 
HeLa and HEK293T cells were seeded onto a 24-well plate at a density of 3 × 10
4
 
(volume of culture media per well: 350 µL). After 24 hours, 50% of the cells were 
treated with sodium azide (20 mM, Sigma-Aldrich) in serum-free culture media for 
30 minutes prior to treatment the peptoids. Cells (treated with NaN3 anduntreated) 
were incubated with 35 µL of Rho-9mer peptoid (100 µM, 2.37) in PBS. Cells were 
incubated for 3 hours at 37ºC prior to washing, trypsination and flow cytometry as 
















Untreated cells 0.4 0.2 
2.37 99.6 0.5 
2.37, NaN3 36.3 2.7 
Table 6.11: Effect of sodium azide on the cellular uptake of Rho-9mer (2.37, 10 µM) in HeLa 








Untreated cells 0.6 0.2 
2.37 97.5 0.7 
2.37, NaN3 23.2 3.7 
Table 6.12: Effect of sodium azide on the cellular uptake of Rho-9mer (2.37, 10 µM) in 
HEK293T cells    (n = 6).  
 
6.3.15. Cytotoxicity assays 
MTT cytotoxicity assays were carried out as according to the general procedures 
(6.2.2.4). Cells were treated with 1, 5, 10 or 20 µL of Rho-9mer (2.37) 100 µM in 
order to obtain a final concentration of 1, 5, 10 or 20 µM, respectively. After 24 
hours of incubation at 37
o
















1.110 0.086 100.0 7.8 
2.37 
1 1.126 0.097 101.4 8.7 
5 1.200 0.058 108.1 5.2 
10 1.218 0.087 109.7 7.8 
20 1.129 0.111 101.7 9.9 
Table 6.13: Percentage of cell vailability (HeLa cells) after 24 hours of incubation with Rho-





















1 0.861 0.097 102.0 11.5 
5 0.844 0.079 100.0 9.3 
10 0.823 0.073 97.6 8.6 
20 0.855 0.050 101.2 5.9 
Table 6.14: Percentage of cell vailability (B16F10 cells) after 24 hours of incubation with Rho-














Untreated cells  1.339 0.138 100.0 10.3 
2.37 
1 1.360 0.135 101.6 10.1 
5 1.311 0.120 97.9 8.9 
10 1.331 0.102 99.4 7.6 
20 1.343 0.150 100.3 11.2 
Table 6.15: Percentage of cell vailability (HEK293T cells) after 24 hours of incubation with Rho-
9mer (2.37) at different concentrations (n = 10).  
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6.4. Experimental for Chapter 3 




A mixture of tert-butyl 4-hydroxy-phenylcarbamate 3.14 (6.27 g, 30 mmol), Cs2CO3 
(9.78 g, 30 mmol), KI (0.17 g, 1 mmol) and 1% DVB cross-linked chloromethyl 
polystyrene 3.13 (5 g, 10 mmol) in acetone (35 mL) was heated at 70°C for 16 hours. 
After reaction, the resin 3.15 was isolated by filtration, washed with water, DMF, 
DCM, Et2O and dried overnight in vacuo at 40°C to give the product as a grey resin 
(7.45 g).  
 
Analysis: 
IR (neat): 3361 (w, νN-H), 2977 (m, νC-H), 2879 (m, νC-H), 1687 (s, νC=O), 1513 (s, 
νC=O), 1159 (s, νC-O) cm
-1
.  
Colorimetric test for the detection of chloromethyl groups in Merrifield resin
325
 
A 75 mM solution of 4-(4-nitrobenzyl)pyridine in toulene with 5% of triethylamine 
(1 mL) was added to 2 mg of resin 3.15. No coloration was observed by naked eyes 
on the resin. As a positive control the colorimetric test was repeated on 2 mg of 
Merrifield resin 3.13 (1% DVB, 2 mmol Cl/g). The resin turned pink. 
 





Resin 3.15 (5 g, 7.5 mmol) was shaken at room temperature with a 20% solution of 
TFA in DCM (75 mL) for 2 hours. At the end of the reaction time, the deprotected 
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resin was filtered and washed with DCM (3 × 50 mL). The resin was then shaken 
with a 10% solution of triethylamine in DCM (75 mL) for 15 minutes at room 
temperature, filtered, washed with DCM (5 × 50 mL), and dried overnight a vacuum 
oven at 40°C to give 3.16 as a beige resin (4.76 g). The presence of free primary 
amine was confirmed by a qualitative ninhydrin test (6.2.1.1). 
 
Analysis: 








A mixture of 2,3,3-trimethyl-3H-indole (0.5 mL, 3.2 mmol) and methyl iodide (1.2 
mL, 19.2 mmol) in acetonitrile (2 mL) was heated in a sealed vial at 150°C for 30 
minutes, by microwave irradiation. After cooling, the pink precipitate was collected 
by filtration, washed with Et2O, ethanol and then dried in vacuo to yield 3.28 as a 







 calculated 371.2, found 371.1 [M]
+




Rf : 0.45 (DCM/MeOH, 9: 1). 
HPLC (Method 2): tR = 4.5 min, purity = 100% (ELSD). 




H NMR (DMSO-d6, 250 MHz): δ = 1.45 (s, 6H, C(CH3)2), 2.70 (s, 3H, N=CCH3), 
3.90 (s, 3H, NCH3), 7.55-7.60 (m, 2H, ArCH), 7.76-7.80 (m, 1H, ArCH), 7.85-7.90 
(m, 1H, ArCH). 
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13
C NMR (DMSO-d6, 63 MHz): δ = 14.1 (C(CH3)2), 24.6 (C(CH3)2), 36.2 
(N=CCH3), 54.8 (C(CH3)2), 116.9, 122.9, 129.0, 129.7 (ArCH), 141.9, 143.6 (ArC), 
197.6 (C=N).  
Mp: 217-219 °C. 
 







A suspension of 1,2,3,3-tetramethyl-3H-indolium iodide 3.28 (1.42 g, 4.13 mmol) 
and N-[(E,2E,4E)-5-anilino-2,4-pentadienylidene]aniline hydrochloride 3.27 (1 g, 
3.44 mmol) in a (1: 1) mixture of acetic acid and acetic anhydride (15 mL) was 
heated at 120°C for 2.5 hours. The reaction was carefully monitored by UV-visible 
spectrometry (the hemicyanine intermediate and symmetrical dicarboxylic acid 
cyanine dye have an absorption maximum around 489 and 750 nm, respectively). At 
the end of the reaction time, the reaction mixture was cooled down and the solvent 
was evaporated in vacuo. The resulting red dark solid was dissolved in DCM (10 
mL) and repeatedly washed with water (5 × 10 mL). After removal of the solvent in 
vacuo, the crude product was precipitated in Et2O (addition of 5 mL of cold Et2O), 
sonicated and collected by filtration. After vacuum drying, 3.17 was yieled as a dark 







 calculated 371.2, found 371.1 [M]
+




Rf : 0.38 (DCM/MeOH, 9: 1). 
HPLC (Method 2): tR = 4.7 min, purity = 93 % (ELSD). 
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1
H NMR (CDCl3, 250 MHz) δ = 1.37 (s, 6H, C(CH3)2), 1.70 (s, 3H, COCH3), 3.67 
(s, 3H, NCH3), 6.57 (dd, J = 14.20 Hz, J = 11.45 Hz, 1H, CH, H3), 6.90-6.94 (m, 2H, 
CH, H3 and H5), 7.08-7.36 (m, 9H, ArCH), 7.90 (dd, J = 14.90 Hz, J = 11.42 Hz, 1H, 
CH, H4), 8.10-8.13 (m, 1H, CH, H2), 8.15 (d, J = 14.00 Hz, 1H, CH, H6). 
UV (MeOH): λabs = 489 nm. 
 
6.4.5. Synthesis of 2-[(1E,3E,5E)-6-(hydroxyanilino)-1,3,5-hexatrienyl]-1,3,3-






4-aminophenol PS 3.16 (0.5 g, 0.8 mmol) was swollen for 10 minutes in DCM (0.75 
mL).  A solution of compound 3.17 (0.9 g, 1.8 mmol) in DCM (5 mL, C = 0.4M) 
was added to the resin 3.16. The mixture was stirred for 1 hour. After reaction, the 
resin was isolated by filtration, washed extensively with DMF (5 × 5 mL), MeOH (5 
× 5 mL), DCM (5 × 5 mL) to remove the symmetrycal dye and dried in vacuo to 
yield 3.18 as a dark resin (0.87 g). The reaction was confirmed by a qualitative 
ninhydrin test (6.2.1.1). 
 
Analysis:  
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A mixture of 2,3,3-trimethyl-3H-indole (0.25 mL, 1.6 mmol) and 6-bromoexanoic 
acid (936 mg, 4.8 mmol) in acetonitrile (1 mL) was heated in a sealed vial at 150°C 
for 1 hour under microwave irradiation. The reaction was left to cool, the solvent was 
evaporated and the residue obtained was suspended in Et2O and filtered. The solid 
was extensively washed with Et2O and DCM several times (5 × 2 mL with each 
solvent) until all starting material had been removed. After drying overnight in a 
vacuum oven (40
o








 calculated  274.1, found 274.2 [M]
+
 (100%). 
Rf: 0.28 (DCM/MeOH, 3:2). 
HPLC (Method 1): tR = 3.7 min, purity = 100% (ELSD). 
1
H NMR (DMSO-d6, 250 MHz): δ = 1.56-1.77 (m, 10H, CH2CH2CH2CH2COOH, 
C(CH3)2), 2.01-2.09 (m, 2H, CH2COOH), 2.46 (t, 2H, J = 7.30 Hz, NCH2CH2CH2), 
3.94 (s, 3H, CH3), 4.72 (t, 2H, J = 7.35 Hz, NCH2CH2CH2), 7.85-7.90 (m, 2H, 
ArCH) , 8.08-8.11 (m, 1H, ArCH), 8.19-8.22 (m, 1H, ArCH).  
13
C NMR (DMSO-d6, 63 MHz) δ = 14.4, 23.4 (C(CH3)2), 24.2 , 25.7, 27.0, 33.5 
(CH2), 35.8 (N=CCH3), 48.1 (CH2), 55.0 (C(CH3)2), 117.0, 123.1, 129.0,  129.7 
(ArCH), 142.0, 144.1,  (ArC), 173.9 (C=O), 197.6 (C=N).  























To PS-bound Hemicyanine 3.18 (250 mg, 0.19 mmol) were added dry pyridine (1.5 
mL), Ac2O (0.18 mL, 1.9 mmol) and 1-(5-carboxypentyl)-2,3,3-trimethyl-3H-
indolium bromide (12 mg, 0.035 mmol) 3.19. The mixture was stirred for 2 hours 
under N2. Afterwards, the resin was isolated by filtration and washed with DCM (2 × 
3 mL). The reaction was repeated using the same conditions as described above. The 
filtrates were then combined and evaporated and the resulting solid was dissolved in 
DCM (5 mL) and washed several times with water (5 × 5 mL). The solvent was 
removed in vacuo. The crude was precipitated by addition of cold Et2O (2 mL), 
sonicated and recovered by centrifugation. The product was washed with Et2O (3 × 2 







 calculated  509.7, found 509.5 [M]
+






Rf : 0.32 (DCM/MeOH, 9: 1). 
HPLC (Method 2): tR = 5.9 min, purity = 97% (ELSD). 
1
H NMR (MeOD, 500 MHz): δ = 1.44-1.55 (m, 2H, CH2, H11), 1.64-1.69 (m, 2H, 
CH2, H12), 1.72 (s, 12H, CH3), 1.85 (m, 2H, CH2, H10), 2.31 (t, 2H, J = 7.45 Hz, CH2, 
H13), 3.61 (s, 3H, CH3), 4.09 (t, 2H, J = 7.50 Hz, CH2, H9), 6.26 (t, 2H, J = 13.10 Hz, 
CH, H1 and H7), 6.56 (t, 1H, J = 12.50 Hz, CH, H3), 6.60 (t, 1H, J = 12.60 Hz, CH, 
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H5), 7.23-7.27 (m, 4H, ArCH, H6’ and H8’), 7.39 (dd, 2H, J = 7.65 Hz, J = 1.13 Hz, 
ArCH, H7’), 7.48 (dd, 2H, J = 7.55 Hz, J = 1.77 Hz, ArCH, H5’), 7.62 (t, 1H, J = 
12.15 Hz, CH, H4), 7.97 (t, 2H, J = 12.90 Hz, CH, H6 and H2). 
13
C NMR (MeOD, 126 MHz): δ = 25.9 (CH2, C11), 26.2 (CH2, C10), 26.3 (CH2, C12), 
26.8, 26.9 (C(CH3)2), 29.8 (NCH3), 33.7 (CH2, C13), 43.2 (CH2, C9), 47.5, 47.7, 47.9, 
48.1, 48.3 (C(CH3)2), 103.7, 104.5 (CH=CH, C1, 7), 114.3 (CH=CH, C3), 121.8 
(ArCH, C5’), 124.4, 124.5 (ArCH, C6’, 8’), 126.0 (CH=CH, C5), 128.2 (ArCH, C7’), 
133.2 (CH=CH, C4), 139.4, 140.8, 141.6, 142.4, 143.2  (ArC), 151.5, 151.9 
(CH=CH, C2, 6), 171.8 (COOH), 173.8, 174.2 (C=N). 




UV/vis (MeOH): λabs = 745 nm, λem = 765 nm. 
 







To 4 aminophenol PS 3.16 (1.5 g, 2.51 mmol) was added a solution of 1,1,3,3-
tetramethoxypropane 3.21 (5.6 mL, 33.9 mmol) and BF3.OEt2 (0.344 mL, 2.79 
mmol) in dry DCM (6.75 mL) and the solution stirred at room temperature for 6 
hours. Dry DIEA (0.71 mL, 4.1 mmol) was added and the mixture stirred for 5 
minutes. The resin was isolated by filtration, washed several times with DCM (15 
mL), and dried in vacuo to yield the product 3.22 as a dark blue-black resin (1.6 g). 
The reaction was confirmed by a qualitative ninhydrin test (6.2.1.1). 
 
Analysis: 
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A mixture of 2,3,3-trimethyl-3H -benz[e]indole (27.6 g, 0.13 mol) and methyl iodide 
(20.50 mL, 0.33 mol) in acetonitrile (125 mL) was heated under reflux for 2 hours. 
At the end of the reaction time, the solution was cooled to room temperature and the 
sovent was removed under vacuum. The residue obtained was washed with Et2O 
several times (5 × 20 mL) and then with ethanol (5 × 20 mL) until removal of the 
starting material. The residue was dried in vacuo and 3.23 isolated as a white/yellow 







 calculated 224.1; found  224.2 [M]
+




Rf: 0.33 (DCM/MeOH, 9:1). 
HPLC (Method 1): tR = 4.1 min, purity = 100% (ELSD). 
1
H NMR (DMSO-d6, 250 MHz) δ = 1.80 (s, 6H, C(CH3)2), 2.95 (s, 3H, N=CCH3), 
4.15 (s, 3H, NCH3),  7.70-7.85 (m, 2H, ArCH) , 8.10 (d, 1H, J = 8.90 Hz, ArCH), 
8.22 (dd, 1H, J = 8.15 Hz, J = 1.4 Hz, ArCH ), 8.32 (d, 1H, J = 8.92 Hz, ArCH), 8.40 
(d, 1H, J = 8.25 Hz, ArCH).  
13
C NMR (DMSO-d6, 63 MHz): δ = 14. 5, 22.6 (C(CH3)2), 35.9 (N=CCH3), 55.3 
(C(CH3)2), 112.9, 124.1, 127.5, 128.7, 129.1, 130.7(ArCH), 136.9, 142.0, 144.1 
(ArC), 197.6 (C=N).  
IR (neat): 2983(w, νC-H), 1637 (s, νC=C), 1462 (s, νC-H) cm
-1
. 
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6.4.10. Synthesis of  2-[(1E,3E)-4-(4-hydroxyanilino)-1,3-butadienyl]-1,3,3-






To 4-{[(E,2E)-3-methoxy-2-propenylidene]amino}phenol PS 3.22 (0.5 g, 0.78 
mmol) and 
1,2,3,3-tetramethyl-3H-indolium iodide 3.23 (1.4 g, 3.9 mmol) was added DMF (4 
mL) and the mixture stirred at 120°C for 15 minutes under microwave irradiation. 
After reaction, The mixture was cooled and the resin was isolated by filtration, 
washed with DMF (3 × 10 mL) and DCM (3 × 10 mL). After overnight drying in a 
vacuum oven at 40
o
C, 3.24 was obtained as a blue-black resin (0.53 g). 
 
Analysis: 











A mixture of 2,3,3-trimethyl-3H-benz[e]indole (7.9 g, 37.7 mmol) and 6-
bromoexanoic acid (15.0 g, 94.5 mmol) in acetonitrile (25 mL) was heated at reflux 
for 2 days. The solution was cooled and the solvent was evaporated in vacuo. The 
dark residue obtained was washed with Et2O and DCM several times (5 × 10 mL for 
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each solvent) until removal of the starting material. After drying under vacuum, 3.25 






 calculated 324.2; found 324.3 [M]
+




Rf: 0.13 (DCM/MeOH, 3:2). 
HPLC (Method 1): tR = 3.1 min, purity = 100% (ELSD).  
1
H NMR (DMSO-d6, 250 MHz,): δ = 1.56-1.70 (m, 10H, CH2CH2CH2CH2COOH, 
C(CH3)2), 1.99-2.07 (m, 2H, CH2COOH), 2.30 (t, 2H, J = 7.10 Hz, NCH2CH2CH2), 
3.03 (s, 3H, CH3), 4.65 (t, 2H, J = 7.18 Hz, NCH2CH2CH2), 7.77-7.90 (m, 2H, 
ArCH) , 8.26 (d, 1H, J = 8.90 Hz, ArCH), 8.30 (dd, 1H, J = 8.75 Hz, J = 1.46 Hz, 
ArCH ), 8.37 (d, 1H, J = 8.95 Hz, ArCH), 8.46 (d, 1H, J = 8.20 Hz, ArCH).  
13
C NMR (DMSO-d6, 63 MHz): δ = 14.6, 21.9 (C(CH3)2), 24.6, 25.8 (CH2), 27.7 
(CH2COOH), 33.6 (NCH2CH2), 36.1 (CH3), 48.2 (NCH2), 55.3 (C(CH3)2), 114.1, 
124.3, 127.5, 128.5, 129.6, 130.7 (ArCH), 135.9 , 137.4 , 138.9 (ArC), 174.7 
(COOH), 197. 6 (C=N).  





6.4.12. Synthesis of 2-{(1E,3E,5E)-5-[3-(5-carboxypentyl)-3,3-dimethyl-1,3-
dihydro-3H-benzo[e]indol-2-ylidene]-1,3-pentadienyl}-1,1,3-trimethyl-1H-benzo [e] 
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To PS-bound hemicyanine 3.24 (0.7 g, 0.75 mmol) were added dry pyridine (5.5 
mL), DIEA (1.3 mL, 7.50 mmol), Ac2O (0.7 mL, 7.50 mmol) and 1-(5-
carboxypentyl)-2,3,3- trimethyl-3H-indolium bromide 3.25 (40 mg, 0.10 mmol). The 
mixture was stirred in the dark for 2 hours under N2. The resin was isolated by 
filtration and washed several times with DCM (5 × 7.5 mL). The filtrates were 
combined and evaporated under vacuum. The resulting blue-green solid was 
dissolved in DCM (5 × 10 mL) and washed several times with water (10 mL). The 
organic layer was dried over MgSO4 and filtered. After removal of the solvent in 
vacuo, the crude product was precipitated by addition of cold Et2O (5 mL). After 
sonication and centrifugation, the blue solid was washed several times with Et2O (5 × 
5 mL) and then purified by column chromatography (silica, eluting with DCM to 








 calculated 583.3; found 583.5 [M
+




Rf: 0.36 (DCM/MeOH, 9:1). 
HPLC (Method 2): tR = 5.4 min, purity = 100% (ELSD and 675 nm). 
1
H NMR (MeOD, 500 MHz): δ = 1.52-1.60 (m, 2H, CH2, H9), 1.69-1.79 (quin, 2H, J 
= 9.65 Hz, J = 8.35 HZ, CH2, H10), 1.88-1.95 (m, 2H, CH2, H8), 2.06 (s, 12H, 
C(CH3)2), 2.23 (t, 2H, J = 9.10 Hz, CH2, H11), 3.77 (s, 3H, NCH3), 4.26 (t, 2H, J = 
9.15 Hz, CH2, H7), 6.34 (d, 1H, J = 14.75 Hz, CH, H5), 6.39 (d, 1H, J = 14.95 Hz, 
CH, H1), 6.71 (t, 1H, J = 16.00 Hz, CH, H3), 7.51 (dd, 2H, J = 8.90 Hz , J = 3.65 Hz, 
ArCH, H7′), 7.59-7.71 (m, 4H, ArCH, H10′ and H6′), 8.02 (d, 2H, J = 11.35 Hz, 
ArCH, H8′), 8.05 (d, 2H, J = 11.25 Hz, ArCH, H11’), 8.28 (d, 2H, J = 10.75 Hz, 
ArCH, H5′), 8.37 (t, 2H, J = 17.80 Hz, CH, H2 and H4).  
13
C NMR (MeOD, 126 MHz): δ = 25.4 (CH2, C9), 25.6 (CH2, C10), 25.9, 26.1 
(C(CH3)2), 26.3 (CH2, C8), 31.2 (NCH3), 34.3 (CH2, C11), 45.0 (CH2, C7), 47.8, 48.4 
(C(CH3)2), 103.2, 103.9 (CH=CH, C1, 5), 114.0 (CH=CH, C3), 122.1 (ArCH, C11’), 
122.9 (ArCH, C5’), 124.4, 124.5 (ArCH, C6’, 10’), 128.6 (ArCH, C7’), 130.4 (ArCH, 
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C8’), 133.4, 134.9, 135.1, 140.9, 141.6 (ArC), 153.5, 154.0 (CH=CH, C2, 4), 172.6 
(COOH),  175.8 (C=N), 176.4 (C=N). 




UV/vis (MeOH): λabs = 678 nm, λem = 704 nm. 
 




The Cy7-9mer peptoid 3.28 was coupled to the resin 2.35 previously Fmoc 
deprotected (50 mg, 0.015 mmol). The carboxy-Cy7 3.20 was first activated in 
solution before being added to the solid support. 
Method 1: NHS-Cy7 
The Cy7 3.20 (23 mg, 0.045 mmol) was activated under nitrogen in the presence 
of N-N’-Disuccinimidylcarbonate (17 mg, 0.0675 mmol) with a solution of 
anhydrous DMF/pyridine (1: 1) (2 mL) at 35°C for 3 hours (reaction was 
followed by TLC and MS). The solvent was evaporated under vacuum and the 
residue was precipitated by the addition of 3 mL of cold Et2O (solid recovered by 
centrifugation) before being dried in a vacuum oven (m/z = 606.33 M
+
). 
The ester succinimide Cy7 was dissolved in a minimum of DMF (0.8 mL) and 
mixed with the Fmoc deprotected 2.35. The mixture was stirred overnight in the 
dark. The resin was isolated by filtration and the filtrate recycled and reused (3 
times) using the same conditions as described above until completion of the 
coupling (negative ninhydrin test, 6.2.1.1). 
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Finally, the resin bound peptoid was deprotected and cleaved from the solid 
support by treatment with a mixture of TFA/TIS/H2O (95: 2.5: 2.5) for 2 hours 
and precipitated in cold Et2O (6.2.1.10) to give 3.28 as a blue solid. It was 
purified by semi-preparative HPLC (Gradient 1) (18 mg, 60% based on 2.35, 
purity 98% (ELSD)). 
 
Method 2: OBt-Cy7 
The Cy7 3.20 (23 mg, 0.045 mmol) and HOBt (6 mg, 0.045 mmol) were 
dissolved in DMF (1.25 mL). DIC (6.6 µL) was added to the solution and mixed 
for 15 minutes. The OBT ester Cy7 was added to 2.35 (Fmoc deprotected). The 
mixture was stirred overnight in the dark. After reaction the resin was isolated by 
filtration and washed with DMF, DCM, MeOH (5 × 1 mL for each solvent) until 
the filtrate was colourless. The completion of the coupling was monitored by a 
ninhydrin test (6.2.1.1). 
Finally, the resin bound peptoids were deprotected and cleaved from the solid 
support as previously decribed (Method 1, protocol 6.2.1.10) to give 3.28 as a 
blue solid. After overnight drying, the compound was isolated in a 94% final 












 (100%), 338.7 [M+6H]
6+














 676.52538; found 
676.53027. 
HPLC (Method 3): tR = 4.9 min; purity > 98% (750 nm). 
1
H NMR (D2O, 500 MHz, eSpresat water suppression): δ = 1.22-1.71 (m, 94H, 12H 
for 2×C(CH3)2-Cy7, 72H for CH2 (H2’’, 3’’, 4’’, 5’’), 10H for CH2 (H11, 12, 16, 17, 18)), 1.79-
1.90 (m, 2H, CH2, H10), 2.37-2.45 (m, 2H, CH2CO, H19),  2.47-2.56 (m, 2H, CH2CO, 
H13),  2.89-3.09 (m, 20H, 18H for CH2NH2 (H6’’) and 2H for CH2NH (H15)), 3.21-
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3.46 (m, 18H, CH2N, H1’’), 3.54-3.60 (m, 3H, CH3-Cy7),  3.93-4.53 (m, 20H, 18H 
for NCH2CO and 2H for CH2N (H9)), 6.21-6.32 (m, 2H, CH-Cy7, H1 and H7), 6.48-
6.62 (m, 2H, CH-Cy7, H3 and H5), 7.24-7.34 (m, 4H, ArCH, H5’ and H7’), 7.40-7.48 
(m, 2H, ArCH, H6’), 7.50-7.65 (m, 3H, 2H for ArCH (H4’) and 1H for CH-Cy7, 
(H4)), 7.83-7.92(m, 2H, CH-Cy7, H2 and H6), 7.94 (s, 2H, CONH2). 
13
C NMR (D2O, 126 MHz): δ = 21.7, 21.9, 22.1, 24.1, 25.0, 25.1, 25.3, 25.4, 25.5, 
25.8, (CH2CH2CH2), 26.4 (CH2, C10), 26.6 (CH2, C19), 26.7, 26.9, 27.7, 27.8 
(C(CH3)2), 30.0 (NCH3), 35.1 (CH2, C13), 39.0, 39.1, 39.2, 39.3 (CH2, C6’’, 15), 47.2, 
47.3, 47.4, 47.5, 47.6, 47.8, 47.9, 48.0, 48.1, 48.2, 48.4  (NCH2 (C9), CH2N (C1’’), 
NCH2CO, (C(CH3)2), 103.3, 104.0 (CH=CH, C1, 7), 115.3 (CH=CH, C3), 120.7 
(ArCH, C4’), 122.3, 122.5 (ArCH, C5’, 7’), 123.4 (CH=CH, C5), 129.1 (ArCH, C6’), 
135.6 (CH=CH, C4), 139.9, 141.1, 141.9, 143.3, 143.6  (ArC), 149.1, 150.9 
(CH=CH, C2, 6), 162.4,  162.7, 163.0, 163.2 (NCO-9mer), 169.8, 170.1 (CO), 172.9, 
173.4 (C=N). 
UV/vis (MeOH): λabs = 744 nm, λem = 777 nm. 
UV/vis (H2O): λabs = 693 nm, λem = 779 nm.  
 




Cy5.5 3.26 (26 mg, 0.045 mmol) was coupled to the Fmoc deprotected peptoid 2.35 
(50 mg, 0.015 mmol), as previously described in 6.4.14. The Method 2 was used to 
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activate the fluorophore.  After cleavage and deprotection, 3.29 was isolated as a 












 (100%), 421.0 [M+5H]
5+













 701.19727; found 701.20514. 
HPLC (Method 3): tR = 4.1 min, purity > 98% (675 nm). 
1
H NMR (D2O, 500 MHz, eSpresat water suppression): δ = 1.10-1.71 (m, 82H, 10H 
for CH2 (H9, 10, 14, 15, 16), 72H for CH2 (H3’’, 4’’, 5’’)), 1.84 (m, 2H, CH2, H8), 1.89 (s, 
12H, C(CH3)2), 2.07-2.14 (m, 4H, CH2CO, H11 and H17), 2.79-2.98 (m, 18H, 
CH2NH2, H6’’), 3.06-3.41 (m, 20H, 2H for NHCH2 (H13), 18H for CH2N (H1’’)), 3.63 
(s, 3H, NCH3),  3.85-4.46 (m, 20H, 2H for NCH2 (H7), 18H for NCH2CO), 6.27 (m, 
2H, CH, H1 and H5), 6.56 (m, 1H, CH, H3), 7.47 (m, 2H, ArCH, H7′), 7.55 (d, J = 
8.40 Hz, 2H, ArCH, H10′), 7.62 (m, 2H, ArCH, H6′), 7.94 (m, 2H, J = 6.20 Hz, ArCH, 
H8′), 7.96-8.02 (m, 4H, ArCH, H11’ and CONH2), 8.12 (m, 2H, CH, H2 and H4), 8.23 
(d, 2H, J = 8.05 Hz, ArCH, H5′).  
13
C NMR (D2O, 126 MHz): δ = 25.2, 25.3, 25.4 25.5, 25.6, 25.8 (CH2CH2CH2), 
26.1, 26.2, 26.3 (C(CH3)2), 26.6, 26.7, 28.8 (CH2CH2CH2), 31.4 (NCH3), 35.1 (CH2, 
C11 and C17), 46.7, 48.4, 48.5, 48.6, 49.5 (CH2, C7, 13, 1’’ and NCH2CO), 52.7 
(C(CH3)2), 103.4, 104.1 (CH=CH, C1, 5), 115.2 (CH=CH, C3), 122.3 (ArCH, C11’), 
123.2 (ArCH, C5’), 124.8, 125.1 (ArCH, C6’, 10’), 128.8 (ArCH, C7’), 130.4 (ArCH, 
C8’), 133.5, 134.8, 141.0, 141.6 (ArC), 153.8, 154.2 (CH=CH, C2, 4), 162.7, 162.8, 
163.1 (NCO-9mer and NHCO), 172.5 (C=N). 
UV/vis (MeOH): λabs = 678 nm, λem = 710 nm.  






- 213 - 
 




One peptoid monomer unit 2.22 (65 mg, 0.130 mmol) was coupled to 2.28 (50 mg, 
0.043 mmol) using the protocol 6.2.1.6 followed by Fmoc deprotection (6.2.1.7). 
Fmoc-Ahx-OH spacer 2.34 (46 mg, 0.130 mmol) was coupled using HOBt/DIC in 
DMF (6.2.1.6). A new loading of the resin 3.33 was calculated using a quantitative 
ninhydrin test 6.2.1.2 (0.57 mmol/g). 
 




Cy7 (22 mg, 0.043 mmol) was activated and coupled to 3.33 (75 mg, 0.043 mmol) 
previously Fmoc deprotected using the Method 2 described earlier (6.4.14). The 
coupling was repeated 3 times with recycling the carboxy-Cy7 (controlled by a 
ninhydrin test, 6.2.1.1). Cy7-1mer was deprotected and cleaved from the solid 
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support (6.2.1.10, 2 hours at room temperature using TFA/TIS/H2O, 95: 2.5: 2.5) to 







 calculated 777.5; found 389.5 [M+H]
2+










  777.54257; found 777.54315.  
HPLC (Method 3): tR = 4.6 min, purity = 97% (ELSD). 
1
H NMR (D2O, 500 MHz, eSpresat water suppression): δ = 1.09-1.38 (m, 8H, CH2, 
H3’’, 4’’, 11, 17), 1.39-1.73 (m, 22H, 12H for 2 × C(CH3)2-Cy7, 10H for CH2 (H2’’, 5’’, 12, 
16, 18)), 1.78 (m, 2H, CH2, H10), 2.14-2.24 (m, 2H, CH2CO, H19),  2.33-2.40 (m, 2H, 
CH2CO, H13),  2.82-3.02 (m, 4H, CH2NH2 (H6’’) and CH2NH, (H15)), 3.27-3.36 (m, 
2H, CH2N, H1’’), 3.50 (s, 3H, CH3-Cy7),  3.90-3.94 (two s, 2H, NCH2CO), 3.98-4.07 
(m, 2H, CH2N, H9), 6.13-6.24 (m, 2H, CH-Cy7, H1 and H7), 6.38-6.54 (m, 2H, CH-
Cy7, H3 and H5), 7.04-7.11 (m, 1H, CH-Cy7, H4), 7.17-7.28 (m, 4H, ArCH, H5’ and 
H7’), 7.33-7.43 (m, 2H, ArCH, H6’), 7.44-7.48 (m, 2H, ArCH, H4’), 7.77-7.88 (m, 2H, 
CH-Cy7, H2 and H6), 8.38 (s, 2H, CONH2). 
13
C NMR (D2O, 126 MHz): δ =22.0, 23.1, 24.4, 25.1, 25.3, 25.6, 25.7, 26.0 
(CH2CH2CH2), 26.5 (CH2, C10), 26.7 (CH2, C19), 27.7, 27.8 (C(CH3)2), 30.1 (NCH3), 
35.2 (CH2, C13), 38.9, 39.1 (CH2, C6’’, 15), 47.3, (CH2N, C1’’), 48.0, 48.1, 48.4  (NCH2 
(C9), NCH2CO), 49.8, 50.1 (C(CH3)2), 103.1, 103.6 (CH=CH, C1, 7), 115.2 (CH=CH, 
C3), 120.8 (ArCH, C4’), 122.4, 122.6 (ArCH, C5’, 7’), 123.4 (CH=CH, C5), 128.9 
(ArCH, C6’), 135.4 (CH=CH, C4), 141.6, 142.9, 143.6  (ArC), 148.7, 149.2 (CH=CH, 
C2, 6), 163.1 (NCO-9mer), 170.0, 170.4 (CO), 173.1, 173.3 (C=N). 
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The Cy5.5-1mer peptoid 3.31 was synthesised as for 3.30 above (6.4.16) using 75 
mg of 3.33 (0.043 mmol). 3.31 was isolated after ether precipitation and overnight 







 calculated 851.6; found 851.5 [M]
+












  851.55822; found 851.55605.  
HPLC (Method 3): tR = 4.9 min, purity = 95% (ELSD). 
1
H NMR (D2O, 500 MHz, eSpresat water suppression): δ = 1.16-1.30 (m, 10H, CH2, 
H3’’, 4’’, 5’’, 9, 15), 1.53-1.63 (m, 2H, CH2, H14),  1.71 (quin, 2H, J = 5.30 Hz, J = 6.20 
HZ, CH2, H10), 1.85 (m, 4H, CH2, H8 and H2’’), 1.99 (s, 12H, C(CH3)2), 2.08-2.17 
(m, 4H, CH2CO, H11 and H17), 2.74-2.83 (m, 2H, CH2NH2, H6’’), 3.09 (t, J = 5.61 Hz, 
2H, NHCH2, H13), 3.64 (s, 3H, NCH3),  3.66-3.71 (m, 2H, CH2N, H1’’), 3.80-3.90 (2 
s, 2H, NCH2CO), 4.18 (m, 2H, CH2, H7), 6.22 (d, 2H, J = 14.05 Hz, CH, H1 and H5), 
6.51 (t, 1H, J = 12.80 Hz, CH, H3), 7.43 (m, 2H, ArCH, H7′), 7.55 (d, J = 9.05 Hz, 
2H, ArCH, H10′), 7.61 (td, J = 12.80 Hz,  J = 1.55 Hz, 2H, ArCH, H6′), 7.94 (d, 2H, J 
= 6.20 Hz, ArCH, H8′), 8.00 (2 d, 2H, J = 9.20 Hz, ArCH, H11’), 8.06 (td, 2H, J = 
13.55 Hz, J = 2.30 Hz, CH, H2 and H4), 8.21 (d, 2H, J = 8.55 Hz, ArCH, H5′), 8.38 
(s, 2H, CONH2). 
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13
C NMR (D2O, 126 MHz): δ = 24.9, 25.0, 25.1, 25.3, 25.4 25.5, 25.6 (CH2CH2CH2, 
C3’’, 4’’, 5’’, 9, 15), 25.9 (CH2, C14), 26.2, 26.4 (C(CH3)2), 26.8 (CH2, C10) , 28.6, 28.8 
(CH2, C8, 2’’), 31.5 (NCH3), 35.0, 35.2 (CH2, C11 and C17), 46.6 , 46.8 (CH2, 
C6’’),48.3, 48.4, 48.7, (CH2, C13, 1’’ and NCH2CO),  49.7 (CH2, C7), 50.2, 50.4 
(C(CH3)2), 104.6, 105.0 (CH=CH, C1, 5), 114.7 (CH=CH, C3), 117.8 (ArCH, C11’), 
123.3 (ArCH, C5’), 124.7, 125.2 (ArCH, C6’, 10’), 127.9 (ArCH, C7’), 129.6 (ArCH, 
C8’), 142.3, 143.8, 143.9, 141.5 (ArC), 153.7, 154.0 (CH=CH, C2, 4), 162.5, 162.8, 
163.1 (NCO-9mer and NHCO), 172.8 (C=N). 
UV/vis (MeOH): λabs = 675 nm, λem = 710 nm. 
 
6.4.18. Cellular uptake of Cy-peptoid in HeLa, B16F10 and HEK293T cells 
Cells were seeded into a 24-well plate. After 24 hours, 35 µL of Cy7-9mer (3.28), 
Cy5.5-9mer (3.29), Cy7-1mer (3.30) or Cy5.5-1mer (3.31) (100 µM) in PBS were 
adde in three random wells. Cellular uptake was analysed after 5, 30 minutes, 2, 4 
and 24 hours of incubation by flow cytometry in 2% FBS in PBS with 0.2% of 
















5 min 63.6 3.1 
30 min 82.9 3.1 
2 h 98.4 0.6 
4 h 99.5 0.2 
24 h 99.8 0.1 


























5 min 77.2 2.1 
30 min 98.3 0.4 
2 h 99.0 0.8 
4 h 99.7 0.2 
24 h 100.0 0.1 
Table 6.17: Cellular uptake of Cy5.5-9mer (3.29, 10 µM) in HeLa cells (n = 6).  
 








5 min 8.9 0.3 
30 min 14.0 1.5 
2 h 29.8 7.8 
4 h 38.0 1.1 




5 min 9.4 0.4 
30 min 16.3 2.0 
2 h 38.0 1.3 
4 h 43.9 1.1 
24 h 48.2 1.0 
Table 6.18: Cellular uptake of Cy7-1mer (3.30, 10 µM) and Cy5.5-1mer (3.31, 10 µM) in HeLa 

















5 min 35.4 1.3 
30 min 60.3 2.0 
2 h 92.3 1.0 
4 h 98.0 0.7 
24 h 99.9 0.1 


















5 min 25.2 0.9 
30 min 65.7 1.2 
2 h 90.0 1.0 
4 h 97.5 1.0 
24 h 99.9 0.1 
















5 min 3.0 0.1 
30 min 4.9 0.2 
2 h 11.2 1.2 
4 h 20.9 2.1 




5 min 2.3 0.6 
30 min 5.4 0.6 
2 h 13.9 0.9 
4 h 26.6 1.6 
24 h 34.8 1.7 
Table 6.21: Cellular uptake of Cy7-1mer (3.30, 10 µM) and Cy5.5-1mer (3.31, 10 µM) in B16F10 
















5 min 80.7 1.9 
30 min 94.8 2.3 
2 h 97.9 1.1 
4 h 99.6 0.4 
24 h 100.0 0.1 






















5 min 86.5 5.1 
30 min 94.4 3.7 
2 h 97.3 1.9 
4 h 99.2 0.7 
24 h 100.0 0.1 















5 min 9.0 0.8 
30 min 12.3 0.6 
2 h 20.8 0.7 
4 h 28.3 1.0 




5 min 9.9 2.3 
30 min 16.9 0.6 
2 h 26.4 0.8 
4 h 32.1 1.8 
24 h 48.2 1.9 
Table 6.24: Cellular uptake of Cy7-1mer (3.30, 10 µM) and Cy5.5-1mer (3.31, 10 µM) in 
HEK293T cells (n = 3). 
 
6.4.19. MTT assays of Cy-peptoid in HeLa, B16F10 and HEK293T cells 
MTT cytotoxicity assays were carried out as according to the general procedures 
(6.2.2.4). Cells were treated with 1, 5, 10 or 20 µL of Cy7-9mer (3.28), Cy5.5-9mer 
(3.29), Cy7-1mer (3.30) or Cy5.5-1mer (3.31) 100 µM in order to obtain a final 
concentration of 1, 5, 10 or 20 µM, respectively. After 24 hours of incubation at 
37
o

























1 1.173 0.088 105.7 7.9 
5 0.838 0.115 75.4 10.3 
10 0.634 0.161 57.1 14.5 




1 1.129 0.083 101.7 7.5 
5 0.975 0.053 87.8 4.8 
10 0.831 0.076 74.9 6.8 




1 1.127 0.062 101.5 5.6 
5 0.954 0.068 85.9 6.1 
10 0.741 0.038 66.8 3.4 




1 1.112 0.069 100.1 6.2 
5 1.095 0.071 98.6 6.4 
10 0.886 0.043 79.8 3.9 
20 0.752 0.085 67.7 7.6 
Table 6.25: Percentage of cell vailability (HeLa cells) after 24 hours of incubation with Cy7-
9mer (3.28), Cy5.5-9mer (3.29), Cy7-1mer (3.30) and Cy5.5-1mer (3.31) at different 

















0.872 0.064 100.0 7.4 
3.28 
 
1 0.879 0.074 100.8 8.5 
5 0.619 0.055 70.9 6.3 
10 0.490 0.068 56.2 7.8 
20 0.348 0.061 40.0 7.0 
3.29 
 
1 0.883 0.074 101.3 8.5 
5 0.664 0.100 76.1 11.5 
10 0.508 0.064 58.3 7.3 
20 0.405 0.097 46.5 11.1 
3.30 
 
1 0.885 0.050 101.5 5.7 
5 0.749 0.053 85.9 6.1 
10 0.581 0.030 66.7 3.5 
20 0.451 0.065 51.8 7.4 
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1 0.909 0.030 104.3 3.4 
5 0.771 0.053 88.4 6.1 
10 0.609 0.029 69.9 3.4 
20 0.517 0.066 59.3 7.6 
Table 6.26: Percentage of cell vailability (B16F10 cells) after 24 hours of incubation with Cy7-
9mer (3.28), Cy5.5-9mer (3.29), Cy7-1mer (3.30) and Cy5.5-1mer (3.31) at different 




















1 1.025 0.049 98.9 4.8 
5 0.914 0.040 88.1 3.9 
10 0.598 0.034 57.6 3.3 




1 1.081 0.056 104.3 5.4 
5 0.956 0.054 92.2 5.2 
10 0.672 0.066 64.8 6.4 




1 1.024 0.073 98.7 7.1 
5 0.884 0.048 85.2 4.6 
10 0.789 0.026 76.1 2.5 




1 1.140 0.059 110.0 5.7 
5 0.992 0.040 95.7 3.9 
10 0.921 0.048 88.8 4.6 
20 0.749 0.069 72.2 6.6 
Table 6.27: Percentage of cell vailability (HEK293T cells) after 24 hours of incubation with Cy7-
9mer (3.28), Cy5.5-9mer (3.29), Cy7-1mer (3.30) and Cy5.5-1mer (3.31) at different 
concentrations (n = 5).  
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The H-Ahx-9mer peptoid 3.32 was obtained after Fmoc deprotection (6.2.1.9) and 
cleavage (6.2.1.10) from the previously prepared Fmoc-Ahx-9mer resin 2.35 (50 mg, 
0.014 mmol). After precipitation in cold Et2O and overnight drying, the 3.32 was 




): C78H158N20O10 calculated 1535.3, found 768.7 [M+2H]
2+
















  768.63132, found 768.63587.  
HPLC (Method 4): tR = 1.0 min, purity >98% (ELSD). 
1
H NMR (D2O, 500 MHz, eSpresat water suppression): δ = 1.48-1.68 (m, 78H, 72H 
for NH2CH2(CH2)4CH2-9mer, 6H for CH2(CH2)3CH2-Ahx), 2.09-2.18 (m, 2H, 
COCH2-Ahx), 2.69 (m, 20H, 18H for NH2CH2-9mer, 2H for CH2NH2-Ahx), 3.18 (m, 
18H, CH2CH2NCH2), 3.82-4.47 (m, 18H for NCH2CO-9mer).   
13
C NMR (D2O, 126 MHz): δ = 24.9, 25.0, 25.1, 25.3, 25.5, 25.6, 26.1, 26.2, 26.3, 
26.5, 26.7, 26.8, 27.0, 27.1, 27.2, 27.3 (NH2CH2(CH2)4CH2-9mer and 
CH2(CH2)3CH2-Ahx), 32.1 (CH2CO-Ahx), 39.2, 39.3 (NH2CH2-9mer), 47.0,47.1, 
47.2, 47.5, 48.0, 48.1 48.2, 48.3, 48.4, 48.5, 48.7, 49.1, 49.2, 49.3 (CH2CH2NCH2-
9mer, NCH2CO), 162.5,  162.6, 162.7, 162.8, 163.0, 163.1, 163.3 (NCO-9mer), 
170.4 (C=O-Ahx). 
 
6.4.21. MTT assays of H-Ahx-9mer (3.32) in HeLa, B16F10 and HEK293T cells  
MTT cytotoxicity assays were carried out as according to the general procedures 
(6.2.2.4). Cells were treated with 1, 5, 10, 20 or 50 µL of H-Ahx-9mer (3.32) 100 
µM in order to obtain a final concentration of 1, 5, 10, 20 or 50 µM, respectively. 
After 24 hours of incubation at 37
o
C, the cells were prepared to be read on the 
























1 1.123 0.101 99.4 8.9 
5 1.218 0.095 107.8 8.4 
10 1.107 0.113 97.9 10.0 
20 1.139 0.100 100.8 8.8 
50 1.118 0.109 99.0 9.6 
Table 6.28: Percentage of cell vailability (HeLa cells) after 24 hours of incubation with H-Ahx-
9mer (3.32) at different concentrations (n = 5.) 
 
B16F10 cells 
















1 0.905 0.074 102.9 8.5 
5 0.883 0.055 100.4 6.3 
10 0.904 0.045 102.7 5.1 
20 0.871 0.045 99.0 5.1 
50 0.880 0.060 100.0 6.8 
Table 6.29: Percentage of cell vailability (B16F10 cells) after 24 hours of incubation with H-Ahx-
9mer (3.32) at different concentrations (n = 5).  
 
HEK293T cells 














1 1.117 0.104 98.3 9.2 
5 1.143 0.117 100.5 10.3 
10 1.127 0.091 99.2 8.0 
20 1.143 0.121 100.5 10.6 
50 1.144 0.106 100.6 9.3 
Table 6.30: Percentage of cell vailability (HEK293T cells) after 24 hours of incubation with H-
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6.4.22. In vitro MTT assays  for in vivo studies (HeLa and HEK293T cells) 
MTT cytotoxicity assays were carried out as according to the general procedures 
(6.2.2.4). Cells were treated with 5 µM of Cy7-9mer (3.28), Cy5.5-9mer (3.29), Cy7-
1mer (3.30) or Cy5.5-1mer (3.31) 100 µM in order to obtain a final concentration of 
5 µM. After 15 and 30 minutes of incubation at 37
o
C, the cells were prepared to be 











(%) Error (%) 
Control cells 
 
0.849 0.103 100.0 8.3 
3.28 
30 min 0.874 0.063 102.9 7.4 
15 min  0.859 0.075 101.1 8.8 
3.29 
30 min  0.843 0.101 99.3 11.9 
15 min  0.849 0.056 100.0 6.6 
3.30 
30 min 0.867 0.054 102.1 6.3 
15 min 0.839 0.069 98.8 8.1 
3.31 
30 min 0.853 0.042 100.5 5.0 
15 min 0.885 0.036 104.3 4.3 
3.32 
30 min 0.850 0.067 100.2 7.9 
15 min 0.818 0.071 96.4 8.3 
Table 6.31: Percentage of cell vailability (HeLa cells) after 15 and 30 minutes of incubation with 
5 µM of Cy7-9mer (3.28), Cy5.5-9mer (3.29), Cy7-1mer (3.30), Cy5.5-1mer (3.31) and H-Ahx-






























1.130 0.128 100.0 8.0 
3.28 
30 min 1.157 0.110 102.4 9.7 
15 min  1.155 0.079 102.2 7.0 
3.29 
30 min  1.139 0.066 100.8 5.8 
15 min  1.143 0.100 101.1 8.9 
3.30 
30 min 1.132 0.092 100.2 8.1 
15 min 1.175 0.053 103.9 4.7 
3.31 
30 min 1.163 0.067 102.9 5.9 
15 min 1.127 0.075 99.7 6.6 
3.32 
30 min 1.167 0.075 103.3 6.7 
15 min 1.123 0.101 99.4 9.0 
Table 6.32: Percentage of cell vailability (HEK293T cells) after 15 and 30 minutes of incubation 
with 5 µM of Cy7-9mer (3.28), Cy5.5-9mer (3.29), Cy7-1mer (3.30), Cy5.5-1mer (3.31) and H-
Ahx-9mer (3.32) (n = 5).  
 
6.4.23. In vitro cellular uptake of Cy7-9mer and Cy5.5-9mer  for in vivo studies 
(HeLa and HEK293T cells) 
Cells were seeded onto a 24-well plate at a density of 3 × 10
4
 cells/well (volume of 
culture media per well: 350 µL). After 24 hours, 17.5 µL of Cy7-9mer (3.28) or 
Cy5.5-9mer (3.29) (100 µM) in PBS were injected in three random wells. Cellular 
uptake was analysed after 15 and 30 minutes of incubation by flow cytometry in 2% 









Untreated cells  0.2 0.1 
3.28 
15 min 80.5 3.2 
30 min 95.0 3.4 
 
3.29 
15 min 80.8 2.1 
30 min 97.4 1.6 
Table 6.33: Cellular uptake of Cy7-9mer (3.28, 5 µM) and Cy5.5-9mer (3.29, 5 µM) in HeLa 















Untreated cells  0.2 0.1 
3.28 
15 min 98.8 1.3 
30 min 99.8 0.2 
3.29 
15 min 99.8 0.1 
30 min 99.8 0.4 
Table 6.34: Cellular uptake of Cy7-9mer (3.28, 5 µM) and Cy5.5-9mer (3.29, 5 µM) in HEK293T 
cells (n = 6).  
 
6.4.24. Confocal microscopy of HeLa cells labelled with Cy5.5-9mer (3.29) 
HeLa cells were prepared and stained as previously described in 6.2.2.5. Cells were 
labelled with 200 µL of Cy5.5-9mer peptoid (3.29, 100 µM) for 24 hours. The Cy5.5 
on the Cy5.5-9mer peptoids was excited using a 633 nm excitation filter and 
collecting emission using a 646-762 nm band-pass filter.  
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6.5.  Experimental for Chapter 4 
6.5.1. Experimental for peptide delivery 




2-chlorotrityl chloride resin 4.5 containing 2-chlorotrityl alcohol resin 4.6 (600 mg, 
loading 1.49 mmol/g) was swollen in DCM (60 mL) for 20 minutes. The DCM was 
filtered off and the resin was washed 3 times with DMF (60 mL) and then with dry 
DCM (3 × 60 mL). The resin was treated with thionyl chloride (1 mL, 13.5 mmol) in 
dry DCM (60 mL). The mixture was stirred for 1 hour at room temperature before 
being filtered. The resin was washed twice with DMF (60 mL) and 3 times with 
DCM (60 mL). The resin 4.5 was dried under vacuum and stored at -18
o
C under N2. 
 
6.5.1.2. Preparation of the preloaded 2-chlorotrityl-alanine resin (4.9) 
 
 
The activated resin 4.5 (250 mg, 0.38 mmol) was swollen in dry DCM (5 mL) for 30 
minutes. Fmoc-Ala-OH 4.7 (140 mg, 0.45 mmol) was dissolved in dry DCM (2.5 
mL) in the presence of DIPEA (0.315 mL, 1.80 mmol). The amino acid solution was 
added to the filtered resin 4.5 the mixture was stirred for 3 hours. The loaded resin 
was filtered and washed 3 times with a solution of DCM/MeOH/DIPEA (17: 2: 1, 5 
mL), then with DCM (3 × 5 mL), DMF (3 × 5 mL) and DCM again (3 × 5 mL).The 
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Fmoc group was removed from the resin 4.8 using the protocol 6.2.1.9 (comfirmed 






Quantitative ninhydrin test (6.2.1.2): loading 1.02 mmol/g. 




6.5.1.3. Synthesis of  Fmoc-K(Boc)-E(OtBu)-I-Q(Trt)-L-V-I-K(Boc)-V-F-I-A-




The supported protected Fmoc acid peptide (4.10) was synthesised on the preloaded 
2-chlorotrityl-alanine resin 4.9 (70 mg, 0.07 mmol) using DIC/HOBT microwave 
assisted SPPS. The resin was first swollen in DCM (0.7 mL) for 20 minutes. Each 
Fmoc-AA-OH (0.21 mmol, Table 6.35) was dissolved in DMF (1.05 mL, 0.2 M) in 
presence of DIC/HOBt (0.21 mmol) and coupled to the resin 4.9 using the protocol 
6.2.1.8 (µw, 20 minutes at 60
o
C). Each amino acid coupling was followed by Fmoc 
deprotection using 20% piperidine in DMF (6.2.1.9). Each step (coupling and Fmoc 
deprotection) was monitored by a qualitative ninhydrin test (6.2.1.1). The final Fmoc 
group was deprotected. The resin was washed with DMF (3 x 0.7 mL), DCM (3 x 0.7 
mL), MeOH (2 x 0.7 mL) and DCM (2 x 0.7 mL) before being dried in vacuo at 
40
o
C for 16 hours. 
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 Reagent Mw (g/mol) Mass (mg) 
HOBt (monohydrate) 153.1 32 
DIC 126.2 (d = 0.81) 26.5 (32.7 µL) 
Fmoc-Ala-OH 311.3 65 
Fmoc-Ile-OH 353.4 74 
Fmoc-Phe-OH 387.4 82 
Fmoc-Val-OH 339.4 71 
Fmoc-Lys(Boc)-OH 468.5 89 
Fmoc-Leu-OH 353.4 74 
Fmoc-Gln(Trt)-OH 610.7 128 
Fmoc-Glu(OtBu)-OH 425.5 90 
Table 6.35: Quantity of reagent used per coupling for SPPS of resin 4.10 and 4.11. 
 
Analysis: 
Theoretical loading (6.2.1.5): loading 0.38 mmol/g. 
Characterisation: a small sample of resin 4.10 was cleaved using a TFA/TIS/DCM 
(90: 5: 5) solution (500 µL) for 2 hours at room temperature. 










1621.94 (correspond to Fmoc-
KEIQLVIKVFIA-OH), found 1621.86 [M+H]
+
 (100%), 1644.87 [M+Na]
+ 
(47.1%). 
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6.5.1.4. Synthesis of  Fmoc-K(Boc)-E(OtBu)-I-Q(Trt)-L-V-I-K(Boc)-V-A-A-
A-2-chlorotrityl resin (4.11) 
 
 
The supported protected Fmoc acid peptide (4.10) was synthesised on the preloaded 
2-chlorotrityl-alanine resin 4.9 (70 mg, 0.07 mmol) using DIC/HOBt microwave 
assisted SPPS as previously decribed for the resin 4.11 (6.5.1.3). 
 
Analysis: 
Theoretical loading (6.2.1.5): loading 0.41 mmol/g. 
Characterisation: a small sample of resin 4.11 was cleaved (before final Fmoc-
deprotection) using a TFA/TIS/DCM (90: 5: 5) solution (500 µL) for 2 hours at room 
temperature. 










1503.87 (correspond to Fmoc-
KEIQLVIKVAAA-OH), found 1504.92 [M+H]
+
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6.5.1.5. Synthesis of Fmoc-K(Boc)-E(OtBu)-I-Q(Trt)-L-V-I-K(Boc)-V-F-I-A-




The supported protected amide peptide (4.12) was synthesised on aminomethyl 
polystyrene resin functionalized with a Rink amide linker (2.28) (200 mg, 0.16 
mmol) using DIC/HOBT microwave assisted SPPS as above (6.5.1.3).  
 
Reagent Mw (g/mol) Mass (mg) 
HOBt  135.5 65 
DIC 126.2 (d = 0.81) 60.6 (74.7 µL) 
Fmoc-Ala-OH 311.3 149 
Fmoc-Ile-OH 353.4 170 
Fmoc-Phe-OH 387.4 186 
Fmoc-Val-OH 339.4 163 
Fmoc-Lys(Boc)-OH 468.5 204 
Fmoc-Leu-OH 353.4 170 
Fmoc-Gln(Trt)-OH 610.7 293 
Fmoc-Glu(OtBu)-OH 425.5 204 
Table 6.36: Quantity of reagent used per coupling for SPPS of resin 4.12 and 4.13. 
 
Analysis: 
Theoretical loading (6.2.1.5): loading 0.38 mmol/g. 
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Characterisation: a small sample of resin 4.12 was cleaved using a TFA/TIS/DCM 
(95: 2.5: 2.5) solution (500 µL) for 4 hours at room temperature. 
m/z (ES
+
): C83H128N16O17  calculated 1621.0, found 811.5 [M+2H]
2+




m/z (MALDI-TOF): C83H128N16O17 calculated 1621.04 (correspond to Fmoc-
KEIQLVIKVFIA-NH2), found 1622.41 [M+H]
+
 (100%). 
HPLC (Method 2): tR = 6.3 min, purity = 86% (ESLD). 
 
6.5.1.6. Synthesis of  H-K(Boc)-E(OtBu)-I-Q(Trt)-L-V-I-K(Boc)-V-A-A-A-




The supported protected amide peptide (4.13) was synthesised on aminomethyl 
polystyrene resin functionalized with a Rink amide linker (2.28) (200 mg, 0.16 
mmol) as above 6.5.1.3 (Table 6.36 for quantities). 
 
Analysis: 
Theoretical loading (6.2.1.5): loading 0.38 mmol/g. 
Characterisation: a small sample of resin 4.13 was cleaved using a TFA/TIS/DCM 
(95: 2.5: 2.5) solution (500 µL) for 4 hours at room temperature. 
m/z (ES+): C74H118N16O17  calculated 1502.8, found 752.4 [M+2H]
2+




m/z (MALDI-TOF): C74H118N16O17 calculated 1502.82 (correspond to Fmoc-
KEIQLVIKVFIA-OH), found 1526.11 [M+Na]
+
 (100%).  
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HPLC (Method 2): tR = 6.1 min, purity = 83% (ELSD). 
 




Dimedone (20 g, 143 mmol) was dissolved in DMF (350 mL) with acetic acid (8.17 
mL, 143 mmol), dicyclohexylcarbodiimide (DCC) (29.5 g, 143 mmol) and 4-
di(methylamino)pyridine (DMAP) (1.8 g, 14.3 mmol). The solution was stirred for 
36 hours at room temperature. The reaction was followed by TLC. Precipitating 
dicyclohexylurea (DCU) was filtered. The solvent was evaporated and the residue 
was dissolved in ethyl acetate. DCU was filtered again and the organic layer was 
washed with a solution of 1N KHSO4 (3 × 150 mL), dried with MgSO4 and filtered. 
The solvent was evaporated and crude product was purified by column 
chromatography, using DCM/EtOAc (97: 3) as eluting phase, to yield compound 
4.20 as a yellow solid (22.1 g, 85%). 
 
Analysis: 
m/z (ES+): C10H14O3  calculated 182.1, found 183.1 [M+H]
+




Rf: 0.68 (EtOAc/DCM, 5: 95). 
HPLC (Method 1): tR = 3.4 min, purity = 98% (ELSD). 
1
H NMR (CDCl3, 250 MHz): δ = 1.01 (s, 6H, C(CH3)2), 2.29 (s, 2H, CH2), 2.46 (s, 
2H, CH2), 2.54 (s, 3H, CH3). 
13
C NMR (CDCl3, 63 MHz): δ = 28.2 (C(CH3)2), 28.5 (CCH3), 30.6 (C(CH3)2), 46.5 
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Fmoc-Lys-OH (1.6 g, 4.2 mmol) and DdeOH 4.20 (2.3 g, 12.5 mmol) were 
suspended in ethanol (35 mL) then TFA (32 µL, 0.4 mmol) was added dropwise. The 
mixture was refluxed for 72 hours. Once all the Fmoc-Lys-OH was consumed 
(monitored by TLC), the solvent was removed under vacuum and the resulting 
orange sticky residue was dissolved in EtOAc (30 mL). The organic phase was 
washed with 1 M KHSO4 (3 x 80 mL) before being dried over MgSO4 and 
concentrated in vacuo. The crude was purified by column chromatography (silica, 
eluting with DCM/MeOH, 8:1) to afford Fmoc-Lys(Dde)-OH 4.14 as a brown yellow 





): C31H36N2O6 calculated 532.3, found 533.3 [M+H]
+
 (100%). 
Rf: 0.21 (DCM/MeOH, 2:1). 
HPLC (Method 1): tR = 3.6 min, purity = 100% (254 nm).  
1
H NMR (CDCl3, 500 MHz): δ = 1.05 (s, 6H, C(CH3)2-Dde), 1.46-1.60 (m, 2H, 
CH2-Lys), 1.73-2.01 (m, 4H, CH2-Lys), 2.32 (m, 3H, CH3-Dde), 2.50 (s, 4H, CH2-
Dde), 3.33 (m, 2H, CH2-NH-Lys), 4.17 (d, J = 7.06 Hz, 2H, CH2-Fmoc), 4.33 (t, J = 
7.01 Hz, 1H, CH-Fmoc), 4.44 (m, 1H, CH), 5.84 (br sg, 1H, NH),  7.27 (t, J = 7.48 
Hz, 2H, ArCH-Fmoc), 7.36 (t, J = 7.38 Hz, 2H, ArCH-Fmoc), 7.57 (t, J = 8.11 Hz, 
2H, ArCH-Fmoc), 7.73 (d, J = 7.50 Hz, 2H, ArCH-Fmoc), 13.26 (br sg, 1H, COOH).  
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13
C NMR (CDCl3, 126 MHz): δ = 18.0 (CH3-Dde), 22.5 (CH2 -Lys), 28.1 (C(CH3)2-
Dde), 30.0 (C(CH3)2-Dde), 31.8 (CH2-Lys), 36.6 (CH2-Lys), 43.2 (CH2NH), 50.6 
(CH-Fmoc), 52.4 (2 x CH2-Dde), 54.0 (CH-Lys), 67.0 (CH2-Fmoc), 107.8 (C=CNH), 
119.9, 125.1, 127.0, 127.7 (ArCH-Fmoc), 141.2, 143.7 (ArC-Fmoc), 156.4 (COO-
Fmoc), 173.9 (C=CNH-Dde), 175.8 (COOH), 198.1 (C=O-Dde). 
 





The acid peptide-peptoid hybrid (4.16) was synthesised from the resin 4.10 (50 mg, 
0.019 mmol) using DIC/HOBT microwave assisted SPPS (unless stated otherwise, 
6.2.1.8, for quantities see Table 6.37). Once every spacer and monomer unit were 
coupled, the Dde group was selectively deprotected using a mixture of 
hydroxylamine and imidazole in NMP/DCM (6.2.1.12). The deprotection was 
monitored by qualitative ninhydrin test (6.2.1.1). 5(6)-Carboxyfluorescein 4.15 (34 
mg, 0.095 mmol) was coupled with the side chain of the Lys over 4 hours using a 
HOBt/DIC (13 mg/15.1 µL,  0.095 mmol) activation in DMF (0.48 mL, 0.2 M) 
(6.2.1.7). The coupling was confirmed by a negative qualitative ninhydrin test 
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(6.2.1.1). The resin was then washed with DCM, DMF and MeOH (3 × 0.5 mL). In 
order to remove the excess of fluorescein and to deprotect the final Fmoc group, the 
resin was mixed with 20% piperidine in DMF (0.5 mL) for 1 hour.
328
 Afterwards, the 
resin was washed with DMF (3 × 0.5 mL) and the basic treatement (20% piperidine, 
0.5 mL) in DMF was repeated for 10 minutes. As the washing solution was still 
fluorescent, the resin was left to stir under these basic conditions for another hour. 
The resin was then washed with DMF, DCM, MeOH and Et2O (3 × 0.5 mL). The 
Fluorescein peptide-peptoid was deprotected and cleaved from the resin using 
TFA/TIS/DCM (90: 5: 5) solution (1.25 mL) for 2 hours at room temperature 
(6.2.1.10). The peptide-peptoid 4.16 was isolated after drying (in vacuo at 40
o
C for 
16 hours) and purification (preparative reverse phase-HPLC, Gradient 3) as a yellow 
solid (39 mg, 58 % based on 4.10). 
 
Reagent Mw (g/mol) Mass (mg) 
HOBt  135.5 8 
DIC 126.2 (d = 0.81) 8.9 µL 
Fmoc-Ahx-OH (2.34) 353.4 20 
Fmoc-Lys(Dde)-OH (4.14) 532.3 30 
Peptoid monomer (2.22) 496.3 28 
 





): C179H305N37O34   calculated  3519.3, found 880.5 [M+4H]
4+
 (10.2%),  
704.8 [M+5H]
5+
 (34.9%), 587.5 [M+6H]
6+
 (100%), 503.7 [M+7H]
7+

















 = 880.89112, found 
880.86172.  
HPLC (Method 3): tR = 3.0 min; purity ≥ 99% (ELSD and 475 nm). 
UV (Tris buffer pH 7.8): λabs = 498 nm. 
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The acid peptide-peptoid hybrid (4.17) was synthesised on the resin 4.11 (50 mg, 
0.021 mmol) using the same protocol as for 4.16. The peptide-peptoid 4.17 was 
isolated as a yellow solid (47 mg, 69% based on 4.11) after preparative reverse-phase 
purification (Gradient 3).  
 
Reagent Mw (g/mol) n (mmol) Quantity (mg) 
HOBt  135.5 0.062 8 
DIC 126.2 (d = 0.81) 0.062 9.7 µL 
DMF 73.1 (d = 0.95) Conc 0.15 M 0.42 mL 
Fmoc-Ahx-OH (2.34) 353.4 0.062 22 
Fmoc-Lys(Dde)-OH 
(4.14) 
532.3 0.062 33 
Peptoid monomer (2.22) 496.3 0.062 31 
5(6)-Carboxyfluorescein 
(4.15) 
356.3 0.103 36 
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HOBt (FAM coupling) 135.5 0.103 14 
DIC (FAM coupling) 126.2 (d = 0.81) 0.103 16.1 µL 
DMF (FAM coupling) 73.1 (d = 0.95) Conc 0.2 M 0.52 mL 
 






): C170H295N37O34  calculated 3401.4, found 851.2 [M+4H]
4+
 (34.9%), 681.1 
[M+5H]
5+
 (100%), 567.8 [M+6H]
6+
















 = 1134.79629, found 
1134.79673.  
HPLC (Method 3): tR = 2.7 min, purity = 98% (ELSD). 
UV (Tris buffer pH 7.8): λabs = 498 nm. 
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The amide peptide-peptoid hybrid (4.18) was synthesised on the resin 4.12 (70 mg, 
0.025 mmol) using the same protocol as for 4.16. The peptide-peptoid 4.18 was 
isolated as a yellow solid (66 mg, 79% based on 4.12) after preparative reverse-phase 
purification (Gradient 3).  
 
Reagent Mw (g/mol) n (mmol) Quantity 
HOBt  135.5 0.075 10 
DIC 126.2 (d = 0.81) 0.075 11.7 µL 
DMF 73.1 (d = 0.95) Conc 0.15 M 0.50 mL 
Fmoc-Ahx-OH (2.34) 353.4 0.075 27 
Fmoc-Lys(Dde)-OH 
(4.14) 
532.3 0.075 40 
Peptoid monomer (2.22) 496.3 0.075 37 
5(6)-Carboxyfluorescein 
(4.15) 
356.3 0.125 45 
HOBt (FAM coupling) 135.5 0.125 17 
DIC (FAM coupling) 126.2 (d = 0.81) 0.125 19.5 µL 
DMF (FAM coupling) 73.1 (d = 0.95) Conc 0.2 M 0.63 mL 
 





): C179H306N38O33   calculated 3518.6, found 880.5 [M+4H]
4+
 (58.2%), 704.6 
[M+5H]
5+
 (100%), 587.3 [M+6H]
6+

















 = 1179.85991, found 
1173.86023.  
HPLC (Method 3): tR = 3.1 min, purity = 100% (ELSD and 475 nm). 
UV (Tris buffer pH 7.8): λabs = 499 nm. 
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The amide peptide-peptoid hybrid (4.19) was synthesised on the resin 4.13 (50 mg, 
0.0185 mmol) using the same protocol as for 4.16. The peptide-peptoid 4.19 was 
isolated as a yellow solid (47 mg, 75% based on 4.13) after preparative reverse-phase 
purification (Gradient 3).  
 
Reagent Mw (g/mol) n (mmol) Quantity 
HOBt  135.5 0.056 8  
DIC 126.2 (d = 0.81) 0.056 8.7 µL 
DMF 73.1 (d = 0.95) Conc 0.15 M 0.38 mL 
Fmoc-Ahx-OH (2.34) 353.4 0.056 20 
Fmoc-Lys(Dde)-OH 
(4.14) 
532.3 0.056 30 
Peptoid monomer (2.22) 496.3 0.056 28 
5(6)-Carboxyfluorescein 
(4.15) 
356.3 0.093 33 
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HOBt (FAM coupling) 135.5 0.093 13 
DIC (FAM coupling) 126.2 (d = 0.81) 0.093 14.5 µL 
DMF (FAM coupling) 73.1 (d = 0.95) Conc 0.2 M 0.47 mL 
 





): C170H296N38O33   calculated 3400.4, found 851 [M+4H]
4+
 (13.2%), 680.9 
[M+5H]
5+
 (42.5%), 567.6 [M+6H]
6+

















 = 669.15306, found 669.16793  
HPLC (Method 3): tR = 2.8 min, purity = 100% (ELSD and 475 nm). 
UV (Tris buffer pH 7.8): λabs = 498 nm. 
 




The peptide 4.21 was synthesised from resin 4.10 (50 mg, 0.019 mmol). The Fmoc-
Ahx-OH 2.34 (20 mg, 0.057 mmol) and 5(6)-carboxyfluorescein 4.15 (41 mg, 0.15 
mmol) were coupled to 4.10 using the protocol 6.2.1.7. Excess of fluorescein and 
Fmoc group were removed by basic treatment (as described in 6.5.1.9). The 
Fluorescein peptide was deprotected and cleaved from the resin using 
TFA/TIS/DCM (90: 5: 5) solution (1.25 mL) for 2 hours (6.2.1.10). The peptide 4.21 
was isolated after precipitation, drying and purification (preparative reverse phase-
HPLC, Gradient 3) as a yellow solid (24 mg, 66% based on 4.10) 
Analysis: 
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): C95H138N16O23   calculated 1871.0, mass 936.6 [M+2H]
2+


















 = 936.50603, found 936.50658.  
HPLC (Method 2): tR = 5.6 min, purity = 99% (ELSD). 
UV (MeOH): λabs = 500 nm. 
 




The Fluorescein-Ahx-9mer peptoid (4.22) was synthesised on the resin Fmoc-Ahx-
9mer 2.35 (50 mg, 0.014 mmol).  5(6)-Carboxyfluorescein 4.15 (25 mg, 0.07 mmol) 
was then coupled to the Fmoc deprotected resin over 4 hours using a HOBt/DIC (10 
mg/10.9 µL,  0.07 mmol) activation in DMF (0.35 mL, 0.2 M) (6.2.1.7). The resin 
was mixed with 20% piperidine in DMF (0.5 mL) to remove the Fmoc group and 
excess of fluorescein.
328
 The resin was then washed with DMF, DCM, MeOH and 
Et2O (3 × 0.75 mL). The Fluorescein peptoid 4.23 was deprotected and cleaved from 
the resin using the protocol 6.2.1.10 to yield a yellow solid (25 mg, 96% based on 
2.35) after drying (in vacuo at 40
o
C for 16 hours). 
Analysis: 
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 (100%), 474.7 [M+4H]
4+











HPLC (Method 3): tR = 2.6 min, purity > 98% (ELSD). 
UV (Tris buffer pH 7.8): λabs = 498 nm. 
 
6.5.1.15. Cellular delivery of 4.16, 4.17, 4.18, 4.19, 4.21 and 4.22  into HeLa 
cells 
Cells were seeded onto a 24-well plate at a density of 3 × 10
4
 cells/well (volume of 
culture media per well: 350 µL). After 24 hours, 35 µL of 4.16, 4.17, 4.18, 4.19, 4.22 
(100 µM in PBS) and 4.21 (100 µM in PBS with 8% of DMSO) were injected in 
three random wells (final concentration 10 µM). Cellular uptake was analysed after 2 
and 24 hours of incubation by flow cytometry in 2% FBS in PBS with 0.2% of 









Untreated cells  0.7 0.1 
 
4.22  
2 h 79.1 2.4 
24 h 98.5 0.7 
4.16 
2 h 71.1 0.9 
24 h 92.0 0.9 
4.17  
2 h 84.3 6.1 
24 h 90.0 1.8 
4.18  
2 h 68.8 0.7 
24 h 86.2 3.9 
4.19  
2 h 67.7 2.9 
24 h 86.8 2.0 
4.21  
2 h 8.3 0.6 
24 h 17.9 6.1 
Table 6.41: Cellular uptake of Fluo-9mer (4.22, 10 µM), peptide-peptoids (4.16, 4.17, 4.18 and 
4.19, 10 µM) and peptide (4.21, 10 µM) in HeLa cells (n = 3).  
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6.5.1.16. Microscopy of 4.16, 4.17 into HeLa cells 
Cells were seeded onto a 24-well plate at a density of 3 × 10
4
 cells/well (volume of 
culture media per well: 800 µL). After 24 hours, 35 µL of 4.16, 4.17 (100 µM in 
PBS) were injected in three random wells (final concentration 10 µM). After 4 hours 
of incubation with the peptoids, cells were washed with PBS and microscopy was 
performed in 2% FBS in PBS without further staining. 
 
6.5.1.17. MTT assays of 4.16, 4.17, 4.18, 4.19 and 4.22 in HeLa cells 
MTT cytotoxicity assays were carried out as according to the general procedures 
(6.2.2.4). In order to obtain a final concentration of  5, 10 and 20 µM, cells were 
treated respectively with 5, 10 and 20 µL of the compound 4.16, 4.17, 4.18, 4.19 and 
4.22 at a starting concentration of 100 µM (in PBS).  After 24 hours of incubation at 
37
o



















5 0.189 0.016 112.0 9.8 
10 0.161 0.010 95.7 6.2 




5 0.181 0.020 107.6 11.7 
10 0.188 0.021 111.3 12.2 




5 0.183 0.010 108.3 5.8 
10 0.166 0.008 98.5 4.6 




5 0.191 0.016 113.2 9.5 
10 0.188 0.013 111.3 7.9 




5 0.190 0.012 112.8 7.1 
10 0.195 0.015 115.4 8.9 
20 0.185 0.010 109.6 6.2 
Table 6.42: Percentage of cell vailability (HeLa cells) after 24 hours of incubation with peptides-
peptoid (4.16, 4.17, 4.18 and 4.19) and Fluo-9mer (4.22) at different concentrations. (n = 6) 
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6.5.2. Experiment for GFP protein delivery 
6.5.2.1. Cys-GFP protein (4.29) expression 
 
The His6-Cys-GFP plasmid (pET 19b-His6-GFP) was prepared and donated by Dr 
David Nagel. (Appendix 4-1) Cys-GFP protein was modified on its N-terminal with 
a spacer composed by six successions of Ser-Gly and the Cys as final amino acid. In 
order to purify the protein, a His-tag (and a cleavage site) was introduced in the 
protein sequences. (Appendix 4-2) 
 




Precast polyacrylamide NuPAGE® Bis-Tris gels from Invitrogen were used. 
 
Running buffer, 1X MOPS (3-(N-morpholino)propanesulfonic acid) buffer: 
For 1 L, 200 mL of 5X MOPS buffer were mixed with 800 mL of deionised water. 
 
5X MOPS buffer: 
250 mM MOPS (52.33 g) 
250 mM Tris-HCl (30.28 g) 
5 mM EDTA (1.86 g) 
0.5% SDS (50 mL of 10%)  
Dissolved in distilled water and adjusted to a final volume of 1 L. 
 
Coomassie staining solution: 
450 mL water 
450 mL Methanol 
100 mL of GAA (Glacial acetic acid) 
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Destaining solution:  
1 hour: 10% GAA and 45% MeOH in water 
Overnight: 10% GAA and 10% MeOH in water 
 
Marker: 
Marker See Blue® Plus2 Prestained Standard (1X) by Invitrogen.  
 
Protocol: 
The desired volume of each sample (0.5 mg/mL of protein) was mixed with a 
required amount of 2X SDS. The mixture was then boiled for 5 minutes and then 
centrifuged at maximum speed for 2 minutes. The blue solution was then loaded into 
the gel.  
The gel was run at 200V for 70 minutes in 1X MOPS buffer. Afterwards, the gel was 
transferred   into the staining solution for 1 hour and decoloured using the destaining 
solution. 
 
6.5.2.1.2. Transformation step and amplification 
 
For the transformation step, competent cells (BL21(RPS)DE3 E.coli strains) from 
Stratagene were used : 
- Specie: E. coli, 
- Cell line: BL21(RPS)DE3 (Stratagene), 




) gal λ(DE3) 
- Application: Transformation, expression host. 
 
LB (Luria Bertani) Broth media: 
10 g/L Tryptone 
5 g/L Yeast extract 
10 g/L NaCl 
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Protocol: 
The His-tag thiol-GFP plasmid was transformed using heat shock and 
BL21(RPS)DE3 competent cells. Plasmid DNA (2 μL) was added to BL21(DE3) 
competent cells (50 μL) and incubated for 15 minutes on ice. The cells were then 
heat shocked for 30 seconds at 42°C. The mixture was incubated on ice for 15 
minutes. The cells were then heat shocked at 42C for 45 seconds before being 
incubated on ice for a further 1 minute. LB broth (400 μL) was added and the cells 
were shaked (250 rpm) for 40 minutes at 37C. Subsequently, the cells (50 μL) were 
spread on a LB containing ampicillin (100 g/mL, Sigma) and chloramphenicol (34 
μg/mL, Sigma) and incubated overnight at 37°C. 
 
6.5.2.1.3. Induction step 
Four colonies of transformed cells were picked into a sterile tube containing 3 mL of 
LB media and antibiotics (100 μg/mL ampicillin and 34 μg/mL chloramphenicol) 
and grown overnight at 37
o
C. The optical density at 600 nm (OD600) was measured 
(~2.0). The cultures were stored at room temperature for 4 hours. 12 samples were 
prepared by dilution of 0.5 mL of overnight cell culture with 5 mL of fresh LB 
media. The cells were grown again for 4 hours at 37
o
C to obtain an OD600 0.9. Then 
in each 50 mL cell culture was added IPTG to give a final concentration of 1 mM. 
IPTG (4.31) was not added to one of the 5mL mixture. This tube was used for non-
induction comparison. All cell cultures were grown overnight at 27
o
C and then stored 
on ice. 
 
6.5.2.1.4. Cell lysis 
Cell lysis buffer: 
300 mM NaCl (60 mL of 5 M solution) 
15 mM imidazole (15 mL of 1 M solution) 
50 mM Tris-HCl (pH 8) (25 mL of 2 M solution) 
10% mM glycerol (125 mL of 80% solution) 
10 mM 2-mercaptoethanol (0.7 mL of 14.3 M solution) 
1 protease inhibitor tablet (Complete EASYpack) 
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Dissolved and mixed in sterile water to obtain a final volume of 1 L. 
Just before use, 1X of PMSF (2.5 mL from a 400X starting solution in isopropanol) 
were added to the mixture. 
 
Protocol: 
Induced cell cultures were mixed into 50 mL centrifuge tubes. Induced (A+) and 
non-induced solutions were spin down at 5000 rpm for 10 minutes at 4
o
C. The 
supernatant was removed. The pellets were detached and washed with 20 mL of 
PBS. Samples were centrifuged again using the same conditions. The His6-Cys-GFP 
(4.30) gave a green pellet. The supernatant was removed by suction and the pellet 
was resuspended into 10 mL of cold cell lysis buffer (4 tubes). Once cells were 
suspended into this buffer, tubes were transferred from ice into dry ice. The cells 
were frozen for 30 minutes. After this step, cells were warm up under hot water to 
defreeze them while keeping them cold. Each defrost tube was put into ice with 0.5 
mL of lysozyme (Lysozyme from chicken egg white, 20 mg/mL, Sigma-Aldrich) to 
give a final concentration of 1 mg/mL. The lysozyme was left to react during 45 
minutes on ice. At the end of the incubation time, each tube, kept on ice, was 
sonicated for 5 minutes (Soniprep 150, MSE)). 0.5 mL of triton-x 0.1% was added to 
each tube which was then again spin down (16000g for 15 minutes at 4
o
C). The clear 
supernatant of each tube was removed, mixed and transferred into a 50 mL 
centrifuge tube on ice (40 mL). In case of the pellets were still green, 10 mL of 
supernatant were used to resuspend them. Sonication, centrifugation and transfer 
steps were repeated. 200 µL of A+ supernatant and of A- supernatants were taken 
and small aliquots were analysed by SDS-PAGE gel to confirm the presence of 
protein 4.30. 
 
6.5.2.1.5. His-Tag purification 
In order to purify the protein, Ni-NTA agarose beads from QIAGEN were used. 
 
Washing buffer: 
300 mM NaCl (60 mL of 5 M solution) 
20 mM imidazole (20 mL of 1 M solution) 
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50 mM Tris-HCl (pH 8) (25 mL of 2 M solution) 
10% mM glycerol (125 mL of 80% solution) 
10 mM 2-mercaptoethanol (0.7 mL of 14.3 M solution) 
Dissolved and mixed in sterile water to obtain a final volume of 1 L. 
Just before use, 1X of PMSF (2.5 mL from a 400X starting solution in isopropanol) 
were added to the mixture. 
 
Elution buffer: 
300 mM NaCl (60 mL of 5 M solution) 
250 mM imidazole (250 mL of 1 M solution) 
50 mM Tris-HCl (pH 8) (25 mL of 2 M solution) 
10 mM 2-mercaptoethanol (0.7 mL of 14.3 M solution) 
Dissolved and mixed in sterile water to obtain a final volume of 1 L. 
Just before use, 1X of PMSF (2.5 mL from a 400X starting solution in isopropanol) 
were added to the mixture. 
 
Protocol: 
Ni-NTA agarose beads (10 mL) were added to 30 mL of PBS, mixed and then 
centrifuged 2000 rpm for 2 minutes.  The washing with PBS was repeated twice. 
Once the beads ready, they were mixed with the His6-Cys-GFP protein (4.30, 40 
mL) for 1 hour. After reaction, the clear supernatant was removed.  25 mL of 
washing buffer were added to the beads and mixed. The mixture was centrifuge 2000 
rpm for 2 minutes at 4
o
C. The washing step was repeated 3 times. The beads were 
suspended in 10 mL of washing buffer and transferred into a SPE column. The 
washing buffer was eluted until the edge of the beads and 10 mL of elution buffer 
were added. The solution was collected as 20 fractions of 0.5 mL. The aliquots were 
passed under the transilluminator (UVP TM 40 Dual intensity Ultraviolet 
transilluminator from Ultra Violet Products) to detect the fractions containing the 
GFP. The fluorescent aliquots were mixed together.  
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6.5.2.1.6. His-Tag cleavage 
Once purified, the His-tag was cleaved from the GFP 4.30 using an Enterokinase 
(light chain, BioLabs, 2 µg/mL), that specifically cleaves the protein after lysine in 
the sequence Asp-Asp-Asp-Asp-Lys.  
 
Reaction buffer: 
50 mM NaCl (1 mL of 5 M solution) 
20 mM Tris-HCl (pH 8) (1 mL of 2 M solution) 
2 mM CaCl (0.1 mL of 2 M solution) 
Dissolved and mixed in sterile water to obtain a final volume of 100 mL. 
 
Protocol: 
1.5 mL of His6-Cys-GFP (4.30, 1755 µg) was mixed with 30 µL of entrokinase and 
1.5 mL of reaction buffer for 16 hours at 25
o
C, 700 rpm on a Thermomixer comfort 
(Eppendorf). After digestion and its SDS-PAGE confirmation (Cys-GFP, 4.29), the 
entrokinase was removed using a large excess trypsin inhibitor agarose (Glycine 
max, soybean, Sigma-Aldrich). 30 µL of inhibitor beads were prepared by mixing 
with reaction buffer and centrifuging (room temperature, 2 minutes, 2000 rpm). This 
step was repeated twice. The beads were added to the entrokinase-GFP 4.29 solution 
and mixed for 2 hours at room temperature.  
 
6.5.2.1.7. Protein desalting and concentration 
The protein 4.29 was desalted using a PD 10 column (GE Healthcare, exclusion limit 
5000 Da, 2.5 mL) and the reaction buffer (6.5.2.1.6). The GFP was concentrated 
using Amicon ultra-4 3000 Da centrifugal filter devices (Millipore) for 10 minutes at 
4000g (concentrate down from 4 mL to 0.5 mL). The location of the protein in the 
upper level of the device was confirmed by transilluminator. 
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6.5.2.1.8. Analysis 





) after measurement of the absorption at 390 nm using a SmartSpec 
3000 (Biorad): 
A = 0.428 at 390 nm  
Concentration of Cys-GFP (4.29) = 77 µM 
C4.29 mg/mL = 2.16 mg/mL. 
 
m/z (MALDI-TOF): calculated 27767.7, found 27766.5 [M+H]
+











A suspension of maleic anhydride 4.27 (4.9 g, 50 mmol) and aminohexanoic acid 
4.32 (6.58 g, 50 mmol) in acetic acid (37.5 mL) was heated to reflux for 90 minutes. 
The solution was then cooled down and the solvent was removed in vacuo.  Residual 
AcOH was removed by azeotrope with toluene (2 × 50 mL). The white residue was 
dissolved in water (50 mL). The aqueous phase was extracted with EtOAc (3 × 50 
mL). The organic phases were combined, dried over MgSO4, filtred and concentrated 
under vacuum. The crude was crystallized in EtOAc (10 mL, overnight at 4
o
C). Clear 
crystals of 4.34 were obtained, filtered, washed with cold EtOAc (3 × 5 mL) and 





): C10H13NO4 calculated 211.0, found 234.0 [M+Na]
+




Rf: 0.63 (EtOAc). 
HPLC (Method 1): tR = 3.3 min, purity = 100% (ELSD). 
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1
H NMR (CDCl3, 360 MHz): δ = 1.21-1.30 (m, 2H, CH2, C4), 1.53-1.62 (m, 4H, 
CH2, C3 and C5), 2.28 (t, J = 7.42 Hz, 2H, CH2, C2), 3.45 (t, J = 7.27 Hz, 2H, CH2, 
C6), 6.62 (s, 2H, HC=CH). 
13
C NMR (CDCl3, 90 MHz): δ = 23.7 (C3), 25.8 (C4), 27.8 (C5), 33.3 (C2), 37.2 (C6), 
133.8 (2C, C=C), 170.5 (2C, C=O), 178.9 (COOH). 









The maleimide-9mer peptoid 4.35 was synthesised from the resin 2.28 (50 mg, 
0.043 mmol) and the monomer 2.22 (65 mg, 0.13 mmol) using the protocols 
6.2.1.8 and 6.2.1.9.  
After coupling of Fmoc-Ahx-OH (2.34, 45.9 mg, 0.13 mmol), the maleimide 
spacer 4.34 (27 mg, 0.13 mmol) was conjugated to the solid supported peptoid 
using a DIC/HOBt (20.3 µL/18 mg, 0.13 mmol) activation in DMF (0.65 mL, 0.2 
M, 6.2.1.7). Finally, the resin bound maleimide-9mer peptoid was deprotected 
and cleaved from the solid support using a solution TFA/TIS/H2O (95: 2.5: 2.5, 
2.5 mL) (6.2.1.10). Maleimide-9mer 4.35 was isolated after overnight drying 
(vacuum oven, 40
o










 (72.3%), 433.2 [M+4H]
4+
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m/z (MALDI-TOF): C88H169N21O13 calculated
 












 = 577.47212, found 
577.45354.  
HPLC (Method 3): tR = 2.0 min, purity > 98% (ELSD). 
1
H NMR (D2O, 500 MHz, presat water suppression): δ = 1.12-1.37 (m, 40H, 4H 
for CH2 (H 4’ and H4’’) and 36H for CH2 (H 3 and H4)) , 1.37-1.68 (m, 44H, 8H for 
CH2 (H 3’, 5’, 3’’ and 5’’) and 36H for CH2 (H 2 and H5)), 2.07-2.17 (m, 2H, CH2, H2’), 
2.40 (t, J = 7.20 Hz, 2H, CH2, H2’’), 2.91 (m, 18H, CH2NH2, H6), 2.98-3.14 (m, 2H, 
CH2, H6’),  3.28 (m, 18H, CH2N, H1), 3.42 (t, J = 6.85 Hz, 2H, CH2, H6’’), 3.89-4.42 
(m, 18H, NCH2CO),  6.77 (s, 2H, HC=CH), 7.47 (br sg, 2H, CONH2). 
13
C NMR (D2O, 126 MHz):
 
δ = 22.1 (CH2, C3’’), 24.9 (CH2, C4’’), 25.2, 25.3, 25.4, 
25.5, 25.6, 26.1, 26.2, 26.3, 26.4, 26.6, 26.7, 27.1, 27.2, 27.3, 27.5 and 27.6 (CH2, 
C5’’,C2’, 4’, 5’,C2, 3, 4, 5), 31.8 (CH2, C2’’), 35.4 (CH2, C2’), 37.2 (CH2, C6’’), 39.1, 39.4, 
39.5, 39.6 (CH2, C6),47.3, 47.4, 47.5, 47.7, 47.8, 47.9, 47.9, 48, 481, 48.2, 48.3, 48.4, 
48.5 (CH2, NCH2CO and C1), 134.3 (HC=CH), 162.4, 162.7, 162. 9, 163.3 (C=O-
9mer), 169.9, 170.1, 170.2, 170.3 (C=O- 9mer and spacer), 173.3 (C=O-maleimide). 
 




The preactivated 2-chlorotrytil chloride resin 4.5 (500 mg, 0.75 mmol) was swollen 
for 20 minutes at room temperature in DCM (5 mL). The resin was then mixed with 
cysteamine 4.36 (289 mg, 0.75 mmol) and DIPEA (0.65 mL, 3.75mmol) in 6 mL of 
DCM. The mixture was stirred overnight. The resin was filtered and washed with 
DCM and DMF (3 × 5 mL each). The coupling was confirmed by a qualitative 
ninhydrin test (6.2.1.1). After overnight drying in a vacuum oven (40
o
C), the resin 
4.37 was isolated as a beige solid (625 mg).  
CHAPTER 6 
- 254 - 
 
Analysis: 
Quantitative ninhydrin test (6.2.1.2): loading 0.75 mmol/g. 








The resin 4.37 (100 mg, 0.075 mmol) was swollen in DCM (1 mL) for 20 minutes at 
room temperature. Rhodamine 2.36 (183 mg, 0.375 mmol) and HOBt (51 mg, 0.375 
mmol) were dissolved in DMF (1.9 mL, 0.2 M). DIC (58.4 µL, 0.375 mmol) was 
added to the solution that was stirred for 15 minutes. The activated solution was 
added to the resin and the mixture was shaked overnight. The resin was isolated by 
filtration and was washed with DMF, DCM, MeOH and Et2O (3 × 5 mL each). The 
modified rhodamine 4.38 was finally released from the solid support by a 2 hour 
treatment with a mixture of TFA/DCM/TIS (50: 45: 5, 2.5 mL). The red solution was 
filtered off, and the resin was washed twice with 1 mL of cocktail solution and DCM 
(3 × 1 mL).  The solvent was evaporated and the remaining product was precipitated 
in cold Et2O (2 x 15 mL). After the centrifugation and overnight drying in vacuo at 







 calculated 546.2, found 546.2 [M]
+








calculated 546.24210, found 546.24337.  
HPLC (Method 3): tR = 4.8 min, purity > 98% (ELSD) 
1
H NMR (D2O, 500 MHz, presat water suppression): δ = 1.13 (t, J = 8.40 Hz, 12H, 
4 × CH3), 2.75 (t, J = 7.85 Hz, 2H, CH2SH), 3.47 (q, J  = 8.55 Hz, J  = 8.90 Hz, 8H, 
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CH2CH3), 3.57 (t, J = 7.70 Hz, 2H, CH2NH), 6.65 (s, 2H, ArH, H5 and H4), 6.76 (d, J 
= 11.75 Hz, 2H, ArH, H7 and H2), 7.02 (d, J = 11.75 Hz, 2H, ArH, H8 and H1), 7.31 
(d , J = 9.65 Hz, 0.5H, ArH, H7’ for isomer 5’), 7.85 (m , 0.5H, ArH,  H5’ for isomer 
6’), 7.92 (d, J = 9.45 Hz, 0.5H, ArH, H6’ for isomer 5’), 8.15 (m, 0.5H, ArH, H4’ for 
isomer 6’), 8.33 (s, 1H, ArH, H4’ for isomer 5’ and H7’ for isomer 6’). 
13
C-NMR (D2O, 126 MHz): δ = 12.3 (CH2CH3),   31.0 (CH2SH),  39.3 (CH2NH),  
45.4 (CH2CH3),  96.7 (ArCH, C5 and C4), 112.7, 113.6 (ArCH, C2 and C7), 128.7 
(ArCH, C5’ for isomer 6’), 129.1, 129.3 (ArCH, C7’ for isomer 6’ and C6’ for isomer 
5’), 130.8 (ArCH, C7’ for isomer 5’), 131.3 (ArCH, C4’ for isomer 6’), 131.6 (ArCH, 
C4’ for isomer 5’), 132.1, 133.4 (ArCH, C1 and C8), 135.2, 137.7, 138.2, 140.5, 
142.6, 155.8, 157.6, 158.3 (ArC), 163.8 (CONH), 174.3 (COOH). 
UV (MeOH): λabs = 560 nm, λem = 589 nm. 





6.5.2.6. Synthesis of 4.39 via coupling between the maleimide-9mer 4.35 and 




Maleimide-9mer 4.35 (10 mg, 5.7 µmol) was dissolved in PBS (1 mL) and the pH 
was adjusted at 7.0 using 1 M NaOH.  The thio-rhodamine 4.38 (3 mg, 5.7 µmol) 
was added and the solution was mixed for 16 hours. The solution was lyophilised and 
the crude was precipated in cold Et2O (1 mL) using TFA (100 µL). After 
centrifugation and drying, 4.39 was isolated as a red solid. A small amount of the 
crude was analysed by MS and HPLC without purification in order to know the 
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efficiency of the couplage. After purification by preparative HPLC (Gradient 1), the 
pure 4.39 (10 mg, 79%) was analysed. 
 





 calculated 2276.1, 570.0 [M+4H]
4+
 (5.7%), 456.2 
[M+5H]
5+
 (58.6%), 380.3 [M+6H]
6+











HPLC (Method 3): tR = 2.3 min, purity > 96% (ELSD). 
 







 569.64857, found 
569.66215. 
HPLC (Method 3): tR = 2.3 min, purity = 100% (ELSD). 
1
H NMR (D2O, 500 MHz, presat water suppression): δ = 1.07 (t, J = 6.55 Hz, 12H, 
4 × CH3), 1.19-1.44 (m, 40H, 4H for CH2 (H 4’ and H4’’) and 36H for CH2 (H 3 and 
H4)) , 1.44-1.71 (m, 44H, 8H for CH2 (H 3’, 5’, 3’’ and 5’’) and 36H for CH2 (H 2 and H5)), 
2.19 (t, J = 7.20 Hz, 2H, CH2, H2’), 2.46 (t, J = 7.50 Hz, 2H, CH2, H2’’), 2.79 (t, , J = 
7.45 Hz 2H, CH2S-Rho), 2.97 (m, 18H, CH2NH2, H6), 3.03 and 3.06 (2 dd, J = 6.70 
Hz, J = 1.05 Hz, 2H, COCH2CHS-succinimidyl), 3.25-3.43 (m, 18H, CH2N, H1), 
3.46 (t, J = 7.82 Hz, 2H, CH2NH-Rho), 3.48 (t, J = 6.65 Hz,  2H, CH2, H6’),  3.53 (t, 
J = 6.65 Hz, 2H, CH2, H6’’), 3.68 (q, J  = 6.55 Hz, J  = 6.50 Hz, 8H, CH2CH3), 4.00-
4.46 (m, 18H, NCH2CO), 4.66 (m, 1H, CHS-succinimidyl),  6.82 (s, 2H, ArCH, H5 
and H4), 6.88 (d, J = 9.55 Hz, 2H, ArCH, H7 and H2), 7.10 (d, J = 9.85 Hz, 2H, 
ArCH, H8 and H1), 7.52 (d, J = 7.50 Hz, 0.5H, ArCH, H7’ for isomer 5’), 7.66 (m, 
0.5H, ArCH,  H5’ for isomer 6’), 7.99 (d, J = 8.15 Hz, 0.5H, ArCH, H6’ for isomer 
5’), 8.10 (m, 0.5H, ArCH, H4’ for isomer 6’), 8.21 (s, 1H, ArCH, H4’ for isomer 5’ 
and H7’ for isomer 6’). 
13
C NMR (D2O, 126 MHz):
 
δ = 12.3, 12.4 (CH2CH3),   22.1 (CH2, C3’’), 25.0 (CH2, 
C4’’),  25.3, 25.4, 25.5, 25.6, 26.1, 26.2, 26.3, 26.4, 27.0, 27.1, 27.2, 27.3, 27.5, 27.6, 
27.8, 27.9 (CH2, C5’’,C2’, 4’, 5’,C2, 3, 4, 5), 31.9 (CH2, C2’’), 35.4 (CH2, C2’), 36.2 (CH2S-
Rho),  37.2 (CH2, C6’’), 39.1, 39.4, 39.5, 39.6, 39.8, 40.0, 41.2 (CH2 (C6), CH2NH-
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Rho, COCH2CHS-succinimidyl), 45.5 (CH2CH3),  47.2, 47.3, 47.5, 47.7, 47.8, 47.9, 
47.9, 48, 48.1, 48.2, 48.3, (CH2, NCH2CO and C1), 54.5 (CHS-succinimidyl), 96.7 
(ArCH, C5 and C4), 112.8, 113.6 (ArCH, C2 and C7), 128.5 (ArCH, C5’ for isomer 
6’), 129.0, 129.3 (ArCH, C7’ for isomer 6’ and C6’ for isomer 5’), 130.8 (ArCH, C7’ 
for isomer 5’), 131.2 (ArCH, C4’ for isomer 6’), 131.6 (ArCH, C4’ for isomer 5’), 
132.1, 133.3 (ArCH, C1 and C8), 137.9, 138.1, 140.5, 142.7, 156.0, 157.6, 158.3 
(ArC),  162.4, 162.7, 163.0, 163.3 (C=O-9mer), 170.1, 170.2 (C=O-spacer), 173.3 
(C=O-maleimide). 
UV (H2O): λabs = 560 nm, λem = 586 nm. 
 
6.5.2.7. Preparation and analysis of the 9mer-Cys-GFP 4.40 
6.5.2.7.1. SDS-PAGE gel protocol 
SDS-PAGE gels were carried out using a Mini-Protean® Tetra Cell from BioRad.  
 
Gel preparation: 
SDS-PAGE was carried out using a SDS-Tris system with 15% polyacrylamide gel. 
Two gels were prepared: the running gel (bottom) containing 15% acrylamide and 
the stacking gel (top) containing 4% acrylamide. 
 
Compound Running gel Stacking gel 
 
H2O 3.5 mL 6.15 mL 
Acrylamide BIS (40%) 3.75 mL 1.01 mL 
Tris buffer 2.5 mL 
( 1.5 M, pH 8.8) 
2.5 mL 
(0.5 M, pH 6.8 ) 
SDS 10% 100 µL 100 µL 
APS (50 mg/mL) 
Ammonium 
peroxodisulfate 
200 µL 200 µL 
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TEMED 15 µL 15 µL 
Table 6.43: Quantities used to prepare one SDS gel. 
 
SDS loading buffer (2X): 
1.5 mL 1.5 M TrisBuffer pH 8.0 
2.0 mL 10% Glycerol 
2.0 mL 0.05% Bromophenol blue 
1.0 mL 10% SDS 
0.4 mL β-Mercapoethanol 
 
Running buffer, TGS (Tris-Glycine-SDS) buffer: 
25 mM Tris  
192 mM Gycine  
0.1% SDS (w/v) 
pH 8.3 
 
Coomassie staining solution: 
450 mL water 
450 mL Methanol 
100 mL of GAA (Glacial acetic acid) 
2.5 g of brillant blue 
 
Marker: 
LMW calibration kit for SDS electropherisis from GE Healthcare. The marker is 
unstained, so it was prepared as a sample (10 µL of marker + 10 µL of SDS loading 
buffer).  
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6.5.2.7.2. Preparation of the bioconjugation 9mer-S-GFP (4.40) 
8 µL of Cys-GFP (4.29, 0.62 nmol) were mixed with 0.5 mL of DTT (4.41, 6.2 nmol, 
10 equiv., 12.4 µM) in PBS pH 7.0. The solution was mixed overnight at 20
o
C using 
the Thermomixer (700 rpm). Excess of DTT was removed using PD SpinTrap G-25. 
The protein mixture was centrifuged 4 times at 800 g and washed with PBS (pH 7.0) 
and concentrated down to 100 µL. The protein was dissolved in 345 µL of PBS (pH 
7.0) and 155 µL of maleimide-9mer 4.35(15.5 nmol, 25 equiv., 100 µM) solution in 
PBS (pH 7.0) was mixed with the reduced protein. The solution was mixed overnight 
in the Thermomixer (20
o
C, 700 rpm). The excess of peptoid was removed by 
centrifugation (PD SpinTrap G-25). The protein mixture was centrifuged 4 times at 
800g and washed with PBS (pH 7.0). The protein was concentrated down to 160 µL 




m/z (MALDI-TOF): found 4.29 = 27852.6 [M+H]
+
 (100%) and 13915 [M+2H]
2+
 
(40%); 4.40 = 29540.4 [M+H]
+
 (13%) 
SDS-PAGE: two bands corresponding to Cys-GFP (4.29) and 9mer-S-GFP (4.40). 
 
6.5.2.7.3. Cellular delivery of the bioconjugate 4.40 and 4.44 into HeLa 
cells 
Cells were seeded onto a 24-well plate at a density of 3 × 10
4
 cells/well (volume of 
culture media per well: 350 µL). After 24 hours, 10 µL (4.40-a and 4.44-a) and 20 
µL of (4.40-b and 4.44-b) of 4.40 and 4.44 (100 µg/mL), 35 µL of 4.35 (100 µM in 
PBS) and 3.5 µL of 4.29 (0.6 mg/mL) were injected in three random wells. Cellular 
uptake was analysed 24 hours of incubation by flow cytometry in 2% FBS in PBS 
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Untreated cells  0.6 0.6 
4.29 6 µg/mL 4.0 2.0 
4.40-a 2.7 µg/mL 18.6 3.4 
4.40-b 5.4 µg/mL 47.5 3.5 
4.35 10 µM 2.0 0.5 
Table 6.44: Cellular uptake of Cys-GFP (4.29), 9mer-S-GFP (4.40) and Mal-9mer (4.35) after 24 
hours of incubation in HeLa cells (n = 6).  
 








Untreated cells  0.8 0.2 
4.29 6 µg/mL 0.9 0.1 
4.44-a 2.7 µg/mL 8.8 1.2 
4.44-b 5.4 µg/mL 14.8 3.3 
4.35 10 µM 1.1 0.6 
Table 6.45: Cellular uptake of Cys-GFP (4.29), 9mer-S-GFP (4.44) and Mal-9mer (4.35) after 24 
hours of incubation in HeLa cells (n = 3).  
 
6.5.2.7.4. Microscopy of the bioconjugate 4.40 into HeLa cells 
Cells were seeded onto a 24-well plate at a density of 3 × 10
4
 cells/well (volume of 
culture media per well: 350 µL). After 24 hours, 20 µL of 4.40 (5.4 µg/mL) were 
injected in random wells. After 24 hours of incubation with the peptoids, cells were 
washed with PBS and microscopy was performed in 2% FBS in PBS without further 
staining. 
 
6.5.2.7.5. MTT assays of the bioconjugate 4.40 and 4.44 in HeLa cells 
MTT cytotoxicity assays were carried out as according to the general procedures 
(6.2.2.4). The cells were treated respectively with 3 and 6 µL of 4.40 and 4.44 (1 
µg/10 µL), 10 µL of 4.35 (100 µM in PBS) and 1 µL of 4.29 (0.6 mg/mL) were 
injected. After 24 hours of incubation at 37
o
C, the wells were read on a microplate 
reader.  
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Control cells  1.146 0.044 100.0 3.9 
4.29 6 µg/mL 1.093 0.054 95.4 4.7 
4.40-a 2.7 µg/mL 1.059 0.086 92.4 7.5 
4.40-b 5.4 µg/mL 1.084 0.079 94.6 6.9 
4.44-a 2.7 µg/mL 1.060 0.125 100.1 11.8 
4.44-b 5.4 µg/mL 1.030 0.173 97.3 16.4 
4.35 10 µM 1.143 0.085 99.8 7.4 
Table 6.46: Percentage of cell vailability (HeLa cells) after 24 hours of incubation with Cys-GFP 
(4.29), 9mer-S-GFP (4.40) and (9mer-S)n-GFP (4.44) and Mal-9mer (4.35) (n = 8).  
 
6.5.2.8. Preparation and analysis of the bioconjugate (9mer-S)n-GFP 4.44 
6.5.2.8.1. Bioconjugation buffers329 
Thiolation reaction buffer: 
100 mM sodium phosphate 
1 mM EDTA 
water 
Adjusted to pH 7.4 with 1 N NaOH 
 
Bioconjugation buffer: 
10 mM sodium phosphate 
1 mM EDTA 
150 mM NaCl 
water 
Adjusted to pH 7.0 with 1 N NaOH  
 
6.5.2.8.2. Preparation of the bioconjugation (9mer-S)n-GFP (4.44) 
8 µL of Cys-GFP (4.29, 0.62 nmol) were added to 0.5 mL of 2-iminothiolane (4.42, 
15.5 nmol, 31 µM) in thiolation reaction buffer. The solution was mixed for 4 hours 
and then the excess of thiolation agent was removed using a PD SpinTrap G-25 and 
PBS (pH 7.0). The thiolated Cys-GFP (4.43) was mixed with 0.5 mL of DTT 
solution (4.41, 6.2 nmol, 10 equiv., 12.4 µM) in PBS pH 7.0. The solution was mixed 
overnight using the Thermomixer (700 rpm, 20
o
C). Excess of DTT was removed 
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purified using a PD SpinTrap G-25. The protein mixture was centrifuged 4 times at 
800g and washed with bioconjugation buffer and concentrated down to 100 µL. The 
protein was dissolved in 345 µL of PBS (pH 7.0) and 155 µL of maleimide-9mer 
4.35 (15.5 nmol, 25 equiv., 100 µM) solution in PBS (pH 7.0) was mixed with the 
protein. The solution was shaked overnight. The excess of peptoid was removed 
using a PD SpinTrap G-25. The protein mixture was centrifuge 4 times at 800g and 
washed with PBS (pH 7.0). The protein was concentrated down to 160 µL (1 µg of 
protein per 10 µL).The sample was analysed using MALDI-TOF and SDS-PAGE. 
 
Analysis:  
m/z (MALDI-TOF): found 4.29 = 27701.2 [M+H]
+
 (100%) and 13836.1 [M+2H]
2+
 
(27%); 4.44 ((9mer-S)n-GFP, n = 1) = 29534.4 [M+H]
+
 (8%) and 4.44 ((9mer-S)n-
GFP, n = 2) = 31355.8 [M+H]
+
 (4%) 
SDS-PAGE: three bands corresponding to Cys-GFP (4.29), (9mer-S)n-GFP (4.44, n 
= 1) and (9mer-S)n-GFP (4.44, n = 2). 
 
6.5.2.9. Via fully protected peptoid 
6.5.2.9.1. Physiologic deprotection of the Dde group on Fmoc-Lys(Dde)-
OH 4.14 
 
Dde deprotection solution: 
500 mM of hydroxylamine.HCl 
25 mM of EDTA Dipotassium 
50 mM of sodium phosphate dibasic 
water 
Adjusted to pH 7.5 with 4M NaOH. 
 
Reaction and analysis: 
50 mg of Fmoc-Lys(Dde)-OH (4.14, 94.9 mmol) were dissolved in 1 mL of 
deprotection solution and mixed for 6 hours. The solvent was removed under 
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 Fmoc-Lys(Dde)-OH, 4.14 Crude after deprotection 
HPLC  
(Method 1, min, λ = 240 
nm) 
3.6 (100%) 3.5 (95%) 
MS (ES
+
) 532.2 369.1 (Fmoc-Lys-OH) 
 
1
H NMR of the crude (500 MHz, CDCl3): δ = 1.51 (m, 4H, CH2-Lys), 1.70-2.04 (m, 
2H, CH2-Lys), 3.17 (m, 2H, CH2-NH-Lys), 4.25 (d, J = 5.75 Hz, 2H, CH2-Fmoc), 
4.41 (t, J = 5.85 Hz, 1H, CH-Fmoc), 4.67 (m, 1H, CH), 5.66 (br sg, 1H, NH),  7.32 
(t, J = 6.80 Hz, 2H, ArCH-Fmoc), 7.41 (t, J = 6.85 Hz, 2H, ArCH-Fmoc), 7.62 (m, 
2H, ArCH-Fmoc), 7.78 (d, J = 7.25 Hz, 2H, ArCH-Fmoc).  
 





1,6-diaminohexane 2.18 (6.4 g, 0.056 mol) and  DdeOH 4.20 (10 g, 0.056 mol) were 
dissolved in DCM (140 mL) and the reaction was stirred 2 hours. The solvent was 
evaporated and the yellow crude 4.45 (16.2 g) was used for the next step without 





): C16H28N2O2 calculated 280.2 , found 281.1 [M+H]
+




Rf: 0.21 (EtOAc). 
HPLC (Method 1): tR = 3.0 min, purity = 66% (ELSD). 
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4.45 was dissolved in THF (80 mL) with TEA (23.3 mL, 0.165 mol). To this solution 
was added, drop-wise, a solution of benzyl 2-bromacetate 2.23 (8.9 mL, 0.056 mol) 
in THF (40 mL) over 2 hours, then the reaction was stirred for another 2 hours at 
room temperature. The THF was removed in vacuo. The white solid was suspended 
in Et2O (200 mL) and then filtered. The solution was concentrated in vacuo and the 
crude product was purified by column chromatography (silica, eluting with EtOAc) 





): C25H36N2O4 calculated 428.3, found 429.1 [M+H]
+






): C25H36N2O4 calculated [M+H]
+
  429.27478, found 429.27471.  
Rf: 0.05 (EtOAc). 
HPLC (Method 3): tR = 3.5 min; purity = 100% (ELSD). 
1
H NMR (CDCl3, 250 MHz): δ = 1.04 (s, 6H, 2×CH3-Dde), 1.39-1.64 (m, 9H, 
DdeNHCH2(CH2)4CH2 and CH2NHCH2 ), 2.29 (s, 4H, 2×CH2-Dde), 2.48 (s, 3H, 
CH3-Dde ); 2.53 (t, J = 6.90 Hz,  2H, CH2CH2NHCH2 ), 3.27-3.36 (m, 2H, 
DdeNHCH2 ), 3.38 (s, 2H, NHCH2CO), 5.1 (s, 2H, CH2-Bn), 7.37 (m, 5H, ArCH-
Bn).  
13
C NMR (CDCl3, 63 MHz) δ = 17.9 (CH3-Dde), 26.7 (DdeNH(CH2)2CH2CH2CH2, 
28.2, 28.9 (C(CH3)2-Dde), 29.7, 30.1 (DdeNHCH2CH2(CH2)2CH2), 43.3 
(DdeNHCH2), 49.3 (CH2CH2NHCH2), 50.9 (NCH2CO), 66.5 (NCH2COOCH2), 
107.8 (C=CNH), 128.3, 128.4, 128.6 (ArCH), 135.6 (ArC), 173.4 (C=CNH-Dde). 
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Fmoc-OSu (3.2 g, 9.3 mmol) was added to a solution of 4.46 (4.0 g, 9.3 mmol) in 
DCM (30 mL). The reaction was stirred at room temperature and monitored by TLC 
(EtOAc, Rf: 0.63) until completion (2 hours). The solvent was removed in vacuo and 
the crude product was purified by column chromatography (silica, eluting with 





): C40H46N2O6 calculated 650.3, found 651.2 [M+H]
+






): C25H36N2O4 calculated [M+H]
+
  651.34286, found 651.34258.  
Rf: 0.49 (EtOAc). 
HPLC (Method 3): tR = 7.2 min, purity = 97% (ELSD) 
1
H NMR (CDCl3, 500 MHz) two rotamers  δ = δ 1.05 (s, 6H, 2 × CH3-Dde), 1.10-
1.73 (m, 8H, DdeNHCH2(CH2)4CH2), 2.39 (s, 4H, 2 × CH2-Dde); 2.57 (s, 3H, CH3-
Dde ), 3.17 (m,  2H, DdeNHCH2 ), 3.37 (m, 2H, CH2CH2NCH2), 3.96 and 4.03 (two 
s, 2H, NCH2CO), 4.15 and 4.27 ( two t,  J = 8.25 Hz, 1H, CH-Fmoc), 4.40 and 4.55 
(two d, J = 8.25 Hz, 2H, CH2-Fmoc),  5.14 and 5.18 ( two s, 2H, CH2-Bn), 7.26-7.37 
(m, 7H, ArCH-Bn and ArCH-Fmoc), 7.41 (m, 2H, ArCH-Fmoc), 7.56 (m, 2H, 
ArCH-Fmoc), 7.77 (m, 2H, ArCH-Fmoc), 13.45 (br sg, 1H, NH-Dde). 
13
C NMR (CDCl3, 126 MHz): two rotamers δ = 18.0 (CH3-Dde), 26.2, 26.3 
(DdeNH(CH2)2CH2CH2CH2), 28.1, 28.3 (C(CH3)2-Dde), 28.9, 29, 29.7 
(DdeNHCH2CH2(CH2)2CH2), 43.4 (DdeNHCH2), 47.2, 47.3 (CH-Fmoc),  48.8, 48.9 
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(CH2CH2NCH2), 49.2 (NCH2CO), 52.8 (2 x CH2-Dde ), 67.0 (NCH2COOCH2), 67.3, 
67.6 (CH2-Fmoc), 107.8 (C=CNH), 120.0, 124.8, 124.9, 127.1, 127.7, 128.3, 128.4, 
128.5, 128.6 (ArCH-Bn and ArCH-Fmoc ), 135.3, 135.4 (ArC-Bn), 141.3, 141.4 
(ArC-Fmoc), 143.9, 144 (ArC-Fmoc), 156.5 (C=O-Fmoc), 159.0 (COO), 169.5, 
169.6 (NCH2CO), 173.5 (C=CNH-Dde), 198.0 (C=O-Dde). 





6.5.2.9.5. Synthesis of [(6-(4,4-dimethyl-2,6-dioxocyclo hexylidene)-




Pd/C 10% (315 mg) was added to a solution of 4.47 (6.15 g, 9.45 mmol) in ethanol 
(120 ml). The air was purged with N2 for 30 minutes. N2 was removed by suction 
(vacuum) and H2 was slowly added thanks to a tap. The reaction was stirred under an 
atmosphere of H2 for 4 hours. The reaction mixture was filtered through celite and 
the filtrate concentrated in vacuo. The product was filtrated through silica gel 






): C33H40N2O6 calculated  560.3, found 561.2 [M+H]
+
 (100%), 583.2 
[M+Na]
+





): C33H40N2O6 calculated  [M+H]
+
  561.29591, found 561.29578.  
Rf: 0.25 (DCM/MeOH, 10: 1). 
HPLC (Method 3): tR = 5.9 min, purity = 98% (ELSD) 
1
H NMR (CDCl3, 500 MHz): two rotamers  δ = 1.01 (s, 6H, 2 × CH3-Dde), 1.09-1.69 
(m, 8H, DdeNHCH2(CH2)4CH2), 2.33 (s, 4H, 2 × CH2-Dde), 2.49 (s, 3H, CH3-Dde ), 
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3.16 (m,  2H, DdeNHCH2 ), 3.38 (m, 2H, CH2CH2NCH2), 3.97 (s, 2H, NCH2CO), 
4.15 and 4.23 (m, 1H, CH-Fmoc), 4.42 and 4.52 (two d, J = 6.72 Hz, 2H, CH2-
Fmoc),  7.31 (m, 2H, ArCH-Fmoc), 7.39 (m, 2H, ArCH-Fmoc), 7.58 (m, 2H, 
ArCHFmoc), 7.75 (m, 2H, ArCH-Fmoc), 13.35 (br sg, 1H, NH-Dde). 
13
C NMR (CDCl3, 126 MHz): two rotamers δ = 18.0 (CH3-Dde), 26.1, 26.6 
(DdeNH(CH2)2CH2CH2CH2), 28.1, 28.3 (C(CH3)2-Dde), 28.9, 30.0 
(DdeNHCH2CH2(CH2)2CH2), 43.4 (DdeNHCH2), 47.1, 47.2 (CH-Fmoc),  48.4 
(CH2CH2NCH2), 48.9 (NCH2CO), 52.7 (2 x CH2-Dde ), 67.8 (CH2-Fmoc), 107.7 
(C=CNH), 119.9, 124.8, 125.2, 127, 127.1, 127.6, 127.7 (ArCH-Fmoc ), 141.2, 141.3 
(ArC-Fmoc), 143.9, 144.0 (ArC-Fmoc), 156.2 (C=O-Fmoc), 163.0 (NCH2COOH), 
173.6 (C=CNH-Dde), 198.1 (C=O-Dde). 
IR (neat): 3354 (m, νO-H), 2963 (w, νC-H), 2864 (w, νC-H), 1696 (m, νC=O), 1572 (s, νN-







6.5.2.9.6. Synthesis of [(6-aminohexyl)-(9H-fluoren-9-yl methoxy 
carbomyl)-amino]-acetic acid 4.49 
 
 
50 mg of 4.48 (89.2 mmol) were dissolved in 1 mL of DCM and 1 mL of Dde 
deprotection solution (6.4.2.9.1) was added to the monomer. The mixture was stirred 
for 6 hours at room temperature. The solvents were removed under vacuum. The 




 Dde monomer, 4.48 Crude after deprotection 
HPLC  
(Method 3, min, ELSD) 
5.9 (99%) 4.7 (100%) 
MS (ES
+
) 561.2 397.2 (4.49) 
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1
H NMR of the crude (CDCl3, 500 MHz): two rotamers  δ = 1.12-1.25 (m, 4H, 
CH2CH2CH2CH2CH2CH2NH2), 1.32-1.47 (m, 4H, CH2CH2CH2CH2CH2CH2NH2), 
1.78 (s, 2H, CH2NH2), 2.63 (m, 2H, CH2CH2NH2), 3.31 (m, 2H, CH2CH2NCH2), 
3.94 (s, 2H, NCH2CO); 4.13 and 4.19 (m, 1H, CH-Fmoc), 4.39 and 4.50 (two d, J = 
6.75 Hz, 2H, CH2-Fmoc),  7.36 (m, 2H, ArCH-Fmoc), 7.44 (m, 2H, ArCH-Fmoc), 
7.62 (m, 2H, ArCH-Fmoc); 7.79 (m, 2H, ArCH-Fmoc). 
 




The Fmoc-9mer(Dde)9-resin 4.50 was synthesised on aminomethyl polystyrene 
resin functionalized with a Rink amide linker (2.28) using the Dde monomer 4.48. 
The resin (100 mg, 0.086 mmol) was first swollen in DCM (1 mL) for 20 
minutes. Each peptoid monomer unit (146 mg, 0.26 mmol) was coupled using 
DIC/HOBt (40.6 µL/35 mg, 0.26 mmol) in DMF (1.3 mL, 0.2 M) coupling 
(6.2.1.8). The first monomer coupling was monitored by qualitative ninhydrin test 
(6.2.1.1), while the following Fmoc deprotections and couplings were controlled 
using chloranil test (6.2.1.3). After coupling, Fmoc deprotection was carried out 
using 20% piperidine in DMF (6.2.1.9). These reactions corresponded to one 
coupling cycle. This coupling cycle was repeated 8 other times in order to obtain 
the desired oligomer. It was essential to control each coupling very carefully 
before moving on with the Fmoc deprotection. Each slightly blue chloranil test 
leaded to a new coupling. The final N-terminal Fmoc group was not deprotected. 
The resin was washed with DMF, DCM, MeOH and Et2O (3 × 1.5 mL) before 
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being dried over night at 40
o
C under vacuum (645 mg, new theoretical loading = 
0.19 mmol/g). 
 




The Fmoc-9mer(Dde)9 peptoid 4.51 was cleaved from the previously prepared 
solid support 4.50 (100 mg, 0.019 mmol) using a solution TFA/TIS/H2O (95: 2.5: 
2.5, 2.5 mL) (6.2.1.10). Fmoc-9mer(Dde)9-NH2 4.51 was isolated after 
purification (preparative reverse phase-HPLC, Gradient 4) as a clear yellowish solid 
(30 mg, 51%). 
  
Analysis:  












 = 781.25396, found 
781.25408.  
HPLC (Method 3): tR = 6.5 min, purity > 98% (ELSD). 
1
H NMR (CDCl3, 500 MHz) δ = δ 1.02 (s, 54H, C(CH3)2-Dde), 1.58-1.72 (m, 72H, 
DdeNHCH2(CH2)4CH2), 2.34 (s, 36H, 2 × CH2-Dde), 2.40 (s, 27H, CH3-Dde ), 3.03 
(t, J = 5.60 Hz, 18H, CH2CH2NCH2), 3.22-3.44 (m, 18H, DdeNHCH2 ), 3.85-4.28 
(m, 21H, 18H for NCH2CO, 1H for CH-Fmoc, 2H for CH2-Fmoc),  7.29 (td, J = 7.55 
Hz, J = 1.10 Hz, 2H, ArCHc-Fmoc), 7.37 (td, J = 7.45 Hz, J = 1.05 Hz, 2H, ArCHb-
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Fmoc), 7.68 (dt, J = 7.45 Hz, J = 0.75 Hz, 2H, ArCHd-Fmoc), 7.75 (dt, J = 7.50 Hz, 
J = 0.80 Hz, 2H, ArCHa-Fmoc), 13.38 (br sg, 9H, NH-Dde). 
13
C NMR (CDCl3, 126 MHz) δ = 17.6 (CH3-Dde), 22.7, 23, 23.2, 25.7, 26.2, 26.6 
(DdeNHCH2(CH2)4CH2),  28.1, 28.2, 29.1 (C(CH3)2-Dde), 43.3, 43.4 (DdeNHCH2), 
44.7 (CH2CH2NCH2), 47.9 (CH-Fmoc),  48.8, 49.2, 49.7, 50.3 (NCH2CO), 50.9, 
51.5, 52.3, 52.8 (2 x CH2-Dde ), 56.2 (CH2-Fmoc), 107.7, 107.8 (C=CNH), 119.6( 
ArCH-Fmoc, Cd), 120.9 (ArCH-Fmoc, Ca),  126.9 (ArCH-Fmoc, Cc), 128.7 (ArCH-
Fmoc, Cb),  138.0, 140.1, 143.2 (ArC-Fmoc), 156.2 (C=O-Fmoc), 162.0,  162.2, 
162.5, 162.6, 162.8 (NHCO-peptoid), 173.4, 173.5, 173.6  (C=CNH-Dde), 195.8, 
196.4 (C=O-Dde). 
 
6.5.2.9.9. Synthesis Fmoc-9mer 4.52 via physiologic Dde deprotection of 




The peptoid 4.51 (20 mg, 0.006 mmol) was mixed overnight in 1 mL of the Dde 
deprotection solution (6.4.2.9.1). The water was removed in vacuo and the crude was 
dissolved in a minimum of TFA (150 µL) and precipitated in cold Et2O (1.5 mL).  
The Fmoc-9mer peptoid (4.55) was dried at 40
o
C under vacuum and was isolated as 









 (54.3%), 412.0 [M+4H]
4+
 (100%), 329.8 [M+5H]
5+
 (39.3%). 
m/z (MALDI-TOF): C87H157N19O11 calculated
 






HPLC (Method 3): tR = 2.2 min, purity = 100% (ELSD). 
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Fmoc-9mer-NH2 4.55 was isolated from the resin 2.33 (50 mg, 0.04 mmol, 6.3.6) 










 (54.3%), 412.0 [M+4H]
4+
 (100%), 329.8 [M+5H]
5+
 (39.3%). 
m/z (MALDI-TOF): C87H157N19O11 calculated
 










 549.44031, found 549.42374.  
HPLC (Method 3): tR = 2.2 min; purity = 98% (ELSD). 
1
H NMR (D2O, 500 MHz, presat water suppression): δ = 1.00-1.70 (m, 72H, 
NCH2(CH2)4CH2NH2) , 2.90 (m, 18H, CH2NH2), 3.11-3.37 (m, 2H, NCH2),  3.82-
4.47 (m, 21H, 3H for CH-Fmoc and CH2-Fmoc, and 18H for NCH2CO),  7.35 (m, 
2H, ArCH-Fmoc, Hc), 7.43 (m, 2H, ArCH-Fmoc, Hb), 7.59 (m, 2H, ArCH-Fmoc, 
Hd), 7.80 (m, 2H, ArCH-Fmoc, Ha), 7.84 (br sg, 2H, CONH2). 
13
C NMR (D2O, 126 MHz): δ = 25.2, 25.3, 25.4, 25.5, 25.6, 25.7, 25.8, 26.5, 26.6, 
26.7, 26.8 (NCH2(CH2)4CH2NH2 ), 39.3, 39.4, 39.5, 39.6 (CH2NH2), 46.6, 47.3, 47.4, 
47.5, 47.7, 47.8, 47.9, 47.9, 48.0, 481, 48.2, 48.3, 48.4, 48.5 (CH-Fmoc, CH2-Fmoc, 
NCH2CO and NCH2CH2), 120.1 (ArCH-Fmoc, Ca), 124.7 (ArCH-Fmoc, Cd), 127.5 
(ArCH-Fmoc, Cc), 127.8 (ArCH-Fmoc, Cb), 141.0, 141.3, 141.7 (ArC-Fmoc),  153.2 
(C=O-Fmoc), 162.7, 163.0, 163.3 (C=O-9mer). 
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50 mg of Fmoc-Leu-OPfp 4.53 (0.096 mmol) was dissolved in 1 mL of DCM and the 
appropriate solution of TFA in DCM was added: 
- 1% of TFA: 0.02 mL of TFA in 0.98 mL of DCM,  
- 5% of TFA: 0.10 mL of TFA in 0.90 mL of DCM, 
- 10% of TFA: 0. 20 mL of TFA in 0.80 mL of DCM, 
- 25% of TFA: 0.50 mL of TFA in 0.50 mL of DCM, 
- 50% of TFA: 1 mL of TFA. 
 
After 15, 30, 60, 90, 120 minutes and 6 hours of stirring, 0.2 mL of each solution was 
collected and mixed with 1 mL of Et3N in DCM. Each collection sample was 






): C27H22FNO4  calculated 519.1, found 520.2 [M+H]
+
 (100%). 
HPLC (Method 1): tR = 5.1 min, purity = 100% (ELSD). 
 
Fmoc-Leu-OH (without active ester): 
m/z (ES
+
): C21H23NO4  calculated 353.2, found 354.1 [M+H]
+




HPLC (Method 1): tR = 4.6 min, purity = 100% (ELSD).  
 
Reaction analysis:  
All the reactions gave the same results (Full data and graph: Appendix 4-9): 
m/z (ES
+
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HPLC (Method 1): tR = 5.1 min, purity = 100% (ELSD). 
 




5 g of 3,6,9 trioxaudecanedioic acid (22.5 mmol) were dissolved in 100 mL of DCM 
before adding the DCC (4.6 g, 22.5 mmol). The solution was stirred for 6 hours. The 
reaction mixture was then filtered and concentrated in vacuo down to a volume of 15 
mL. The required volume of solution of 4.54 was directly added onto the desired 
solid support without further purification. 
 




Resin 4.50 (50 mg, 9.5 µmol) was swollen in DCM for 20 minutes. The Fmoc group 
was deprotected (6.2.1.9, confirmed by a chloranil test 6.2.1.3) and the cyclised 
PEG 4.54 (0.5 mL, 750 µmol) in 0.5 mL of DCM was added to the resin. The 
mixture was stirred for 16 hours. DCC (6 mg, 28.5 µmol) in DCM (0.5 mL) was 
first mixed with the resin for 30 minutes before adding the pentafluorophenol 4.56 (5 
mg) in DCM (0.5 mL). The mixture was stirred for 6 hours. The peptoid was then 
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cleaved from the solid support using a 4 hour treatment of 50% of TFA in DCM. 
After the TFA treatment, the solvent was removed in vacuo and the crude analysed. 
The product isolated corresponded to H-9mer(Dde)9-NH2.  
 
Analysis: 
m/z (MALDI-TOF): C176H266N19O33 calculated 3268.9, found 2900.2 [M+H]
+
 
(100%) H-9mer(Dde)9-NH2, 3122.3 [M+H]
+
 (9.8%). 
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6.5.3. Experimental for eGFP plasmid delivery  
 
The eGFP DNA plasmid (pEGFP-C1) was prepared by members of the Bradley 
group (0.4 µg/µL in TE buffer, 4.7 kb, 1534 kDa calculated from average Mw base = 
327.0 g/mol). 
 
6.5.3.1. Preparation of agarose gel (0.7%) for electrophoresis analysis 
Gel preparation and running conditions: 
0.245 g of agarose type I-B was mixed with 35mL of TEB (pH 7.5). The agarose was 
diluted by heating the mixture at 60
o
C (water bath) for 20 minutes. 2.5 μL of 
ethidium bromide (10 mg/mL in water, Sigma-Aldrich) were added to the solubilised 
agarose. The solution was heated for 15 minutes in a boiling water batch (100
o
C) 
before being poured into a electrophoresis casting mould containing the desired 
comb. The gel was left to set for 45 minutes at room temperature and the comb was 
carefully removed. Each well was filled with the sample to analyse. The gel was then 
covered with TBE buffer and ran for 56 minutes at 90 V. The gels were viewed and 
photographed under UV-light. 
 
Sample preparation: 
Maker: Ladder 1KB from New England Biolab 10 μL + 10 μL of water. 
Sample: 5 μL of reaction (0.05 μg of DNA) + 15 μL of water + 5 μL of bromophenol 
blue. Each sample was quickly mixed using a Vortex. 
 
6.5.3.2. Determination of the DNA/peptoid ratio by gel retardation assays  
 
Each solution was prepared as described in Table 6.47. Both peptoid 2.37 (Rho-
9mer) and 4.61 (HO-PEG-PEG-9mer) were dissolved in PBS to a final concentration 
of 100 µM. 
The DNA (pEGFP-C1) was first mixed with the PBS (pH 7.4) and the peptoid was 
added. The solution was quickly mixed using a vortex before being stirred for 30 
minutes at 25
o
C, 1400 rpm (Thermonix). The mixtures were analysed via 
electrophoresis. 
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Volume DNA (µL) 
(0.4 µg/µL) 
Volume of peptoid 
(2.37 or 4.61, 100 
µM) 
Volume of PBS 
1: 2 2.5 µL 3.4 µL 94.1 µL 
1: 5 2.5 µL 8.5 µL 89.0 µL 
1: 10 2.5 µL 17.0 µL 80.5 µL 
1: 20 2.5 µL 34.0 µL 63.5 µL 
1: 30 2.5 µL 51.0 µL 46.5 µL 
1: 40 2.5 µL 68.0 µL 29.5 µL 
1: 50 2.5 µL 85.0 µL 12.5 µL 
 
Table 6.47: Volumes of reagents used for the DNA complexation assays. 
 





For each tranfection sample (triplicate), 2 μL eGFP plasmid (0.8 µg, 0.4 µg/µL) were 
diluted in 50 μL of Opti-MEM
®
 medium and gently mixed. 2 μL of Lipofectamine™ 
2000 was gently mixed with 20 μL of Opti-MEM
®
 medium and then incubated for 5 
minutes at 25
o
C.  The diluted DNA was combined with the transfecting agent, mixed 
gently and incubated for 20 minutes at 25
o
C to allow complex formation to occur. 
This solution was added to cells.  
 
Cells were seeded onto a 24-well plate at a density of 3 × 10
4
 cells/well in growth 
media (DMEM, volume of culture media per well: 350 µL). Once the cell confluence 
was between 70 and 90% (usually 24 hours), the growth media was removed, the 
cells were washed with PBS and new fresh serum- and antibiotic free Opti-MEM
®
 
medium was added (500 µL). The well plate was incubated (37°C/5% CO2) for one 
hour before addition of the DNA/lipofectamine complexes. Cells were incubated for 
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Transfection using peptoid: 
4 μL of eGFP plasmid (1.6 µg, 1 pmol) was diluted with 14 μL pf PBS (pH 7.4). 102 
μL of Rho-9mer 2.37 or HO-PEG-PEG-9mer-NH2 (4.61) (100 μM, 10.46 nmol) 
were added and the solution was quickly vortexed before being stirred for 30 minutes 
at 25
o
C (Thermomix, 1400 rpm). This solution was then added to cells (one third, 40 
μL of complex solution per well plate). 
 
Cells were seeded onto a 24-well plate at a density of 3 × 10
4
 cells/well in growth 
media (DMEM, volume of culture media per well: 350 µL). Once the cell confluence 
was between 70 and 90% (usually 24 hours), the DNA/peptoid complexes were 
added (0.5 µg of DNA/well). Cells were incubated for 24 and 48 hours prior to 
analysis by flow cytometry and microscopy (for 4.58 after 48 hours). 
 
Results: 








Untreated cells  0.3 0.2 
pEGFP 
24 h 1.4 0.6 
48 h 1.6 0.5 
2.37, Rho-9mer 
24 h 1.7 0.2 
48 h 2.3 0.8 
4.58, pEGFP/Rho-9mer  
24 h 2.8 0.3 
48 h 20.7 2.6 
Lipofectamine/pEGFP 
24 h 10.0 1.4 
48 h 41.0 3.1 
Table 6.48: Cellular uptake of HEK293T cells transfected (for 24 and 48 hours) with plasmid 
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Untreated cells 0.4 0.2 
pEGFP 1.8 0.8 
4.61, PEG-9mer 0.7 0.6 
4.62, pEGFP/PEG-9mer 26.9 1.3 
Lipofectamine/pEGFP 48.4 0.5 
Table 6.49: Cellular uptake of HEK293T cells transfected (for 48 hours) with plasmid pEGFP-
C1 using PEG-9mer (4.62) and lipofectamine as positive control (n = 3).  
 
6.5.3.4. Confocal microscopy in HEK293T using the DNA/Rho-9mer complex 
4.58 
6.3 μL of eGFP plasmid (2.5 µg, 1.6 pmol) was diluted with 14 μL pf PBS (pH 7.4). 
160 μL of Rho-9mer 2.37 (100 μM) were added and the solution was quickly 
vortexed before being stirred for 30 minutes at 25
o
C (Thermomix, 1400 rpm).  This 
solution was then added to cells. 
HEK293T cells were seeded on a 6-well plate, stained and analysed as described in 
6.2.2.5. The cells were labelled for 24 hours with 180 µL of DNA/Rho-9mer 
complex (4.61) prior to imaging (2.5 µg of DNA/well). The rhodamine dye on the 
Rho-9mer peptoids 2.37 was excited using a 561 nm excitation laser and collecting 
emission using a 567-630 nm band-pass filter. GFP was excited using a 490 nm 
excitation laser and collecting emission using a 528-550 nm band-pass filter. 
 
6.5.3.5. DNA delivery in lymph node cells (collaboration with Dr. Stefano 
Caserta) 
Complexation: 
10 and 20 μL of Rho-9mer (2.37, 100 μM) were mixed (vortex) with respectively 90 
and 80 μL of PBS. The desired amount of DNA (0.4 μg/μL, 0.1, 0.5, 1, 5 and 10 μg) 
was then added to the peptoid solution before being vortexed. The DNA/peptoid 
solutions were gently mixed (Thermonix, 600 rpm) at 4
o
C for 30 minutes. 
Afterwards, the solutions were directly added to the cells. 
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Cellular uptake 
Lymph node cells were seeded at a density of 2 × 10
6
 cells/well ((cultured with 
cytokines, volume of culture RPMI per well: 350 µL). Once cells settled as a 
monolayer, the DNA/peptoid solutions were added. T cells were stimulated with 
plate-bound 5 µg/mL anti-CD3 (145-2C11, BD Pharmingen) and 2 µg/mL anti-
CD28 (37.51, BD Pharmingen) for 24 hours during incubation with the peptoids. 
After 4 days of incubation with the complexes, cells were washed with PBS and 
analysed using a flow cytometer (LSR II, BD). 
 




The HO-PEG-PEG-9mer peptoid 4.61 was synthesised on aminomethyl 
polystyrene resin functionalized with a Rink amide linker (2.28) using the 
monomer 2.22 as described in 6.3.6. The solid supported 9mer peptoid was then 
coupled to the Fmoc-PEG-spacer 4.62 (Sigma-Aldrich) (71 mg, 0.13 mmol) using 
the coupling procedure 6.2.1.8 (DIC: 20.3 µL, HOBt: 18 mg, 0.13 mmol; DMF: 
0.65 mL, 0.2 M). The success of the coupling was controlled by a chloranil test 
(6.2.1.3). Afterwards, the Fmoc group was deprotected with 20% piperidine in 
DMF (6.2.1.9) and controlled by qualitative ninhydrin test (6.2.1.1). The cyclised 
PEG 4.57 (1 mL, 1.5 mmol) in DCM (1 mL) was added to the solid supported 
peptoid and mixed overnight at room temperature. The final coupling was 
monitored by qualitative ninhydrin test (6.2.1.1). Finally, the HO-PEG-PEG-9mer 
peptoid was deprotected and cleaved from the solid support using a solution 
TFA/TIS/H2O (95: 2.5: 2.5, 2.5 mL) (6.2.1.10). HO-PEG-PEG-9mer 4.64 was 
isolated after ON drying (vacuum oven, 40
o
C) as a sticky clear product in 92% 
yield (73 mg). 
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): C94H185N21O20 calculated 1929.6, found 644.0 [M+3H]
3+
 (51.2%), 483.3 
[M+4H]
4+
 (100%), 396.9 [M+5H]
5+
 (13.3%). 












 = 644.20852, found 
644.20811.  
HPLC (Method 3): tR = 0.6 min. purity > 98% (ELSD). 
1
H NMR (D2O, 500 MHz, eSpresat water suppression): δ = 1.25-1.50 (m, 36H, CH2, 
H 3’’ and H4’’), 1.51-1.79 (m, 40H, 36H for CH2 (H 2’’ and H5’’) and 4H for CH2 (H 10 
and H17)), 2.34-2.45 (m, 2H, CH2, H20), 2.48-2.60  (m, 2H, CH2, H20), 3.00-3.16 (m, 
18H, CH2NH2, H6’’),  3.18-3.38 (m, 22H, 18H for CH2N (H1’’), 4H for CH2NH (H9 
and H18)), 3.40-3.66 (m, CH2O, H3, 4, 5, 6, 11, 12, 13, 14, 15, 16), 3.72-4.36 (m, 22H, 18H for 
NCH2CO (Hα), 4H for OCH2CO (H2 and H7), 7.52 (br sg, 2H, CONH2). 
13
C NMR (D2O, 126 MHz):
 
δ = 24.8, 25.0, 25.1, 25.2, 25.3, 25.4, 25.5, 26.2, 26.3, 
26.4, 26.5, 26.6, 27.0, 27.1, 27.2, 27.3, 27.4 (CH2, C2’’, 3’’, 4’’, 5’’, 10, 17), 37.7, 37.9 
(CH2, C20, 21), 39.1, 39.2, 39.3, 39.4, 39.5, 39.7 (CH2, C6’’, 9, 18), 47.2, 47.3, 
47.4,47.5, 47.6, 48.4, 48.5, 48.6, 48.7 (CH2, N-CH2-CO and C1’’), 69.7, 69.8, 71.2, 
71.4, 71.5 (CH2O, H3, 4, 5, 6, 11, 12, 13, 14, 15, 16), 158.9, 162.4, 162.7, 163.0, 163.3, 169.5, 
169.6, 170, 174.5 (C=O-9mer and PEG), 176.2 (COOH). 
 
6.5.3.7. MTT assays of DNA/peptoid complex in HEK293T cells 
 
MTT cytotoxicity assays were carried out as according to the general procedures 
(6.2.2.4).  
Cells were seeded onto a 96-well plate. Once the cell confluence was between 70 and 
90% (usually 24 hours), the cells were treated with 10.8 µL of 4.58 and 4.62 (0.1 µg 
of DNA /well), 13 µL of Rho-9mer (2.37, 100 µM, final concentration 13 µM) and 
of PEG-9mer (4.61, 100 µM, final concentration 13 µM) and 2.5 µL of eGFP 
plasmid (0.04 µg/µL, 0.1 µg of DNA/well) in 8 random wells. At day 2, 10.8 µL of 
4.61 (0.1 µg of DNA/well), 13 µL of Rho-9mer (2.37, 100 µM, final concentration 
13 µM) and 2.5 µL of eGFP plasmid (0.04 µg/µL, 0.1 µg of DNA/well) were 
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 1.097 0.077 100.0 7.0 
pEGFP,  
 24 hours 0.988 0.129 90.1 11.7 
pEGFP,  
48 hours 1.078 0.098 98.3 8.9 
2.37, Rho-9mer,  
24 hours 1.054 0.141 96.1 12.9 
2.37, Rho-9mer,  
48 hours 1.110 0.193 101.2 17.5 
4.58, pEGFP/Rho-9mer, 
 24 hours 1.048 0.152 95.6 13.8 
4.58, pEGFP/Rho-9mer,  
48 hours 1.123 0.107 102.4 9.7 
4.61, PEG-9mer,  
48 hours 1.063 0.134 97.0 12.2 
4.62, pEGFP/PEG-9mer,  
48 hours 1.124 0.166 102.5 15.1 
 
Table 6.50: Percentage of cell vailability (HEK293T cells) after 24 and 48 hours of incubation 
with the DNA/peptoid complexes (n = 8).  
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6.6. Experimental for Chapter 5 
6.6.1. Preparation of the Fmoc-9mer(Boc) resin (2.33) using the oxyma reagent. 
 
The 9mer peptoid resin 2.33 was prepared as previously described in 6.3.6 but in this 
synthesis the HOBt was substituted with Oxyma. New theoretical loading (6.2.1.5) 
calculated from the measured Rink amide resin (6.3.5) was 0.27 mmol/g. 
 
6.6.2. Synthesis of the NLLP (5.17) without purification 
 
The resin 2.32 (6.6.1, 300 mg, 0.081 mmol from theoretical loading) was deprotected 
using 20% piperidine in DMF (6.2.1.9) and then fully deprotected and cleaved from 
its support by treatment of the cleavage mixture TFA/TIS/ H2O (95: 2.5: 2.5, 7.5 mL) 
and precipitated in cold Et2O (6.2.1.10). The compound 5.17 was isolated as a very 





): C72H147N19O9  calculated 1422.2, found 712.2 [M+2H]
2+
 (32.5 %), 
475.2 [M+3H]
3+
 (100%), 356.6 [M+4H]
4+
 (71.8%), 285.5 [M+5H]
5+
 (8.9%). 
Peaks of the 8mer: 634.0 [M+2H]
2+
 (9.7%), 317.5 [M+3H]
3+




m/z (MALDI-TOF): C72H147N19O9 calculated
 





 (38.7%). Peaks of the others peptoids: 8mer 1288.40 
[M+H]
+
 (47.2%), 7mer 1109.91 [M+H]
+
 (14.3%), 6mer 953.83 [M+H]
+
 (8.4%). 
HPLC (Method 3): tR= 0.84 min, purity > 98% (ELSD). 
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6.6.3. Stability of Boc under TFA conditions on solution phase: Test on the Fmoc-
Lys(Boc)-OH 
The stability of the Boc group was tested in solution phase against TFA using Fmoc-
Lys(Boc)-OH. 
Protocol 
25 mg of (0.021 mmol) of Fmoc-Lys(Boc)-OH were dissolved in DCM (0.5 mL) and 
the following volumes of DCM, H2O and TFA were added (Table 6.51). The 
mixture was mixed at room temperature for 2 hours. Every 15 minutes, a sample of 
15 µL was collected and added in 100 µL of MeOH containing 3% of Et3N (to 
neutralise the TFA).  Each sample was then analysed by HPLC and MS. 
 
Solution 
Volume added (mL) 
DCM H2O TFA  
1% TFA/DCM 0.5 0 0.01 
2% TFA/DCM 0.5 0 0.02 
3% TFA/DCM 0.5 0 0.03 
4% TFA/DCM 0.5 0 0.04 
5% TFA/DCM 0.5 0 0.05 
10% TFA/DCM 0.5 0 0.10 
15% TFA/DCM 0.5 0 0.15 
20% TFA/DCM 0.5 0 0.20 
1% TFA in DCM/H2O 
(99:1) 
0 0.5 0.01 
2% TFA in DCM/H2O 
(99:1) 
0 0.5 0.02 
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3% TFA in DCM/H2O 
(99:1) 
0 0.5 0.03 
4% TFA in DCM/H2O 
(99:1) 
0 0.5 0.04 
5% TFA in DCM/H2O 
(99:1) 
0 0.5 0.05 
10% TFA in DCM/H2O 
(99:1) 
0 0.5 0.10 
15% TFA in DCM/H2O 
(99:1) 
0 0.5 0.15 
20% TFA in DCM/H2O 
(99:1) 
0 0.5 0.20 
Table 6.51: Preparation of the various TFA solution used for the Boc stability study. 
 
Results 
Analysis of Fmoc-Lys(Boc)-OH as a positive control: 
m/z (ES
+





 (53.8%), 469.1 [M+H]
+
 (17.3%). 
HPLC (Method 1): tR = 4.5 min, purity = 100% (ELSD). 
 
Analysis of Fmoc-Lys-OH as a negative control: 
m/z (ES
+
): C21H24N2O4  calculated 368.2, found 369.0 [M+H]
+
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Solution % of Fmoc-Lys-OH formed 
30 minutes 2 hours 
1% TFA/DCM 0 0 
2% TFA/DCM 0 1  
3% TFA/DCM 1 12  
4% TFA/DCM 3 24  
5% TFA/DCM 10 65 
10% TFA/DCM 100 - 
15% TFA/DCM 100 - 
20% TFA/DCM 100 - 
1% TFA in DCM/H2O 
(99:1) 
0 0  
2% TFA in DCM/H2O 
(99:1) 
0 0  
3% TFA in DCM/H2O 
(99:1) 
0 0  
4% TFA in DCM/H2O 
(99:1) 
0 0  
5% TFA in DCM/H2O 
(99:1) 
0 5 
10% TFA in DCM/H2O 
(99:1) 
25 63 
15% TFA in DCM/H2O 63 90 
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(99:1) 
20% TFA in DCM/H2O 
(99:1) 
95 100  
Table 6.52: Results of the Boc group stability against TFA. 
Method 1, ESLD. (Full data: Appendix 5-1) 
 
6.6.4. Preparation of the Fmoc-3mer(Boc)3 resin (5.19) 
 
The Fmoc-3mer(Boc)3 resin 5.19 was prepared as previously described for 2.33 
using oxyma (3 couplig cycles). The final Fmoc deprotection was not carried out. 
The resin was washed with DMF (3 x 3 mL), DCM (3 x 3 mL), MeOH (3 x 3 mL), 
Et2O (3 x 3 mL) and dried in vacuo for 30 minutes. The resin (321 mg) was stored 
under N2 at -4
o
C. The loading of the resin 5.19 was calculated using the quantitative 
ninhydrin test (0.46 mmol/g, 6.2.1.2). 
Characteristion of Fmoc-3mer-NH2 peptoid (5.20) 
 
The compound 5.20 was isolated as 16 mg (95.4%) after cleavage and deprotection 










): C39H61N7O5  calculated 707.5, found 708.5 [M+H]
+




m/z (MALDI-TOF): C39H61N7O5 calculated
 










 708.48124, found 708.48131. 
HPLC (Method 3): tR = 2.6 min, purity > 97% (ELSD). 
1
H NMR (D2O, 500 MHz, eSpresat water suppression) δ = 1.25-1.40 (m, 12H, CH2, 
H 3’’ and H4’’), 1.40-1.68 (m, 12H, CH2, H 2’’ and H5’’), 2.93 (m, 6H, CH2NH2, H6’’),  
3.29 (m, 6H, CH2N, H1’’), 3.83-4.00 (m, 6H, NCH2CO, Hα), 4.32 (t, J = 7.05 Hz, 1H, 
CH-Fmoc), 4.45 (d, J = 7.50 Hz, 2H, CH2-Fmoc),  7.60 (m, 2H, ArCH), 7.71 (m, 2H, 
ArCH), 7.81 (d, J = 8.65 Hz, 2H, ArCH), 7.89 (d, J = 8.95 Hz, 2H, ArCH). 
13
C NMR (D2O, 126 MHz)
 
δ = 25.1, 25.4, 25.5, 25.6, 26.4, 26.5, 27.1, 27.2, 27.3 
(CH2, C2, 3, 4, 5), 39.2, 39.3, 39.4 (CH2, C6), 47.4, 47.5, 47.7, 48.4, 48.5, 48.6, 48.7 
(CH2 (NCH2CO and C1) and CH-Fmoc), 68.3 (CH2-Fmoc), 120.0, 124.7, 127.4, 
127.8 (ArCH), 141.0, 141.2, 141.7 (ArC), 162.4, 162.7, 162.8, 163.3, 169.5, 169.6, 
170.0 (C=O-3mer), 178.2 (C=O-Fmoc). 
 
6.6.5. Synthesis of the Fmoc-3mer(Boc)3-NH2 peptoid (5.21)  
 
 
6.6.5.1. Strategy 1 : Selective Rink amide cleavage using low TFA 
conditions. 
All the following experiments were carried out on 50 mg (0.023 mmol) of 5.19. The 
resin was used dried and was mixed with 1.25 mL (25 mL/g of dry resin) of one of 
the following cleavage mixture.  Two methods were tested: 
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- Cycle: the resin was treated at room temperature with the TFA solution 
(1.25 mL, Table 6.54) for 10 minutes. The resin was filtered, washed with DCM (3 × 
1 mL) and a fresh solution was added to the resin. The filtrate was collected in 5 mL 
of DCM containing 3% of TEA. This cycle was repeated as needed (more details 
below). After each cycle, the filtrate was concentrated in vacuo and was analysed by 
HPLC and MS. The colour change of the resin was observed. 
- Constant: the resin was treated with the TFA solution for 2 hours and a 
sample of the solution (50 µL) was collected after 30 minutes and 2 hours. Each 
sample was diluted in 1 mL of DCM containing 3% of TEA. Each sample was 
analysed by HPLC and MS. The colour change of the resin was observed and 
recorded. 
Correspondance analysis/product: 
Product HPLC (ELSD) 
(Method 3, min) 
MS 
(MALDI-TOF) 
Fmoc-3mer-NH2, 5.20 2.6 708.46 [M+H]
+
 
Fmoc-3mer(Boc)1-NH2 3.6 808.52 [M+H]
+
 








Table 6.53: Analysis of the several Boc protected 3mer peptoids. 
 
Results for the method “cycle”: 
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DCM/TFA/H2O 














































95: 4: 1 
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96: 3: 1 
1 Nothing Nothing Yellow 
2 Nothing Nothing Yellow 
3 Nothing Nothing Yellow 
4 Nothing Nothing Yellow 
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Results for method “constant”: 
















































































97: 2: 1 
30 minutes Nothing Nothing Yellow 
2 hours Nothing Nothing Yellow 
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96: 3: 1 














































Table 6.55: Results for the Rink amide cleavage carried out with the method “constant”. 
 
6.6.5.2. Strategy 2: Selective Rink amide cleavage using continous flow 
Protocol 
The resin was transferred in a solid-phase extractor (a polypropylene syringe 
equipped with a frit and a valve) and a solution of TFA/DCM/H2O (Table 6.56) was 
passed through it for an hour under gravity. Over an hour, 5 mL of TFA solution 
were used at a continuous flow. The solution was collected into 10 mL DCM 
containing 3% of TEA. At the end of the reaction time (1 hour), the resin was 
washed three times with DCM (1 mL) and the DCM mixture was concentrated in 
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vacuo. The crude was then analysed by HPLC, MS and precipitation (described 
below). The resin was also tested using a qualitative ninhydrin test (6.2.1.1). 
 
Test of precipitation in cold Et2O  
The filtrates containing the peptoid were collected and concentrated in vacuo (0.2 
mL). The concentrated mixture was then added dropwised in a centrifuge tube 
containing cold Et2O (2.5 mL). The precipitated peptoid was then sonicated and 


























Nothing Nothing Nothing  1. Yellow 
2. Light blue  
DCM/TFA/H2O 
93:6:1 
Nothing Nothing Nothing  1. Yellow 
2. Light blue 
DCM/TFA/H2O 
92:7:1 




















































Table 6.56: Results for the Rink amide cleavage carried out by continuous flow. 
Colour of the resin interpretation: Yellow: no formation of cationic species, no cleavage; Orange to 
red: formation of cationic species, cleavage.  
Ninhydrin test interpretation: Yellow: no free NH2 on the resin; Blue: free NH2 on the resin. 
 
6.6.6. Synthesis of Boc-9mer(Boc)-NH2 (5.22) 
 
 
500 mg (0.135 mmol calculated from the theoretical loading) of resin 2.33 (6.6.1) 
were swollen in DCM (5 mL) for 20 minutes before being Fmoc deprotected 
(6.2.1.9). Once the Fmoc group was removed, the resin was Boc deprotected and 
cleaved (6.2.1.10). The cleaved peptoid (5.17) was dissolved in water (3 mL) and the 
solution was basified by slow addition of TEA (0.4 mL, pH > 10). To the 9mer 
solution (5.17) was added di-tert-butyl carbonate (665 mg, 2.02 mmol) in DCM (3 
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mL). The mixture was mixed for 1 hour. After reaction, the aqueous phase was 
isolated and washed with 2 mL of DCM (3 times). The organic layers were combined 
and concentrated in vacuo.  The Boc-9mer(Boc)9-NH2 was purified by preparative 
HPLC (Gradient 2). After freeze drying, the Boc-peptoid was isolated as a white 









 (68.1%), 404.7 [M+6H]
6+
 (100%), 347.1 [M+7H]
7+
 (23.4 %). 
m/z (MALDI-TOF): C122H227N19O29 mass calculated
 
2422.7, mass found 2446.6 
[M+Na]
+
 (100%), 2462.5 [M+K]
+
 (92%). 




 606.67963, found 606.65079.  
HPLC (Method 4): tR = 3.8 min; purity > 98% (ELSD). 
1
H NMR (CDCl3, 500 MHz): δ = 1.25-1.40 (m, 36H, CH2, H 3 and H4), 1.41-1.53 
(m, 126H, 36H for CH2 (H 2 and H5)) and 90H for CH3-Boc), 3.11 (m, 18H, 
CH2NHBoc, H6), 3.32 (m, 18H, CH2N, H1), 3.95-4.23 (m, 18H, NCH2CO). 
13
C NMR (CDCl3, 126 MHz):
 
δ = 26.2, 26.3, 26.4, 26.5, 26.6, 26.7 (CH2, C 3, 4), 
27.6, 27.7, 27.8 (C(CH3)3), 28.3, 28.4, 28.5, 28.6 (CH2, C2, 5), 40.2, 40.3, 40.4, 40.5 
(CH2, C6), 46.7, 46.8, 46.9, 47.1, 47.6, 47.7, 47.9, 48, 48.1, 48.4, 48.6, 48.8, 48.9 
(CH2, NCH2CO and C1), 78.8, 78.9, 79, 79.7 (C(CH3)3), 155.9, 156.0, 156.1, 156.2, 
156.3 (C=O-Boc), 162.4, 162.5, 162.7 (C=O-9mer). 
 
6.6.7. qNMR 
6.6.7.1. Formulae to calculate the concentration of an unknown analyte314 
Integration for 1 analyte proton 
[analyte] =                                                                                  × [standard] 
Integration for 1 standard proton 
Equation 6.6: Calculation of the analyte concentration. 
Concentration in mM. 
Integration for 1 proton was calculated by dividing the integration on the spectrum 
by the number of proton expected for this signal. 
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6.6.7.2. qNMR with 2,5-dimethylfuran (2,5-DMFu) 
Relaxation delay 
In order to have a good reproducibility, the experiments were carried out in the same 
tube. The NMR tube was prepared with 2,5-DMFu (12 mM, ) and peptoid 5.22 (6 
mM estimated) in CDCl3. The spectra were obtained at 400 MHz, after 16 scans 
(acquisition time 2 seconds). 
Integration measurements were the same for all spectra and were measured between 
the following ppm values: 
- CH3 for 2,5-DMFu (5.25): 2.239 -2.302 ppm (measured),  
- CH=CH for 2,5-DMFu (5.25): 5.833 -5.872 ppm (fixed). 
- CH2N for the peptoid 5.22: 3.202 -3.488 ppm 
- NCH2CO for the peptoid 5.22: 3.804-4.364 ppm. 
 
Effect of number of scans and of the acquisition time 
The NMR tube was prepared with 2,5-DMFu (12 mM) and peptoid 5.22 (6 mM 
estimated) in CDCl3. The spectra were obtained at 400 MHz using D1 = 10 seconds. 










Ratio peptoid proton 
CH2N:NCH2CO 
16 2 1 : 3.01 1 : 1.005 
16 16 1 : 3.02 1 : 1.005 
16 32 1 : 3.01 1 : 1.006 
32 2 1 : 3.01 1 : 1.005 
64 2 1 : 3.02 1 : 1.006 
128 2 1 : 3.01 1 : 1.005 
 
Table 6.57: Effect of the number of scans and of the aquisition time on the NMR spectrum. 
 
CHAPTER 6 
- 297 - 
 
Effect of concentrations 
A solution of Fmoc-Lys(Boc)-OH was prepared in CDCl3 (5.6 mM). A solution of 



















7.15 0.1 3.0 4.8 0.6 2 
12.5 0.2 6.0 4.2 0.6 2 
16.6 0.3 8.4 3.73 0.6 2 
42.8 0.6 33.4 0.8 0.1 2 
37.5 0.6 17.6 1.4 0.2 2 
33.3 0.6 14.8 1.6 0.3 2 
Table 6.58: Preparation of the NMR solutions for study of the concentration effects. 
Integration of 2,5-DMFu was measured at δ = 5.87 ppm (s, 2H, CH) and the integration of the analyte, 
Fmoc-Lys(Boc)-OH, was measured at δ = 7.75 ppm (d, 2H, ArCH-Fmoc). 
 
A known volume of each solution was transferred into a NMR tube. Volumes used 
and expected concentration were summarised in the Table 6.58. 
1
H NMR of the 
mixture was recorded at 400 MHz (NS = 16, D1 = 10 seconds, AQ = 2 seconds and 
298 K). The calculated concentration was obtained using the equation 1. 
 
Quantification of protected peptoid Boc-9mer(Boc)9-NH2, 5.22 
A solution containing an estimated concentration of 6 mM (246 mg in 17 mL of 
CDCl3) of protected peptoid 5.22 and 12 mM of 2,5-DMFu (5.25) in CDCl3 was 
prepared. The NMR spectrum was recorded three times on a 400 MHz spectrometer 
using the following parameters: 
- NS = 16,  
- AQ = 2 seconds,  
- D1 = 10 seconds,  
- T = 298 K. 
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Once recorded, the spectrum was treated in order to obtain the best signals (base line 
and phase correction). The concentration was 5.22 calculated using the equation 1 
and the average of the 3 spectrum integrations. The integrations were measured with 
the heterocyclic 2,5-DMFu proton normalised at 1 and the peptoid proton were 
measured for H1, H6 and Hα. This was defined due to the non-satisfying integrations 
between 2 and 1 ppm. 
Results:  
Integration per peptoid proton: 0.4883. 
Concentration of peptoid: 5.86 mM ± 0.17 mM. 
 
6.6.8. Synthesis of NLLP 5.17: Boc deprotection using 1,4-dioxane/HCl 4N 
 
The peptoid 5.22(85.2 mg, 0.035 mmol) was dissolved in DCM (2 mL) and 3 mL of 
1,4-dioxane/HCl 4N were added. The solution was mixed for an hour before 
removing the solvent in vaccuo. However 1,4-dioxane was still present in the NMR 
spectrum. 10 lyophilisations using 5 mL of water were carried out. The mass (white 
sticky solid) was 72 mg (mass exact using qNMR 50 mg). The ratio 1,4-dioxane 
(CH2, 3.75 ppm) / proton 9mer (CH2N, 3.28 ppm) was 0.8 therefore the amount of 




): C72H147N19O9  calculated 1422.2, found 712.2 [M+2H]
2+
 (23.7 %), 
475.2 [M+3H]
3+
 (100%), 356.6 [M+4H]
4+
 (68.2%), 285.5 [M+5H]
5+
 (5.3%).  
m/z (MALDI-TOF): C72H147N19O9 calculated
 





 (100%), 1461.21 [M+K]
+
 (35.9%). 




 475.06213, found 475.06471. 
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HPLC (Method 3): tR = 0.82 min, purity = 100% (ELSD). 
1
H NMR (D2O, 500 MHz, eSpresat suppression water): δ = 1.29-1.46 (m, 36H, CH2, 
H 3 and H4), 1.47-1.73 (m, 36H, CH2, H 2 and H5), 2.99 (m, 18H, CH2NH2, H6), 3.23-
3.51 (m, 18H, CH2N, H1), 3.93-4.53 (m, 18H, NCH2CO) 7.56 (br sg, 2H, CONH2). 
13
C NMR (D2O, 126 MHz):
 
δ = 25.1, 25.2, 25.3, 25.4, 25.5, 25.6, 26.4, 26.5, 26.6, 
27, 27.1, 27.2, 27.3 and 27.4 (CH2, C2, 3, 4, 5), 39.2, 39.3, 39.4 (CH2, C6), 47.4, 47.5, 
47.7, 48, 4, 48.5, 48.6, 48.7 (CH2, NCH2CO and C1), 162.4, 162.7, 162.99, 163.3, 
169.5, 169.6, 170 (C=O- 9mer). 
 
6.6.9. Synthesis of NLLP 5.17: Boc deprotection using TFA 
 
The peptoid 5.22 (85.2 mg, 0.035 mmol) was dissolved in DCM with 20% TFA (3 
mL). The solution was mixed for an hour before removing the solvent in vaccuo. The 
mass was 59 mg (mass exact using qNMR 50 mg). 
Analysis:  
m/z (MALDI-TOF): C72H147N19O9 calculated
 





 (100%), 1461.55 [M+K]
+
 (72.5%). 
HPLC (Method 3): tR = 0.83 min; purity = 100% (ELSD). 
(m/z and  NMR identical to the one reported for 5.17 in section 6.6.7). 
 
6.6.10. Synthesis of NLLP 5.17: Boc deprotection using Et2O/ HCl 1M 
 
 
The peptoid 5.22 (85.2 mg, 0.035 mmol) was dissolved in a minimum of Et2O (3 
mL) and transferred in a centrifuge tube. 10 mL of Et2O/HCl 1M were added and the 
CHAPTER 6 
- 300 - 
 
mixture was shaken for an hour. The formation of unprotected NLLP 5.17 was 
observed by the formation of a white precipitate. The mixture was cooled down, 
centrifuged and the product washed with cold Et2O (10 mL) three times. The white 
sticky solid was dried under N2. The NMR showed remaining traces of Et2O that 
were removed after 3 days under vacuum. The mass was 65 mg (mass exact using 
qNMR 50 mg). 
 
Analysis:  
m/z (MALDI-TOF): C72H147N19O9 calculated
 





 (100%), 1461.66 [M+K]
+
 (48.7%). 
HPLC (Method 3): tR = 0.85min, purity = 100% (ELSD). 
(m/z and  NMR identical to the one reported for 5.17 in section 6.6.7). 
 
6.6.11. MTT assays of the NLLP in cell lines 
MTT cytotoxicity assays were carried out on HeLa, HEK293T and B16F10 cells 
according to the general procedures (6.2.2.4). Cells were treated with 1, 5, 10, 20 or 
50 µL of 100 µM NLLP (5.17) solution in PBS in order to obtain a final 
concentration of 1, 5, 10, 20 or 50 µM, respectively. After 24 hours of incubation at 
37
o



















1 1.133 0.107 100.9 9.5 
5 1.185 0.104 105.5 9.2 
10 1.091 0.089 97.1 8.0 
20 1.144 0.125 101.8 11.1 
50 1.101 0.105 98.0 9.3 
Table 6.59: Percentage of cell vailability (HeLa cells) after 24 hours of incubation with NLLP 





















1 0.879 0.075 100.8 8.6 
5 0.860 0.048 98.6 5.5 
10 0.901 0.047 103.3 5.4 
20 0.857 0.058 98.3 6.6 
50 0.876 0.048 100.5 5.6 
Table 6.60: Percentage of cell vailability (B16F10 cells) after 24 hours of incubation with NLLP 



















1 1.094 0.129 96.3 11.3 
5 1.142 0.087 100.5 7.7 
10 1.114 0.103 98.0 9.1 
20 1.143 0.120 100.6 10.6 
50 1.139 0.108 100.3 9.5 
Table 6.61: Percentage of cell vailability (HEK293T cells) after 24 hours of incubation with 









Figure 1.1: Modified with permission from Molecular biology of the cell; 
Figure 1.2: Modified with permission from Molecular biology of the cell;  
Figure 1.3: Modified with permission from Molecular biology of the cell;  
Figure 1.4: Modified with permission from Molecular biology of the cell;  
Figure 1.11: Modified from “Cell-Penetrating Peptides—Mechanisms of Cellular Uptake and 
Generation of Delivery Systems” (Figure 1) with permission from Prof. Maria C. Pedroso de 
Lima; 
Figure 3.2: Adapted with permission from “Bright ideas for chemical biology”. Copyright 
2012 American Chemical Society. 
Figure 4.6: Modified with permission from nobelprize.org; http://www.nobelprize.org/nobel 
_prizes/chemistry/laureates/2008/illpres.html. 
 APPENDICES 
- 303 - 
 
APPENDIX 2: 
DATA FOR CHAPTER 2 
 
1. Expansion of the HPLC trace (λ = 580 nm, Method 3) and measurement of the area of 
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2. TO-PRO-3 analysis of primary immune cells. 
a. S2 Drosophila cells 
 
Figure 6.1 : TO-PRO-3 analysis of primary S2 Drosophila cell viability. 
Cells were treated with 0, 1 and 10 μM for one hour prior TO-PRO-3 analysis. A) Histogram plotting the 
rhodamine fluorescence (X axis) against the number of event (Y axis) before gating; B) Histogram plotting the 
rhodamine fluorescence (X axis) against the number of event after  gating; C) Gating of the histogram plotting 
the TO-PRO-3 fluorescence (X axis) against rhodamine fluorescence (Y axis) for untreated cell; D) ) Gating of 
the histogram plotting the TO-PRO-3 fluorescence (X axis) against rhodamine fluorescence (Y axis) for cells 
treated with 1 μM of Rho-9mer (2.37) ; E) ) Gating of the histogram plotting the TO-PRO-3 fluorescence (X 
axis) against rhodamine fluorescence (Y axis) for cells treated with 10 μM of Rho-9mer (2.37). The red arrows 
show the Intact cells, while the black ones point the dead cells. Data courtesy of Dr. Stefano Caserta from the 
Institute of Immunology & Infection Research (Prof. Rose Zamoyska) at the University of Edinburgh. 
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b. Mouse F5 hybridoma cells  
 
Figure 6.2 : TO-PRO-3 analysis of primary Mouse F5 hybridoma cell viability. 
Cells were treated with 0, 1 and 10 μM for one hour prior TO-PRO-3 analysis. A) Histogram plotting the 
rhodamine fluorescence (X axis) against the number of event (Y axis) before gating; B) Histogram plotting the 
rhodamine fluorescence (X axis) against the number of event after  gating; C) Gating of the histogram plotting 
the rhodamine fluorescence (X axis) against TO-PRO-3 fluorescence (Y axis) for untreated cell; D) ) Gating of 
the histogram plotting the rhodamine fluorescence (X axis) against TO-PRO-3 fluorescence (Y axis) for cells 
treated with 1 μM of Rho-9mer (2.37) ; E) ) Gating of the histogram plotting the rhodamine fluorescence (X 
axis) against TO-PRO-3 fluorescence (Y axis) for cells treated with 10 μM of Rho-9mer (2.37). The red arrows 
show the Intact cells, while the black ones point the dead cells. Data courtesy of Dr. Stefano Caserta from the 
Institute of Immunology & Infection Research (Prof. Rose Zamoyska) at the University of Edinburgh. 
A) B) 
C) D) E) 
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APPENDIX 3: 
DATA FOR CHAPTER 3 
 
Cellular uptake of Cy1-9mer (3.30) and Cy5.5-1mer (3.31). 
HeLa, B16F10 and HEK293T cells incubated with 10 μM of peptoids (Cy7-1mer (3.30) and 
Cy5.5-1mer (3.31)) for 5, 30 minutes, 2, 4 and 24 hours at 37
o
C. The errors bar represents the 
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APPENDIX 4: 
DATA FOR CHAPTER 4 
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2. His6-tag-Cys-GFP (4.30) sequence data 
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4. Analysis of the first coupling assay via single thiol-maleimide coupling (the coupling did 
not work) 
a. MALDI-TOF spectrum  
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6. Analysis of the first coupling assay via multiple thiol-maleimide coupling (the coupling 
did not work) 
a. MALDI-TOF spectrum after reaction 
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7. Cellular uptake of the bioconjugate 4.44 ((9mer-S)n-GFP) in HeLa cells  
 
 
Graph 6.1 : Cellular uptake of the bioconjugate 4.44. 
% uptake measured for the Cys-GFP (4.29, 6 µg/mL), (9mer-S)n-GFP bioconjugate (4.44-a: 2.7 µg/mL and 
4.44-b: 5.4 µg/mL) and maleimide-9mer (4.35, as negative control, 10 µM) as the % of cells with a fluorescent 
emission exceeding untreated control as 0% uptake (incubation time = 24 hours). The errors bar represents the 
standard error of the average (n = 3). 
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8. MTT analysis of the 9mer-S-GFP bioconjugate (4.40 and 4.44) in HeLa cells. 
HeLa cells were incubated with Cys-GFP (4.29, 6 µg/mL), 9mer-S-GFP bioconjugate (4.40 
and 4.44, a: 2.7 µg/mL and b: 5.4 µg/mL) and maleimide-9mer (4.35, as negative control, 10 
µM) for 24 hours before being treated with MTT. Healthy cells corresponded to 100% cell 
viability. The errors bar represents the standard error of the average (n = 8).  
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9. Data for the stability of the OPfp ester against TFA. 
The % of each compound was calculated via the area of each HPLC (ELSD) peak. 
1 % of TFA % of Fmoc-Leu-Opfp % of hydrolysis product 
0 min 100 0 
15 min 100 0 
30 min 100 0 
60 min 100 0 
90 min 100 0 
120 min 100 0 




5 % of TFA % of Fmoc-Leu-Opfp % of hydrolysis product 
0 min 100 0 
15 min 100 0 
30 min 100 0 
60 min 100 0 
90 min 100 0 
120 min 100 0 
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10 % of TFA % of Fmoc-Leu-Opfp % of hydrolysis product 
0 min 100 0 
15 min 100 0 
30 min 100 0 
60 min 100 0 
90 min 100 0 
120 min 100 0 




25 % of TFA % of Fmoc-Leu-Opfp % of hydrolysis product 
0 min 100 0 
15 min 100 0 
30 min 100 0 
60 min 100 0 
90 min 100 0 
120 min 100 0 
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50 % of TFA % of Fmoc-Leu-Opfp % of hydrolysis product 
0 min 100 0 
15 min 100 0 
30 min 100 0 
60 min 100 0 
90 min 100 0 
120 min 100 0 
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APPENDIX 5: 
DATA FOR CHAPTER 5 
1. Table of the stability Boc group in solution phase: 
 
Solution 
% of Fmoc-Lys-OH formed 
15 minutes 30 minutes 45 minutes 60 minutes 
1% TFA/DCM 0 0 0 0 
2% TFA/DCM 0 0 0 1 
3% TFA/DCM 0 0.9 1 2 
4% TFA/DCM 0 3 7 11 
5% TFA/DCM 4 10 16 36 
10% TFA/DCM 99 100 100 100 
15% TFA/DCM 100 100 100 100 
20% TFA/DCM 100 100 100 100 
1% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
2% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
3% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
4% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
5% TFA in DCM/H2O 
(99:1) 
0 0 0 1 
10% TFA in 
DCM/H2O (99:1) 
18 25 30 42 
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15% TFA in 
DCM/H2O (99:1) 
53 63 70 75 
20% TFA in 
DCM/H2O (99:1) 





% of Fmoc-Lys-OH formed 
75 minutes 90 minutes 105 minutes 120 minutes 
1% TFA/DCM 0 0 0 0 
2% TFA/DCM 1 1 1 2 
3% TFA/DCM 4 6 10 12 
4% TFA/DCM 15 17 20 24 
5% TFA/DCM 45 51 59 65 
10% TFA/DCM - - - - 
15% TFA/DCM - - - - 
20% TFA/DCM - - - - 
1% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
2% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
3% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
4% TFA in DCM/H2O 
(99:1) 
0 0 0 0 
5% TFA in DCM/H2O 
(99:1) 
1 1 1 1 
10% TFA in 
DCM/H2O (99:1) 
46 53 57 63 
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15% TFA in 
DCM/H2O (99:1) 
80 84 88 90 
20% TFA in 
DCM/H2O (99:1) 
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3. Analysis of the products obtained after cleavage of the resin 5.19 using 
DCM/TFA/H2O (95: 5: 1) for 4 cycles of 10 minutes: MS and HPLC analysis of the 
cycle 2, 3 and 4. 
a. MALDI-TOF spectrum of material recovered at the first cycle cleavage 
 
 
b. MALDI-TOF spectrum and HPLC (ELSD) trace of material recovered 









c. MALDI-TOF spectrum and HPLC (ELSD) trace of material recovered 








d. MALDI-TOF spectrum and HPLC (ELSD) trace of the material 
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4. MALDI-TOF spectrum of the products obtained after cleavage of the resin 5.19 
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7. Relaxation delay assay: 1H NMR spectrum (zoom between 6.2 and 2.0 ppm) of 
Boc-9mer(Boc)9-NH2 peptoid (5.22) in presence of  2,5-DMFu in CDCl3, 400 MHz. 
a. D1 = 1 second 
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c. D1 = 30 seconds 
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8. Suppression of 1,4-dioxane xignals in the 9mer 5.17 after Boc deprotection of the 




After 0 lyophilisation 
After 3 lyophilisations 
After 7 lyophilisations 
After 10 
lyophilisations 
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9. Analysis of the pure NLLP 5.17 
The spectra were obtained after deprotection of 5.22 with 20% TFA in DCM. The 
others deprotections gave very similar analytical spectrum. 
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